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Cardiovascular disease contributes significantly to global morbidity and mortality 
and is particularly prevalent among individuals with Type 2 diabetes, which is 
thought to in part be due to the association between diabetes and the metabolic 
syndrome.  Traditional cardiovascular risk prediction scores perform well in the 
general population but their use in people with Type 2 diabetes is limited as they are 
thought to underperform in high risk groups.  Indeed, the use of any risk prediction in 
people with Type 2 diabetes is a point of discussion among clinicians as people with 
diabetes are thought by some to be at immediate high risk of CVD, whereas others 
view them as having a degree of modifiable risk which can be addressed using risk 
prediction.  In the general population, novel markers such as cIMT and carotid 
plaque, as well as other potential biomarkers of cardiovascular risk, have been 
explored as possible adjuncts to risk scores in the prediction of cardiovascular 
disease.  The evidence for their use in general populations has been established, 
although there have been no firm conclusions with regard to recommendations for 
their use, which is partly due to the high degree of variability in cIMT measurement.  
However, the evidence for their use in people with Type 2 diabetes is sparse, despite 
the use of such markers as surrogate CV endpoints in clinical trials.    
This thesis aimed to describe the frequency, distribution and change of cIMT and 
carotid plaque, as well as to explore the relationship of cIMT and carotid plaque with 
cardiovascular risk factors, prevalent cardiovascular disease and future 
cardiovascular events in older people with Type 2 diabetes.  The association between 
cIMT, carotid plaque and other novel risk markers was also explored.   
The analysis was performed using data from the Edinburgh Type 2 Diabetes Study 
(ET2DS).  This study is a large, prospective cohort study of 1066 men and women 
with Type 2 diabetes, aged 60-75 years at recruitment, living in Edinburgh and the 
Lothians.  cIMT and carotid plaque were measured at year 1 follow up of the study.  





from the data collection performed at baseline and year 1.  A mean of 3.5 years of 
follow up was available for analysis and is complete for the baseline cohort as data 
linkage was performed.   
Mean values of cIMT in the ET2DS were comparable with other studies of cIMT in 
people with Type 2 diabetes and may indeed be higher than cIMT in the general 
population.  Measurement of cIMT by the sonographer was comparable with 
computer aided measurements.  Increasing cIMT was independently associated 
(although only modestly) with increasing age, male sex and raised systolic blood 
pressure.  Mean cIMT was associated with prevalent vascular disease and was 
predictive of incident global cardiovascular events and coronary artery events (but 
not stroke) over and above UKPDS risk factors, although the clinical impact of this 
on the reclassification of vascular risk (as demonstrated by net reclassification index 
(NRI)) was limited.  
There was a high prevalence of carotid plaque, and in particular “high risk” plaque, 
in the ET2DS.  Different measures of carotid plaque were independently associated 
with several cardiovascular risk factors.  Carotid plaque thickness was independently 
associated, albeit modestly, with increasing age, male sex, duration of diabetes and 
hypertension, plaque score with increasing age, hypertension, smoking and low BMI, 
and high risk plaque with hypertension and low BMI.  All measures of carotid plaque 
were associated with prevalent vascular disease.  However, despite these 
associations, carotid plaque did not have any additional predictive value for incident 
cardiovascular events over and above UKPDS risk factors.   
Finally, measures of cIMT and carotid plaque in the ET2DS were associated with the 
biomarkers ankle brachial index (ABI) and NTproBNP.  In addition these markers 
were significantly higher in those individuals with prevalent vascular disease, 
suggesting a more extensive exploration of the association of these markers in 







cIMT and carotid plaque are modestly associated with traditional cardiovascular risk 
factors and prevalent cardiovascular disease in older adults with Type 2 diabetes.  
cIMT has been shown to be predictive of incident events while carotid plaque was 
not, in people with Type 2 diabetes, over and above traditional cardiovascular risk 
factors, although its impact on risk reclassification may only be small.  Further 
evidence is required from the longer follow up of the ET2DS before firm conclusions 
can be drawn on the usefulness of cIMT and carotid plaque as risk markers in people 
with Type 2 diabetes.  In addition, large collaborative studies could be used to further 
explore the relationship of carotid plaque, and change in cIMT with incident 
cardiovascular events, as well as exploring the additive effect of cIMT and plaque on 






Chapter 1: Cardiovascular Disease, Diabetes 
and Carotid Ultrasound 
 
Introduction 
In 2008, the World Health Organisation (WHO) stated that cardiovascular disease 
(CVD) is the leading cause of morbidity and mortality worldwide, as well as the 
leading cause of death in people with Type 2 diabetes (WHO 2008).  Although there 
is now considerably greater awareness and improved management of both modifiable 
vascular risk factors and acute vascular events, following decades of research, 
cardiovascular disease remains an extensive burden on health care systems.  As is the 
case for many other major medical conditions, restrictions imposed upon health care 
funding in many countries means that there must be an element of patient selection 
when prescribing both pharmaceutical and non-pharmaceutical management plans 
for cardiovascular disease.  Methods for predicting who might be at a greater 
cardiovascular risk, and therefore gain the most benefit from early intensive 
management (the most economically and medically beneficial strategy), range from 
highly invasive imaging procedures to non-invasive cardiovascular risk scores.  
However, none of these methods alone currently provide an accurate estimation of 
risk which is suitable for use in every patient and indeed, many events occur in 
people in whom risk was not identified as being raised (Taylor 2002).  This has led to 
increasing interest in the use of ‘novel’ risk markers in the prediction of events.  
Non-invasive markers of vascular risk, including carotid intima media thickness and 
carotid plaque, have recently been cited as having the potential to improve risk 
prediction over and above traditional risk scoring (such as Framingham scores) in the 
general population (Calonge N, Petitti DB et al. 2009; Nambi V, Chambless L et al. 
2010; Simon A, Megnien JL et al. 2010; Nambi V, Chambless L et al. 2012; Peters 




An additional growing burden upon health is Type 2 diabetes (T2DM). As well as 
the damage this chronic disease inflicts upon the renal, visual and neurological 
systems, Type 2 diabetes confers an increased cardiovascular risk over and above 
that of people without diabetes.  Those with Type 2 diabetes more frequently present 
with vascular disease at an earlier age and often present with advanced disease at 
diagnosis due to the silent damage inflicted upon vessel walls by hyperglycaemia and 
the effects of established vascular risk factors that usually accompany a diagnosis of 
T2DM.  However, there remains controversy as to whether Type 2 diabetes should 
be considered a risk equivalent for CVD (Haffner, Lehto et al. 1998) or a risk factor 
for CVD (Wong ND, Glovaci D et al. 2012; Sattar N 2013).  If it is considered a risk 
equivalent, individuals should immediately be classed as high risk and treated as 
such.  However, if it is to be considered as a risk factor for CVD, there is still a 
spectrum of risk and individuals could arguably be characterised in a similar way to 
the general population in terms of cardiovascular risk management.    
Traditional risk scores that are used to predict incident cardiovascular events have 
largely been developed in people initially free of such events in the general 
population and as such, are thought to be less accurate for people with Type 2 
diabetes.  As in the general population, there is also an opportunity to use markers 
such as cIMT and carotid plaque in the evaluation of cardiovascular risk in people 
with T2DM.  However the use of these markers in people with Type 2 diabetes is 
less well documented than in the general population.  The United States Preventive 
Services Task Force (USPSTF) statement recently published (United States 
Preventative Services Task Force 2009), stated that whilst there was some evidence 
for the use of cIMT in risk prediction, more evidence for its use in people with 
diabetes was required. 
This thesis aims to explore cIMT and carotid plaque in a large population based 
cohort of older people with Type 2 diabetes, assessing their relationship with 
traditional cardiovascular risk factors and prevalent cardiovascular disease, as well as 




carotid plaque to predict future vascular events in this group.  It will also address 
methodological issues around the measurement of cIMT in an epidemiological study.  
The introductory chapter provides a review of the current literature regarding 
cardiovascular disease, Type 2 diabetes and carotid ultrasound; the second chapter  
describes the specific aims and objectives of this thesis; Chapter 3 describes the 
methodology used in this thesis; Chapters 4,5 and 6 will describe descriptive, cross 
sectional and longitudinal analysis results; and Chapter 7 will be a discussion of the 
results in the context of current literature, with  recommendations for further 
research.   
 
1.1 Cardiovascular disease 
 Definition & frequency in the UK 1.1.1
Cardiovascular disease is defined as a disease process which affects the structure and 
function of the heart, arteries and veins (WHO Regional Office for Europe 2012) .  
This includes outcomes such as myocardial infarction, angina, stroke, transient 
ischaemic attack (TIA) and intermittent claudication amongst many others.  There 
are several terms that are used to describe different aspects of CVD, the most 
common of which are coronary heart disease, coronary artery disease, 
cerebrovascular disease and peripheral arterial disease.  Whilst the common 
underlying pathology of these diseases is the process of atherosclerosis, each term 
describes a distinct anatomical location, reflecting the specific vessels and organs 
involved.  Coronary heart disease and coronary artery disease commonly describe 
atherosclerotic disease of the coronary arteries and includes outcome events such as 
myocardial infarction and angina.  Cerebrovascular disease refers more specifically 
to disease affecting the cerebral arteries, and includes stroke and transient ischaemic 
attacks (TIA) as outcomes, whilst peripheral arterial disease refers specifically to 
diseases of the arteries of the limbs, in particular, the lower limbs.  Intermittent 
claudication is the chief symptom of peripheral vascular disease.  The term 




different groups, and there can be some confusion regarding the specific diseases 
being referred to.   
For the purposes of this thesis, the terms coronary artery disease and 
cerebrovascular disease will be adopted to describe myocardial infarction (MI) & 
angina, and stroke & TIA respectively, while the term cardiovascular disease will 
refer to coronary artery disease and cerebrovascular disease as a group. 
In 2010, the estimated prevalence of CVD in Scotland was 16.3% for men and 14.0% 
for women (of all ages), as reported in the British Heart Foundation Coronary Heart 
Disease Statistics 2012 (Townsend N, Wickramasinghe K et al. 2012), using data 
from the Scottish Health Survey 2010.  Figures for men and women in England are 
reported as 13.6% and 13.0% respectively (using data from the Health Survey 
England 2006).  Figure 1-1 describes the prevalence of CAD, MI, angina, and stroke 
that were estimated by the Scottish Health Survey 2010. 



















Due to general improvements in risk factor management, the incidence of myocardial 
infarction is reducing in the UK.  In Scotland, there was a 25% reduction in the 
incidence of MI in the period 2000 – 2009 (figure 1-2).  However, incidence remains 
higher in men than in women, although the difference between the sexes lessens with 
increasing age.  In 2009, incidence of myocardial infarction was 255 per 100,000 per 
year in Scottish men and 113 per 100,000 in Scottish women.  There are comparable 
data for England in the years 2005-2007, which also highlights the ongoing North-
South divide in vascular disease, with the incidence of MI 20% higher in Scottish 
men and 35% higher in Scottish women than their English counterparts (Townsend 
N, Wickramasinghe K et al. 2012). 
Figure 1-2 Age standardised incidence rate of myocardial infarction (per 100,000/year) in Scotland 
(Source: BHF CHD statistics, 2012) 
 
The British Heart Foundation describes not only the incidence of MI but also angina 
and stroke (Townsend N, Wickramasinghe K et al. 2012).  Stroke incidence has also 
decreased over the decades and in 2009, incidence in Scottish men was 202 per 
100,000 per year and in Scottish women 160 per 100,000 per year (figure 1-3).  
Again, a comparison to figures from England in the period 2005-2007 highlight the 
North-South divide, with incidence of stroke in 2007 in Scottish men at 208 per 
















men, incidence was 178 per 100,000 per year and in English women it was 139 per 
100,000 per year.   
Figure 1-3 Age standardised incidence rate of stroke (per 100,000/year) in Scotland (Source: BHF 
CHD statistics, 2012) 
 
Age standardised incidence rates for angina in 2009 in Scotland, England, Ireland 
and Wales are described in figure 1-4.    Again, Scotland demonstrates a high 
incidence of angina in both men and women, with incidence of 48.6 per 100,000 per 
year in men and 37.7 per 100,000 per year in women, although overall, the highest 
incidence was noted in Welsh men and Scottish women (Townsend N, 














Figure 1-4 Age standardised incidence of Angina (per 100,000 per year) in 2009 (Source: BHF CHD 
statistics, 2012) 
 
 Pathology & presentation 1.1.2
The global burden of cardiovascular disease worldwide is predominantly that of 
coronary artery disease and cerebrovascular disease, the underlying pathology of 
which is usually atherosclerosis. 
Atherosclerosis  
In most cases, events such as myocardial infarction are preceded by atherosclerotic 
changes of the vessel wall in which the major cardiovascular risk factors, 
predominantly smoking, hypertension and dyslipidaemia, play an important role.  
Atherosclerosis is a progressive disease, and there are many different stages of 
disease, from early, non-invasive changes of the vessel wall to the occlusive changes 
seen in advanced, symptomatic atherosclerosis (Lusis AJ 2000).  Atherosclerotic 
changes can be seen in the vessel wall as early as childhood.  Larger arteries such as 
the aorta, show these changes first, followed by the coronary arteries, and by the 4th 
decade of life, changes can be seen in the cerebral arteries (Lusis AJ 2000). 















Some of the main sources of endothelial injury are blood pressure associated shear 
stress, elevated low density lipoprotein (LDL) cholesterol, chemical toxins in 
cigarette smoke, reduced high density lipoprotein (HDL) cholesterol, insulin 
resistance and glycosylated end products produced in diabetes (Fuster 1994; Epstein 
and Ross 1999; Zaman, Helft et al. 2000).   
The initial changes seen in artery walls are commonly known as “fatty streaks”.  
These appear as white streaks in the artery wall and are due to the presence of 
cholesterol containing macrophages – foam cells – in the sub endothelial layer of the 
vessel wall.  The driver behind the presence of foam cells in the artery wall is the 
deposition of LDL molecules within the endothelium.  Endothelial cell morphology 
at sites of turbulent blood flood makes the endothelium more permeable to molecules 
such as LDL, leading to a higher propensity to lesion formation.  Raised LDL levels 
also lead to increased uptake of LDL into the endothelium.  The LDL molecules can 
become oxidised and cause direct damage to the surrounding wall tissue, promoting 
an inflammatory response as well as reducing the production of nitric oxide (a potent 
vasodilator).  The production of pro-inflammatory molecules by the endothelial cells 
causes monocytes to be activated in response to the inflammation and invade the 
wall, where macrophage differentiation occurs.  The macrophages then ingest the 
highly modified oxidised LDL molecules, and gradually enlarge, becoming known as 
foam cells as this process continues (Lusis AJ 2000).    
The inflammatory process is further promoted by the death of the foam cells and so 
the cycle continues, with proliferation and migration of smooth muscle cells from the 
tunica media to the intima in response to cytokines released from damaged 
endothelial cells.  The smooth muscles cells migrate to the intimal layer and 
proliferate, and generate excess extra-cellular matrix which produces a fibrous lesion 
in the artery wall (Lusis AJ 2000).  Platelets are also attracted by the ongoing 
endothelial damage and they too release growth factors which can also result in the 
migration and proliferation of local smooth muscle cells (Willerson JT, Yao SK et al. 




can exacerbate the deposition of LDL cholesterol in the endothelium.  The main 
function of HDL cholesterol is to remove cholesterol from tissues and return it to the 
liver, where it is excreted in bile.  If HDL cholesterol levels are reduced, LDL 
cholesterol can continue to promote uptake of cholesterol into tissues unopposed. 
As the process of atherosclerosis progresses, the early arterial wall changes begin to 
extend.  Further inflammatory changes lead to plaque development and the 
subsequent changes associated with the plaque can lead to complete occlusion of the 
artery, with infarction of the tissue supplied by the artery. The altered smooth muscle 
cell function leads to the formation of a fibrous cap over the lesion and it is at this 
point that the lesion can protrude into the lumen of the artery.  Matrix 
metalloproteinase production is altered, leading to a remodelling of the artery wall, 
and compensatory dilatation of the artery, until plaque stenosis reaches 40-50%, at 
which point dilation can no longer compensate (Glagov S 1994; Godin D, Ivan E et 
al. 2000; Hall HA and Bassiouny HS 2012).    Plaque stability is related to plaque 
structure.  More stable plaques tend to have smaller lipid cores, thicker fibrous caps 
and fewer inflammatory cells.  Those plaques that are prone to rupture and are less 
stable tend to have large lipid cores, thin fibrous caps, more inflammatory cells 
(Zaman, Helft et al. 2000; Davies, Rudd et al. 2004).  
Angina and myocardial infarction  
When an individual with coronary atherosclerosis exercises or is under emotional 
stress, the oxygen demand of the myocardium increases but the narrowed vascular 
lumen restricts the volume of oxygenated blood that can be carried to the tissues, 
resulting in ischaemia in the myocardial tissue (Fuchs RM and Becker LC 1982).   
As the individual rests, oxygen demand reduces and the available supply of 
oxygenated blood is again adequate and so chest pain resolves.  The tissue is not 
usually damaged and can return to normal function.  The manifests clinically as 
angina - the classical symptoms of which are exertional chest pain or chest tightness 
and in some cases, autonomic symptoms associated with the chest discomfort, such 




drugs such as nitrates and in the case of recurrent severe episodes, coronary artery 
stenting or bypass grafting can be implemented to return blood flow to near normal.  
This predictable pattern of angina is typically referred to as stable angina.  However, 
in some cases, chest pain can occur at rest or at a lesser level of exertion than usual.  
Angina symptoms may also worsen over a short period of time.  This is known as 
unstable angina and is a higher risk entity than stable angina.  It is usually the effect 
of an unstable plaque rupturing and further restricting the lumen.  If left untreated, it 
is more likely to lead to myocardial infarction.  Unstable angina can be identified as 
one sub classification of the acute coronary syndrome (Newby DE, Grubb NR et al. 
2014) .  
 As an atherosclerotic plaque evolves, plaque rupture and clot formation are 
common.  If the contents of the plaque are dispersed or a portion of thrombus 
becomes separated, embolisation to the coronary arteries can occur.  If the embolus is 
of sufficient diameter, there can be complete occlusion of the coronary artery.  The 
supply of oxygenated blood to the myocardium is completely restricted and this 
results in infarction of the tissue (Newby DE, Grubb NR et al. 2014).  The infarcted 
tissue becomes necrotic and will release its contents e.g. cardiac enzymes such as 
troponin and creatinine kinase (Thygesen, Alpert et al. 2012).   This damage to the 
tissue is irreversible and can be fatal if a large portion of the myocardium becomes 
dysfunctional.  Thrombolysis or primary percutaneous interventions offer the best 
chance of recovery as they can restore blood flow to near normal (Newby DE, Grubb 
NR et al. 2014).  Typical symptoms include a severe and intractable central crushing 
chest pain, often with radiation to the left arm or jaw.  The pain does not resolve with 
rest and may be accompanied by a sense of impending death, nausea and vomiting. 
TIA and stroke  
Transient ischaemic attacks are characterized by temporary weakness or other 
neurological symptoms.  They are commonly the result of small emboli from plaque 
in the carotid arteries or thrombus from the heart (as a result of atrial fibrillation) 




occlusion of the carotid arteries by plaque can cause such narrowing that the blood 
flow to the cerebral tissue is markedly reduced.  There is usually spontaneous 
resolution of the interruption to blood flow and so there is usually only ischaemia of 
the cerebral tissue and not complete infarction.  As a result, the neurological 
dysfunction normally resolves spontaneously.  However, risk factor management will 
be necessary following an event to prevent further episodes (Langhorne P 2014).   
Like TIAs, the pathology underlying a stroke is usually embolism of a thrombus 
from the heart or carotid arteries, or in some cases, massive haemorrhage from a 
cerebral aneurysm or other vascular abnormality. Cerebral blood flow is usually 
completely obscured and cerebral tissue will be damaged irreversibly after 3 hours of 
oxygen deprivation.  As such, in the case of ischaemic stroke only (thrombolysis is 
contraindicated in haemorrhagic stroke), thrombolysis is not given after 4.5 hours as 
it cannot reverse any damage that has occurred (Langhorne P 2014).   
 Diagnosis 1.1.3
Angina  
During periods of chest pain, angina can be diagnosed on a 12 lead ECG as ST 
segment depression in any lead.  Exertional chest pain can be elicited during exercise 
stress testing.  Patients undergo ECG whilst performing progressive exercise 
(walking) on a treadmill and the appearance of ischaemic changes (ST segment 
depression) during exercise can be diagnostic of angina.  This test can also be used to 
demonstrate the severity of disease in people with known angina. If stress testing is 
not conclusive, more invasive diagnostic testing may be required (Newby DE, Grubb 
NR et al. 2014).  Coronary artery angiography can reveal any narrowing of the artery 
lumen and can be used to diagnose the site and extent of obstruction, allowing 
stenting to be undertaken (Newby DE, Grubb NR et al. 2014). 
Myocardial infarction  
Myocardial infarction usually presents with a history of acute, unremitting and 




and/or jaw.  There may also be complete circulatory collapse associated with cardiac 
arrest (Newby DE, Grubb NR et al. 2014).  The ECG during myocardial infarction 
typically displays ST segment elevation, representing infarction of the myocardial 
tissue.  Current diagnostic standards include the measurement of troponin-I or 
troponin-T - subunits of the cardiac enzyme troponin.  Any elevation of troponin 
(according to individual lab standards) indicates damage to the myocardium and can 
be diagnostic of an MI (SIGN 93 2013).  Angiography may be necessary to identify 
occlusions and is usually undertaken as part of the primary treatment of myocardial 
infarction.  Primary percutaneous intervention is used as a first line treatment in 
many health boards, including NHS Lothian.  Angiography will demonstrate a 
complete occlusion of one or more of the coronary arteries.  Angioplasty and/or 
stenting may be carried out depending on the severity of disease (Newby DE, Grubb 
NR et al. 2014). 
In epidemiological studies and clinical trials, systematic coding of 12 lead ECGs, 
such as Minnesota coding (Prineas RJ, Crowe RS et al. 1982) are often used to 
identify changes specific to angina and MI.  In addition, tools such as the Rose chest 
pain questionnaire can be used to elicit further information regarding coronary artery 
disease (Rose G, McCartney P et al. 1977). 
TIA  
Transient ischaemic attacks usually present with a history of short lived, self-limiting 
rapid onset neurological deficits, which can result in temporary numbness, weakness 
or paralysis of the limbs or face.  In addition, if the retinal vessels, optic radiation or 
visual cortex are affected, there may be a temporary visual defect.  Following a 
diagnosis of suspected TIA, a brain CT can rule out any cerebral abnormalities and 
carotid ultrasound is performed looking for evidence of carotid stenosis or plaque 
(NICE CG68 2008).  However, CT is often normal and carotid ultrasound tends to 





Like a transient ischaemic attack, acute stroke presents with rapid onset of numbness, 
weakness or paralysis of the limbs and/or face.  Depending on the location of the 
cerebral ischaemia, there may be paralysis of an entire side of the body or it may be 
limited just to the face.  Symptoms tend not to resolve spontaneously as there is 
infarction of the cerebral tissue, and as a result, the neurological deficit may be long 
term.  CT imaging of the brain is important for management of an evolving stroke.  
Ischaemic and haemorrhagic strokes have differing appearances on CT (NICE CG68 
2008)    
 Traditional cardiovascular risk factors 1.1.4
As well as the accepted non-modifiable risk factors of age, gender and ethnicity, the 
major modifiable environmental cardiovascular risk factors for CVD include 
hypertension, dyslipidaemia, obesity, smoking, and physical inactivity, in addition to 
diabetes.   
Age, gender & ethnicity 
Age is one of the major non-modifiable risk factors for cardiovascular disease with 
rate of disease increasing steadily across increasing age groups in both men and 
women (Castelli WP 1984; Tunstall-Pedoe H, Kuulasmaa K et al. 1994; Rich-
Edwards JW, Manson JAE et al. 1995).  The additive effect of vascular stress and 
other cardiovascular risk factors on the vessel wall is thought to contribute to the 
effect of age on vascular risk. Men are more likely to develop coronary artery disease 
than women (Jousilahti P, Vartiainen E et al. 1999), although once women reach the 
menopause, the difference between the sexes attenuates (Pappa T and Alevizaki M 
2012). Several theories have been postulated for this, including that either oestrogen 
is a protective factor for CAD, or that testosterone increases the risk for CAD (Pappa 
T and Alevizaki M 2012), however, there is still no clear answer to this question.  
Those from certain ethnic backgrounds are also known to be at higher risk of CVD 
than those from other backgrounds, including an increased prevalence of CAD in 




other people living in the UK, who were not born in the UK (Townsend N, 
Wickramasinghe K et al. 2012).  In the UK, both men and women of South Asian 
origin had a higher risk of CAD and stroke than European people (Chaturvedi 2003) 
and people of Afro-Caribbean origin had a reduced risk of CAD but an increased risk 
of stroke when compared to European residents.  This may be due in part to higher 
levels of glucose intolerance, central obesity, fasting triglycerides and insulin levels 
in South Asians when compared with Europeans (McKeigue PM, Shah B et al. 
1991).  This is also seen in people of Afro Caribbean descent; however, their levels 
of LDL cholesterol and triglycerides are lower than that of Europeans. Black 
Caribbean, South Asian, Pakistani and Bangladeshi men have a higher prevalence of 
diabetes (Townsend N, Wickramasinghe K et al. 2012), supporting the theory that 
ethnic differences may be influenced by differences in insulin resistance and 
endothelial dysfunction (Chaturvedi 2003).  
Hypertension, dyslipidaemia and smoking 
The three most “traditional” cardiovascular risk factors are hypertension, smoking 
and dyslipidaemia.  Hypertension is prevalent throughout the UK.  The Scottish 
Health Survey (2010) revealed that 35% of men and 30% of women in Scotland had 
hypertension (defined as systolic blood pressure >140mmHg or diastolic blood 
pressure >90mmHg), comparable with rates in England (Townsend N, 
Wickramasinghe K et al. 2012).  On a meta-analysis of data from over 1 million 
subjects, the Prospective Studies Collaboration in 2002 revealed that each 20mmHg 
rise in systolic blood pressure (equivalent to 10mmHg increase in diastolic blood 
pressure) CAD risk doubles for adults aged 40-69 years (Prospective Studies 
Collaboration 2002). Essential hypertension is a complex condition and the 
pathophysiology is not fully understood.  Exposure of the vessel wall to raised 
arterial pressure promotes the formation of atheromatous lesions which in turn 
increase the risk of vascular events such as MI or stroke.  Therefore, the aim of 
management is to reduce blood pressure.  NICE guidelines recommend a target blood 




target blood pressure is tighter, with a target systolic pressure of <130 and target 
diastolic pressure of <80 (SIGN 116 2010).   
Dyslipidaemia is a term that is usually used when referring to hyperlipidaemia 
(raised total cholesterol, LDL cholesterol or triglycerides), with the exception of 
HDL cholesterol which is abnormal when reduced.  There are several factors which 
are known to disrupt lipid levels.  Cholesterol production occurs primarily in the 
liver, but dietary intake and lifestyle factors can also contribute.  Increased 
consumption of lipids such as saturated fats, and reduced levels of physical activity 
and genetic factors can lead to raised plasma lipid levels.  Additionally, insulin 
resistance has also been linked with altered blood lipid levels, including raised 
triglyceride levels and low HDL levels (Garg A 1996).  In terms of the association 
between dyslipidaemia and cardiovascular disease risk, the Prospective Studies 
Collaboration identified an independent positive association between total 
cholesterol and ischaemic heart disease, but not stroke (Prospective Studies 
Collaboration 2007).  This relationship persisted at all levels of blood pressure.  
There is also a strong body of evidence that statin use can reduce the occurrence of 
vascular outcomes (Taylor F, Huffman MD et al. 2013), supporting a role of 
dyslipidaemia in the development of cardiovascular disease. 
The association between smoking and cardiovascular disease is well described.  The 
effect of smoking on the endothelium encourages the development of atherosclerotic 
plaque.  A 50 year study of the relationship between smoking and cause specific 
mortality (commenced in 1951 following case control studies that highlighted a 
possible link between cigarette smoking and lung cancer) highlighted the increased 
mortality rate for ischaemic heart disease associated with smoking (Doll, Peto et al. 
2004).  Men who continued to smoke had an age standardized mortality rate of 10.01 
per 1000men/year for IHD, compared with 6.19 per 1000 men/year for lifelong non-
smokers, whilst former smokers were in between with a mortality rate of 7.61 per 
1000 men per year.  A similar trend was seen for current smokers versus never 




An increase in mortality rate was also seen for both IHD and CVD as the number of 
cigarettes smoked increased (Doll, Peto et al. 2004).  The prevalence of cigarette 
smoking in Great Britain has decreased substantially over the decades.  From 1972-
1994, prevalence in men decreased from 52% to 28%, and in women, from 41% to 
26%, and indeed has continued to fall, albeit at a slower rate.    More recent figures 
from 2010 estimate the prevalence of cigarette smoking in the UK to be 21% for men 
and 20% for women (Townsend N, Wickramasinghe K et al. 2012). 
Lifestyle (diet and activity) and obesity 
Lifestyle factors also play an important role in the development of cardiovascular 
disease, including diet and physical activity.  A diet high in saturated fat and salt, and 
low in fibre, fruit and vegetables can lead to hypercholesterolaemia, hypertension 
and a greater risk of cardiovascular disease (Townsend N, Wickramasinghe K et al. 
2012).  Excessive calorie intake leads to obesity, whereas expending excess calories 
through physical exercise prevents the development of obesity and overweight.  The 
first study which demonstrated a link between level of activity and cardiovascular 
risk, published over 5 decades ago by Morris et al, demonstrated that those people 
with more physically demanding jobs such as bus conductors or postmen, had a 
lower rates of cardiovascular disease (Morris, Heady et al. 1953).  Initial limitations 
of the study, such as confounding by obesity and other vascular risk factors, were 
later accounted for and Morris et al were able to demonstrate the cardioprotective 
nature of physical activity (Morris, Chave et al. 1973).  More recently, Myers et al 
demonstrated that exercise capacity was predictive of all-cause mortality (Myers, 
Kaykha et al. 2004).   
Obesity is an independent risk factor for cardiovascular disease (Poirier and Eckel 
2002; Poirier, Giles et al. 2006), as well as being a major factor in the development 
of Type 2 diabetes and other vascular risk factors such as hypercholesterolaemia and 
hypertension (Townsend N, Wickramasinghe K et al. 2012).  Mean body mass index 
(BMI) has increased over the past 30-40 years, a combination of both reduced 




early 1970s, both men and women largely had a BMI within the ‘normal range’ of 
20-25 but by the early 1990s, the mean BMI was above 25 and has continued to 
increase, to such an extent that by the 2050, it is estimated that 60% of UK men and 
50% of UK women will be obese (Butland, Jebb et al. 2007).  Childhood obesity is 
also a growing problem, bringing with it the increased burden of diabetes and its 
associated risks.  Prevalence of both overweight and obese children has increased in 
English children from 1974 to 2003 (Stamatakis, Primatesta et al. 2005).   
 Cardiovascular risk management & assessment 1.1.5
Primary and secondary prevention  
Despite the many manifestations of cardiovascular disease, the overall management 
of these conditions has a common theme.  The primary aim is to reduce exposure to 
cardiovascular risk factors and prevent events.  Blood lipids, blood pressure and 
smoking are the major risk factors to target and these can be tackled with a 
combination of lifestyle adaptation and medication.  Primary prevention is the 
management of cardiovascular risk factors in someone with no prior history of 
cardiovascular disease (SIGN 97 2007).  The aim of primary prevention is to educate 
patients with regards to diet, lifestyle and potential medical intervention, in order to 
stop them having a first event. In Scotland, SIGN Guideline 97 provides information 
and advice for clinicians initiating primary prevention (SIGN 97 2007). Control of 
blood pressure, blood lipids, platelet function and lifestyle factors such as smoking 
cessation are the main stay of primary prevention of CAD.  Statins are the mainstay 
of the management of elevated plasma cholesterol, and anti-hypertensive agents such 
as beta blockers and ACE-inhibitors among many others are used to reduce blood 
pressure.  Lifestyle interventions to reduce smoking are available, including the use 
of nicotine replacement therapy and newer pharmacological agents such as 
bupropione.  Aspirin had also been used as an anti-platelet therapy although the 
usefulness of this in primary prevention has been called into question recently 
following publication of data regarding the risk/benefit of aspirin (Antithrombotic 
Trialists' (ATT) Collaboration, Baigent C et al. 2009; Fowkes FR, Price JF et al. 




cardiovascular risk with a view to optimising cardiovascular risk factor management.  
Risk scores, family history and current medical history are taken into account when 
assessing an individual’s risk of having a cardiovascular event.  Other methods of 
risk evaluation involving direct measurement of disease, for example coronary 
angiography and coronary artery calcium (CAC) determined by CT involve higher 
doses of radiation than for example ultrasound, and in the case of angiography is 
more invasive, and therefore may not be suitable investigations for risk prediction in 
general healthcare settings.  Interest has therefore increased in the use non-invasive 
measures of atherosclerosis, including the carotid intima media thickness.   
Secondary prevention is the management of cardiovascular risk factors, initiated after 
someone has a vascular event, with the aim of preventing a further event occurring.  
Additional medication may be added on top of current treatments and the importance 
of lifestyle modification is reinforced (SIGN 93 2013).  
Cardiovascular risk assessment scores  
Primary prevention describes managing cardiovascular risk factors before any 
cardiovascular events occur. Therefore, information regarding an individual’s future 
risk of events must be taken into consideration when considering how aggressive a 
strategy should be implemented. This is particularly desirable in a general population 
because included in that population are individuals who are at low risk, intermediate 
risk and high risk of vascular disease.  Subsequently, not all members require active 
risk factor management, whereas some require rather more intensive risk factor 
management.  In addition to guiding the correct management of individual patients, 
risk prediction also allows health systems to target expensive treatments to those who 
will gain the most benefit.   
Because the symptoms of cardiovascular disease usually only manifest once disease 
is significantly advanced, there is a need for cardiovascular risk prediction tools to 
use early markers of disease risk that are easily measurable, for example 




include the combination of known cardiovascular risk factors into risk prediction 
models or algorithms.  A variety of such risk scores have been developed and 
proposed for use in the general population, including the Framingham Risk Score 
(Anderson KM et al., 1991), SCORE (Conroy RM et al., 2003), ASSIGN 
(Woodward M et al., 2007) and QRISK2 (Hippisley-Cox J et al., 2007, Collins GS 
and Altman DG, 2010), among others.  These algorithms are based upon known 
cardiovascular risk factors, including age, sex, smoking status, diabetes status, total 
& HDL cholesterol and systolic blood pressure, and differ from each other primarily 
in the exact risk factors included in the model.  Although their non-invasive nature 
means they are often used in clinical practice, cardiovascular risk algorithms have 
been shown to be inaccurate in low risk populations and high risk populations, such 
as those people with diabetes (Brindle P et al., 2006).  Until recently, in the United 
Kingdom, the National Institute for Health and Clinical Excellence (NICE) 
recommended the use of the Framingham risk equation when evaluating individual 
patient risk in the general population, and following an update to their guidance did 
not recommend any particular score and left the selection of the appropriate tool to 
the clinician (Collins GS and Altman DG 2010).    However, the most recent NICE 
guideline for managing cardiovascular disease recommends the use of the QRISK2 
risk score when evaluating cardiovascular risk (NICE CG 181 2014) .   
Many of the traditional risk factors for cardiovascular disease discussed previously, 
as well as history of cardiovascular disease and diabetes are common features of 
many risk prediction algorithms.  As an example to illustrate the differences in 
choice of included predictors, listed in table 1-1 are the key factors considered in the 
four well known and commonly used risk scores: Framingham, QRISK2, ASSIGN 
and SCORE (Anderson KM, Odell PM et al. 1991; Conroy RM, Pyörälä K et al. 
2003; Hippisley-Cox J, Coupland C et al. 2007; Woodward M, Brindle P et al. 2007; 




Table 1-1 Example of predictor variables included in cardiovascular risk scores developed and used 
in the general population 
 Framingham QRISK2 ASSIGN SCORE 
OUTCOME CHD    
Age     
Sex     
Diabetes     
Smoking     
Number of cigarettes     
Systolic Blood Pressure     
Total Cholesterol     
HDL Cholesterol     
Cholesterol/HDL Ratio     
BMI     
Postcode     
Scottish Postcode     
Previous CVD     
History of angina/MI     
CKD     
AF     
Blood pressure treatment     
RA     
Family history of CHD/Stroke     
HDL=high density lipoprotein, BMI=body mass index, CVD=cardiovascular disease, MI=myocardial infarction, CKD=chronic 
kidney disease, AF=atrial fibrillation, RA=rheumatoid arthritis, CHD=coronary heart disease 
 
Alternative methods of risk prediction 
Although cardiovascular risk scores are effective in clinical practice, they do not 
capture the full extent of an individual’s risk, especially in lower or higher risk 
groups (Brindle P, Beswick A et al. 2006).  Therefore, researchers have turned to 
other methods to inform and improve current methods. The most prominent of these 
are non-invasive markers of cardiovascular risk.  Included in this category are 
physical markers such as carotid intima media thickness, carotid plaque, coronary 
artery calcium score and ankle brachial index (ABI).  Other potential additions to 
existing risk scores being considered include biochemical markers such as ABI, 
eGFR, albuminuria, IL-6, CRP, NTproBNP (Ridker PM, Rifai N et al. 2002; Weir 
MR 2007; Fowkes FG, Murray GD et al. 2008; Lee JK, Bettencourt R et al. 2012; 
Donfrancesco C, Palleschi S et al. 2013).  cIMT and plaque are easily assessed using 
carotid B mode ultrasound, and ankle brachial index can be measured using a hand 




thoracic computed tomography (CT).  However, compared with other non-invasive 
markers, this carries a slightly greater risk to individuals due to the use of radiation.  
Because the main focus of this thesis is cIMT and carotid plaque, they will be 
discussed in more detail in section 1.3 of this chapter.  Novel biomarkers are 
discussed in the following section.   
 Novel cardiovascular biomarkers 1.1.6
Several other potential markers of vascular risk are being considered for use in 
vascular risk prediction.  These include estimated glomerular filtration rate (eGFR), 
microalbuminuria, interleukin-6 (IL-6), C-reactive protein (CRP) and N-terminal 
pro-brain natriuretic peptide (NTProBNP).  Ultrasound markers such as cIMT and 
carotid plaque will be discussed in detail in section 1.3 and 1.4 of this chapter. 
Ankle brachial index 
The ankle brachial index is a measure of peripheral arterial disease.  It is the ratio of 
the systolic pressure in the ankle to the systolic pressure in the arm.  As well as being 
an indicator of peripheral arterial disease, there is evidence that it is a marker of 
generalized atherosclerosis.  There is evidence of a relationship between ABI and 
vascular risk factors and prevalent vascular disease, as well as a prospective 
relationship between ABI and future vascular risk.  Newman et al found that in the 
older adult participants of the Cardiovascular Health Study (CHS) there was an in 
inverse relationship between ABI and vascular risk factors, with those with a lower 
ABI having higher levels of vascular risk factors (Newman, Siscovick et al. 1993).  
There was a similar pattern seen between ABI and prevalent subclinical and clinical 
CVD. Thus, those with a lower ABI had a greater cardiovascular risk, even those 
with only a modest reduction in ABI.  More recent data from the Edinburgh Artery 
Study demonstrated that ABI was predictive of cardiovascular events and mortality, 
independently of conventional cardiovascular risk factors (Leng, Fowkes et al. 1996; 
Wild, Byrne et al. 2006).  These findings have been replicated by other European 




al. 2004; van der Meer, Bots et al. 2004).  More recently, a large meta-analysis by 
Fowkes et al was published and included data from over 48000 individuals.  It 
demonstrated that ABI may provide additional information over and above the 
Framingham risk score in prediction of cardiovascular events ((Fowkes FG, Murray 
GD et al. 2008).  Ankle brachial index has also been found to be similar to cIMT in 
terms of ability to predict future vascular risk and in fact combination of the two 
measures improve prediction (Price JF, Tzoulaki I et al. 2007).   
eGFR and microalbuminuria 
It has been established that individuals with chronic kidney disease (CKD) are more 
likely to die than develop renal failure, especially from cardiovascular disease (Keith 
DS, Nichols GA et al. 2004) and several recent studies also point to the estimated 
glomerular filtration rate (eGFR) as a marker of cardiovascular risk.  One study by 
Donfrancesco et al suggests that even a modest reduction of eGFR in a low risk 
general population can significantly increase the risk of incident cardiovascular 
disease and all-cause mortality (Donfrancesco C, Palleschi S et al. 2013).   A recent 
meta-analysis of 1 234 182 individuals from 21 different studies identified eGFR as 
being an independent predictor of all cause and cardiovascular mortality, with 
increasing hazard ratios as eGFR falls below 75mg/ml/1.73m2 (Chronic Kidney 
Disease Consortium 2010).   
Microalbuminuria, the excretion of albumin into the urine, has also been increasingly 
linked with cardiovascular disease.  Early work by Keen et al first described 
microalbuminuria in diabetic patients in 1969 (Keen H, Chlouverakis C et al. 1969).  
It was first linked to essential hypertension in 1974 by Parving et al, and in 1984, 
Mogensen et al published data  demonstrating that microalbuminuria could predict 
early mortality in maturity onset diabetes (Parving H-H, Mogensen CE et al. 1974; 
Mogensen CE 1984).  A 2007 review highlighted that there is evidence that 
microalbuminuria can risk prediction for CVD over and above traditional vascular 




identified microalbuminuria as an independent predictor of both all cause and 
cardiovascular mortality (Chronic Kidney Disease Consortium 2010).   
Interleukin-6 
Interleukin-6 is a pro-inflammatory cytokine secreted by T cells and macrophages in 
response to infection and trauma.  Its potential as a marker of vascular risk has been 
discussed in recent studies.  Several published studies have described the relationship 
between circulating levels of IL-6 and risk of cardiovascular disease (Ridker PM, 
Rifai N et al. 2000; Danesh J, Kaptoge S et al. 2008; Sattar, Murray et al. 2009).  The 
results of the Rancho Bernardo Study, published in 2012, highlight a strong 
association between circulating IL-6 and all-cause, CVD, cancer and liver related 
mortality (Lee JK, Bettencourt R et al. 2012).  They demonstrated a CVD risk factor 
adjusted HR of 1.38 (95% CI, 1.16–1.65) for CVD mortality. Adjustment for CRP 
levels attenuated the effects somewhat but the association between IL-6 and CVD 
mortality remained statistically significant.  A study of 121 Japanese participants 
identified that IL-6 was a strong independent predictor of future cardiovascular 
events (HR 2.80 (1.34–5.83) for highest tertile of IL-6) (Nishida H, Horio T et al. 
2011).   
C reactive protein 
CRP is a general marker of inflammation.  Measurement of high sensitivity CRP 
(hsCRP) has been incorporated into several guidelines for the assessment and 
management of those suspected of having CVD.  The relationship between hsCRP 
and CVD in men and women has been assessed in several studies (Kuller LH, Tracy 
RP et al. 1996; Ridker PM, Cushman M et al. 1997).  Its use over and above 
traditional risk factors has also been assessed (Ridker PM, Rifai N et al. 2002).  
However, more recent evidence suggests that the role of CRP in the prediction of 
cardiovascular risk may not be clear cut.  In 2006, Sattar and Lowe highlight that 
while early studies may have demonstrated that hs-CRP was predictive of vascular 
events over traditional risk factors, more recent studies show a far less strong 




CRP as well as the remaining questions regarding the causal role CRP plays lead 
them to conclude that the current focus should remain on traditional risk factors.   
NTproBNP 
Several studies have established the potential for NTproBNP (the pro-hormone 
fragment of brain-type natriuretic peptide secreted by the ventricular myocardium 
during ventricular stretch (Heart Protection Study Collaborative Group 2007) in the 
prediction of cardiovascular events.  A large study of 3199 individuals in the Heart 
Outcomes Prevention Evaluation (HOPE) Study (a secondary prevention population) 
assessed the incremental predictive value of a range of plasma biomarkers and found 
that while various inflammatory markers were related to future cardiovascular risk, 
the model containing NTproBNP as well as traditional cardiovascular risk factors 
was more predictive of future vascular events (HR1.72 per 1-SD change in 
NTproBNP) (Blankenberg, McQueen et al. 2006).  In a further study of 20536   
individuals in the MRC/BHF heart protection study, high NTproBNP levels were 
highly predictive of major cardiovascular events including MI, stroke and 
revascularisation (adjusted RR 2.26), coronary events (RR 3.09) and stroke (RR 
1.80) (Heart Protection Study Collaborative Group 2007).   
 
1.2 Type 2 diabetes and vascular disease  
Type 2 diabetes is a chronic condition characterised by hyperglycaemia, insulin 
resistance and relative insulin deficiency.  It occurs primarily in individuals aged 40 
years and above, in particular those who are overweight and obese.  As insulin 
resistance progresses, insulin production by the endocrine pancreas increases, to 
counter the effect.  Continual over-production of insulin leads to a failure of the 
pancreatic islet cells and plasma glucose levels begin to rise (Pearson ER and 
McCrimmon RJ 2014).  This is the stage at which Type 2 diabetes becomes clinically 
apparent, or detectable by laboratory tests, as blood glucose levels are no longer 




deficiency as the balance between available insulin and the effect of insulin 
resistance is disrupted.  A clinical diagnosis of Type 2 diabetes most often occurs 
after years of subclinical hyperglycaemia and consequently, at the point of diagnosis, 
the long term damage to end organs has already been initiated.  Long term 
complications include diabetic nephropathy, neuropathy, retinopathy (microvascular 
complications) and an increased risk of cardiovascular disease (macrovascular 
disease), and due to the long subclinical phase of Type 2 diabetes, these 
complications may be somewhat advanced at the point of diagnosis.   
 Pathology of Type 2 diabetes 1.2.1
Type 1 and Type 2 diabetes demonstrate differing pathologies.  Type 1 diabetes is 
thought to result from autoimmune destruction of beta cells, which once reaching a 
critical mass loss, results in a symptomatic lack of endogenous insulin production, 
requiring exogenous insulin treatment (Atkinson, Eisenbarth et al. 2014).  
Previously, it was believed that the beta cell loss in Type 1 diabetes was complete 
but more recent work has demonstrated persistent residual C peptide secretion, 
suggesting that in some individuals, there are remaining beta cells that may retain 
some function (Keenan, Sun et al. 2010).  In contrast, Type 2 diabetes displays a 
spectrum of insulin resistance and relative insulin deficiency.  In the early stages of 
disease, the pancreas continues to produce insulin, and as such, the initial 
management can range from simple diet and lifestyle modification, to a variety of 
pharmacological interventions, including metformin, sulphonylureas and insulin, as 
well as non-pharmacological management.  However, once the disease has 
progressed to levels of insulin resistance that outweigh the physiological effect of the 
available endogenous insulin, despite lifestyle modification and oral hypoglycaemic 
agents, exogenous insulin therapy and insulin sensitising medications are often the 
only remaining option.  
Insulin resistance  
Insulin resistance is defined as the resistance of target tissues to the action of insulin.  




islet cells in the pancreas are stimulated to release insulin in response to both the 
elevated plasma glucose and the effect of gut hormones.  In normal glucose tolerant 
people, insulin then acts upon tissues such through insulin receptors, activating a 
complex signalling cascade which promotes the transport of the glucose receptor 
GLUT4 to the cell surface, which in turn allows the uptake of glucose into the cells 
via these receptors (Pearson ER and McCrimmon RJ 2014).  This reduces the plasma 
glucose concentration and as it continues to fall, insulin production in the pancreas 
also falls.  This, along with regulation of hepatic glucose production, maintains 
plasma blood glucose at normal levels (Pearson ER and McCrimmon RJ 2014).   In 
people with Type 2 diabetes, the same level of insulin is unable to exert the same 
effect on glucose levels and so the pancreas increases insulin production to 
compensate.  The pathology underlying insulin resistance is complex.  It is currently 
thought that there may be a genetic basis to insulin resistance and there is strong 
evidence in favour of this, with a 58% concordance of development of Type 2 
diabetes in twins (Newman B, Selby JV et al. 1987). 
Insulin resistance itself is related to a number of cardiovascular risk factors, 
including hypertension, central obesity and dyslipidaemia.  This constellation of 
conditions is often referred to as the Metabolic Syndrome (Pearson ER and 
McCrimmon RJ 2014).  Visceral obesity in particular seems to be associated with 
insulin resistance.  Intra-abdominal adipose tissue is metabolically active and 
produces cytokines such as TNF-α and IL-6, which disrupt the action of insulin in 
adipose tissue.  Other conditions in which insulin resistance is affected include 
infection, in which insulin resistance is also mediated by TNF-α.  Visceral adiposity 
is also associated with the development of non-alcoholic fatty liver disease (NAFLD) 
and leads to the production of excess free fatty acids which increase hepatic glucose 
production and can lead to insulin resistance.   
Insulin deficiency and pancreatic beta cell dysfunction 
The second component thought to underpin the pathology of Type 2 diabetes is a 




previously discussed, the pancreatic pathology in Type 2 diabetes is not the same as 
that of Type 1 Diabetes, and whilst there is a failing of the pancreatic beta cells, there 
is rarely such a complete failure and most people with Type 2 diabetes continue to 
produce insulin in some quantity.  The resulting effect is a relative deficiency of 
insulin, as resistance to insulin causes a requirement for the pancreas to overproduce 
insulin to compensate for the increased demands to produce the same effect as in 
normal glucose tolerant individuals. However, many people with insulin resistance 
can continue to produce enough insulin to counteract the resistance without 
developing diabetes (Weyer C, Bogardus C et al. 1999) . An example of this which is 
often used is that of an obese person with insulin resistance who does not go on to 
develop diabetes (Gerlich JE 1999).  In the broadest terms, those who do go on to 
develop diabetes, the ability to produce insulin in response to resistance decreases 
with time due to a progressive loss of beta cell function.  At this point, insulin 
resistance and demand exceeds production, which results in hyperglycaemia and the 
development of diabetes (Buchanan TA 2001). 
The pathology underlying pancreatic beta cell insufficiency is not well understood.  
Several hypotheses have been put forward, including the effects of glucose toxicity 
and lipotoxicity on reduced beta cell mass.  One theory suggests that there is a failure 
of receptors in the pancreas that respond to rising glucose levels and so pancreatic 
beta cell mass does not increase in response (Kasuga M 2006).  However, there is 
believed to be more than just loss of beta cell mass.  The role of beta cell dysfunction 
in Type 2 diabetes has recently been reviewed by Ferrannini and Mari (Ferrannini 
and Mari 2014).  They highlight that in Type 2 diabetes, insulin resistance is 
associated with several beta cell function abnormalities.  Firstly, they suggest that 
there is increased fasting insulin secretion and total stimulated insulin output (as a 
result of hyperglycaemia) and that with time, there is a reduction in the total insulin 
output.  Further to this, reduction in glucose sensitivity of the beta cell is thought to 
be a key part of beta cell defect, and in addition, they highlight that a reduction in the 
incretin effect (increased insulin production in response to oral glucose loading) is 




reduction in the ability of the beta cells to respond rapidly to changes in glucose 
levels (rate sensitivity).  Ferrannini describe these changes as “predominantly 
functional and potentially reversible”,  
Resulting hyperglycaemia 
Hyperglycaemia is the resultant end product of insulin resistance and insulin 
deficiency.  As insulin resistance worsens and eventually, pancreatic insulin 
production reduces, blood glucose levels start to rise.  The effect of hyperglycaemia 
on body physiology is wide and varied and is responsible for many symptoms of 
diabetes, including polydipsia & polyuria, visual problems, fatigue, weight loss; poor 
wound healing or recurrent infections, dry mouth & skin; tingling in feet or heels, 
erectile dysfunction, cardiac arrhythmia, stupor, coma and seizures.  The classical 
triad of polydipsia, polyuria and polyphagia are usually the key symptoms of 
hyperglycaemia and are a common presentation of Type 1 diabetes, along with 
weight loss.  While acidosis is common at presentation in Type 1 (diabetic 
ketoacidosis), it is becoming increasingly so for those with Type 2 diabetes (hyper-
osmolar non-ketotic acidosis (HONK)).  Ketosis is usually absent in Type 2 diabetes 
as there is still some residual insulin production, which prevents lipolysis from 
occurring, leading to production of ketones (Pearson ER and McCrimmon RJ 2014).   
 Risk factors and frequency of Type 2 diabetes in the UK 1.2.2
There is no single identified trigger point for the development of Type 2 diabetes.  
Most commonly, there is a complex multifactorial pathway that leads to an eventual 
diagnosis.  A variety of lifestyle factors can precede the development of diabetes 
(table 1-2).  These risk factors are very similar to those of cardiovascular disease and 
the metabolic syndrome, a cluster of risk factors that put an individual at increased 




Table 1-2 Risk Factors for Type 2 Diabetes 
Age > 45 years 
Obesity (especially central obesity) 
Impaired glucose tolerance 
Previous gestational diabetes  
Family history of diabetes 
Given birth to a baby weighing more than 9 pounds  
HDL cholesterol < 35mg/Dl 
Plasma triglycerides > 250 mg/Dl 
High blood pressure ≥140/90 mmHg 
Low activity level (exercising less than 3 times a week) 
Metabolic syndrome 
Polycystic ovarian syndrome 
Ethnicity 
 
In October 2011, the Quality and Outcomes Framework (QOF) provided statistics on 
the prevalence of diabetes (both Type 1 and Type 2) in the UK and these were 
reported by Diabetes UK (table 1-3).  In Scotland, the estimated prevalence of 
diabetes in adults over 17 years of age was 4.3% (n=223,494), with a UK average of 
4.45% for the period April 2010-March 2011.  NHS Lothian had a prevalence of 
3.67%, just below the Scottish and national averages (Quality & Outcomes 
Framework 2010-2011).  The prevalence of diabetes has increased in recent years, 
with prevalence in the UK in 2006 estimated at 3.54% (Diabetes UK), with a year on 
year increase evident from QOF data.  In 2004, the WHO estimated worldwide 
prevalence of diabetes for all ages in 2000 was 2.8% but they project that by 2030, 
this will have risen to 4.4% (Wild, Roglic et al. 2004).  Thus, it is evident that 
diabetes poses, and will continue to pose, a significant challenge for health care 




Table 1-3 Prevalence of Diabetes in the UK (Source: Diabetes UK) (Diabetes UK 2011) 
Country Prevalence Number of people 
England  5.5 % 2,455,937 
Northern Ireland  3.8 % 72, 693 
Scotland  4.3 % 223,494 
Wales  5.0 % 160, 533 
 
 Diagnosing Type 2 diabetes 1.2.3
The development of Type 2 diabetes occurs over a considerable period of time.  As 
insulin resistance worsens and pancreatic function begins to decline, patients often 
remain asymptomatic.  It is because of this that the diagnosis of Type 2 diabetes is 
most commonly made at a point of opportunistic screening, such as that done in GP 
practices, or when patients present to a hospital clinic with other medical problems.  
The presence of a raised glucose leads to follow up testing with an oral glucose 
tolerance test. Diagnosis in the UK is made following a fasting blood glucose of >7 
mmol/l or an oral glucose tolerance test OGTT of >11mmol/l 2 hours after glucose 
loading, in addition to symptoms of diabetes (World Health Organization 2006).  If 
fasting glucose is <7mmol/l but OGTT is between 7.8 and 11.1mmol/l, a diagnosis of 
impaired glucose tolerance is made.   In 2011, the WHO produced updated 
guidelines for the diagnosis of diabetes, stating that HbA1c can be used to diagnose 
type 2 diabetes in certain patient groups (World Health Organization 2011).  
However there are constraints on the patients in which this testing can be used and 
additional guidance regarding management in cases where HbA1c is not raised and 
yet there is still a clinical suspicion of diabetes.  
Although detection of Type 2 diabetes in this way can lead to diagnosis before 
symptoms appear, there can already be damage to the retina, kidneys and coronary 
arteries.  In some cases, an abnormality in these organs is what prompts testing for 




vision.  Occasionally, Type 2 diabetes presents acutely with the uncontrolled 
symptoms of diabetes.  These are: excessive thirst, polyuria, polydipsia, nocturia, 
fatigue, weight loss and non-healing wounds.  This is similar to the presentation of 
Type 1 Diabetes, but as discussed earlier, often there is no acidosis at diagnosis, 
although patients with Type 2 diabetes can present with similarly raised glucose 
levels. 
 Microvascular complications of Type 2 diabetes 1.2.4
The complications of Type 2 diabetes are manifest in many different anatomical beds 
and can be broadly categorised as microvascular, macrovascular and neuropathic.  In 
terms of cardiovascular disease, both microvascular disease and macrovascular 
disease are of importance.  The microvascular complications of Type 2 diabetes are 
most commonly manifest in the renal, retinal and nervous systems (Fowler MJ 
2008).   
Diabetic retinopathy 
Diabetic retinopathy is the most common microvascular complication of diabetes. 
Duration and severity of hyperglycaemia are the main factors underlying the 
development of retinopathy.  In addition, the UKPDS study published data 
suggesting that hypertension may also play a role in some patients with Type 2 
diabetes. In some cases, the development of retinopathy starts before a diagnosis of 
diabetes has been made (Fong DS, Aiello LP et al. 2004).  Aldose reductase, 
glycoproteins, oxidative stress and growth factors have all been implicated in the 
development of diabetic retinopathy (Fowler MJ 2008).   
Diabetic neuropathy 
Diabetic nephropathy is the leading cause of renal failure in the USA (Fowler MJ 
2008).  Similarly to diabetic retinopathy, almost 7% of people with Type 2 diabetes 
may have microalbuminuria at the point of diagnosis of diabetes (Gross JL, De 
Azevedo MJ et al. 2005).  Glucose control has strong associations with the 




disease prevention.  In addition treatment with ACE inhibitors has been shown to 
reduce development of nephropathy in people with Type 2 diabetes but not those 
with Type 1 diabetes (Gerstein HC 2000; Gross JL, De Azevedo MJ et al. 2005).   
Diabetic neuropathy is another complication that is related to both the magnitude and 
duration of hyperglycaemia.  The American Diabetes Association describes 
peripheral neuropathy in diabetes as a diagnosis of exclusion (American Diabetes 
Association - Standards of Medical Care in Diabetes 2011).  Diabetic neuropathies 
can take a variety of forms, including sensory and autonomic neuropathy, and many 
people with neuropathy go on to undergo amputation as a result of the increased risk 
of foot ulceration and injury in cases of neuropathy.  They cause significant 
morbidity and affect many difference body systems, including the digestive tract and 
cardiac function in addition to sensory dysfunction (Fowler MJ 2008).   
 Macrovascular complications of Type 2 diabetes 1.2.5
The Task Force on Diabetes and Cardiovascular Diseases of the European Society of 
Cardiology (ESC) and of the European Association for the Study of Diabetes 
(EASD) published a guideline on diabetes and cardiovascular disease.   In this, they 
highlight that people with diabetes have a 2 to 3 times higher risk of developed 
coronary artery disease than those people without diabetes (Rydén, Standl et al. 
2007). They highlight that there is a difference in cardiovascular risk between people 
with Type 1 and Type 2 diabetes, noting that CVD caused 44% of mortality in 
people with Type 1 diabetes, compared with 52% in people with Type 2 diabetes 
(Morrish, Wang et al. 2001). 
Macrovascular complications of Type 2 Diabetes include coronary artery disease, 
stroke and peripheral vascular disease.  The pathology that underlies macrovascular 
disease in diabetes is atherosclerosis.  In those people with diabetes, development of 
atherosclerosis seems to be accelerated and several major factors have been 
postulated as possible mechanisms, including hyperglycaemia, dyslipidaemia and 




2008).  Endothelial cells, smooth muscle cells and platelets can all be affected by 
these factors through a variety of mechanisms, resulting in endovascular injury.  
Endothelial production of nitric oxide is one of the key factors involved in vascular 
health.  Nitric oxide has a vital role in the control of vascular relaxation, through its 
promotion of vessel dilation (Moncada S, Palmer RM et al. 1991; Moncada S 1999).   
Additionally, nitric oxide plays a role in several other steps that are protective of the 
vessel wall.  It inhibits platelet activation, reduces leucocyte adhesion to the 
endothelium and subsequent migration into the vessel wall (which reduces 
inflammation) and lessens smooth muscle cell proliferation and migration (Moncada 
S, Palmer RM et al. 1991; Moncada S 1999; Verma S and Anderson TJ 2001).  In 
diabetes, nitric-oxide mediated vasodilation is impaired and nitric oxide mediated 
vasodilation is limited while platelet aggregation is increased (Fowler MJ 2008).   
Chronic subclinical inflammation has also been implicated in the development of 
both atherosclerosis and Type 2 diabetes.  The Hoorn Study investigated the link 
between endothelial dysfunction and low grade inflammation and cardiovascular 
mortality in people with Type 2 diabetes (de Jager J, Dekker JM et al. 2006).  The 
basis for the work they undertook was the commonly held belief that endothelial 
dysfunction and low grade inflammation can explain why deteriorating glucose 
tolerance is associated with cardiovascular events in those with Type 2 diabetes.   
The association between diabetes and the metabolic syndrome also plays a key role 
in the development of cardiovascular disease, as the major risk factors for Type 2 
diabetes are the same as those for cardiovascular disease.  People with Type 2 
diabetes have an increased risk of cardiovascular disease, such that people with 
diabetes and no previous history of myocardial infarction have as a high a risk of 
future myocardial infarction as people without diabetes who have a previous 
myocardial infarction (Haffner, Lehto et al. 1998).  This has led to Type 2 diabetes 




Metabolic syndrome  
Typically, individuals with Type 2 diabetes display a poorer cardiovascular risk 
factor profile than those in the general population.  The complex interplay between 
Type 2 diabetes, cardiovascular disease and the metabolic syndrome goes some way 
to explaining this phenomenon.  The metabolic syndrome is a group of risk factors 
that, collectively, lead to an increased risk of developing cardiovascular disease, 
Type 2 diabetes and liver disease.  The components necessary for a diagnosis of 
metabolic syndrome include: dyslipidaemia, increased body fat (in particular central 
obesity), insulin resistance and hyperglycaemia, fatty liver disease, hypertension, 
raised inflammatory and pro-thrombotic markers and endothelial dysfunction 
(Kalofoutis C, Piperi C et al. 2007).  Following initial work done in the late 1980s by 
Reaven (Reaven 1988) where he described “syndrome X”, the original theory has 
been extended to suggest that the underlying pathology of the metabolic syndrome 
lies in the presence of obesity, which leads to insulin resistance, however, the exact 
mechanism underlying the syndrome is still unidentified (Ferrannini, Natali et al. 
1997).    
The metabolic syndrome is commonly diagnosed by the International Diabetes 
Federation (IDF) and American Heart Association (AHA) criteria (Alberti, Eckel et 
al. 2009), which are demonstrated in table 1-4.  These criteria are very similar to the 
criteria for the diagnosis of Type 2 diabetes, reflecting the close relationship between 
the two. 
Table 1-4 IDF/AHA criteria for diagnosis of metabolic syndrome 
3 or more of the following: 
 Increased waist ethnicity specific waist circumference  
 Body mass index (BMI) above 30 kg/m2,  
 Blood pressure above 130/85 or treatment for hypertension 
 Triglycerides above 1.7 mmol/L or treatment for this abnormality 
 HDL cholesterol <1.03 mmol/L in men and <1.29 mmol/L in women or treatment 
for this abnormality 





The metabolic syndrome underlies the pro-atherogenic risk factor profile displayed 
in people with diabetes.  In addition to impaired glucose regulation, people with 
Type 2 diabetes are more like to be hypertensive and centrally obese, have an 
adverse lipid profile, microalbuminuria and raised inflammatory markers (Kalofoutis 
C, Piperi C et al. 2007).  50% of people with diabetes are hypertensive at the time of 
diagnosis (Stults and Jones 2006), while the lipid profile often includes low 
circulating HDL cholesterol, with a moderate elevation in triglyceride levels (Solano 
and Goldberg 2006).   Diabetes itself causes a 2-4 fold increase in the risk of CVD, 
and in the presence of concomitant hypertension, total mortality and stroke, that risk 
is doubled, while the CHD risk is tripled, and the development of microvascular 
complications is hastened (Reboldi, Gentile et al. 2009).   
The association of diabetes with the metabolic syndrome is strong and may account 
for the increased prevalence of cardiovascular disease in this group (Isomaa, 
Almgren et al. 2001; Stern MP, Williams K et al. 2004). 
 Managing cardiovascular risk in Type 2 diabetes 1.2.6
In the UK, guidelines from NICE and SIGN provide guidance to clinicians for the 
management of cardiovascular disease in people with Type 2 Diabetes (NICE CG87 
2008; SIGN 116 2010).  As people with Type 2 diabetes are known to be at increased 
risk for CVD, the overarching principal is one of aggressive management of any 
pertinent vascular risk factors, to the same extent as secondary prevention of CVD in 
the non-diabetic populations.  Risk factors are generally managed using the same 
agents and targets for blood pressure and lipids are broadly the same as the general 
population,  unless complications co-exist (NICE CG87 2008), for example, blood 
pressure targets are 140/80mmHg unless renal, eye or cerebrovascular disease are 
present at which point in becomes 135/85mmHg.     
There are differing opinions in the literature concerning the value of cardiovascular 
risk prediction in individuals with diabetes.  Because individuals with diabetes 




several guidelines recommend managing all people with diabetes as high risk.  
However, other guidelines take a different approach, whereby there is considered to 
be a spectrum of risk with the population of diabetes that still requires quantification. 
They support the argument that it is important to perform risk prediction in people 
with Type 2 diabetes because as in the general population, there is evidence that 
intensive therapy can reduce cardiovascular and all-cause mortality (Gæde, Lund-
Andersen et al. 2008).  Unfortunately, not all health systems can afford a blanket 
policy of treatment and so varying elements of risk prediction must be performed in 
different populations to identify those at highest risk.  As discussed in chapter 1, 
unlike in the general population, the use of risk prediction scores in Type 2 Diabetes 
is not clear cut, and is limited by their accuracy in this population.  However, we 
know that people with Type 2 diabetes have an increased risk of cardiovascular 
disease.  Therefore, the development of scores specifically for use in people with 
Type 2 diabetes has been tackled by several groups, including the UK Prospective 
Diabetes Study (UKPDS).   
Some clinical guidelines recommend that people with Type 2 Diabetes be considered 
as high risk from the point of diagnosis.  The Scottish Intercollegiate Guidelines 
Network (SIGN) published a guideline on assessing cardiovascular risk (SIGN 97 
2007).  This guideline, advised that adults with Type 2 diabetes who are over the age 
of 40 years do not require risk assessment, as they are automatically at a high CVD 
risk (>20%) due to their clinical history.  The risk assessment that they discuss is 
based on risk scores alone, and does not include the use of adjuncts such as intima 
media thickness.  The 2009 NICE guidelines for managing CVD risk in people with 
Type 2 diabetes suggest that people with Type 2 diabetes should be considered as 




 is not overweight  
 is normotensive (< 140/80 mmHg in the absence of antihypertensive 
therapy)  
 does not have microalbuminuria  
 is a non-smoker 
 does not have a high-risk lipid profile  
 has no history of cardiovascular disease and  
 has no family history of cardiovascular disease. (NICE Clinical Guideline 87 
2009) 
 
In this situation, they recommend that it would be of use to perform annual 
cardiovascular risk estimation using the UKPDS risk score in people who meet these 
criteria (NICE CG87 2008) (however, it should be noted that the advice in this 
guideline was updated in 2014 to recommend that the QRisk2 score be used for risk 
assessment in people with diabetes (NICE CG 181 2014)).  The American Diabetes 
Association (ADA) states only that there should be assessment of risk factors 
(American Diabetes Association - Standards of Medical Care in Diabetes 2011).  
Guidelines from the International Diabetes Federation recommend the use of 
diabetes specific risk scores (International Diabetes Federation 2005), while others 
recommend scores such as Framingham or DECODE (Rydén, Standl et al. 2007).   
In 2009, Chamnan et al published a systematic review focusing on cardiovascular 
risk assessment scores in people with diabetes, in which they examined scores that 
were developed in both individuals with diabetes and those developed in a general 
population (Chamnan P, Simmons RK et al. 2009).  They highlight that there is 
evidence of improvement in the risk of fatal and non-fatal cardiovascular events in 
people with diabetes following multifactorial interventions, such as the Steno-2 study 
(Gæde, Vedel et al. 2003; Gæde, Lund-Andersen et al. 2008).  However, for chiefly 
economic reasons, many countries have to practice a rationing approach to managing 
cardiovascular risk, with risk assessed prior to prescription of preventive therapies, 
allowing the highest risk patients to be prioritised for treatment (Chamnan P, 




in people with diabetes.  The authors also highlight two other reasons for the use of a 
risk prediction tool (Chamnan P, Simmons RK et al. 2009).  Firstly, they may be 
used to provide an individual’s risk (absolute risk) and secondly, they may be used to 
encourage individuals to improve their lifestyle, in which case the score is required 
to reflect the modifiable risk, rather than a risk predicted from fixed variables. 
 Cardiovascular risk prediction scores in Type 2 1.2.7
diabetes 
Several groups have attempted to develop risk algorithms that are specific to the 
diabetic population using diabetic cohorts in the development, in order to produce a 
risk score that might be more accurate in this group.  Although there have been 
several scores developed that have good discriminatory values, there is still no strong 
evidence as to which score is best suited for use in Type 2 diabetes (van Dieren S, 
Beulens JWJ et al. 2012).   
Two major reviews have summarised the main risk scores used in and developed for 
diabetic populations (Chamnan P, Simmons RK et al. 2009; van Dieren S, Beulens 
JWJ et al. 2012) (the latter providing what is essentially an update of the former).  
The authors examined several different risk scores, including scores developed both 
in general populations and diabetic populations, in addition to reviewing scores that 
have been validated in diabetic populations.  They noted that the predictive ability of 
scores varied in different populations and conclude that scores developed in general 
populations were likely to underestimate risk in people with T2DM.  Similarly, those 
scores developed in diabetic populations required to be better validated in other 
populations before definitive conclusions can be made as to their use.   
Their overarching conclusion of both reviews is that it may be more useful to have 
population specific scores rather than one universal score for all populations.  This 
would seem to be a sensible approach to risk prediction.  Some of the scores that 





Risk scores developed in diabetic populations 
There are several examples of risk scores that have been developed in diabetic 
populations rather than in general populations.  The most commonly included risk 
factors are age, sex, duration of diagnosed diabetes, HbA1c and smoking (van Dieren 
S, Beulens JWJ et al. 2012).   
An early score by Yudkin et al used a sample of 2138 American subjects with Type 2 
diabetes to develop a model for predicting CHD risk over 10 years, including six 
predictor variables in the model (Yudkin and Chaturvedi 1999).  Several years later, 
the UKPDS risk engine was developed in Oxford, and was based on data from 53 
000 patient years from individuals with Type 2 diabetes enrolled in the UKPDS 
study (Stevens RJ, Kothari V et al. 2001).  UKPDS found that previous risk scores 
were less accurate in people with diabetes and the use of simply a dichotomous 
variable for diabetes or glycaemia in previous risk scores was identified as a target 
for change.  The authors instead used HbA1c as a diabetes marker and additionally 
replaced age with age-at-diagnosis and time since diagnosis of diabetes.  The 
inclusion of these variables aimed to address the role that each plays in the 
development of the complications of diabetes (Stevens RJ, Kothari V et al. 2001).  
The first version was developed in a population of 4540 men and women with Type 
2 Diabetes but no history of cardiovascular disease (Stevens RJ, Kothari V et al. 
2001).  An additional version that is specific for stroke was developed in 4549 people 
with T2DM and no previous stroke (Kothari V, Stevens RJ et al. 2002).    
The ARIC investigators also published a model developed in people with diabetes 
(Folsom AR, Chambless LE et al. 2003).  They based the model on 1273 subjects 
with Type 2 diabetes in the US and it predicted risk of CHD over 10 years.  They 
achieved an area under the curve of 0.76 for men and 0.78 for women.  Another 
score that predicted CHD risk (although over only 5 years) was the DARTS score 
(Diabetes Audit and Research in Tayside, Scotland) (Donnan, Donnelly et al. 2006).  
This score included a similar number of predictors to the initial ARIC score and the 




The Hong Kong Diabetes registry was used to create 3 scores – one for stroke (Yang, 
So et al. 2007), one for CHD (Yang, So et al. 2008) and one for heart failure (Yang, 
Ma et al. 2008).  These studies were published on data from just over 7000 people 
with Type 2 diabetes living in China.  They predicted risk over 5 years and achieved 
AUC ranging from 0.70 for CHD to 0.85 for heart failure.  These results were similar 
to those of the Swedish National Diabetes Register (Cederholm, Eeg-Olofsson et al. 
2008).  11,646 people with Type 2 diabetes were used to develop the score using a 
Cox model and it predicted the risk of CVD over a 5 year period.  The reported AUC 
was 0.70.   
More recently a study published in New Zealand developed a risk model in a cohort 
of people with Type 2 diabetes living in New Zealand (Elley, Robinson et al. 2010).  
CVD and CHD risk was predicted over 5 years and used 10 predictors.  The AUC for 
CVD was 0.68 and for CHD 0.71.  A further score from Australia by Davis et al as 
part of the Freemantle diabetes study (Davis, Knuiman et al. 2010) reported an AUC 
of 0.80 in the prediction of CVD.  Additionally, the ADVANCE collaborative group 
(Kengne, Patel et al. 2011) reports the use of 10 predictors to create a cox model that 
predicted 4 year risk of CVD.  A similar AUC was seen in both the initial testing and 
validation in an independent cohort (0.71 and 0.69 respectively).   
Scores externally validated in a diabetic population 
Van Dieren et al highlight in their comprehensive review article that of the 12 risk 
scores they identified that have been developed in diabetic populations, and the 33 
general population risk scores that account for diabetes, 31% had been externally 
validated in a general population (van Dieren S, Beulens JWJ et al. 2012), including 
the ADVANCE, Fremantle, DCS, DARTS, UKPDS, HMRS, Framingham, CUORE, 
Decode and PROCAM scores.    There was great variation in the discriminative 
ability of these scores in diabetics, including the even the UKPDS and Framingham 
scores, which had AUC ranging from 0.65-0.76 for the UKPDS score and 0.56-0.80 




Dieren S, Beulens JWJ et al. 2012), suggesting that risk scores do not perform well 
in patients with diabetes.   
The poor performance of risk scores in people with diabetes, as well as the increased 
incidence of cardiovascular disease in this population, has opened the door to 
exploration of methods to improve risk prediction in people with diabetes.  Novel 
biomarkers such as carotid intima media thickness (which has been extensively 
studied in the general population as a marker of vascular risk) and carotid plaque, are 
starting to be explored in addition to traditional cardiovascular risk factors 
(Yamasaki Y, Kodama M et al. 2000; Bernard S, Sérusclat A et al. 2005).   
 
1.3 Carotid ultrasound and cIMT 
Visualisation of the carotid artery using ultrasound is regularly undertaken as part of 
investigations for transient ischaemic attacks (TIA) although the primary objective in 
that situation is usually assessing blood flow in the vessel and any stenosis resulting 
from atherosclerosis of the wall, with a view to performing carotid endarterectomy.  
However, in 1984 Pignoli et al suggested that measuring the thickness of the carotid 
wall may be a more accurate measure of atherosclerosis given that atherosclerosis is 
primarily a pathology of the artery wall and there is often luminal expansion to 




 Anatomy of the neck 1.3.1
 
Figure 1-5 Arteries of the neck (reproduced from 
http://www.texasheartinstitute.org/HIC/Topics/cond/CarotidArteryDisease.cfm) 
 
The carotid arteries are the major arteries of the neck (figure 1-5).  The 
brachiocephalic trunk branches from the aorta, and bifurcates into the right common 
carotid artery and the right subclavian artery.  The left common carotid artery and the 
left subclavian artery are branches of the aortic arch itself.  On both the right and left 
sides, as the common carotid artery extends upwards into the neck, it bifurcates into 
the internal and external carotid arteries, with the internal artery entering the skull to 
provide the cerebral blood supply, and the external artery supplying structures 
external to the skull. 
The three key anatomical areas that are considered most important when measuring 
carotid intima media thickness are the common carotid artery, the carotid bifurcation 
and the internal carotid artery.  The common carotid artery is the most accessible 
portion of the carotid artery in terms of surface anatomy.  It runs along the course of 
the sternocleidomastoid muscle on the anterior aspect of the neck and as such, it is 
ideally located for non-invasive assessment by ultrasound.  The bifurcation is located 
at the level of the thyroid cartilage, and the internal carotid extends up behind the 




 Structure & pathology of the carotid artery wall 1.3.2
 
Figure 1-6 Diagrammatic representation of the anatomical structure of the carotid artery wall 
 
The carotid wall shares common anatomy with all arterial structures.  The wall 
comprises three layers – the tunica intima, tunica media and tunica adventitia (figure 
1-6) – with each layer performing a unique role.  The intima is the layer adjacent to 
the lumen of the vessel and consists of a layer of endothelial cells and an elastic layer 
known as the internal elastic lamina.  The endothelium is the biologically active 
section of the intima and it is supported by the elastic lamina.  The media is primarily 
composed of smooth muscle cells surrounded by a layer of extracellular matrix 
comprising elastin, collagen and proteoglycans.  The media has an important 
structural role but is also responsive to intimal injury, when smooth muscle cells 
proliferate and it promotes inflammatory cell migration.   The external elastic lamina 
separates the media from the adventitia.  The adventitia is primarily composed of 




The intima media thickness is defined as the distance between the luminal edge of 
the intima and the adventitial edge of the media (Wikstrand J 2007) however, the 
pathology underlying the thickening of the intima media complex is not fully 
understood.   Thickening of the intima media complex is most often associated with 
atherosclerosis whereas thickening of the media is often due to hyperplasia related to 
shear stress on the vascular wall as a result of hypertension (Johnsen SH and 
Mathiesen EB 2009).  Therefore, thickening of the intima-medial complex could be 
due to either or both of these processes, highlighting that it is not well defined 
whether or not cIMT thickening is a precursor of atherosclerosis or simply a response 
to stress on the wall. This is further complicated because when measuring cIMT, it is 
not always possible to delineate the intima from the media and it is therefore difficult 
(or perhaps impossible) to attribute any thickening to one or the other processes.   
 Ultrasound measurement of cIMT 1.3.3
Traditionally, the detection and quantification of atherosclerotic disease in arteries 
was done by invasive methods, including contrast angiography.  However, since the 
mid-1980s, work has been advancing to develop reliable, non-invasive methods for 
the quantification of carotid intima media thickness, as well as atherosclerotic 
plaques.  
Ultrasound modes used in measurement of cIMT 
There are several different modes of ultrasound that have a variety of different uses.  
A-mode ultrasound is used primarily for therapeutic ultrasound treatment and is not 
usually involved in imaging.  In B mode ultrasound, a linear array of transducers 
simultaneously scans the desired area of investigation, allowing a 2 dimensional 
picture to be formed on screen.  It is this mode that is most commonly used in 
diagnostic ultrasound.  Current technology allows for real time image analysis, 
producing a moving 2D image on screen.  M mode ultrasound, which is a form of 
ultrasound that detects motion, is primarily used in echocardiography and fetal 




Doppler mode ultrasound is perhaps most commonly associated with carotid 
imaging.  Measurement and visualisation of blood flow in vessels of the neck is 
made possible by utilising the principles of the Doppler Effect.  This mode of 
ultrasound is commonly used when investing stenosis of the carotid artery in patients 
affected by transient ischaemic attacks (TIA).  It is also possible to discern the 
outline and luminal projection of arterial wall plaques.  However, it does not provide 
a detailed assessment of plaque thickness and cannot provide any more information 
regarding the vessel wall. B mode ultrasound however, can provide a more detailed 
image of the artery wall, hence its use in the measurement of cIMT.  It enables direct 
visualisation of the artery wall (Pignoli P 1984), enabling measurement of intima-
media thickness.   
Use of B mode ultrasound in measuring cIMT 
The initial advances in this field were made by Pignoli et al.  The group looked at 
measuring cIMT in vitro and in vivo, using B mode ultrasound.  Their initial work, 
published in 1984, demonstrated a significant association between pathological 
measurement of cIMT and B mode ultrasound measurement of the complex.  This 
original study measured cIMT in a small number of normal and moderately diseased 
arteries in vitro (Pignoli P 1984).  They continued to take this work forward by 
examining the relationship between measurements made both in vitro and in vivo, 
and determining what anatomical structures account for what images on the 
ultrasound. 
The characteristic B mode image of the intima media complex of the arterial wall is 
of a “double line pattern”.  This pattern consists of two parallel echogenic lines that 




Figure 1-7 Graphic representation of B mode ultrasound of cIMT 
 
In figure 1-7, the first line of the double echo represents the intima of the artery wall 
and the leading edge of this structure (marked A) represents the intimal-luminal 
interface.  The area of hypogenicity (black section) represents the media of the wall 
and finally the second line of the echo (second light grey section) represents the 
adventitia.  The edge between the media and adventitia is called the media-
adventitial interface (marked B).  
Pignoli et al took specimens from men aged 20-74, and included a mix of normal and 
pathological specimens.  They measured the intima media thickness, in a marked 
region of the artery wall, using both gross pathology and histology.  Once this was 
done, they prepared the arterial segments and placed them in water tanks.  They then 
measured the same segment of the arterial wall using a B mode ultrasound.  This 
enabled them to compare histological and pathological cIMT with that measured by 
B mode ultrasound.   
The next step was to measure in situ specimens in cadaveric specimens.  They 
measured the cIMT by B mode ultrasound in common carotid arteries that were 













significantly different in the in situ and excised specimens.   This was then extended 
to assessing cIMT in 10 living subjects.  This demonstrated that the characteristic 
“double line pattern” was visible in living specimens and that the mean cIMT was 
similar to that found in the in vitro study. 
And so, Pignoli et al had shown B mode ultrasound to be a valid and useful tool in 
measuring cIMT in vivo.  It was this work that laid the foundations for the use of B 
mode ultrasound as a reliable, and importantly, non-invasive method for such 
measurements.  These findings were further confirmed by Persson et al in 1994 
(Persson J, Formgren J et al. 1994).  The group compared measurement of cIMT 
using B mode ultrasound with the same distance measure using light microscopy.   
They found that cIMT measured by B mode ultrasound correlated highly with that 
defined by light microscopy (r 0.82, p<0.001) – however, one must bear in mind that 
whilst there is a good correlation between these measures, this does not necessarily 
mean that there will be good agreement as even poorly agreeing measures can 
produce good correlation (Bland JM and Altman DG 1986).  They noted that cIMT 
measured by light microscopy was consistently smaller, however, this was attributed 
to tissue shrinkage (Persson J, Formgren J et al. 1994). 
The main advantages of using ultrasound for this purpose lie in its flexibility, low 
cost and low risk.  There is little to no long term effects of ultrasound exposure and 
new technological advances mean that ultrasound can be easily done at the bedside if 
required.  Compared to other imaging modes, ultrasound is also inexpensive, making 
it more accessible.  The major disadvantage to its use is unreliable penetration of 
deep structures in obese patients.  Whilst not a major concern when imaging the 
neck, this must be considered, especially given the relationship between obesity and 
potential vascular risk. 
The carotid artery branches from the common carotid artery into the internal and 
external carotid artery.  The point of branching is known as the carotid bifurcation.  




position in the neck.   The bifurcation and internal carotids are more difficult to 
visualize due to their anatomical obscurity and consequently they cannot be 
measured in all individuals.  Kanters et al found that there can be a higher proportion 
of missing values when cIMT is measured in these areas, as well as a higher degree 
of measurement variation (Kanters SD, Algra A et al. 1997).  A moderate correlation 
between cIMT at different sites was noted by Howard et al, however, cIMT at once 
site could not predict cIMT at another (Howard G, Burke GL et al. 1994).  This has 
led to the cIMT in the common carotid artery being favoured as a site of 
measurement due to ease of access and reliability.   
Summary measures of intima media thickness 
Despite the publication of various guidelines concerned with the measurement of 
cIMT, there is no unified summary measure of cIMT.  Because of the variety of 
protocols which studies use to measure cIMT, different methods are used to 
summarize cIMT (Lorenz MW, Markus HS et al. 2007).  The simplest of these is the 
mean – an average of all the measurements taken for cIMT.  For example, in the 
Edinburgh Type 2 Diabetes Study, 6 measurements were made in total (3 on the left, 
3 on the right).  The mean cIMT would be the mean of those 6 readings.  In other 
studies, it would be the mean of the mean cIMT at each segment of the carotid tree.  
In some cases, the maximum cIMT is used.  This too is often used to different effect 
in different studies.  In some, it is the higher of the mean of the left and mean of the 
right.  In others, it represents the mean of the maximum right and maximum left 
readings.  This heterogeneity leads to many difficulties when it comes to comparing 
studies of cIMT. 
 Measurement variation 1.3.4
Measurement variation is a problem which is widespread in all research 
methodology.  In epidemiological studies, error and variability can lead to bias and 




Physiological measurements are prone to variability from many sources, including 
the machine or equipment used and the subjective view of the individual taking the 
measurement.  In terms of carotid intima media thickness, variation can be 
introduced by the ultrasound machine used, the ultrasonographer taking the readings, 
the skill of the reader performing measurements using software after image 
acquisition and even the patient themselves.  The first of these – the ultrasound 
machine – is not of as much importance as it was previously.  Machines are built to 
an industry standard and error and variation are often due to selection of 
inappropriate settings (eg gain) or poor maintenance of machines.  Physical factors 
and anatomy of the patient contribute to variability in several ways. Firstly, a more 
physical than anatomical property, is movement of the carotid artery. In comparison 
to other arteries, there is relatively little movement of the carotid artery; nonetheless, 
this remains a source of error (Kanters SD, Algra A et al. 1997).  However, a more 
important factor to consider is the position of the carotid segments in the neck.  
Whilst the carotid is a very superficial artery, not all segments are as easily 
accessible by ultrasound as the common carotid.  Measurements of the internal and 
external carotids, and the carotid bifurcation, are more prone to missing data due to 
inaccessibility.  Several studies have documented this and the ACAP Study found 
that the CCA segments could be visualized in 99% of cases, the bifurcation 88% and 
the ICA 67%, which highlights the differences in accessibility of each of these 
segments (Espeland MA, Craven TE et al. 1996).  Part of this may be due to an 
inability of the patients to move into or maintain the position required for 
measurement of cIMT.   
The largest source of measurement error and variability however, is the sonographer 
and reader.  Human error is a major factor in many physiological measurements and 
no less so in cIMT measurement.  The actual imaging of the cIMT is usually 
undertaken by a sonographer.  They may or may not perform cIMT measurement 
there and then.  If not, the image is stored, either as a longitudinal image or as a 
video, and measurement is performed later by a reader (either the same sonographer 




who have measured cIMT have looked more specifically at variability in cIMT 
within their studies. An example would be the study by Salonen et al in 1991.  In this 
study, inter-observer variation was the main source of variability, with only 4% 
attributable to intra-observer variation (Salonen R, Haapanen A et al. 1991).  The 
findings of the Rotterdam study were similar.  They measured cIMT using the 
controls described above – a single radiographer and multiple off line readers - and 
demonstrated that 87% of variability in cIMT following repeat scanning was due to 
between-subject variation and 13% was due to inter-observer variation in both 
readers and sonographers (Bots ML, Mulder PG et al. 1994).  A study by Lundby-
Christensen et al examined reproducibility of cIMT in those with and without Type 2 
diabetes (Lundby-Christensen L, Almdal TP et al. 2010).  They found that 
reproducibility was good in both people with and without diabetes.   
As would be expected, it is easier to control for many of these sources of variation in 
a research setting than in clinical practice.  The use of simple measures such as a 
single radiographer making measurements, using the same machine for each 
participant and using several readers to perform offline measurements can all reduce 
variation; however assessment of cIMT measurement accuracy should be an 
important feature of any research study.   
 Automated edge detection software 1.3.5
Tackling measurement variation has led researchers to investigate a variety of 
techniques aimed at reducing measurement variation.  In clinical trials and 
epidemiological studies, it is usually relatively simple to have the same sonographer 
or reader perform measurements at each follow up, dependent on the length of the 
trial or study.  However, this is not as applicable in a clinical setting.  Work rotas, 
staff turnover and availability, and importantly, health care budgets all affect the 
availability of specific staff members for performing measurement of cIMT in 
specific patients.  And so, focus has fallen upon finding a way to remove this source 





Figure 1-8Automated edge detection of cIMT (reproduced from Robertson et al, Appendix F) 
 
 
There has been considerable interest in the development of automated and semi-
automated measurement protocols for cIMT measurement (figure 1-8).  By removing 
the human aspect of cIMT measurement, and replacing it with a computer algorithm, 
the inherent inter-reader variability could be removed.  However, finding an 
algorithm that is capable of analysing all scans of cIMT done on all types of 
ultrasound machine is a difficult task.  As such, many ultrasound machine 
manufacturers have developed their own in-house software to be used on their own 
machines.  These allow real time measurement of cIMT by the algorithm and remove 
human error.  However, many measurements are still made on machines on which 




There have been recommendations from both the ASE and Mannheim consensuses 
that edge detection software should be used where possible to make measurements of 
cIMT (Touboul PJ, Hennerici MG et al. 2007; Stein JH, Korcarz CE et al. 2008; 
Touboul PJ, Hennerici MG et al. 2012).  Initially, there were only programmes that 
were based on user dependent edge detection techniques.  However with time, there 
has been evolution from those which require a significant level of user input, to 
systems which use algorithms to allow user independent identification of the lumen-
intima interface and the media-adventitia interface of the cIMT. Several different 
methods are discussed in a 2010 review of computer aided cIMT measurement by 
Molinari et al (Molinari, Zeng et al. 2010). 
On ultrasound imaging, the adventitia and the lumen have differing pixel intensities, 
with the lumen having bright pixel intensity in comparison to the lumen. The 
underlying basis of edge detection software lies in the detection of this pixel gradient 
as the unique intensity profiles make both the lumen and adventitia easily identifiable.  
The intima media thickness is the area that lies between these 2 landmarks.  As 
described in the review by Molinari, several groups have approached this challenge 
from a number of different angles.  Liguori et al, who applied an edge detection 
technique, describe a measurement uncertainty of 0.02mm.  However, the major 
problems that existed with their approach were noise interference and that the system 
was not fully automated (Liguori, Paolillo et al. 2001).  More recent publications have 
also employed edge detection techniques using a gradient based algorithm have 
shown improved measurement error (Stein, Korcarz et al. 2005) (Faita, Gemignani et 
al. 2008).   
Many of these systems still rely on the user acquiring the image initially and then 
selecting the region of interest in which the system can make measurements, which 
still introduces an element of potential error.  However, fully automated systems have 
been considered by several groups, including Molinari et al, who have worked to 
develop a fully automated edge detection system (Molinari, Zeng et al. 2010), in 




Although several groups have developed potential edge detection systems, based on a 
variety of algorithms, there is still a requirement to compare these to the current 
methods of cIMT measurement, which is manual measurement.  Peters et al found 
semi-automated and manual measurements to be highly reproducible (Peters SA, den 
Ruijter HM et al. 2011).  The relationship between cIMT and cardiovascular risk 
factors was also preserved by the use of semi-automated measurements.  A similar 
finding was seen in the MESA study, between edge detection readings and manual 
readings (Polak JF, Pencina MJ et al. 2011).   
The crucial factor that will support the use of automated methods in clinical practice 
is the reduction in inter-reader bias.   
Multiple versus single measurement of cIMT 
Traditionally, ultrasound measurement of cIMT involves taking small numbers of 
measurement of cIMT online, using calipers (figure 1-9).   






For example, in the Edinburgh Type 2 Diabetes Study, 3 measurements were taken 
on each side of the neck (common carotid).  Other studies may take up to 12 
measurements on each side (common, bifurcation and internal carotid).  Taking only 
small number of measurements poses several problems.  As has been previously 
discussed, there are important differences between intima-media thickening and 
plaque/atherosclerosis.  While it is recommended that cIMT measurements are made 
in areas free of plaque, intimal thickening is not uniform throughout the length of the 
vessel wall.  Whilst plaque is defined as a focal thickening >1.5mm, taking one, three 
or even twelve measurements may not provide a good representation of a constantly 
varying intimal medial thickness. 
It is important to consider the importance of this however.  Whilst it may not be a 
problem if the measurements taken capture the largest cIMT of the vessel, true risk 
may be missed if measurements are made in a thinner area. Some obvious problems 
arise when considering how to measure cIMT down the length of the vessel.  Plaque 
is the first of these obstacles that must be overcome.  Some degree of user input may 
still be necessary to define areas free of plaque in which measurements can be made.   
Automated measurement of cIMT provides the ability to take multiple measurements 
in a relatively short period of time.  Measurements can be made at predefined 
intervals and an average produced.  However, the amount of input required from the 
user depends on the way in which the software works.   The necessity of the absence 
of plaque in the measurement of cIMT means that user input may be required to 
select an area for analysis that is free of plaque.   
There has been limited work looking specifically at the association between edge 
detected cIMT measurements and cardiovascular risk factors, compared with manual 
cIMT measurements.  In 2011, Polak et al published a study which addressed this 
using an edge detection system to measure cIMT thickness on over 5000 people 
(Polak JF, Pencina MJ et al. 2011).  The cIMT measurements made by edge 




and showed less inter-reader variability, although interestingly, they were no more 
reproducible (as has been shown in other studies).   The associations of edge detected 
cIMT were almost as strong as those from manual cIMT with the exception of 
diabetes and HDL cholesterol, which were stronger for edge detected cIMT.   
 Use of cIMT in risk prediction - consensus statements 1.3.6
The use of cIMT in clinical practice has not currently reached a high degree of 
saturation.  Clinical trials more commonly utilize cIMT as a surrogate end point for 
cardiovascular disease.  Clinical trials, indeed any kind of research study, demand a 
high degree of accuracy in measurement of any factor and so in an attempt to 
standardize the way in which measurements of cIMT are made, a number of 
guidelines and consensus statements have been developed by different groups, 
including the American Society of Echocardiography, among others (Touboul PJ, 
Hennerici MG et al. 2004; Roman MJ, Naqvi TZ et al. 2006; Touboul PJ, Hennerici 
MG et al. 2007).  
In 2004 a group of European researchers drafted the Mannheim Consensus (Touboul 
PJ, Hennerici MG et al. 2004).  As mentioned, they aimed to standardize cIMT 
measurement with the aim of allowing more accurate analysis and meta-analysis of 
cIMT data.  They also addressed the issue of classifying early and late atherosclerotic 
change, defining plaque and cIMT separately. They highlight that there are many 
differences between plaque and cIMT, including different associations with 
established vascular risk factors, as well as differing associations with incident 
vascular disease (Ebrahim, Papacosta et al. 1999; Taylor 2002; Den Ruijter, Peters et 
al. 2013).  In terms of measurement of cIMT, the consensus recommends that 
measurements be made in the common carotid artery (as this is the most easily 
visualized of the carotid segments) in a 10mm segment free from plaque with the 
double echo visible.  Measurements should also be made on the far wall.  In an 
update of this statement published in 2007, they address which measure of cIMT to 
make (ie mean cIMT, maximum cIMT etc).  Whilst they make no definite 




cIMT (which may represent a more advanced disease state) and also that cIMT and 
plaque should always be considered separately (Touboul PJ, Hennerici MG et al. 
2007).  A 2011 update this guideline published in 2012 highlights the importance of 
harmonizing the methods of collecting cIMT across epidemiological and 
interventional studies to facilitate easier comparison of results.  They also provide 
further criteria for distinguishing early plaque from thickened cIMT.  It also 
recommends against serial cIMT measurement in individual patients (Touboul PJ, 
Hennerici MG et al. 2012) 
Further guidelines have also been released by the American Society of 
Echocardiography (Roman MJ, Naqvi TZ et al. 2006; Stein JH, Korcarz CE et al. 
2008).  A key suggestion from these guidelines is that cIMT measurement is most 
likely to be of benefit in those people deemed to be at intermediate risk by 
cardiovascular risk scores as this group represents both those at true high risk, true 
intermediate and true low risk.  Therefore additional information from cIMT 
measurements may allow clinicians to tease out the true risk status of an individual.  
The ASE guidelines of 2008 also highlight that it is important to measure carotid 
plaque as well as cIMT.   
The Mannheim Consensus does not make reference to what should be considered 
either a “normal” cIMT or a “high risk” cIMT.  IN contrast, the ASE guidelines for 
the use of carotid ultrasound suggest that a cIMT value in the 75th percentile should 
be considered high risk  
 Association of cIMT with vascular risk factors 1.3.7
cIMT is known to be associated with the traditional cardiovascular risk factors.  
Increasing age, male sex, smoking, blood pressure, BMI, WHR, sedentary lifestyle, 
family history, ethnicity and presence of diabetes are all predictive of cIMT 
(Mannami T, Konishi M et al. 1997).  Several studies have demonstrated an 
association of cIMT with increasing age, including the National Institute for 




al. 2000) and the Edinburgh Artery Study (EAS) (Allan, Mowbray et al. 1997).  
These studies also demonstrated that cIMT was higher in men than in women.  The 
AXA study found associations between cIMT and BMI, systolic and diastolic blood 
pressure, plasma lipids, glucose and smoking, although some sex differences existed 
for several risk factors (Gariepy J, Salomon J et al. 1998).  The Insulin Resistance 
Atherosclerosis Study (IRAS) demonstrated an important association between cIMT 
and established diabetes (Wagenknecht, D'Agostino Jr et al. 1998), which will be 
discussed later in this thesis.  Lifestyle factors such as dietary cholesterol, BMI and 
smoking were associated with progression of cIMT in the Monitored Atherosclerosis 
Regression Study (MARS) (Markus, Mack et al. 1997).  Hypercholesterolaemia has 
also been associated with increased cIMT (Wendelhag, Wiklund et al. 1993; Joensuu 
T, Salonen R et al. 1994; Gariepy, Simon et al. 1995). 
A study in 2000 by Baldassarre investigated the association between cIMT measured 
in routine clinical practice and cardiovascular risk factors in 963 participants from a 
general population sample.  The authors report that cIMT correlated with systolic 
blood pressure, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and 
blood glucose  (Baldassarre, Amato et al. 2000). cIMT was linearly associated with 
the number of risk factors present (p<0.003). They also showed that cIMT was 
higher in men than women and that those with CHD and PAD had higher cIMT than 
controls.   
Ebrahim et al examined the association between cIMT in the common carotid and 
bifurcation with CV risk factors (Ebrahim, Papacosta et al. 1999).   They found in 
800 men and women drawn from a national cohort (British Regional Heart Study) 
that cIMT of the common carotid had a different pattern of risk factor association 
compared with cIMT of the bifurcation.  cIMT of the bifurcation had a stronger 
association with age than common carotid cIMT.  In addition, cIMT in the 
bifurcation showed a significant association with plasma lipids, whereas common 




In 2010, a cross sectional analysis of cIMT and vascular risk factors in the 
IMPROVE study demonstrated that cIMT was positively associated with latitude, 
age, gender, pack years and hypertension, and negatively associated with education 
level (Baldassarre, Nyyssönen et al. 2010).  The authors comment that the 
association of cIMT with latitude reflects the known north-south gradient of CHD 
mortality (Sans, Kesteloot et al. 1997; Baldassarre, Nyyssönen et al. 2010).  The 
PARC study demonstrated an association between cIMT and age, male sex, smoking, 
total cholesterol, HDL cholesterol and systolic blood pressure on linear regression 
(Touboul, Vicaut et al. 2007).   
cIMT and ethnicity has also been studied and several studies have demonstrated that 
there are differences in cIMT according to ethnic origin.  It has been demonstrated 
that cIMT in black people is greater than that in white people (Howard, Sharrett et al. 
1993; Urbina, Srinivasan et al. 2002).  Both these groups had a higher cIMT than that 
of Hispanic people (D'Agostino, Burke et al. 1996).  
 Association of cIMT with incident coronary events 1.3.8
In order to further explore the relationship between cIMT and vascular risk, several 
large epidemiological studies have expanded on the cross sectional work by the 
studies that have been discussed so far.   
In the first instance, studies have shown that there is a correlation between cIMT and 
the extent of coronary artery atherosclerosis (Geroulakos G, O'Gorman DJ et al. 
1994; Coskun U, Yildiz A et al. 2009).  However, there are large studies that have 
examined the relationship between cIMT and incident vascular disease (Salonen JT 
and Salonen R 1993; Chambless LE, Heiss G et al. 1997; O'Leary DH, Polak JF et al. 
1999; Chambless LE, Folsom AR et al. 2000; Iglesias del Sol A, Bots ML et al. 
2002; Hollander M, Hak AE et al. 2003; Rosvall M, Janzon L et al. 2005; Rosvall M, 
Janzon L et al. 2005; Lorenz MW, von Kegler S et al. 2006; Folsom, Kronmal et al. 




One of the earliest studies examining this relationship was a Finnish study of 1257 
men free of vascular disease and aged 43-60 years (Salonen JT and Salonen R 1993).  
After 3 years of follow up, a 0.1mm increase in carotid IMT represented an 11% 
increase in risk of myocardial infarction.  Following this study, the Atherosclerosis 
Risk in Communities Study (ARIC) found a similar relationship.  They followed up 
12841 men and women free of cardiovascular disease at recruitment and aged 45-64 
years.  Mean cIMT was associated with an increased risk of cardiovascular disease. 
This relationship persisted after adjustment for age, sex and race (HR 5.07 (95% CI 
3.08-8.36) and HR 1.87 (95% CI 1.28-2.69) for men and women respectively).  They 
performed additional analysis controlling for established cardiovascular risk factors 
and found that whilst a higher cIMT (>0.8mm) maintained a relationship with 
incident events, this was not the case for cIMT <0.8mm (Chambless LE, Heiss G et 
al. 1997).   
Another epidemiological study that addressed this relationship was the 
Cardiovascular Health Study (CHS).  In their study of 4476 subjects free from CHD 
(mean age 72.5 years) they followed up incident vascular events, including stroke 
and myocardial infarction over approximately 6 years.  Like the ARIC study, they 
also adjusted the results for conventional cardiovascular risk factors and found that 
those with an cIMT in the higher quintiles had increased risk for MI or stroke when 
compared with the lower quintiles (adjusted RR 3.15 (95% CI 2.19-4.52) (O'Leary 
DH, Polak JF et al. 1999).  They also noted that they relationship appeared to be 
linear.     
In the Rotterdam Study, increased cIMT was predictive of myocardial infarction, 
even after adjustment for age and sex.  The Rotterdam study is a prospective study 
that measured cIMT in 5851 men and women aged 55 and above and followed up 
incident events for an average of 4.6 years.  cIMT was measured in the common 
carotid, bifurcation and internal carotid, and in addition a combined cIMT value was 
derived from these three measures. Of these, only cIMT in the common carotid artery 




significantly associated with incident MI (Iglesias del Sol A, Bots ML et al. 2002).  
Interestingly, these results were in contrast to an earlier publication from the 
Rotterdam study that found that adding cIMT to established vascular risk factors did 
not improve prediction of CHD (Iglesias del Sol A, Moons KG et al. 2001).  
Following on from the work of the Rotterdam study was the Carotid Atherosclerosis 
Progression Study (CAPS).  Researchers studied 6962 people who were initially 
drawn from a primary health care scheme.  cIMT was measured at all carotid 
segments.  They followed up 5056 participants for myocardial infarction, stroke and 
death for an average of 4.2 years.    Of the segments measured, all were found to 
have increased HR for all outcomes before adjustment.  Adjusted HRs remained 
significant only for cIMT at the CCA and bifurcation for MI and a combined 
outcome of MI, stroke or death (Lorenz MW, von Kegler S et al. 2006). 
The Malmo Diet and Cancer Study (MDCS) enrolled 5163 subjects into their 10 year 
cohort (Rosvall M, Janzon L et al. 2005).  They measured cIMT in addition to 
carotid plaque and stenosis, and found that all three were associated with incident 
fatal and non-fatal MI, or CHD death.  The adjusted HR for cIMT was 1.23 (95% CI 
1.07-1.41), which persisted on additional adjustment for carotid plaque.   
In 2007, in order to review the evidence for the use of cIMT in risk prediction, 
Lorenz et al undertook a systematic review and meta-analysis of large 
epidemiological studies examining cIMT in relation to incident events.  They 
identified that the studies included used variety of ultrasound protocols and summary 
measures of cIMT which introduced a degree of heterogeneity between the studies.  
When they estimated relative risk they found that cIMT was predictive of MI (age 
and sex adjusted RR 1.26 (95% CI 1.21-1.30)) (Lorenz MW, Markus HS et al. 2007).  
This led them to conclude that cIMT may be of use in cardiovascular risk prediction. 
Following the publication of this review, there have been several other large 
epidemiological studies that have published data concerning cIMT and incident 




participants in the Framingham Offspring study in 2011.  In addition to assessing the 
relationship between cIMT and incident events, they also looked at the effect of 
cIMT on reclassification of risk (Polak, Pencina et al. 2011) after measuring cIMT in 
both the common and internal carotid arteries.  The authors report that both common 
carotid (HR 1.13 (1.02 to 1.24)) and internal carotid cIMT (HR 1.21 (1.13-1.29)) 
predicted coronary events but that only the internal carotid cIMT improved risk 
prediction above traditional risk factors (NRI 7.6%, P<0.001).   
In 2012, MESA published the results of a further study examining the role of novel 
risk markers in cardiovascular risk assessment in those people deemed to have an 
intermediate risk of vascular disease.  In this study, carotid intima media thickness 
did not associate with incident cardiovascular events (HR 1.17, 95% CI, 0.95-1.45) 
(Yeboah J, McClelland RL et al. 2012).  The overall result of this study was that 
coronary artery calcium was the best predictor of vascular risk in this group and 
provided the greatest improvement in risk classification.    
A large meta-analysis by Den Ruijeter et al comprising data from 14 population-
based cohorts (45, 828 individual participants) examined the association between 
cIMT and incident MI and stroke.  They identified 4007 incident events over a 
follow up period of 11 years and fitted a model that was adjusted with common 
Framingham risk factors and then added cIMT to estimate absolute 10 year risk. The 
net reclassification improvement was small (0.8%; 95% CI, 0.1%-1.6%) and 
specifically in those at intermediate risk, it was 3.6% (95% CI, 2.7%-4.6%) (Den 
Ruijter HM, Peters SA et al. 2012).  The conclusion of this meta-analysis was that 
while there was an increase in prediction, it was unlikely to be of any clinical use. 
Another recent meta-analysis performed in the Netherlands also examined the 
association between cIMT and future vascular events.  They too found that cIMT did 
not add to the predictive value of traditional risk factors (van den Oord, Sijbrands et 
al. 2013).  While the meta-analysis revealed that a 1 SD increase in cIMT was 




stroke (HR 1.31, 95% CI 1.26–1.36), and the HR for the combined end point of MI 
and stroke was 1.26 CI 1.17-1.36, there was no significant increase in the areas under 
the curve increased from 0.726 to 0.729 (p = 0.800). 
The IMPROVE study examined the use of both a range of cIMT measures and a 
measure known as interadventitia common carotid artery diameter (ICCAD). Using 
data from cohort study covering 5 European countries (3,703 subjects with a median 
age 64.4 years) with median follow up of 36.2 months, and 215 first cardiovascular 
events, they found that an average of 8 maximal cIMT measurements either alone or 
combined with ICCAD improved classification of events and nonevents better than 
common carotid IMT and they recommend a strategy involving cIMT and ICCAD in 
addition to Framingham risk factors in predicting risk (Baldassarre D, Hamsten A et 







Table 1-5 Prediction of cardiovascular events by cIMT in epidemiological studies 
Study Subjects (n) Outcome Adjusted* HR for cIMT (95% CI) RR (95% CI) 
Kuopio Ischaemic Heart Disease Study (KIHD)  1257 MI - - 
















Cardiovascular Health Study (CHS) 4476 
MI/ 
Stroke 
- 3.15 (2.19-4.52) 
‡
 
Rotterdam Study  5851 MI - 




Rotterdam Study  5479 Stroke - 2.23 (1.48-3.36) 
†
  
Malmo Diet and Cancer Study (MDCS)  5163 MI 1.23 (1.07–1.41)
 ‡
 - 
Malmo Diet and Cancer Study (MDCS)  5163 Stroke 1.21 (1.02-1.44)
 ‡
 - 
Carotid Atherosclerosis Progression Study (CAPS)  6962 MI/Stroke/death 1.16 (1.05-1.27)
 ‡‡
 - 










Multi-Ethnic Study of Athersclerosis (MESA)  6698 All CVD 1.3 (1.1-1.4)
 ‡
 - 
Framingham Offspring Study  2965 All CVD 
Mean CCA 1.13 (0.000-0.007)
 ‡
 




CCA – common carotid artery, ICA – internal carotid artery, MI – Myocardial Infarction, CHD-coronary heart disease, CVD-cardiovascular disease HR hazard ratio, RR relative risk 
*=age sex and risk factor adjusted, except ARIC – age, race and centre adjusted only,  
†-highest vs lowest cIMT   ‡ - per 1SD increase in cIMT   ‡‡ - per 0.15mm increase in cIMT  
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 Association of cIMT with incident stroke 1.3.9
As well as an association with coronary artery disease, studies have also examined 
the relationship between cIMT and stroke, given the more direct anatomical 
relationship between the carotid artery and the cerebral vasculature.  In 2003, the 
Rotterdam study assessed both carotid plaque and cIMT.  When they compared the 
association between both and incident stroke, they found that a cIMT >0.84mm was 
a stronger predictor than plaque, with a relative risk of 2.42 after adjusting for 
established CV risk factors (highest tertile versus lowest tertile) (Hollander M, Hak 
AE et al. 2003).  Other studies that have produced results supporting this finding 
include the MDCS study which demonstrated a hazard ratio of 1.21 for cIMT in 
prediction of incident stroke.  This was found to persist even when the results were 
adjusted for carotid plaque (Rosvall M, Janzon L et al. 2005).  In support of this, 
Prati et al found that in their study of 1348 participants, common carotid artery cIMT 
>1mm had a RR of 10.4% versus cIMT <1mm for ischaemic stroke, TIA and 
vascular death  (Prati, Tosetto et al. 2008).  However, when they added cIMT or 
plaque to Framingham risk factors, IMT only improved prediction in those with a 
Framingham risk >20%.  Chien et al found a similar HR per 1mm SD change in 
cIMT for stroke of 1.47 (1.28-1.69) in 2190 Chinese participants (Chien, Su et al. 
2008).   
Not all studies have supported the findings so resolutely.  Both the ARIC and CHS 
studies have demonstrated a relationship between stroke and IMT that was not linear.  
In ARIC, whilst increasing cIMT and stroke incidence were associated, the 
relationship was not as strong when conventional risk factors were taken into 
consideration (Chambless LE, Folsom AR et al. 2000).  These findings were 
mirrored by the CHS which demonstrated a non-linear relationship between cIMT 
quintiles (O'Leary DH, Polak JF et al. 1999). 
In contrast, the more recent MESA study has published conflicting results on cIMT 
and stroke.  In their 2008 publication, they report a hazard ratio per 1mm SD change 
in cIMT of 1.4 (1.2-1.8) for stroke in 6698 participants after median follow up of 3.9 
years (Folsom, Kronmal et al. 2008).  However, a subsequent paper published in 
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2011 from the same study (including 5520 participants) could not find an association 
between cIMT and stroke with a non-significant hazard ratio of only 0.89 (95%CI 
0.8-1.3) after adjusting for traditional risk factors, although they did see an 
significant association for change in cIMT (Polak, Pencina et al. 2011) 
 cIMT and clinical risk prediction 1.3.10
Before cIMT can be considered for use in clinical practice, its ability to predict 
vascular events must be compared with the current accepted methods of risk 
prediction.  The most common methods of risk prediction (as have already been 
discussed) are risk scores which incorporate the major cardiovascular risk factors.  
Therefore, cIMT must be compared with these factors.  One way of assessing this is 
to add cIMT into models containing risk factors.  This method has been 
recommended by the recent USPSTF statement (United States Preventative Services 
Task Force 2009).  In addition, net reclassification index and clinical net 
reclassification can be assessed.  This is the number of people who are reclassified 
based on risk.  Clinical NRI applies specifically to those deemed to be at 
intermediate risk. 
Several studies have adopted this approach, including ARIC and CAPS.  In the ARIC 
data, adding both cIMT and plaque to traditional risk factors improved prediction of 
vascular events.  Overall, 23% of cases had their risk reclassified.  This resulted in a 
net reclassification index of 9.9% and clinical NRI of 21.7% (Nambi V, Chambless L 
et al. 2010).  In addition, they found that measuring cIMT in the CCA was sufficient 
for using in clinical risk prediction (in comparison to all segment cIMT).   
Not all studies have found such a positive finding and have cast doubt on the 
usefulness of cIMT in risk prediction.  The CAPS study found that cIMT in addition 
to established risk factors, did not improve risk classification, with a net 
reclassification index of -1.41% (Lorenz, Schaefer et al. 2010).  A 2010 narrative 
review of the data published on cIMT and plaque in risk prediction found that 
although cIMT did predict CHD independently, it contributed only modestly to risk 
prediction and they concluded that carotid plaque may be a more useful measure of 
vascular risk (Simon A, Megnien JL et al. 2010).  A systematic review of examined 
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cIMT in addition to other novel risk markers and they had an opposite conclusion – 
that they found strong evidence that cIMT could improve risk prediction (Peters 
SAE, den Ruijter HM et al. 2012).  The NRI of the studies included ranged from -1.4 
to 11.6%.   
Several guidelines have been highlighted by the Mannheim Consensus, which 
address the use of cIMT in assessing CVD risk in clinical practice including the 
Report of the National Cholesterol Education program Adult Treatment Panel III, 
which recommends its use to detect subclinical atherosclerosis, which aids decision 
making in the management of blood lipids (van den Oord, Sijbrands et al. 2013); and 
ESH/ESC guidelines used in Spain that recommend cIMT for the use in detecting 
target organ damage in hypertension (Antithrombotic Trialists' (ATT) Collaboration, 
Baigent C et al. 2009).  However, the ACC/AHA published recommendations in 
2013 that were not in support of cIMT in the assessment of cardiovascular risk of 
first CVD event, citing the basis for this decision as primarily a 2012 individual 
participant data meta-analysis published by Den Ruijter et al of the USE cIMT 
initiative (Den Ruijter HM, Peters SA et al. 2012), in combination with concerns 
about measurement accuracy (Goff, Lloyd-Jones et al. 2013).  
 cIMT progression and vascular risk 1.3.11
Progression or indeed regression of cIMT has been used as a surrogate 
cardiovascular outcome in the trials of several drugs (ENHANCE and METEOR 
trials).  The assumption underlying its use is that progression of cIMT is associated 
with increased vascular risk and regression with decreasing risk, however, the 
evidence underlying this relationship is not clear.  Several large meta-analyses have 
attempted to address this and the results have been mixed.  A large meta-analysis 
recently published included 41 studies and addressed whether cIMT regression 
predicted reduction of cardiovascular events.  The authors reported that although 
there was reduction in the number of events, there was no relationship between the 
regression of cIMT and the events, suggesting that reduction in cIMT does not reflect 
a reduction in cardiovascular events (Costanzo P, Perrone-Filardi P et al. 2010).  A 
further meta-analysis including 28 studies identified that mean change in cIMT was 
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associated with a lower likelihood of non-fatal MI (Goldberger, Valle et al. 2010).  
However, this was noted only in selected RCTs that were included in their analysis.  
Because of these inconsistent findings, they conclude that while there is some 
evidence that change in cIMT is associated with change in event likelihood, they 
urge caution in the use of cIMT as a surrogate endpoint.  In 2012, the PROG IMT 
collaboration published a meta-analysis of data from 36 948 individuals from 16 
cohorts (Lorenz, Polak et al. 2012).  The authors report that after mean follow up of 7 
years, change in cIMT from two ultrasound scans was not associated with increased 
cardiovascular risk, and draw no firm conclusions on its use as a surrogate end point.  
They also reported that the “average” cIMT (the average of the two ultrasound 
readings) did independently associated with cardiovascular risk (adjusted HR 1.16 
(1.10-1.22), suggesting that cIMT may still be useful in risk prediction rather than as 
a surrogate endpoint.   
1.4 Carotid plaque 
Atherosclerotic plaque development is the end product of atherosclerotic change in 
the vessel wall.  Plaques form on the vessel wall as a consequence of exposure of the 
wall to vascular risk factors such as hypertension, dyslipidaemia or inflammation 
(see section 1.4). Interest in the presence of atherosclerotic plaques in the carotid 
artery is growing and there is interest in both plaque burden and plaque morphology.  
Several authors have suggested that plaque represents a more advance stage of 
disease, and as such may be more predictive of vascular events than cIMT (Ebrahim, 
Papacosta et al. 1999).   
There are many different aspects of plaque that can be measured using carotid 
ultrasound.  Plaque thickness is perhaps the simplest facet, and is primarily assessed 
by measuring either the thickness of the plaque itself or the degree of carotid stenosis 
– that is, the encroachment of the plaque on the lumen of the vessel.  The Mannheim 
consensus defines plaque as a focal protrusion into the lumen of >1.5mm or >50% of 
the surrounding IMT (Touboul PJ, Hennerici MG et al. 2012).  There is also interest 
in plaque area, plaque volume and plaque morphology, and the relationship of these 
aspects of plaque with cardiovascular disease.  In terms of plaque morphology, 
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plaque echogenicity and structural appearance have attracted most interest, 
particularly when considered in the context of cerebrovascular disease.  However, 
there has also been limited work that has assessed the impact of carotid plaque 
morphology on the future risk of coronary artery events.   
 Quantitative measures of carotid plaque 1.4.1
Similarly to cIMT, carotid plaque can be assessed using B mode ultrasound of the 
carotid artery.  In addition, Doppler ultrasound can be used to assess stenosis of the 
artery lumen and make quantitative assessments of plaque.  Several aspects of carotid 
plaque can be measured – maximum plaque thickness, total plaque area and total 
plaque volume are three commonly measurable variables.  In addition, plaque 
morphology (ie the composition) can also be assessed.  Plaque is sometimes 
described by the plaque “burden”, which is a loose term used to describe the number, 
size and/or volume of plaques present at specific anatomical sites, commonly the 
carotid artery.  Age is sometimes substituted for plaque burden however, it is the 
plaque burden which is the true risk factor – and individuals of the same age will 
have differing plaque burden.   The different methods for measuring plaque are 
discussed below.  Consensus statements have attempted to address plaque 
measurement but there are no firm recommendations.  The Mannheim consensus 
suggests the measurement of the following plaque characteristics: Plaque location, 
thickness, area and number, scanned in longitudinal and cross-sections must be 
recorded, but highlight that there is not enough current evidence to support the 
measurement of plaque morphology  as of yet (Touboul PJ, Hennerici MG et al. 
2012).   
Maximum plaque thickness 
Maximum plaque thickness is the maximum thickness of any given plaque, from the 
media adventitial interface to the lumen-intima interface.  It is similar to intima 
media thickness but is measured specifically in a focal plaque.  The reading captures 
only the thickness of the plaque at the maximum point.   
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Total plaque area and plaque volume 
Total plaque area involves measurement of the surface area of plaque in an artery.  
Similarly, total plaque volume is a measure of the volume of plaque present.  Both 
can be estimated using carotid ultrasound, with total plaque area and plaque volume 
represent the 2D and 3D quantification of plaque burden, respectively; whereas 
plaque thickness represents only a 1 dimensional measure of plaque and is more alike 
to intima media thickness, even though it is a specific measure of a plaque (Pollex 
RL, Spence JD et al. 2005).  Plaque area is typically measured on a cross sectional 
longitudinal image of the carotid artery and involves measurement of all visible 
plaques.  The perimeter of each visible plaque is traced  and the areas summed to 
create total plaque area (Spence, Eliasziw et al. 2002). Spence et al also performed a 
study in 1686 subjects where they measured total plaque area at baseline and 
followed them up for a mean of 2.5 ± 1.3 years for incident cardiovascular events 
(Spence, Eliasziw et al. 2002).  After adjusting for baseline characteristics, they 
found that the risk of cardiovascular disease increased with each quartile of plaque 
area. They also noted that those people who showed a progression in plaque area 
with time had an increased risk of vascular events compared with those who had no 
change or regression (15.7% vs 7.6% and 9.4% respectively).  An additional study by 
Spence et al found that over 1 year, plaque area increased by 2 times as much as 
plaque thickness, which suggests mean that plaque area may be a more sensitive 
indicator of atherosclerosis (Spence 2002).   
Total plaque volume is a similar measure to plaque area but requires the use of 3D 
ultrasound to quantify the plaque volume along a longitudinal section of the carotid 
artery.  3D ultrasound uses a series of cross sectional slices which are added together 
to determine the volume.  Thus, accuracy of volume is dependent on the number of 
cross sectional slices that are taken.  Spence et al examined the reliability of 3d 
ultrasound measurement of plaque volume and found intra and inter-observer 
variability of 94% and 93.2% respectively (Landry, Spence et al. 2004).  
Measurement variation reduced as plaque size increased.  A systematic review by 
Makris et al, identified 7 studies examining reproducibility of carotid plaque volume 
measurements using 3D ultrasound (Makris, Lavida et al. 2011).  They found that 3D 
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ultrasound measurements were reliable although they note heterogeneity between 
studies and recommend that further evidence is needed to assess whether 3D 
ultrasound is superior to 2D ultrasound assessment of carotid plaque. 
 Plaque morphology 1.4.2
B mode ultrasound can also be used to assess the morphology of carotid plaque 
which can suggest the structure and composition of the plaque and there is evidence 
to suggest that plaque morphology might be useful in assessing how vulnerable a 
plaque is (Grønholdt MLM, Nordestgaard BG et al. 2001; Liapis, Kakisis et al. 2001; 
AbuRahma, Wulu et al. 2002; Honda O, Sugiyama S et al. 2004).  Plaques which are 
more likely to rupture tend to be rich in lipid and haemorrhage (Epstein, Fuster et al. 
1992; Davies 1996).   
Assessing plaque morphology on ultrasound brings with it many similar limitations 
to those seen in intima media measurement.  Classification of a plaque as echolucent 
or echogenic by a sonographer can be a subjective process, although the use of 
predetermined criteria can reduce this to some extent. However, the development of 
computer quantification of echolucency has helped to a great extent.  Gray scale 
median (GSM) is measured after image normalization and there have been 
demonstrated links between low GSM (echolucent plaque) and plaque instability 
(Hall HA and Bassiouny HS 2012).   The Mannheim Consensus update of 2012 notes 
that the value of recording plaque texture remains uncertain and that this is an area 
that requires further research (Touboul PJ, Hennerici MG et al. 2012) although some 
studies have started to explore this area.   For example,  Prati et al developed a risk 
score incorporating various aspects of plaque composition including stenosis degree, 
plaque surface irregularity, echolucency and texture.  They found that the total 
plaque risk score was a powerful predictor of cerebrovascular events (Prati, Tosetto 
et al. 2011). 
Echogenicity 
Plaque echogenicity can be characterised on the basis of it echogenicity on 
ultrasound.  Low echogenicity plaques appear on ultrasound as being black or nearly 
black (echolucent) and are usually referenced in comparison with blood.  In contrast, 
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high echogenicity plaques appear as white (echogenic) and can be referenced with 
bone.  Echolucent plaques tend to be lipid rich and are prone to rupture (Grønholdt 
MLM, Nordestgaard BG et al. 2001; Honda O, Sugiyama S et al. 2004), whereas 
echogenic plaques tend to be calcified and fibrinogen rich. 
Heterogeneity 
Plaque heterogeneity is a way of classifying the texture or composition of the plaque.  
Similarly to echogenicity, plaque heterogeneity can be classified into 2 broad 
categories.  Heterogeneous plaque is defined as plaque with >20% of the plaque 
differing in echogenicity to the rest of the plaque.  Homogeneous plaques have a 
structure that is consistent throughout.  An example of a heterogeneous plaque might 
be a plaque with a lipid core that also possesses intra-plaque haemorrhage as well as 
a calcified portion.  A homogenous plaque would be a plaque composed of only a 
lipid core.  Heterogeneous plaques are also considered to be at increased risk of 
adverse clinical consequences (Petersen C, Pecanha PB et al. 2006).   
Relationship of ultrasound appearance of plaques with histology 
Several studies have demonstrated the link between B mode ultrasound appearance 
of plaques and histological appearance of plaque.  Many of these studies are based 
upon work done in the exploration of the association between plaque type and carotid 
endarterectomy.  In 1995, a large multi-centre study by the European Carotid Plaque 
Study Group published data on 270 carotid endarterectomy specimens and found that 
ultrasound determined plaque morphology was associated with histological findings.  
Plaque echogenicity on ultrasound was inversely associated with plaque composition 
(European Carotid Plaque Study Group and Sillesen 1995).    
One must then look to examine the relationship between histological plaque 
appearance and future vascular risk.  A paper by Hellings et al published in 2010 
described the association between plaque histology and future cardiovascular risk in 
a prognostic  study (Hellings WE, Peeters W et al. 2010).  Subjects who had 
undergone carotid endarterectomy had their plaque specimens analysed 
histologically and those who had plaque haemorrhage or intraplaque vessel 
formation had a higher risk of the primary outcome (vascular event including CVD 
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death, non-fatal stroke and non-fatal MI, or vascular intervention) with a HR of 1.7 
(95% CI 1.2 – 2.5) and 1.4 (95% CI 1.1 – 1.9) respectively.  This relationship was 
independent of clinical risk factors and medication use. Interestingly, other 
histological aspects of plaque such as macrophage infiltration, large lipid core, 
calcifications, collagen and smooth muscle cell infiltration were not associated with 
an increased risk of a vascular outcome. 
In 2007, a study was published of pathological specimens taken from symptomatic 
carotid endarterectomy patients that were examined using ultrasound prior to 
excision (Snow, Ben-Sassi et al. 2007). Of 33 predominantly echolucent plaques on 
USS, 27 were haemorrhage or lipid rich.  Of 17 plaques that were characterised as 
echogenic, 11 were found to be predominantly fibrotic.  They concluded that 
ultrasound plaque assessment may be useful in identifying potentially unstable 
(echolucent) plaques and help in the selection of individuals for carotid 
endarterectomy.   
In 2011, a Japanese study that examined the ability of diagnostic tools to predict 
plaque type (in order to stream line selection of patients for carotid endarterectomy) 
demonstrated that plaque morphology on carotid ultrasound was closely associated 
with histological findings following carotid endarterectomy, although 
ultrasonography was not sufficient for all patients and they suggest that a 
combination of US and MRI could be useful (Arai, Yamaguchi et al. 2011).   
 Reproducibility of plaque assessment 1.4.3
An early study by Joakimsen et al examined the reproducibility of carotid plaque 
assessment using a ultrasound (Joakimsen O, Bønaa KH et al. 1997).  They found 
that plaque occurrence displayed good inter and intra-observer agreement (K value 
0.72 95%CI 0.6-0.84 vs 0.76 95%CI 0.63-0.89).  There was only a moderate degree 
of agreement with regards plaque thickness, with mean absolute differences ranging 
from 0.25-0.55mm.  Plaque morphology classification however showed a high 
degree of agreement.  Therefore, ultrasound assessment seems to be a good way of 
assessing plaque occurrence and morphology but not such a good way of measuring 
plaque thickness.  
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 Association of carotid plaque with vascular risk factors 1.4.4
Like cIMT, there have been several studies that have demonstrated an association 
between carotid plaque and cardiovascular risk factors.  Increasing age is associated 
with increased plaque presence (Lemne, Jogestrand et al. 1995; Bonithon-Kopp, 
Touboul et al. 1996; Mannami T, Konishi M et al. 1997; Aminbakhsh, Frohlich et al. 
1999; Homma S, Hirose N et al. 2001; Sun, Lin et al. 2002).  Systolic blood pressure, 
smoking, total/HDL cholesterol ratio and BMI have also been associated with plaque 
presence (Bonithon-Kopp, Touboul et al. 1996; Mannami T, Konishi M et al. 1997; 
Aminbakhsh, Frohlich et al. 1999; Ebrahim, Papacosta et al. 1999; Sun, Lin et al. 
2002).   The British Regional Heart Study (BRHS) demonstrated a linear relationship 
between increasing plaque presence and increasing BRHS risk score (which contains 
traditional CV risk factors) (Zureik, Touboul et al. 1999).   
In Canadian study of 168 Oji-Cree adults with an average age of 38.2 years, total 
plaque area was strongly associated with age, sex, smoking and total cholesterol, but 
not hypertension (Al-Shali K, House AA et al. 2005).  Total plaque volume however 
was associated only with age, sex and diabetes.   
A study by Ebrahim et al in 1999 showed that 57% of men and 58% of women had 
carotid plaque.  Prevalence increased with age and cIMT was on average 0.1mm 
higher in people with plaque compared with those without and there was an inverse 
association between plaque prevalence and HDL cholesterol (Ebrahim, Papacosta et 
al. 1999).  The presence of plaques was associated with cardiovascular risk factors 
(smoking, deprivation and fibrinogen), as well as prevalent vascular disease.  A later 
study by Virani et al in 2011 found that in the ARIC study, maximum plaque 
thickness (defined as the maximum plaque thickness recorded in 12 segments of the 
carotid artery) was strongly associated with blood lipids including total cholesterol, 
LDL and HDL cholesterol after full risk factor adjustment (Virani SS, Catellier DJ et 
al. 2011).  They also identified that plaques found on MRI to have a lipid rich core 
(those that would be described as echolucent on US) had a strong relationship with 
lipid ratios such as total/HDL ratio after full adjustment for CV risk factors.   
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Spence et al identified that the distribution of carotid plaque area increased with age 
and was higher in men than in women (Spence 2006).  
Data from the PIVUS study that plaque size (as quantified by plaque volume) 
demonstrated different associations with vascular risk factors than plaque 
echogenicity (Andersson, Sundström et al. 2009).   
Data from the Tromsø Study established that HDL cholesterol was associated with 
echolucent carotid plaques (adjusted OR 0.69 (95%CI 0.52-0.93) in 6727 participants 
in a population health survey (Mathiesen EB, Bønaa KH et al. 2001).   
 Carotid plaque and prediction of coronary events 1.4.5
Carotid plaque has been investigated in relation to prediction of coronary events.  
Because there is no definitive measure of carotid plaque, the studies vary in exactly 
which measure is used in prediction.  Several studies have linked carotid plaque with 
an increased risk of coronary events (Honda O, Sugiyama S et al. 2004; Seo Y, 
Watanabe S et al. 2006; Reiter, Effenberger et al. 2008).  Honda et al established that 
echolucent (lipid rich plaques) as identified by low integrated backscatter on US 
predicted coronary artery plaque complexity and also the development of coronary 
artery complication sin a sample of 71 individuals with ACS and 215 with stable 
CAD.   
A German study by Reiter et al examined echolucency and the risk of major 
cardiovascular events in high risk patients.  They determined the change in plaque 
composition over 7.5 months and found an association with future major 
cardiovascular events in those people with increasing plaque echolucency.  However, 
there was no relationship between absolute levels of GSM at either baseline or follow 
up (Reiter, Effenberger et al. 2008).   
In a related study, Swedish investigators examined the relationship between non-
stenotic femoral plaques and future vascular risk.  They used B mode ultrasound to 
assess plaque in the femoral arteries and record plaque occurrence, plaque size and 
plaque characteristics including echogenicity and echolucency.  They found that 
plaque occurrence and size were predictive of future vascular events, as was plaque 
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echolucency to some extent, although there was no significant difference between 
echogenic and echolucent plaque (Schmidt, Fagerberg et al. 2005).   
Spence et al also found an association between plaque area and risk of stroke, MI or 
death.  In a study of 918 patients, the higher quartile of plaque area was associated 
with a 3 fold increase in risk for stroke, MI or death (Spence 2002).   
Hirano et al published a study of 413 patients with CAD and carotid plaque and 
assessed the predictive ability of plaque echolucency and plaque size for incident 
coronary events (Hirano M, Nakamura T et al. 2010).  They found that in multi-risk 
factor adjusted models, the model with both plaque echolucency and plaque 
thickness was a better predictor of incident events (AUC 0.80) than either the model 
with just plaque thickness (AUC 0.74) and the model with only plaque echolucency 
(AUC 0.76).   
The MESA study explored carotid plaque metrics measured using ultrasound (plaque 
presence, thickness and stenosis) in relation to incident CVD.  They demonstrated 
that all measures of plaque were predictive of coronary artery disease and 
cardiovascular disease but not stroke (Polak, Szklo et al. 2013).  The authors also 
found that the NRI for CVD was less than that for CHD suggesting plaque was more 
useful in predicting CHD.  More recently, the authors reported the results of a study 
of carotid plaque morphology determined by magnetic resonance imaging in relation 
to incident vascular disease (Zavodni, Wasserman et al. 2014).  The authors reported 
that when MRI plaque remodeling index and lipid core were added to a model 
containing traditional risk factors, the AUC was increased from 0.696 to 0.734, 
suggesting the plaque characteristics were useful in improving prediction of 
cardiovascular risk.     
 Carotid plaque and prediction of stroke 1.4.6
Carotid plaque is known to be a pathological cause of stroke and TIA, with 
narrowing of the carotid arteries by enlarging plaques causing critical stenosis and 
reduction in blood flow to the brain (ischaemic stroke).  In addition, thrombus or 
plaque material may embolise and are carried straight to the cerebral arteries, where 
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partial or complete occlusion can lead to stroke.  The mechanism is dependent on the 
characteristics of the plaque present in the carotid artery.  Stable, fibrotic plaques 
tend to cause stenosis whereas lipid rich, haemorrhagic plaques are more likely to 
rupture and embolise their contents.   Thus plaque morphology has been explored in 
relation to stroke, with several studies reporting that when compared with echogenic 
plaques, echolucent plaque has been shown to be associated with a higher risk of 
cerebrovascular ischaemic events (Pedro LM, Pedro MM et al. 2000; Grønholdt 
MLM, Nordestgaard BG et al. 2001; Mathiesen EB, Bønaa KH et al. 2001).  .   
In a 1998 study, Polak et al reported that hypoechoic (echolucent) plaque was 
associated with incident stroke (RR 1.72) after adjusting for cardiovascular risk 
factors (Polak JF, Shemanski L et al. 1998).  The authors also reported that stenosis 
was associated with incident stroke.  Additionally, Hollander et al published data 
from the Rotterdam study in 2002 which demonstrated a relationship between carotid 
plaque, stroke and cerebral infarction.  In 4217 asymptomatic adults older than 55 
years of age, carotid plaque at any area increased the risk of stroke and cerebral 
infarction (Hollander M, Bots ML et al. 2002).  In support of these results, Shaalan et 
al have reported that plaques with more calcification were more stable and were 
associated with a lower risk of ischaemic events than plaques with less calcification 
(Shaalan, Cheng et al. 2004). 
There is also evident that heterogeneous plaque is associated with an increased risk 
of stroke.  Petersen et al established a relationship between heterogeneous plaque and 
death in a study of 541 hospitalised cardiology patients in Pisa, Italy (Petersen C, 
Pecanha PB et al. 2006).  In multifactorial models, plaque heterogeneity had a 
relative risk of 1.6 95% CI 1.2-2.14) for death.   
Some studies have examined multiple facets of carotid plaque.  Mathieson et al 
showed that in the Tromsø study, echolucent plaques were associated with an 
increased risk of future cerebrovascular events, independent of the degree of arterial 
stenosis and cardiovascular risk factors (Mathiesen EB, Bønaa KH et al. 2001).  
They also determined that total plaque area appeared to be predictive for first ever 
stroke, with fully adjusted HR (for highest quartile vs no plaque) of 1.73 (95%CI 
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1.19-2.52) for men and 1.62 (95%CI 1.04-2.53) for women (Mathiesen EB, Johnsen 
SH et al. 2011).  Similarly, Prati et al investigated the ability of carotid plaque 
morphology to predict future stroke over and above Framingham Risk factors.  They 
developed a plaque score (total plaque risk score (TPRS)) that included degree of 
stenosis, plaque surface irregularity, echolucency and texture.  They found that a 
high TPRS was a strong predictor of cerebrovascular events.  When they added 
TPRS to conventional Framingham risk factors, the area under the ROC curve was 
significantly increased compared with just the Framingham risk factors (0.90 vs 0.88, 
p=0.04) (Prati, Tosetto et al. 2011).   
1.5 Carotid plaque or cIMT in prediction of vascular 
risk? 
Carotid intima media thickness and carotid plaque both represent alteration to the 
artery wall but their differing relationships with cardiovascular risk factors and CVD 
mean it is unclear which might be of most use in the prediction of vascular events.  
Indeed, Ebrahim et al hypothesised in 1999 that it may be the presence of plaque at 
the carotid bifurcation, rather than the cIMT, that represents a higher risk of disease 
and suggested that efforts be made to address this (Ebrahim, Papacosta et al. 1999). 
It has been argued that carotid intima media thickness does not represent early 
atherosclerosis, with much of the thickening being due to medial hyperplasia in 
response to hypertension, and that rather, it may in fact represent a precursor to 
atherosclerosis (Spence JD 2012).  Plaque on the other hand is a manifestation of 
atherosclerosis, so it has been suggested that carotid plaque might be a better choice 
as a predictor of future vascular disease than intima media thickness (Inaba, Chen et 
al. 2012).   
In 2011, Mathieson et al explored the association between carotid plaque, cIMT and 
first ischaemic stroke in the Tromsø Study (Mathiesen EB, Johnsen SH et al. 2011).  
They followed up 3240 men and 3344 women over a 10 year period after measuring 
cIMT and carotid plaque at baseline.  They found that carotid plaque area had a 
higher hazard ratio for stroke than cIMT per 1 SD increase (for men and women 
respectively, HR 1.23 95% CI 1.09–1.38 and 1.19 (95% CI, 1.01–1.41 vs HR 1.08 
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95% CI 0.95–1.22 and HR 1.24 95% CI 1.05–1.48).  In addition, there was a higher 
risk for those in the highest quartile of plaque area versus no plaque (HR 1.73 95% 
CI 1.19–2.52 for men and 1.62 95% CI 1.04–2.53 for women) whilst there was no 
difference across the quartiles of cIMT.  They also demonstrated that plaque area 
was a better predictor for MI than cIMT in the general population (Johnsen, 
Mathiesen et al. 2007).   
Other studies that have examined the predictive ability of plaque versus cIMT were 
summarized in a meta-analysis by Inaba et al that compared cIMT with carotid 
plaque in the prediction of coronary artery events.  They identified 11 population 
based studies and found that carotid plaque was better at predicting future MI than 
cIMT.  They also undertook a meta-analysis of 27 diagnostic studies that examined 
coronary artery disease and found an increased, but non-significant, diagnostic odds 
ratio of carotid plaque for detecting CAD (Inaba, Chen et al. 2012). 
A study by Nambi et al used data from the ARIC study to examine the effect of 
adding cIMT and carotid plaque to TRFs in cardiovascular risk prediction (Nambi V, 
Chambless L et al. 2010).  They found that net reclassification index was similar for 
TRFs + cIMT and TRFs + plaque.  However, NRI was higher when both cIMT and 
plaque were added to TRFs, suggesting that adding both cIMT and carotid plaque to 
TRFs would improve risk stratification. 
The emerging evidence that plaque may be more predictive of vascular events led to 
an editorial comment by J. David Spence (Spence JD 2012) on the meta-analysis 
performed by Inaba et al (Inaba, Chen et al. 2012) in which he highlights an 
important point – why is plaque not measured at the same time as cIMT, as no 
additional equipment is required?    Therefore, the evidence is not clear as to which 
might be of more use and indeed, whether or not combing cIMT and plaque would in 
fact provide additional value.   
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1.6 cIMT and Type 2 diabetes 
Given that cardiovascular risk scores are known to underperform in people with 
Type 2 diabetes, and the continued excess morbidity from vascular disease, there is a 
need to find additional sources of information regarding future vascular risk in this 
group.  The United States Preventive Services Task Force (UKPSTF) released a 
recommendation statement regarding the use of non-traditional risk factors in the 
prediction of cardiovascular risk.  Carotid intima media thickness is included in their 
list of non-traditional risk factors, along with high-sensitivity CRP (hs-CRP), ankle-
brachial index (ABI), leukocyte count, fasting blood glucose level, periodontal 
disease, coronary artery calcification (CAC) score on electron-beam computed 
tomography (EBCT), homocysteine level, and lipoprotein(a) level.  They highlight 
that there is still insufficient evidence to make a definitive statement on the use of 
non-traditional risk factors, including cIMT, and highlight where there are still gaps 
in the available research.  With regards diabetes, they stated that there is a need to 
clarify clinicians’ views on whether diabetes is a CHD risk equivalent state or is 
instead a risk factor for CHD. As a result, they suggest that non-traditional risk 
factors associations with cardiovascular risk should be assessed in diabetic 
populations (United States Preventative Services Task Force 2009).   
 cIMT in Type 2 diabetes  1.6.1
Several studies have demonstrated increased cIMT in people with Type 2 diabetes in 
comparison with non-diabetic individuals.  A 1994 study by Pujia et al measured 
cIMT in 54 subjects with NIDDM and 54 controls and found that cIMT was 
significantly higher in subjects with NIDDM compared with controls (0.765 vs 
0.692mm respectively), along with higher plasma triglycerides and lower HDL 
cholesterol (Pujia, Gnasso et al. 1994).  cIMT was positively correlated with age, sex 
and negatively correlated with HDL cholesterol.  Another early article published by 
Niskanen et al in 1996 demonstrated that in 84 individuals with NIDDM compared 
with 119 non-NIDDM individuals, those with diabetes had an increased cIMT at 
both the common carotid and bifurcation (Niskanen L, Rauramaa R et al. 1996). 
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In 2006, Brohall et al conducted a systematic review and meta-analysis of studies 
examining IMT in Type 2 diabetes (Brohall G, Odén A et al. 2006).    They 
identified 23 studies comprising 24111 subjects.  The overall finding was that 
subjects with diabetes had a cIMT which was on average 0.13mm higher (95% CI: 
0.109–0.1310) than subjects without diabetes. In addition, those with impaired 
glucose tolerance (IGT) also had a significantly higher cIMT, on average 0.04mm.   
In a follow up study by Brohall et al, they examined cIMT in people with IGT 
compared with controls and in addition performed a meta-analysis.  They found that 
in the case control sub study, there was no increase in the occurrence of subclinical 
atherosclerosis.  The meta-analysis revealed a contrasting result, demonstrating a 
small increase in the CCA IMT in people with IGT (Brohall G, Schmidt C et al. 
2009).  Einarson et al performed a meta-analysis examining the relationship between 
cIMT and blood glucose.  They used 15 592 patients from 11 studies and found a 
correlation between cIMT and post-prandial glucose.  The effect size between 
diabetics and normal was 0.294 (0.245-0.343) and between IGT and normal was 
0.137 (0.072-0.202) (Einarson TR, Hunchuck J et al. 2010).  These results suggest 
that there is a small but significant relationship between glucose and cIMT.  A 1999 
study by Temelkova-Kurktschiev et al also found that cIMT was significantly higher 
in 71 people with newly diagnosed Type 2 diabetes when compared with matched 
controls (mean cIMT 0.95 vs 0.85mm respectively) (Temelkova-Kurktschiev, 
Koehler et al. 1999).   
Lee et al have also demonstrated that people with diabetes had a higher cIMT than 
those without diabetes, and indeed, those with diabetes and CAD had a higher cIMT 
than those with diabetes and no CAD, and both had higher cIMT than non-diabetic 
individuals (Lee E, Emoto M et al. 2009).  On multifactorial logistic regression, they 
found that a high cIMT >1.3mm was associated with concurrent CAD (OR 2.205 
(1.52-3.20) p<0.001).   
A Spanish study published in 2011 compared cIMT in people with diabetes, people 
with hypertension and controls.  They found that cIMT was greatest in people with 
diabetes compared with those with hypertension and controls (0.781mm v 0.738mm 
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and 0.686mm respectively), although progression of cIMT was greatest in people 
with hypertension (Gómez-Marcos, Recio-Rodríguez et al. 2011).   
 Association of cIMT with CV risk factors in people with 1.6.2
Type 2 diabetes 
Before cIMT can be investigated in association with incident disease, it is important 
to establish the relationship between cIMT and cardiovascular risk factors.  The use 
of cIMT as a surrogate marker in clinical trials suggests that cIMT is known to be 
associated with cardiovascular risk factors and cardiovascular disease in people with 
Type 2 diabetes. This section describes published literature on the relationship 
between cIMT and risk factors in people with Type 2 diabetes.  While there are 
several papers that report this, very few publications address this topic as a primary 
aim.   
In their study of normotensive Type 2 diabetic participants, Kong et al found a 
positive association of cIMT with increasing age, male sex and smoking (Kong, 
Elatrozy et al. 2000), while Wagenknecht et al have reported an association between 
cIMT and duration of diabetes in their cross sectional study of 489 people with Type 
2 diabetes (Wagenknecht, D’Agostino et al. 1997) 
Niskanen et al demonstrated in 1996 that mean cIMT in 84 older adults with diabetes 
was associated with a variety of factors including post-glucose 1 hour plasma insulin, 
serum LDL triglyceride and apolipoprotein B (Niskanen L, Rauramaa R et al. 1996). 
However, in 2000, Guvener et al found reported that the major determinants of cIMT 
in people with Type 2 diabetes were age and BMI (Güvener, Tütüncü et al. 2000).   
Smoking has also been associated with cIMT in diabetes as in the general population.  
Karim et al found that mean carotid IMT was higher in smoking than in non-smoking 
subjects with diabetes, although the difference was not statistically significant after 
adjusting for age, gender and other confounders (Karim, Buchanan et al. 2005).  
A 2006 cross sectional study by Yokoyama et al assessed the relationship between 
components of the metabolic syndrome and cIMT in people with Type 2 diabetes and 
no history of CVD (Yokoyama, Kuramitsu et al. 2007).  They found that cIMT 
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increased according to the number of metabolic syndrome components present 
(p=0.002) and the presence of higher blood pressure and higher abdominal obesity 
influenced cIMT.   
The association between glucose fluctuations in people with Type 2 diabetes and 
cIMT was explored by Chen et al in 2010 (Chen, Zhang et al. 2010).  Using data 
obtained from continuous glucose monitoring, a case control study of 36 subjects 
with diabetes and 10 controls several glucose fluctuation parameters increased with 
increasing cIMT and the authors hypothesize that glucose fluctuations may 
accelerate the development of atherosclerosis in older people with Type 2 diabetes.  
This echoes the findings of a 1999 study that examined the association of post 
prandial glucose levels with cIMT in 403 people aged 40-70 years without diabetes.  
They found an association between post prandial hyperglycaemia and increased 
cIMT, suggesting that hyperglycaemia exerts a damaging effect on the endothelium 
(Hanefeld, Koehler et al. 1999).  A similar study by Esposito et al examining post 
meal glucose peaks found that incremental glucose peaks were correlated with cIMT 
(Esposito K, Ciotola M et al. 2008). 
A 2009 study by Butt et al examined cIMT in 200 people with Type 2 diabetes and 
described the association with cardiovascular risk factors.  cIMT was only correlated 
with duration of diabetes, BMI and HDL cholesterol, with an inverse correlation 
being seen in the case of HDL cholesterol (Butt MU and Zakaria M 2009).  A study 
in 380 Korean subjects with newly diagnosed Type 2 diabetes assessed the 
association between cardiovascular risk as determined by the UKPDS risk engine 
and cIMT, among other non-invasive markers (Seon, Min et al. 2011).  After 
adjusting for age, both the 10 year CHD risk and 10 year stroke risks correlated with 
cIMT.  In addition, cIMT correlated with age, HbA1c and gender.   
Inflammatory markers have also been shown to be associated with cIMT in people 
with diabetes.  A study of 105 patients with Type 2 diabetes by Kang et al 
demonstrated that serum high sensitivity CRP was correlated with parameters of 
cIMT and also BMI, WHR as well as plasma lipids (Kang ES, Kim JH et al. 2004).   
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 Association of cIMT with prevalent vascular disease in 1.6.3
people with Type 2 diabetes 
As well as an association with cardiovascular risk factors, it has been important to 
establish an association with cIMT and cardiovascular disease in other vascular beds. 
In 2003, Hunt et al examined carotid intima-media thickness in 1127 non-diabetic, 
66 pre-diabetic and 303 diabetic individuals (Hunt KJ, Williams K et al. 2003).  They 
found that age and sex adjusted mean cIMT of both the ICA and CCA was higher in 
those with pre-diabetes than those without diabetes, although only the ICA IMT 
remained significantly higher after adjustment for established CV risk factors.   
An early Japanese study examined the relationship between cIMT and coronary 
artery disease in 80 people with Type 2 diabetes (40 with CAD determined by 
coronary angiography and 40 with no known CAD) (Mitsuhashi, Onuma et al. 2002).  
Those with known CAD had significantly higher cIMT compared with those without 
CAD.  In addition they noted that cIMT was higher in those who had had CABG 
compared with those who had another procedure.  cIMT, along with hypertension, 
hyperlipidaemia and hyperuricaemia, was significantly associated with prevalent 
CAD on forward stepwise logistic regression, although this was not significant when 
all variables were entered on logistic regression.   
Lee et al examined cIMT and plaque in relation to ischaemic stroke in patients with 
Type 2 diabetes (Lee EJ, Kim HJ et al. 2007).  They found that those subjects with 
MR diagnosed stroke had significant differences in sex, current smoking, 
hypertension and HDL cholesterol compared with controls.  Those with ischaemic 
stroke had significantly higher mean CCA IMT compared to controls.  On logistic 
regression, there was an association between mean cIMT and ischaemic stroke (OR 
5.29 (95% CI 1.05-26.7)), although this relationship did not persist after adjustment 
for cerebrovascular risk factors (OR 1.64 (95% CI 0.14-19.4)).   A similar pattern 
was seen for max cIMT.  
In 2009, Djaberi et al assessed cIMT in 150 asymptomatic diabetic patients, who also 
underwent CT coronary angiography.  cIMT was increased in people with 
obstructive stenosis compared with no atherosclerosis and they found a cut off cIMT 
 
  84 
value of 0.67mm gave a good sensitivity and specificity when predicting obstructive 
coronary stenosis. cIMT was an independent predictor of coronary atherosclerosis 
(p<0.01) (Djaberi R, Schuijf JD et al. 2009).    In 2010, they examined data 
evaluating the relationship between cIMT and myocardial perfusion in 98 people 
with Type 2 diabetes.  Increased cIMT was associated with abnormal myocardial 
perfusion on SPECT scanning.  An increased cIMT was associated with both the 
extent of abnormal perfusion, measured by summed stress score (SSS), and the 
prevalence of abnormal perfusion (Djaberi, Schuijf et al. 2010).   
In a small study of 91 Japanese subjects with Type 2 diabetes, multi-slice CT 
coronary angiography and carotid ultrasound were used to assess coronary artery 
stenosis and carotid IMT (Kasami, Kaneto et al. 2011).  Those subjects that 
demonstrated a higher degree of coronary stenosis had a higher max cIMT than those 
with a lesser degree of stenosis, and for the middle grades of stenosis this 
relationship persisted after adjustment for age, sex, duration of diabetes, hypertension 
and dyslipidaemia.   
 cIMT and risk prediction in diabetes 1.6.4
The association between cIMT and future vascular risk in people with Type 2 
diabetes has not been well documented.  The literature was systematically searched 
to identify publications reporting the results of longitudinal studies investigating 
cIMT as a potential predictor of cardiovascular risk in people with Type 2 diabetes.   
Search strategy 
Titles and abstracts of studies listed in Medline and Pubmed from 1946 until 31st 
December 2013 were searched using the following search terms: [(carotid intima 
media thick* OR carotid atherosclerosis) AND (cardiovascular* OR coronary heart* 
OR stroke OR myocardial inf* OR MI) AND (type 2 diab* OR niddm)].  Reference 
lists of key papers and reviews were searched for additional sources.   
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Selection Criteria 
Criteria for selection were: 1) studies of humans, 2) studies of type 2 diabetes, 3) 
ascertainment of incident cardiovascular events, 4) cIMT measured using ultrasound 
and 5) reports results in addition to risk factors. 
Included studies 
579 studies were identified.  The titles and abstracts were assessed for inclusion 
using the selection criteria.  Six studies were identified that met the criteria.  Of 
those, 4 were prospective studies and 1 was a retrospective study.  A summary of the 
included studies is provided in table 1-6. 
Table 1-6 Summary of studies of cIMT and cardiovascular risk that were identified by literature 
search and met selection criteria 
 Study Design Follow up 
(years) 
N Age CVD outcome CIMT 
measure 




Bernard Prospective  5 229 55.5 CVD and CAD CCA  
Ataoglu Retrospective 10 102 53 CVD CCA 
Malik Prospective 6.4 881 65 CHD and CVD CCA and ICA 
Yoshida Retrospective 5.4 783 - CVD CCA 
Den 
Ruijter 
Meta-analysis 8.7 4220 61 CVD (MI or stroke) CCA  
 
Japanese researchers measured cIMT in 287 subjects with Type 2 diabetes who were 
free of cardiovascular disease (Yamasaki Y, Kodama M et al. 2000).  They measured 
it at baseline and after mean follow up of 3.1 years.  They noted an annual 
 
  86 
progression of cIMT of 0.04±0.004mm/year and identified risk factors that were 
associated with progression of cIMT.  The risk factors identified were baseline 
cIMT, HbA1c and age.  In addition they examined the factors that predicted incident 
non-fatal CHD and found that after adjusting for risk factors, baseline cIMT and a 
low HDL level were independent predictors.   
In 2005, Bernard et al published a study of cIMT in 229 patients with Type 2 
diabetes aged 35-75 years who were free of any cardiovascular complications but 
with at least one cardiovascular risk factor.  They found that age, cIMT, carotid 
plaques, number of plaques, Framingham Risk score and a suboptimal exercise 
tolerance test were associated with incident vascular events.  cIMT was an 
independent predictor of CV events and the predictive ability of cIMT was similar to 
that of the Framingham score.  When added to a Cox model containing Framingham 
risk score, the combination of cIMT and Framingham risk factors improved 
prediction of events compared to Framingham risk factors alone (Bernard S, 
Sérusclat A et al. 2005).  This suggests that using cIMT to predict future vascular 
risk in people with Type 2 diabetes may be of use.   
In 2009, a Turkish group published the results of a retrospective cohort study that 
addressed the addition of cIMT to FRS for predicting vascular events in Type 2 
diabetes (Ataoglu, Saler et al. 2009).  They found that in 102 subjects who were 
followed up for 10 years, cIMT could be useful in addition to Framingham risk 
scoring.   However, caution must be applied to these results as they are the results of 
a retrospective cohort and the effect of bias and confounding may be greater in this 
cohort than in a prospective study.   
More recently, a study by the MESA researchers included 881 individuals with 
diabetes (Malik S, Budoff M et al. 2011).  The authors examined the association of 
both cIMT and coronary artery calcium with CAD and CVD over 6.4 years of follow 
up.  Conversely to previous studies, they identified that cIMT was not predictive of 
events in people with Type 2 diabetes (HR 1.7 (0.7-4.3) for 4th vs 1st quartile of 
cIMT).   
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In 2012 another retrospective Japanese study, including 738 people with T2DM but 
free of CVD, demonstrated that cIMT added to the predictive ability of the FRS in 
the study sample (Yoshida, Mita et al. 2012).  They used Cox proportional hazards 
models to examine the predictive ability of cIMT and brachial-ankle pulse wave 
velocity for cardiovascular events and found that cIMT and not abPWV predicted the 
events.  They then examined the additional effect of cIMT on FRS and found that 
adding cIMT to FRS improved prediction of cardiovascular events.  
The smaller sample size of the previous study was tackled by a large meta-analysis 
published by the USE-IMT collaboration, which demonstrated that in a cohort of 
4420 people with diabetes identified from the cohorts in the collaboration, cIMT did 
not add to cardiovascular risk prediction in individuals with diabetes (Den Ruijter, 
Peters et al. 2013).  While, the authors reported an adjusted hazard ratio of 1.22 
(1.14-1.32) of cIMT for incident cardiovascular events, the effect on reclassification 
was limited.  They identified that a model containing Framingham risk factors alone 
had an AUC of 0.68 and that on addition of cIMT, AUC increased to 0.69, while the 
net reclassification of the cIMT model was small (1.7%).   However, this study has 
several limitations.  Because the individuals are drawn from general population 
cohorts, the definition of diabetes varied over each study which may lead to 
inaccuracy in the diagnosis of diabetes in the group.  They also identify other 
limitations.  Information regarding severity or duration of diabetes is missing and 
data acquisition protocols will have varied with each study, leading to cIMT 
measurement variation across the studies (Den Ruijter, Peters et al. 2013).  The 
authors additionally note that they have not addressed carotid plaque in their 
analysis, which may be a potential avenue for future exploration in people with 
diabetes.   
Summary 
This search of the literature has confirmed that the evidence for the use of cIMT as a 
predictor of cardiovascular events in people with Type 2 diabetes is limited and 
mixed.  There is heterogeneity among the studies in terms of the population studied 
and populations tend to be at the older end of the spectrum of diabetes. The results of 
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the meta-analysis, when taken into context with current research in cIMT in the 
general population, suggests that cIMT may not be as useful as first thought in the 
prediction of cardiovascular risk.  However, the answer is still not clear cut and this 
will be only be addressed by replication of results in further diabetes populations. 
1.7 Carotid plaque and Type 2 diabetes 
Although there is a growing body of evidence for the use of carotid plaque in the 
prediction of cardiovascular risk in the general population, as described in section 1.4 
of this chapter, carotid plaque in persons with diabetes has been not been as 
extensively studied.   
 Association of carotid plaque with CV risk factors and 1.7.1
prevalent CVD in people with Type 2 diabetes 
There are few studies specifically examining the relationship between carotid plaque 
and cardiovascular risk factors in individuals with Type 2 diabetes.  In 2012, Cardoso 
et al reported the independent associations of cardiovascular risk factors with plaque 
score (a composite of plaque presence and degree of stenosis) in 441 people, aged up 
to 80 years, with Type 2 diabetes (Cardoso, Marques et al. 2012). They found that 
the main correlates of plaque score were older age, cigarette smoking and the use of 
antihypertensive medications.   
Additionally, a recent prospective study by Irie et al found that gender, BMI and 
low-HDL-cholesterol are important determinants of the content of the vascular wall 
in diabetic subjects (Irie, Katakami et al. 2014).  
Pollex et al demonstrated that people with Type 2 diabetes and impaired glucose 
tolerance had greater plaque development than normoglycaemic controls (Pollex RL, 
Spence JD et al. 2005).  That study examined plaque in 49 Oji-Cree Canadians and 
49 age and sex-matched controls and measured total plaque volume.  They found that 
total plaque volume and cIMT were only moderately correlated, and interestingly 
noted that use of carotid plaque as an outcome would require a smaller sample size 
than that of cIMT (Pollex RL, Spence JD et al. 2005).  However, it was noted that the 
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difference between the 2 groups in baseline plasma lipid levels could explain the 
difference in plaque volume seen.   
A 2007 study by Ostling et al performed carotid ultrasonography on people with a 
known right carotid artery plaque (47 people with diabetes and 51 without diabetes).  
They assessed plaque echogenicity using standardised gray-scale median values 
(GSM).  A lower GSM indicates a more echolucent plaque.  The investigators noted 
that GSM values were significantly lower in the group with diabetes, compared with 
those without diabetes (37.0±14.8 v 45.5±15.4, P=0.007), indicating a higher 
prevalence of echolucent plaques in subject with diabetes.   When they looked at the 
association between plaque echogenicity and vascular risk factors, they found that 
only triglycerides were associated with plaque echogenicity (Ostling G, Hedblad B et 
al. 2007).   
Several studies have examined the relationship between carotid plaque and prevalent 
disease (both presence and extent).  Akazawa et al performed B mode ultrasound of 
the carotid artery and multi-slice CT coronary angiography on 277 Japanese subjects 
with Type 2 diabetes but without known coronary artery disease.  They created a 
plaque score (the sum of plaque thickness in the carotid artery) and found that when 
plaque score was inserted into a multiple regression model containing traditional 
cardiovascular risk factors, it was a significant predictor of extent of disease in the 
coronary artery (Akazawa, Tojikubo et al. 2012).  Lee et al performed a cross 
sectional study to examine the CCA-cIMT and plaque score in relation to ischaemic 
stroke in people with Type 2 diabetes (Lee EJ, Kim HJ et al. 2007).  Using brain 
MRI and carotid ultrasonography, they found that those with Type 2 diabetes and 
acute stroke had a higher CCA-cIMT and plaque score than those with diabetes who 
were free of stroke.  Unadjusted odds ratios suggested that carotid plaque scores 
were risk factors for acute ischaemic stroke in people with Type 2 diabetes (OR 3.14 
(95% CI 1.67-5.93).  However, once cerebrovascular risk factors were accounted for, 
the association became non-significant (OR 2.14 (95% CI 0.80-5.73).   
A Chinese study performed dual source computer tomography angiography in 125 
people with Type 2 diabetes and suspected cerebrovascular disease (He C, Yang Z et 
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al. 2010).  They examined the prevalence of carotid and cerebrovascular plaques.  
They found that 91.2% of subjects (n=114) had atherosclerotic plaques detected.  
45% of those plaques were non-calcified, 39% were calcified and 16% were of 
mixed composition.  In addition, they noted that there was an extensive distribution 
of plaque – 55.8% of people had a 1-5 diseased segments, and 30.7% had 6-10 
diseased segments.  The most common site of plaque was the cavernous ICA.   
A small Czech study of 38 subjects who underwent stress myocardial single positron 
emission computed tomography (SPECT) reported an association between 
ultrasound detected atheromatous plaque and an abnormal SPECT scan (Charvat, 
Michalova et al. 2006).  An abnormal SPECT scan suggests a myocardial perfusion 
defect, suggesting ischaemic heart disease.  And so this result suggests that carotid 
plaque is associated with prevalent ischaemic heart disease in this study.   The major 
limitation of this work is the study sample size but it does give an indication of a 
relationship between plaque and cardiovascular disease in people with Type 2 
diabetes.   
 
 Carotid plaque and risk prediction in people with Type 2 1.7.2
diabetes 
Publications reporting the prospective association between carotid plaque and future 
vascular risk in people with Type 2 are sparse.  The literature was systematically 
searched to identify publications reporting the results of longitudinal studies 
investigating carotid plaque as a potential predictor of cardiovascular risk in people 
with Type 2 diabetes 
Search Strategy 
Titles and abstracts of studies listed in Medline and Pubmed from 1946 until 31st 
December 2013 were searched using the following search terms: [(carotid plaque OR 
carotid atherosclerosis) AND (cardiovascular* OR coronary heart* OR stroke OR 
myocardial inf* OR MI) AND (type 2 diab* OR niddm)].  Reference lists of key 
papers and reviews were searched for additional sources.  
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Selection Criteria 
Criteria for selection were: 1) original research, 2) studies of humans, 3) studies of 
type 2 diabetes, 4) ascertainment of incident cardiovascular events, 5) carotid plaque 
measured using ultrasound and 6) reports results in addition to risk factors. 
Included Studies 
529 studies were identified.  The titles and abstracts were assessed for inclusion 
using the selection criteria.  Two studies were identified that met the criteria.  A 
summary of the included studies is provided in table 1-7. 
Table 1-7 Summary of studies of carotid plaque and cardiovascular risk that were identified by 
literature search and met selection criteria 
 Study Design Follow up 
(years) 
N Age CVD outcome Plaque 
measure 
Katakami Prospective 7.9 85  CVD Echolucency 
Irie Prospective  4.6 287 65 CVD Echolucency 
 
Only 2 prospective publications were identified.  The first publication by Katakami 
et al, reported the results of a pilot study in 85 adults with Type 2 diabetes who were 
asymptomatic of cardiovascular disease and who were followed up for around 8 
years.  Using the calibrated-IBS (a measure of the echolucency of a plaque) and 
plaque thickness to assess carotid plaque, the authors report that incident events were 
higher in individuals with low calibrated IBS values.  They also report that both 
calibrated IBS value and plaque thickness were independently predictive of events 
even after adjusting for Framingham risk score (HR 0.80 (0.7-0.9) and 1.94 (1.12-
3.21) respectively) (Katakami, Takahara et al. 2012).  The negative relationship 
between IBS and risk is because a low IBS value represents more echolucent (ie high 
risk) plaque.   
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Building on the results of the pilot study by Katakami, Irie et al published data on a 
study of 287 adults with diabetes.  Plaque echolucency was determined using gray 
scale median (a computer aided method of  quantifying plaque echogenicity) (Irie, 
Katakami et al. 2013).  The advantage of this method over the calibrated IBS method 
used in their pilot study (Katakami, Takahara et al. 2012) was that it did not require 
specific software or hardware and so might be a more generalizable method.  The 
authors reported risk factor adjusted hazard ratios of 4.55 for echolucent plaque and 
1.44 for plaque thickness in a model for cardiovascular events.  Adding plaque 
thickness to traditional risk factors significantly increased the area under the curve 
(AUC 0.60-0.73, p<0.05) and addition of plaque echolucency to both risk factors and 
plaque thickness increased the AUC to 0.82 (p<0.05).   
Summary 
The systematic review performed here highlights just how lacking data for the use of 
carotid plaque in risk prediction in people with Type 2 diabetes is. While the results 
of the study presented above are promising, the small sample size and specific 
population under study limit the generalizability of the results.  The evidence base in 
the general population is also small and it is still not clear whether cIMT or plaque 
may yield better prediction for CVD.  What is clear is that much work is required to 
characterise this relationship in people with Type 2 diabetes before any firm 
conclusions can be made.   
1.8 Chapter summary 
Cardiovascular disease is a major cause of morbidity and mortality.  It is particularly 
prevalent in individuals with Type 2 diabetes, and despite increased management of 
established cardiovascular risk factors, it is still the main cause of death in this group.  
Identification of people with Type 2 diabetes who are at higher risk may allow for 
more intensive management of risk factors and reduce the occurrence of events.  
However, risk scores do not adequately predict risk in people with Type 2 diabetes so 
researchers have turned to non-invasive markers of risk in attempts to improve 
prediction.  One such marker is carotid intima media thickness, which is frequently 
used as a surrogate marker of vascular disease in clinical trials, and there is evidence 
 
  93 
from general population studies that this may be useful in addition to current risk 
prediction methods, although this evidence is not definitive.  The USPSTF 
recommends that cIMT be assessed in people with diabetes in order to fully assess its 
value as a prognostic marker.  There is some evidence that cIMT is associated with 
both cardiovascular risk, prevalent disease and future vascular risk but it is not 
conclusive.  Carotid artery plaque is also of interest as a potential marker of vascular 
risk.  It is also measurable by ultrasound and may be more predictive than cIMT for 
vascular disease.  However, evidence for its use in Type 2 diabetes is limited and 
more research is required.   
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Chapter 2: Aims and Objectives 
 
The emergence of cIMT and carotid plaque as novel markers of cardiovascular risk 
in the general population has stimulated interest in their use in higher risk 
populations such as those with Type 2 diabetes.  However, the USPSTF statement of 
2009 highlights that there is a lack of evidence for the use of more novel markers 
such as cIMT in people with Type 2 diabetes (despite their use as surrogate 
cardiovascular outcomes in clinical trials in diabetic populations).  In addition, the 
Mannheim consensus statement on cIMT and carotid plaque highlights that while 
there is a wide range of evidence for the use of cIMT, the evidence base for the use 
of carotid plaque in risk prediction remains sparse (Touboul PJ, Hennerici MG et al. 
2012).  Therefore, the overriding aim of this thesis is to explore the associations of 
both cIMT and carotid plaque with cardiovascular risk factors (both traditional and 
novel), prevalent cardiovascular disease and future cardiovascular risk in a large 
cohort of older people with Type 2 diabetes, using   data from the Edinburgh Type 2 
Diabetes Study.  
 
2.1 Aims 
This thesis will address several key aims: 
1. To determine the frequency and distribution of cIMT and carotid plaque in older 
people with Type 2 Diabetes and investigate methods of cIMT measurement in 
the ET2DS 
2. To determine the association of cIMT and carotid plaque with traditional 
cardiovascular risk factors and with more novel biomarkers of cardiovascular risk 
(those being explored in studies as of potential use in CV risk scores), including 
ABI, ACR, IL-6, CRP and NT proBNP 
3. To determine association of cIMT and plaque with prevalent cardiovascular 
disease (CAD and cerebrovascular disease) in people with Type 2 diabetes 
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4. To assess the potential of cIMT and plaque as predictors of incident 
cardiovascular events and possible associations over and above UKPDS variables 
 
2.2 Objectives 
The aims described above will be achieved through a series of individual objectives: 
1. Describe the study sample demographics and determine intra-reader variability in 
cIMT measurement in the ET2DS and investigate the effect of multiple 
measurements on cIMT values 
2. Describe the frequency, distribution, prevalence and change in cIMT and plaque 
over time in the ET2DS  
3. Determine the cross sectional association of cIMT and plaque with traditional 
and novel CV risk factors, in people with Type 2 diabetes,  
4. Determine the association between cIMT and plaque, with prevalent CVD eg 
MI/Stroke. 
5. Determine the incidence of vascular events in the ET2DS and describe associated 
cardiovascular risk factors 
6. Determine the association between cIMT, carotid plaque and incident vascular 
events  
7. Use statistical modelling to examine the predictive ability of cIMT and plaque for 
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Chapter 3: Methods 
 
3.1 Introduction 
This chapter describes the methods of the research included in this thesis.  The 
research was performed using individual participant data from the Edinburgh Type 2 
Diabetes Study (ET2DS), a large, population-based cohort study that was established 
in Edinburgh in 2006.  The main objectives of the ET2DS are to investigate the 
relationship between a wide range of risk factors and the long term complications of 
Type 2 diabetes, with a particular focus on cognition, liver disease and vascular 
disease.   Prior to this thesis, subjects were assessed at baseline and year 1, and I 
subsequently participated in further data collection at year 4 follow up clinics.  Data 
for this thesis have been drawn from all three data collection points of the ET2DS 
and focuses exclusively on the vascular aspects of the study.  Methods relevant to the 
research included in the thesis are described below and draw on published material 
(Price JF, Reynolds RM et al. 2008; Marioni, Strachan et al. 2010) as well as 
describing my own contribution to follow-up data collection and the statistical 
analysis undertaken. 
 
3.2 Edinburgh Type 2 Diabetes Study  
The ET2DS comprises 1066 men and women with Type 2 diabetes aged 60-74 years 
and living in Edinburgh and the Lothians at baseline (2006-2007).  The full study 
protocol is detailed in the 2008 publication by Price et al (Price JF, Reynolds RM et 
al. 2008).  
 Recruitment, clinic invitations and attendance 3.2.1
Potential eligible participants were identified from the Lothian Diabetes Register 
(LDR), a large computerised database containing details of over 20,000 people with 
Type 2 diabetes living in Edinburgh and the Lothians.  Exclusion criteria were 
minimal and included subjects in whom it was not possible to confirm a clinical 
diagnosis of Type 2 Diabetes, non-English speakers (due to the nature of cognitive 
 
  97 
tests undertaken), corrected visual acuity worse than 6/36, those unwilling to give 
consent and those physically unable to take part in the examination.   
The aim of the study was to recruit 1000 subjects in order to achieve approximately 
90% power at a two-sided 5% level of significance, to detect a Pearson correlation 
coefficient of ≥ 0.10, between continuous outcome measures (e.g. cognitive test 
scores) and predictor variables (Price JF, Reynolds RM et al. 2008). It was estimated 
that a sample size of 800 would retain 90% power to detect a correlation coefficient 
of ≥ 0.12 between risk factors and outcome measures after drop outs and loss to 
follow up. This sample size, with the same levels of power and significance, was 
determined to be sufficient to detect any risk factor that contributed 1% or more to 
the variance in outcome, both at baseline and at follow-up (Price JF, Reynolds RM et 
al. 2008).   
A sample of men and women aged between 60 and 74 years on 1st August 2006 was 
obtained by randomly selecting participants by sex and 5 year age bands from the list 
of eligible participants extracted from the LDR.  5454 subjects were initially invited 
to take part in the study, 3286 of whom replied.  1252 expressed an interest in 
participation in the study and of those, 1077 attended baseline clinics. Four 
participants were unable to take part in the examinations for physical or emotional 
reasons and 7 did not meet the criteria for Type 2 Diabetes after detailed review of 
clinical evidence leaving a total of 1066 participants at baseline (figure 3-1).  
Baseline clinic appointments took place between 14th August 2006 and 29th August 
2007 at the Wellcome Trust Clinical Research Facility (WTCRF) at the Western 
General Hospital (WGH), Edinburgh. 
Participants were invited to attend a further research clinic one year after recruitment.  
Of the 1066 that attended at baseline, 939 (88%) agreed to attend the year one clinic.  
(12 subjects were not invited to the year 1 clinics; 2 had died, 5 refused to be 
contacted out with the originally planned 4-year follow up, 3 were deemed unsuitable 
for contact by the study team and 2 withdrew from further contact after the baseline 
clinic).  Of those that were invited but did not attend the year 1 clinic, 19 could not 
be contacted, 23 were unable or unwilling to attend on health grounds, 38 were 
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unable or unwilling to attend for other reasons, 21 cancelled or did not attend the 
appointment and 13 had died. A further 1 person was unable to complete the 
examination (figure 3-2).  Year 1 clinic appointments took place between 26th 
October 2007 and 27th August 2008 at the Wellcome Trust Clinical Research Facility 
(WTCRF) at the Western General Hospital (WGH), Edinburgh. 
In 2010, appointments were sent out for year 4 follow up appointments. Because of 
the extended time between the follow up clinics, prior to contacting subjects for the 
year 4 follow up clinic, I prepared a newsletter about the study which was sent out in 
December 2009 to all subjects, reminding them that clinics would be starting again, 
and asking them to inform the study of any change in contact details or 
circumstances. This provided an opportunity to identify any subjects who were 
deceased, in addition to those who were not able or willing to continue in the study at 
this point.  Any mail that was returned was tracked using the NHS Lothian health 
records (Med Trak) to identify any change of address or death.  When participants 
were contacted with appointments, those who chose not to attend were recorded as 
declined. Of the 1066 people who attended baseline clinics, 974 were invited to 
attend the year 4 clinics.  Of those that were not invited, 81 had died and 10 had 
withdrawn after the baseline clinic.  Of the 974 that were available to be invited, 15 
people could not be contacted, 30 people withdrew from the study and 100 declined 
to attend.  Of those that withdrew themselves, 9 gave no reason, 6 were too unwell, 2 
had dementia and one did not have diabetes.  Of those that were withdrawn by the 
study team, 5 were too unwell to undergo assessment and 7 had dementia.  Of the 
100 that declined to attend, 39 were unwell, 43 gave no reason, 10 cited personal 
reasons, 5 were full time carers and 3 gave other reasons (figure 3-3).   In total, 830 
participants returned for the year 4 follow up.  Clinical examinations for the year four 
follow up were undertaken by me and three other researchers between 17th May 
2010 and 20th May 2011 at the WTCRF.  Those who were unable to attend due to ill 
health or other reasons were sent a self-completion questionnaire. For those who did 
not return the questionnaire, a questionnaire was sent to their GP. Participants who 
did not attend appointments were telephoned and offered a further appointment.   
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Prior to each data collection clinic attendance (at each wave) and following 
confirmation of an appointment time via telephone, participants were sent an 
appointment letter and a self-completion questionnaire, along with an information 
leaflet, a urine specimen container, with instructions for collecting early morning 
urine (baseline and year 4 only), and a map of the hospital.   Each participant was 
asked to fast overnight, or for at least 4 hours prior to the clinic visit (depending on 
appointment time) to facilitate blood sampling and ultrasound scanning.  Those 
subjects who fasted overnight were instructed to omit diabetic medications and to 
bring them to the appointment to take when a light breakfast was provided.     
Data were collated in a password protected Microsoft Access database.  All data 
were manually entered and double data entry examination was completed to ensure 
data had been entered accurately.   
 Ethical approval 3.2.2
All participants in the ET2DS provided informed consent prior to each wave of the 
study.  In addition the study had full ethical approval from the Lothian Medical 
Research Ethics Committee.  Full ethical permission was granted for ISD data 
linkage performed at baseline and follow up.   
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2168 no reply 
1066 baseline 
participants 
2034 not interested 
1252 interested in 
attending 
  
1077 attended clinic 
appointments 
  Further exclusions applied:- 
4 unable to take part in 
examinations 
7 did not meet criteria for type 2 
diabetes 
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1054 invited to year 
1 clinic 
2 died 
5 refused to be contacted 





23 “unwel l” 
38 unwi l l ing 
21 DNA 
13 died 
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974 invited to year 4 
clinic 
 






100 declined to attend 
15 unable to contact 
30 withdrawals 
39 “unwel l” 
43 no reason 
10 personal  reasons  
5 ful l  time carer 
3 other 
 
Withdrawn by patient 
9 no reason 
6 unwel l  
2 dementia  
1 no diabetes  
 
Withdrawn by team 
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3.3 Clinical examinations 
 Height & weight 3.3.1
Height at baseline was recorded using a wall mounted height tape.  Subjects were 
asked to remove shoes and to stand with their heels and back against the wall.  Eyes 
were lined up with the centre of the ear to allow measurement of maximum height.  
Measurements were recorded to the nearest 0.1cm.  Weight was measured without 
outdoor clothing, shoes or heavy items and recorded on the data collection form to 
the nearest 0.1kg.   
 Electrocardiogram 3.3.2
An ECG was recorded using a GE Marquette MAC 1200 ECG machine.  Electrodes 
were positioned following preparation of the skin (cleaning, drying, exfoliating or 
shaving as required).  Four electrodes were applied to the limbs and six to the chest.  
The ECG was obtained with the patient lying still and relaxed.   ECGs were coded by 
a senior clinician using the Minnesota coding system (Prineas RJ, Crowe RS et al. 
1982) and entered manually into the database. 
 Brachial blood pressure 3.3.3
Brachial blood pressure was measured in the right arm, directly after ankle brachial 
pressure index was measured.  The cuff was applied to the right arm and using a 
stethoscope, systolic pressure was read when clear, repetitive tapping sounds 
appeared for 2 consecutive beats.  The diastolic pressure was taken when the tapping 
sounds were no longer audible.  
 Ankle brachial pressure index 3.3.4
Following 5 minutes of rest, the sphygmomanometer cuff was placed around the arm 
and the hand held Doppler was placed over the brachial artery at the point of 
maximum pulsation.  The cuff was inflated to 30mmHg above the estimated systolic 
pressure.  The pressure was reduced at a rate of 2-3mmHg per second and systolic 
pressure was recorded when clear sounds first appeared.  Measurements were 
recorded to the nearest 2mmHg.  This was repeated in the both arms and both feet 
(dorsalis pedis and posterior tibial pulses) to obtain 6 readings.  ABI was calculated 
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using the lowest ankle pressure as the numerator and the highest brachial pressure as 
the denominator.   
 
3.4 Self-completed questionnaires 
Subjects were sent out a questionnaire prior to attending the baseline, year 1 and year 
4 clinics (appendices A, B and C).  At baseline, in addition to basic demographic 
questions (date of birth, education level, marital status, ethnicity) this questionnaire 
included: questions regarding previous medical diagnoses and procedures; date of 
diagnosis of diabetes; current and recent medications; alcohol consumption; smoking 
history (have they ever smoked and if so, how many cigarettes/cigars/pipe per day 
and for how long); the WHO chest pain questionnaire (Rose G, McCartney P et al. 
1977) and the Edinburgh Claudication Questionnaire (Leng GC and Fowkes FG 
1992). At year 1, questions regarding current medication use were repeated, in 
addition to other conditions not related to this thesis. At year 4, the self-completion 
questionnaire included the same questions as baseline and in addition, questions 
regarding new medical diagnoses in the past 4 years as well as further questions 
regarding current medications, and use of specific medications in the past 6 months.  
In the baseline and year 4 questionnaires, the responses regarding events, diagnoses 
and operations were coded using ICD 10 and OPCS codes, prior to data entry.  
Medications were coded using BNF coding.  The chest and leg pain questionnaires 
were coded at the time of the clinic.  Any questions that the subject could not answer 
were completed with the assistance of study staff and all responses checked before 
the subject left the clinic, where possible.   
 
3.5 Blood & urine sampling and processing 
 Venepuncture & urine sample collection 3.5.1
Venous blood samples were obtained on the day of clinic attendance.  After a period 
of fasting, a tourniquet was applied above the antecubital fossa and an appropriate 
sampling site identified.  Skin was cleaned using alcohol wipes and venepuncture 
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undertaken using a Monovette blood collection system.  Samples for processing and 
storage by study staff (for later analysis) were immediately labelled with the study 
number and the date the blood was taken and placed directly onto ice for processing 
at the end of the clinic.  Samples sent to the Western General Hospital Combined 
Haematology and Biochemistry Laboratory were labelled with the minimum required 
data set and sent to the laboratory at the end of each clinic.  Reasons for any tubes 
not being filled were noted, as was the time of venepuncture.  Attempts were made to 
obtain blood samples from each participant.  Where blood sampling was not possible 
on the day of clinic attendance, subjects were invited back to a further appointment 
for blood sampling.  When that was not possible, home visits were carried out where 
possible in order to obtain samples.  Samples processed by study staff were 
centrifuged before being separated and stored at -80C.  CRP, IL-6 and NTproBNP 
were measured in these samples. 
An early morning urine specimen was collected for measurement of urinary albumin 
and creatinine for calculation of the albumin: creatinine ratio (ACR).  Participants 
were sent instructions and a sample tube to collect an early morning urine sample.  
Samples were stored on ice on receipt at the clinics and frozen at -80C for later 
analysis.   
 Analysis of samples 3.5.2
Serum isotope dilution mass spectrometry–traceable creatinine, plasma HbA1c, total 
cholesterol and HDL cholesterol were measured in venous blood and creatinine 
measured in urine (for calculation of albumin:creatinine ratio) and analysed 
according to standard protocols in the Department of Biochemistry, Western General 
Hospital, Edinburgh, UK. Serum creatinine measurement was used to estimate 
glomerular filtration rate (eGFR) using the CKD-EPI equation ((Levey, Stevens et al. 
2009)). Assays for plasma CRP and IL-6 were performed in the University 
Department of Medicine, Glasgow Royal Infirmary, as described by Marioni et al 
(Marioni, Strachan et al. 2010). CRP was assayed using a high-sensitivity 
immunonephelometric assay (Tzoulaki, Murray et al. 2007), while IL-6 antigen 
levels were determined using high-sensitivity ELISA kits (R&D Systems, Oxon, 
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U.K.).  Plasma NT-proBNP concentrations were determined using the Elecsys 2010 
electrochemiluminescence method  (Roche Diagnostics, Burgess Hill, UK) calibrated 
using the manufacturer's reagents. Manufacturer's controls were used with limits of 
acceptability defined by the manufacturer. Low control CV was 6.7% and high 
control CV was 4.9%. 
 
3.6 Ultrasound scanning  
Ultrasound of the carotid arteries was performed at both year 1 and year 4 by the 
same specially-trained ultrasonographer.  Images were captured using a Siemen’s 
Elegra Ultrasound. A 2-5-MHz transducer was used.   
 cIMT measurement at Year 1 and Year 4 3.6.1
The cIMT was measured according to the ET2DS ultrasound SOP (appendix D).   
The subject was positioned at 45 degrees, with the head turned to the side 
contralateral to measurement.  The probe was placed on the neck until the carotid 
artery could be visualised.  The probe was then turned so that the artery wall was 
parallel with the transducer.  Measurements were made of the intima media thickness 
at a point 1cm below the bifurcation of the common carotid, in an area free of 
plaque.  Three measurements were made on each side.  An image was frozen and 
saved for each measurement.  Images were securely stored on a University of 
Edinburgh hard drive. 
 Carotid plaque assessment at Year 1 and Year 4 3.6.2
Plaque was defined in the SOP as a focal structure encroaching into the arterial 
lumen of at least 0.5 mm or 50% of the surrounding IMT value, or with a thickness 
>1.5 mm as measured from the media-adventitia interface to the intima-lumen 
interface, and was judged subjectively by the ultrasonographer.  Carotid plaque was 
assessed as present or absent in both right and left common carotids, internal 
carotids, external carotids and carotid bifurcations.   
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Plaque morphology was assessed subjectively by the sonographer.  Echolucency was 
defined as presence of one or more plaques appearing black or almost black as 
flowing blood (compared with echogenic plaque which appears white or almost 
white, similar to the far wall media-adventitia interface).   Heterogeneous plaque was 
recorded if one or more plaques were present in which echogenicity of more than 
20% of the plaque area differed substantially from the echogenicity of the rest of the 
plaque.   
Plaque thickness was also assessed.  The plaque with the maximum thickness was 
identified on each side and measured using cross hairs placed by the 
ultrasonographer.  Plaque thickness was recorded for both left and right.   
 Viewing and storage of carotid ultrasound images 3.6.3
At year 1, all ultrasound images were downloaded from the ultrasound in a 
proprietary format.  Prior to use in this thesis, they were required to be converted to 
DICOM format in order for use with University software.  File conversion was 
undertaken by Dr Calum Gray of the Clinical Research Imaging Centre, University 
of Edinburgh.   
At year 4, images were downloaded directly from the ultrasound machine in DICOM 
format onto MO discs and transferred by me to a networked hard drive using an MO 
disc reader.  Images were recorded and saved by me in separate files for each subject, 
labelled by subject number.  I stored the images on a networked drive, which was 
backed up, and a copy was also stored on a portable hard drive (Freecom Hard Drive 
Classic 3.5” 500GB USB-2.0). 
Following this, I was able to view both year 1 and year 4 images using MicroDicom 
viewer.  Analyze 10.0 software was used to prepare images for use with the IMT 
measurement software (detailed later in this thesis).   
 IMT measurement validation at Year 4 3.6.4
In order to assess intra-observer variability in the measurement of cIMT, I selected 
individuals to undergo repeat cIMT measurement at year 4.  Subjects who reattended 
the clinic for other reasons were invited to be rescanned at the time of return.  52 
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subjects were recruited to this validation study and each subject returned to the clinic 
at a time suitable for them.  They underwent repeat cIMT measurement using the 
same ultrasound protocol as was used at the previous 2 measurement sessions.  The 
sonographer was blinded to the previous year 4 measurements.  Data were recorded 
in a Microsoft Access database.   
 
3.7 IMT measurement software 
In collaboration with Dr Calum Gray and Dr Tom MacGillivray of the Image 
Analysis team at the Clinical Research Imaging Centre (CRIC), part of the Wellcome 
Trust Clinical Research Facility in Edinburgh, I contributed to the development of a 
computer programme that could be used perform serial measurement of IMT along a 
length of carotid artery wall using the frozen images stored at the time of ultrasound 
assessment.  The aim of developing this software was to allow for a comparison 
between taking only 2 or 3 measurements at points on the vessel wall and taking 
multiple measurements along the wall.  Broadly speaking, once an outline of the IMT 
of vessel wall is identified by the user, the software finds a line of best fit along the 
midpoint of the wall section identified, and takes measurements of the cIMT at an 
angle perpendicular to this line (see software SOP, appendix E).  
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 Program algorithm 3.7.2
Figure 3-4 Schematic for calculating cIMT (reproduced from software SOP, Appendix E) 
 
The assumption of the program is that measurements of IMT taken along the vessel 
wall must be taken perpendicular to the edges as far as possible to take into account 
any bend in the wall, which allows the measurement of IMT to be a meaningful 
value (figure 3-4).  Users have control over the best fit line pixel distance and the 
number of pixels between each cIMT reading.  This can be defined after the image is 
prepared, allowing the number of readings taken per image to be altered as required.  
A line of best fit is made between the two user drawn lines and then perpendicular 
lines were drawn between the edges and the best fit lines.  These are deemed to be 
the intima media thickness.    
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 Preparation of images 3.7.3
Figure 3-5 Outline of interfaces following manual tracing (reproduced from software SOP, 
Appendix E) 
 
Analyze 10.0 was used to create an object map of each image (figure 3-5).  This 
involved tracing the outline of the lumen-intima media border using a spline.  Then, 
using a new spline, the line of the media-adventitial interface was traced.  The 
sections of artery wall that were identified for measurement were free of plaque, as 
judged by each user, in keeping with the study SOP for measurement of IMT.  As 
long a section of artery wall as possible was measured.  The splines were then 
toggled if appropriate to create a more accurate fit and then these edits were applied 
to the object map.  The object map was then saved, along with a copy of the image. 
Once I was experienced in processing the images, I trained a further two readers to 
assist in preparing the images. Two hundred and thirty five participants’ images were 
prepared.   The time that it took to prepare each set of images limited the number of 
participants’ images that could be included in the sample.  This limited the statistical 
analysis that could be performed as the way in which the images were selected was 
not completely random (as preparing the images took a lot longer than was initially 
expected).  
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 Processing of images 3.7.4
Figure 3-6 Screenshot of software measurement output (reproduced from software SOP, Appendix 
E) 
 
Following preparation of the images, processing of the images by the software was 
performed in batches overnight.  The name of the image file and the object map file 
were inserted into an Excel spread sheet which was then used by the software to 
process the files in batches. The number of measurements could be easily altered if 
needed and the measuring process rerun if required.    However, for the purposes of 
this thesis a line of best fit distance of 50 pixels and measurement distance of 10 
pixels was chosen for analysis.  Once measured, the programme automatically 
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exported the measurements to an excel spread sheet where they were stored.  In 
addition to the raw individual measurements, the mean, maximum and minimum 
values were summarised, as well as number of measurements and standard deviation 
of the mean. 
 Limitations of IMT software 3.7.5
The major limitation of this process was image quality and the possibility of human 
error introduced when the IMT borders were traced.  The machine on which the 
images were obtained could not produce images of a high enough quality to allow 
automatic edge detection to be used.  Human error was introduced at the point of line 
selection. However, these limitations were felt to be acceptable in the context of this 
research as the comparable measure is the sonographer measurements which are 
open to the same limitations, and the main aim of the research was to find the overall 
effect of increasing the number of measurements used to calculate the mean cIMT.   
 
3.8 Determination of prevalent and incident events 
Prevalent and incident cardiovascular events used in this thesis were identified using 
several sources of information to ensure that all possible events were captured.  At 
both baseline and year 4 follow-up, events and diagnoses that were reported by 
participants in the self-completed questionnaire or on ECG were identified.  
Attempts were made to confirm these diagnoses using data linkage from ISD.  
Additionally, any events that were not reported by subjects but were present on ISD 
linkage were identified.  Further evidence was obtained from general practitioners 
and hospital notes where required.  
I was responsible for the identification and confirmation of incident cardiovascular 
events following the year 4 follow up clinic, while baseline events had been 
determined by members of the baseline study team on completion of the baseline 
clinics.   
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 Non-fatal events 3.8.1
All possible cardiovascular events were confirmed by an events committee 
comprising 2 clinically qualified members of the ET2DS team, as recommended by 
the FDA in 2010 (Centre for Drug Evaluation and Research 2008). Data was 
collected by one team member and the criteria applied.  Cases were then discussed 
by the 2 panel members and decisions in cases where more detail was need were 
discussed following further data collection from hospital notes.  In the case of any 
discrepancies in decisions making, a third clinically qualified consultant was 
available to adjudicate. 
Questionnaire and Examination 
Baseline 
At baseline, subjects completed a questionnaire (appendix A) and were asked if they 
had ever had a doctor diagnosis of angina, MI, stroke, coronary intervention and 
peripheral intervention.  They were also asked to report current medication use and 
whether they were taking medication for angina, hypertension, raised cholesterol or 
if they were taking aspirin.  They also completed the WHO chest pain Questionnaire 
(Rose G, McCartney P et al. 1977).  The ECG taken as baseline was also available to 
provide information, having been coded using the Minnesota coding system by 
clinically trained members of the study team (coded as ischaemic if Minnesota codes 
were 1.1 to 1.3; 4.1to 4.2; 5.1 to 5.3; 7.1, and coded as Q-waves if Minnesota codes 
were 1.1.1 to 1.2.5; 1.2.7; or 9.2 plus 5.1 or 5.2 (Prineas RJ, Crowe RS et al. 1982). 
Year 4 
The self-reported questionnaire at year 4 (appendix C) asked subjects to report 
whether they had had a doctor diagnosis of angina, MI, stroke, coronary intervention 
and peripheral intervention in the 4 years since their baseline clinic attendance.  They 
were also asked about current medication use, completed the WHO chest pain 
questionnaire again, and a repeat ECG was taken and coded using the Minnesota 
coding system by a clinically trained member of the study team (as at baseline). 
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Information Services Division Data Linkage 
At baseline, data concerning deaths and hospital discharges were obtained from the 
Information Services Division (part of NHS National Services Scotland).   
Baseline Data Linkage 
Identifying data were sent to ISD and data linkage performed to capture all hospital 
discharge codes (both ICD 9 and 10) and OPCS 4 codes for each subject, from the 
earliest point available up until baseline.  The SMR linked dataset was used to 
perform the linkage (SMR01, 04, 06 and GROS deaths records).  All ICD 10 codes 
for cardiovascular disease (I20-I25, I61, I63-I66, I252, I679, I694, G45 and G659) or 
where not available, ICD 9, were extracted manually from the ISD data linkage. 
Year 4 Data Linkage 
Prior to performing linkage, an application was made to ISD.  Full ethical permission 
was granted.  Information was obtained regarding all hospital discharges and 
procedures for each subject between 1st January 2007 and 20th May 2011.  
Information was also obtained regarding all deaths in that period.  Subjects were 
again linked to the SMR linked dataset.  All ICD 10 codes for cardiovascular disease 
(I20-I25, I61, I63-I66, I252, I679, I694, G45 and G659) were extracted manually 
from the ISD data linkage. 
Hospital Notes and GP Information at Year 4 
In situations where there was discrepancy between data linkage and self-report of an 
event, or where individuals did not meet the full criteria (detailed later) for a given 
event, I searched individual hospital notes for information to help confirm or refute a 
diagnosis.  If hospital notes were uninformative or unavailable, GPs were asked to 
confirm any events.   
 Fatal Events 3.8.2
Next of Kin Reporting of Deaths 
During the process of appointment making, reports received from spouses/family 
members of a participant’s death were noted in the database, along with a provisional 
cause of death if given.  In addition, correspondence in response to the study 
newsletter also provided information of participant death.   
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ISD Linkage to Death Information 
Linkage to the combined dataset at ISD allowed identification of all registered 
hospital and out-of-hospital deaths, and provided a cause of death.   
Confirmation of Cause and Date of Death 
All deaths notified by next of kin or by ISD data linkage were investigated. Those 
deaths notified by ISD data linkage had the date of death and underlying cause of 
death noted.  Those deaths notified by next of kin were cross referenced with the ISD 
linkage and those that were not present on both lists were investigated further using 
medical records so that cause and date of death could be confirmed.   
 
3.9 Criteria for definition of cardiovascular events 
 ET2DS criteria for prevalent CVD at baseline (2006/2007)  3.9.1
MI 
Myocardial infarction was recorded if 2 out of 3 of the following criteria were met: 
(i) Self-report (subject‘s recall of a doctor‘s diagnosis) of heart attack 
(ii) Myocardial infarction indicated by WHO chest pain questionnaire 
(iii) ECG evidence of ischaemia 
OR if both of the following were present: 
(i) Self-report (subject‘s recall of a doctor‘s diagnosis) of heart attack 
(ii) Prior hospital discharge code for MI (ICD10 codes I21-I23, I252) 
Stroke 
Stroke was recorded if 2 out of 3 of the following criteria were present:  
(i) subject recall of a doctor‘s diagnosis of stroke 
(ii) prior hospital discharge code consistent with stroke (ICD10 codes I61, 
I63-I66,I679, I694) 
(iii) confirmation by clinical notes reviews that event not due to transient 
ischemic attack (TIA). 
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TIA 
Transient ischaemic attack was recorded if two out of three of the following 174 
criteria were present: 
(i) subject recall of a doctor‘s diagnosis of stroke 
(ii) prior hospital discharge code consistent with TIA (eg. ICD10 codes G45, 
G659) 
(iii) confirmation by clinical notes reviews that event due to TIA. 
TIA was also recorded if subjects volunteered a self-reported history of TIA, “mini 
stroke” or “slight stroke” on the questionnaire. 
Angina 
Angina was recorded if two out of three of the following criteria were met: 
(i) self-report of doctor-diagnosed angina or taking regular anti-anginal 
medication 
(ii) angina indicated on WHO Chest Pain Questionnaire 
(iii) Ischaemic ECG codes 
OR if both the following criteria were met: 
(i) self-report of doctor-diagnosed angina or taking regular anti-anginal 
medication 
(ii) prior hospital discharge code for ischemic heart disease (ICD10 codes 
I20-I25). 
 
 ET2DS criteria for incident CVD at year 4 (2010/11) 3.9.2
I identified potential vascular events, operations and procedures using the self-
reported questionnaire, GP questionnaire, ECG and hospital discharge coding. I then 
developed and applied the following criteria and searched hospital notes for 
additional information if the criteria were not immediately met.  If there was doubt as 
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to whether criteria had been met even after searching hospital notes, possible cases 
were discussed by the events panel on an individual basis and a consensus decision 
was made.   
Fatal MI 
Either death certificate confirmed OR criteria for non-fatal MI within 4 weeks of 
unexplained/sudden death. 
Non-fatal MI/ACS 
Either ICD-10 code for new MI from ISD record linkage to discharges from Scottish 
hospitals (SMR), with date confirming that event occurred after baseline clinic visit 
PLUS one or more of the following (supporting evidence): 
i) Subject report of a doctor diagnosis of MI on the 4-year self-completion 
questionnaire, with date consistent with ISD report OR NEW subject report 
of MI as cause of chest pain on the WHO CPQ 
ii) Minnesota ECG codes for MI which were not present at baseline 
iii)  GP report of an MI on postal GP questionnaire (for clinic non-attenders only), 
with date consistent with ISD report 
OR If criteria for MI met following scrutiny of the clinical notes (hospital and/or 
GP notes) of any subject with one or more individual indicators of a possible MI, 
except ECG (see (a) above) but not meeting the full criteria under (a). 
 
Angina 
Either A diagnosis of angina during follow-up required that subjects did not meet 
criteria for angina at baseline, plus either: 
 
i) ICD-10 code for angina as PRIMARY diagnosis code from ISD record 
linkage to discharges from Scottish hospitals (SMR), with date confirming 
that diagnosis occurred after baseline clinic 
OR At least two of the following: 
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i) Subject report of a doctor diagnosis of angina (or of taking medication for 
angina) with date consistent with diagnosis after baseline 
ii) New ischaemic ECG at year 4 
iii)  Angina on WHO chest pain questionnaire  
OR Clinical diagnosis of angina recorded by a doctor on scrutiny of the notes of 
any subject with one or more individual indicators of possible new angina (new ICD 
code for angina but not primary code, new self-report of doctor diagnosis or 
medication, new angina on WHO chest pain questionnaire) but not meeting full 
criteria under 1 or 2 above. 
(N.B. If actual date of diagnosis of angina cannot be ascertained, then date should be 
date of follow-up clinical appointment) 
New possible other IHD 
A diagnosis of ‘possible other IHD’ during follow-up required that subjects did not 
meet any of the criteria for events listed under ‘all IHD’ at baseline (including 
‘possible other IHD’), plus: 
i) ICD code for IHD with date consistent with diagnosis since baseline in 
subjects without MI, angina or coronary intervention at follow-up. 
Fatal stroke 
Death certificate confirmed or criteria for non-fatal stroke within 6 weeks of 
unexplained/sudden death 
Non-fatal stroke 
Either ICD-10 codes for stroke as PRIMARY diagnosis 
OR Self-report of stroke confirmed as stroke on scrutiny of clinical notes 
OR  Non-primary ICD-10 codes for stroke, confirmed as stroke on scrutiny of 
clinical notes 
TIA 
Either ICD-10 code for TIA as PRIMARY diagnosis on ISD data 
OR  Self-report of stroke confirmed as TIA on scrutiny of clinical notes 
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3.10 Data analysis 
Data were collected and entered into a Microsoft Access database and exported to 
IBM SPSS v19 for data analysis. 
 Double data entry 3.10.1
In order to assess the accuracy of the data collected at year 4 and the resultant 
variables, the paper records of a random sample of 80 individuals (10%) were 
selected from the cohort and used for double data entry.  I, along with three other 
study team members re-entered 20 sets of notes each into the database.  Comparison 
of the resulting dataset with the original data set revealed an error rate of 0.007.  On 
discussion with senior study team members, this was felt to be an acceptable level of 
error and it was agreed that the resultant variables were reliable for use.   
 Data cleaning and outliers 3.10.2
Following completion of data entry at year 4, all data in the database was analysed 
for outlying or unusual values.  These were examined on an individual basis and 
compared with original copies of the results.  Input errors were changed to the 
correct value on the original database, and detailed logs of any changes were kept.  
Those values which could not be explained by input error were removed from the 
database if not biologically plausible, and retained if simply high but true values.  As 
part of this procedure I prepared the year 1 and year 4 cIMT and plaque and the year 
4 renal function, lipids, ECG, ABPI and brachial blood pressure. 
The year 1 cIMT measurements were examined for any outlying or unusual results 
(<0.5mm or >1.5mm), and those that were identified as having been incorrectly 
measured by the sonographer (following analysis of stored images) were removed 
from the database.  Examples of this include where a plaque has clearly been 
measured instead of an area of IMT free of plaque, or where the measurement 
callipers were incorrectly placed.  Measurements that were simply data input errors 
were corrected following comparison with images, and any other unusual values that 
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could not be explained in this way were dealt with on a case by case basis.  Any 
values that could not be explained were removed from the database.  
Year 4 IMT measurements were dealt with in the same way, as were plaque 
measurements. 
 
 Variables used in this thesis 3.10.3
Variables included in this thesis are summarized in table 3-1. 
Demographic Variables – Age at year 1 is a continuous variable calculated as [date 
of year 1 clinic appointment – date of birth].  Sex is a binary variable (male or 
female). SIMD is a 5 level categorical variable (1 being most deprived quintile and 5 
being least deprived).   
Diabetes Variables – Duration of diabetes is calculated as [date year 1 appointment 
– date of diagnosis of diabetes] and is used as a log10 transformed variable in 
analyses.  HbA1c is a continuous variable (%Hb) and diabetes treatment was 
recorded as a 3 level categorical variable – diet alone, oral medication alone or 
insulin ± oral medication.   
Blood Pressure Variables – Systolic and diastolic blood pressure are continuous 
variables reported in mmHG.  The use of antihypertensive medications is a binary 
variable (yes or no). 
Lipid Variables – Total and HDL cholesterol are continuous variables (mmol/l) and 
use of lipid lowering medication is a binary variable (yes or no). 
Smoking Variables – Smoking status is described as a 3 level categorical variable 
(current, ex or never smoker). 
Obesity Indices – BMI is a continuous variables calculated using height and weight 
measured at baseline clinics, using the formula BMI = weight (kg) / [height (m)]2.   
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Novel Markers – IL-6, ACR and CRP are continuous variables on a log scale (due 
to non-normal distribution).  ACR and eGFR are also continuous variables.  ABPI is 
calculated as [lowest ankle pressure (mmHg) / highest brachial pressure (mmHg)].  
All novel markers were log10 transformed for use in analyses. 
Carotid Ultrasound Variables –All cIMT variables are continuous variables.  There 
is no definitive recommendation on which summary measure of cIMT to use. Several 
measures of cIMT will be used in this thesis.  Mean cIMT is the mean of all 6 cIMT 
readings; maximum cIMT is the highest of the 6 IMT readings; maximum mean 
cIMT is the higher of mean left and mean right IMT; mean maximum cIMT is the 
mean of the maximum right and maximum left IMT.  Plaque presence (at least 1 
plaque in any segment of the carotid arteries) is reported as a binary variable (yes or 
no).  Mean plaque thickness is the mean of the right and left plaque thicknesses. 
Maximum plaque thickness is the higher of the right and left plaque thicknesses. 
Plaque score is the sum of the areas in which at least one plaque is present 
throughout the left and right carotid tree (min 0 areas, max 8 areas), based on a 
method used by Lee et al (Lee EJ, Kim HJ et al. 2007).  Plaque score was also used 
as a binary variable (score ≤4 or score >4).  Plaque echogenicity is a 4 level 
categorical variable (echogenic/no plaque only, echolucent plaque only, 
heterogeneous plaque only, both types of plaque).  It is also considered as a binary 
variable (low risk plaque (echogenic/no plaque) vs high risk plaque (echolucent, 
heterogeneous or both types).   
Cardiovascular Event Outcomes – Event variables for prevalent and incident CVD 
are binary (yes or no). Outcomes are (for both prevalent and incident events): 
 Any CVD – either angina, fatal or nonfatal MI, TIA, fatal or non-fatal stroke, 
and any cardiovascular death. 
 Any CAD – either fatal or nonfatal MI or angina 
 Any cerebrovascular – either fatal or non-fatal stroke or TIA 
 Any fatal (incident only) – any fatal cardiovascular event (including other 
ischaemic heart disease)   
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In most cases, prevalent events were taken from baseline data.  In addition, because 
cIMT was measured at year 1, any incident events recorded between baseline and 
year 1 were subsequently attributed to “prevalence”.   
Table 3-1 Collection time point for variables used in this thesis 
Demographic Baseline Year 1 Year 4 
Date of birth BMI ABI IMT and Plaque 
SIMD Smoking variables Systolic BP Incident CVD events 
Sex NTproBNP Diastolic BP  
Age IL-6 Lipids  
 eGFR HbA1c  
 ACR Medication use  
 CRP IMT & plaque  
 Prevalent CVD events Duration DM  
SIMD=Scottish Index of Multiple Deprivation, BMI=body mass index, NTproBNP=amino terminal brain natriuretic peptide, 
IL-6=interleukin 6, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, CRP=c reactive protein, 
CVD=cardiovascular disease, ABI=ankle brachial index, BP=blood pressure, HBA1c=glycated haemoglobin, DM=diabetes 
mellitus, IMT=intima media thickness 
 
 Statistical analysis  3.10.4
In the analyses presented in this thesis, a p value of less than 0.05 was generally 
taken to denote statistical significance, as is standard in most epidemiological 
research.  Consideration was given to correcting for the effect of performing multiple 
analyses, using the Bonferroni method.  At a level of <5% significance, there is a less 
than 5% chance the null hypothesis is rejected, even though it is true (type I error).  
As the number of analyses increases, the likelihood of a type I error increases and so 
in the Bonferroni method, the level of significance is divided by the number of 
analyses performed to reduce the level below which a result is considered significant, 
thereby reducing the likelihood of type I errors.  However, the consequence of this is 
an increase in type II errors, whereby the null hypothesis is accepted, despite being 
untrue.  (Perneger TV 1998) highlights that the main problem with this approach is 
that the point at which one limits the number of tests divided by (eg in on paper, or in 
one study or indeed, a researchers entire lifetime) becomes arbitrary and in the 
context of research undertaken with a predetermined hypothesis (as in this thesis), it 
is more important to consider the significance of test results in the context of other 
tests, taking care to keep the number of tests undertaken to the minimum required for 
the research.  This was the approach adopted in this thesis.   
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Descriptive analysis and cross sectional analysis of carotid variables 
with risk factors 
Variables for analysis were drawn from the year 1 data rather than baseline where 
possible, as IMT was first measured at the year 1 clinic.  Baseline demographics of 
the study population are described to allow comparison with those who attended year 
1 follow up.  Variables that were not measured at year 1 were substituted with the 
corresponding baseline variable (BMI, smoking status and pack years, NTproBNP, 
IL-6, eGFR, ACR and CRP). 
Histograms of continuous variables were visually inspected for normality.  Most 
variables were normally distributed.  Those variables that were not normally 
distributed were duration of diabetes, ACR, NTproBNP, IL-6 and CRP.  Log10 
transformation was used to transform all the variables except pack years, which was 
square root transformed.  Histograms of variables after transformation were 
inspected to confirm that a normal distribution had been achieved (figure 3-5). For 
normally distributed variables, mean and standard deviation are quoted, and for 
skewed variables, median and interquartile ranges are described. 
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Figure 3-8 Histograms of untransformed and transformed skewed variables 
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Unadjusted associations between continuous variables were assessed using Pearson 
correlation coefficients.  The r value and corresponding p value are reported.  Partial 
correlation was used to examine age and sex adjusted correlation coefficients.  R 
values and p values are reported.  For categorical variables, unadjusted and age and 
sex adjusted associations with continuous variables was assessed using ANOVA (β 
values and p values reported).  Chi squared testing was used to examine relationships 
between two categorical variables (chi square and p value reported).    
Linear regression models were used to examine the multifactorial determinants of the 
continuous IMT and plaque variables.  Variables were entered into the model and β 
coefficients and p values reported.  Model variance explained is also reported (r2).   
Association of carotid variables with prevalent CVD 
Logistic regression models were used to assess the association between prevalent 
CVD and measures of cIMT and plaque.  Four models were fitted: 
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Model 1 Unadjusted  
Model 2  Age and sex 
Model 3 model 3 Age, sex, SIMD, duration of DM, HbA1C, diabetes treatment, 
systolic blood pressure, diastolic blood pressure, Antihypertensive 
use, total cholesterol, HDL cholesterol, lipid lowering medication use, 
smoking, BMI 
Model 4 Age, sex, SIMD, duration of DM, HbA1C, diabetes treatment, systolic 
blood pressure, diastolic blood pressure, Antihypertensive use, total 
cholesterol, HDL cholesterol, lipid lowering medication use, smoking, 
BMI, ankle brachial index, albumin creatinine ratio, interleukin 6, c 
reactive protein, NTproBNP 
 
cIMT measurement validation 
52 subjects were recruited to have a second IMT measurement performed.  Subjects 
returned at varying intervals after the first scan.  As only one sonographer was used, 
only intra-observer variability could be evaluated.  IMT measurements were recorded 
in millimetres to 1 decimal point at both sessions.  The mean values of cIMT were 
calculated for the first session and the second session.  A mean of both the right and 
left measurements was calculated as well as a mean of all 6 measurements.   
Kolmogorov-Smirnov tests were performed on the mean values and were found to be 
non-significant at the 99% level, so the data was assumed to be normally distributed, 
thus parametric tests could be used.  Pearson correlation coefficients were calculated 
and the paired t test used to compare the means.  Intra-class correlation was 
calculated to assess intra-observer variability.   Limits of agreement between both 
sessions were evaluated using Bland Altman plots.  Analysis was performed on all 
52 subjects (regardless of time between scans) and on a subgroup who had their 
second scan within 4 months of the first.   
cIMT measurement software analysis 
Measurements of mean cIMT made using the cIMT software were compared with 
those made in the same 233 individuals by the sonographer.  Pearson correlation 
coefficients and paired student t tests were used to compare inter-correlations and the 
mean of each measurement in the sub-population. Due to the small sample size, no 
further statistical analyses were performed. 
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Association of carotid variables with incident cardiovascular disease 
The association between year 1 cIMT and plaque and future vascular events was 
determined using Cox Proportional Hazards modelling. Time to event was calculated 
by subtracting the date of year 1 appointment from the date of the first event, or from 
the date of censoring in the case of non-events (defined at 31st August 2011).  
Cardiovascular events were examined in 4 ways – any cardiovascular event (fatal 
and non-fatal MI, angina, fatal and non-fatal stroke or TIA), any CAD (Fatal or non-
fatal MI or angina), any Cerebrovascular disease (Fatal or non-fatal Stroke or TIA) 
and any fatal event (fatal MI, fatal Stroke, fatal other IHD). Firstly, variables were 
entered into the model unadjusted.  Then, they were adjusted for age, sex and 
previous CVD (to take account of the risk inferred by previous disease).  Following 
this, full adjustment for variables (where available) used in the UKPDS risk score 
was undertaken.  The UKPDS risk score variables were chosen because scores such 
as the Framingham score take limited account of diabetes status and were developed 
in general populations. As such, the UKPDS, which was developed in and is for use 
by individuals with diabetes, was felt to be a more appropriate representation of 
current risk prediction in people with Type 2 diabetes.  Ethnicity was not included as 
the majority of the cohort was of the same ethnicity.  Atrial fibrillation was also 
excluded as this information was not available at the time of analysis.  Stepwise 
regression and construction of individual multifactorial models were not undertaken 
given the low proportion of overall variability in cIMT that was explained by the 
totality of the measured various risk factors. 
Cox Regression Model A Unadjusted 
Cox Regression Model B Age, Sex and Previous CVD adjusted 
Cox Regression Model C Age, Sex, Previous CVD, duration of diabetes, 
HbA1c, systolic BP, total cholesterol, HDL, smoking status  
The Cox proportional hazards assumption was assessed for included variables using 
log minus log plots.  All variables met the proportional hazards assumption for each 
outcome event.   
 
  130 
Following the construction of the Cox models, assessment of any improvement in the 
model on addition of the test variables was assessed by determining the area under 
the ROC curve for each model (AUC).  The predicted individual risk (XBeta) for 
each model under investigation was saved as a new variable during Cox Regression 
and used to create a ROC curve.  The area under each curve was calculated and 
compared. 
In order to assess the potential effect on risk classification of any variables which 
survived Cox analysis, the net reclassification index was employed.  Net 
reclassification index is a method which evaluates the proportion of subjects moving 
accurately or inaccurately from one risk category to another after change to a 
prediction model.  In this thesis, participants were assigned to a level of risk (low, 
intermediate or high) based on arbitrary tertiles calculated from the X beta values of 
each model, as described by de Ruijter et al ((de Ruijter W, Westendorp RGJ et al. 
2009).  While this does not correspond directly to meaningful clinical risk levels, the 
small number of events led to a number of zero cells in the cross tabulations.  The 
tertiles for each model were cross tabulated (separately for the event and non-event 
groups) and net reclassification index calculated using the following formula: 
NRI= [Pup(events)-Pdown(events)]-[Pup(nonevents)-Pdown(nonevents)] 
Where: 
Pup(events)=[number of events moving up/number of events]  
Pdown(events)= [number of events moving down/number of events]  
Pup(nonevents)= [number of nonevents moving up/number of nonevents] 
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Chapter 4: Results 1 - Characteristics of study 
population and descriptive statistics for risk 
factor variables and carotid ultrasound 
parameters 
 
This chapter describes the socio-demographic characteristics and representativeness 
of the ET2DS study population and the sub-population used for analyses presented in 
this thesis.  It also presents descriptive statistics for included vascular risk factor 
variables which are both traditional cardiovascular risk factors (including those in the 
UKPDS risk score) and more ‘novel’ biomarkers (including ABI, ACR, eGFR, 
plasma IL6, CRP and NTproBNP), which are starting to be explored in terms of their 
potential as cardiovascular risk predictors in other study populations.  It further 
describes the results of carotid ultrasound measurements at Year 1 and Year 4 follow 
up as well as change in ultrasound measurements between these time points.  Finally, 
an assessment of measurement methods used in the study is presented. 
 
4.1 ET2DS study population 
 Baseline socio-demographic characteristics  4.1.1
Baseline socio-demographic characteristics of the ET2DS study population are 
presented in table 4-1 (column 1).  At recruitment, mean age of participants of the 
ET2DS (n=1066) was 67.9 years, and 547 (51.3%) participants were male. One 
hundred and twenty-seven (11.9%) were in the first quintile of the Scottish Index of 
Multiple Deprivation (most deprived), 208 (19.5%) were in the second quintile, 188 
(17.6%) were in the third quintile, 194 (18.2%) were in the fourth quintile and 349 
(32.7%) were in the top quintile (least deprived). 
 Representativeness 4.1.2
Representativeness of the recruited ET2DS population was assessed by researchers 
involved in the baseline phase of the ET2DS (Marioni, Strachan et al. 2010).  The 
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results of this analysis are presented in table 4-1.  Clinical and socio-demographic 
characteristics recorded on the Lothian Diabetes Register were compared between 
those individuals who had been invited, at random, to participate and had attended 
(participants n=1066), with those who had declined or did not respond (‘non-
participants’, n=4386). 
Mean age of participants and non-participants was similar (both 67.9 years), but 
participants were more likely to be male (51.3% vs. 41.9%).  In addition, there was a 
higher proportion of individuals from less deprived backgrounds in the participant 
group.  Mean systolic blood pressure was slightly lower in participants but mean 
cholesterol, mean HbA1c, duration of diabetes and proportion receiving insulin 
treatment were similar between participants and non-participants.   
Table 4-1 Comparison of clinical characteristics recorded on the Lothian Diabetes Register in ET2DS 
participants and non-participants (adapted from (Marioni, Strachan et al. 2010)) 
 Participants (n=1028-1066) Non-Participants (n=4020-4385) 
Mean Age (years) 67.9 (4.2) 67.9 (4.4) 
Male sex  51.3 (547) 41.9 (1839) 
Deprivation rank    
1st quintile (most deprived) 11.9 (127) 16.8 (736) 
2nd quintile 19.5 (208) 25.9 (1134) 
3rd quintile 17.6 (188) 18.7 (820) 
4th quintile 18.2 (194) 17.8 (782) 
5th quintile (least deprived) 32.7 (349) 20.8 (897) 
Duration of diabetes <5 years  48.4 (516) 48.7 (2135) 
Insulin Treatment 17.4 (185) 16.1 (704) 
Cholesterol (mmol/l) 4.3 (0.9) 4.2 (0.96) 
Systolic blood pressure  (mmHg) 133.3 (16.44) 137.2 (18.15) 
HBA1c (%Hb) 7.4 (1.12) 7.4 (1.36) 
Values are mean (SD) or % (n) HbA1c=glycated haemoglobin 
For the purposes of the research presented in this thesis, baseline demographic and 
cardiometabolic characteristics were also compared between subjects attending 
baseline, one year follow up and four year follow up respectively (table 4-2), and 
between those that had a full set of valid IMT readings at the one year visit and those 
that did not (table 4-3).   
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Of the 1066 participants in the ET2DS, 939 (88.1%) attended the year 1 follow up 
clinic and 831 (77.9%) attended the year 4 follow up clinic.  In general, mean 
baseline characteristics were similar across the cohort at all three time points. At year 
1 and year 4, there was a slightly lower proportion of subjects who had been current 
smokers at baseline (both 12.5%) compared with the entire cohort (14.0%) and 
baseline systolic blood pressure was slightly lower at 132.5 ±15.7 mmHg in those at 
year 4 compared with the whole cohort (133.3 ± 16.4 mmHg).  However, even these 
differences were small.  
Table 4-2 Baseline characteristics of study participants attending baseline, 1 year and 4 year 
follow-up of the ET2DS 
  All subjects 
(n=1066) 
Year 1 participants 
(n=939) 
Year 4 Participants 
(n=831) 
Demographics Age at Baseline (years) 67.8 (4.17) 67.8 (4.15) 67.7 (4.14) 
 Sex  (male) 546 (51.3) 487 (52.0) 430 (51.7) 
     
Diabetes  Duration of Diabetes (years) 6.0 (8) 6.0 (8.0) 6.0 (8.0) 
 HbA1C (%Hb) 7.39 (1.12) 7.37 (1.11) 7.39 (1.13) 
 Diabetes Treatment     
 Diet Alone 201 (18.9) 182 (19.4) 166 (20.0) 
 Oral Hypoglycaemics 689 (64.6) 607 (64.7) 530 (63.8) 
 Insulin ± Oral Hypoglycaemics 176 (16.5) 149 (15.9) 135 (16.2) 
     
Blood Pressure Systolic BP (mmHg)  133.3 (16.3) 133.2 (16.2) 132.5 (15.7) 
 Diastolic BP(mmHg) 69.1 (9.0) 69.0 (9.0) 68.9 (8.8) 
     
Blood Lipids Total Cholesterol 4.31 (0.90) 4.31 (0.89) 4.33 (0.91) 
 HDL Cholesterol 1.30 (0.36) 1.29 (0.35) 1.29 (0.35) 
     
Smoking Smoking Status     
 Current smoker 148 (14.0) 117 (12.5) 104 (12.5) 
 Ex smoker 501 (47.4) 443 (47.5) 392 (47.2) 
 Never smoker 409 (38.7) 373 (40.0) 332 (40.0) 
     
Obesity Index BMI (kg/m2) 31.3 (5.6) 31.3 (5.6) 31.2 (5.5) 
Renal ACR 1.8 (3.0) 1.8 (3.0) 1.8 (3.2) 
BP=blood pressure, HDL=high density lipoprotein, BMI=body mass index 
Values are mean (SD), median (Interquartile range), or n (%)  
 
4.2 One year follow up study population 
 Missing data 4.2.1
cIMT  
Of the 939 subjects that attended year 1 follow up, 916 subjects had valid cIMT 
readings at year 1 and 904 had valid plaque readings. In terms of cIMT 
measurements, the remaining 23 participants had no valid cIMT readings due to 
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problems with the measurement of cIMT at the clinic eg physical barrier to 
measurement or incorrect measurements taken. This also applied to those with 
missing plaque measurements. A comparison of baseline characteristics between 
those subjects with and without cIMT measurements at year 1 is made in table 4-3.  
There were no significant differences between the two groups, with the exception of 
smoking, where only 13.0% of people with cIMT measurements were current 
smokers compared with 22.4% of people without cIMT measurements.   
 
Table 4-3 Comparison of baseline characteristics of subjects with and without valid cIMT 
measurements at year 1 follow up of the ET2DS 
  Subjects with valid year 1 
cIMT measurements 
(n=916) 
Subjects without valid 
year 1 cIMT 
measurements (n=150) 
P value 
Demographics Age at Baseline (years) 67.9 (4.2) 67.9 (4.4) NS 
 Sex  (male) 51.7 (474) 48.7 (73) NS 
     
Diabetes  Duration of Diabetes (years) 6.0 (8.0) 6.0 (7.8) NS 
 HbA1C (% Hb) 7.38 (1.12) 7.53 (1.12) NS 
 Diabetes Treatment     
 Diet Alone 19.7 (180) 14.7 (22)  
 Oral Hypoglycaemics 64.5 (591) 66.0 (99) NS 
 Insulin ± Oral Hypoglycaemics  15.8 (145) 19.3 (29)   
     
Blood Pressure Systolic BP (mmHg)  133.2 (16.4) 133.9 (17.1) NS 
 Diastolic BP(mmHg) 69.1 (9.0) 69.1 (9.2) NS 
     
Blood Lipids Total Cholesterol (mmol/l) 4.31 (0.89) 4.31 (0.95) NS 
 HDL Cholesterol (mmol/l) 1.29 (0.35) 1.30 (0.43) NS 
     
Smoking  Current smoker 13.0 (119) 22.4 (33)  
 Ex smoker 46.9 (430) 48.3 (71) 0.002** 
 Never smoker 40.1 (367) 29.3 (43)  
     
Obesity Index BMI (kg/m2) 31.3 (5.7) 32.1 (5.7) NS 
BP=blood pressure, HDL=high density lipoprotein, BMI=body mass index, NS=not significant (p>0.05)  
Values are mean (SD), median (Interquartile range) or % (n)  ** significant p<0.01 
 
Other Variables 
At year 1, there were differing degrees of missing data for each variable (table 4-4).  
Age and BMI were complete for all subjects.  Duration of diabetes (years), systolic 
BP, diastolic BP, ABI, eGFR and IL-6 had missing data of less than 1%.  HbA1c, 
total cholesterol, HDL cholesterol, CRP and NTproBNP had a missing data level 
between 1% and 2%.  Continuous variables with higher missing data levels were 
albumin creatinine ratio (58.5%, n=550) and mean and maximum plaque thickness 
(5.4%, n=51 for both).  Categorical variables used in this thesis demonstrated less 
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missing data than continuous variables.  Sex, SIMD quintile, diabetes treatment, 
antihypertensive use and lipid lower medication use were complete.  Smoking status 
had <1% missing data.   
Table 4-4 Missing data in study population used in this thesis 
  Total in group N missing % missing 
Demographics Age (years) 939 0 0.0 
 Sex (male) 939 0 0.0 
 SIMD 939 0 0.0 
Diabetes  Duration of diabetes (years) 939 7 0.8 
 HbA1c (%Hb) 939 10 1.1 
 Diabetes Treatment 939 0 0.0 
Blood Pressure Systolic BP (mmHg) 939 5 0.5 
 Diastolic BP (mmHg) 939 5 0.5 
 Antihypertensive use (yes) 939 0 0.0 
Lipids Total Cholesterol (mmol/l) 939 10 1.1 
 HDL Cholesterol (mmol/l) 939 10 1.1 
 Lipid Lowering Medication (yes) 939 0 0.0 
Smoking Smoking status 939 1 0.1 
Obesity Index BMI (kg/m2) 939 0 0.0 
CVD Risk Marker ABI 939 6 0.6 
Renal Function eGFR (ml/min/1.73m2) 939 7 0.7 
 ACR (mg/mmol) 939 550 58.5 
Plasma Biomarkers CRP (mg/l) 939 16 1.7 
 IL-6 (pg/ml) 939 2 0.2 
 NTproBNP (pg/ml) 939 9 1.0 
Carotid Ultrasound Mean cIMT (mm) 939 23 2.4 
 Max cIMT (mm) 939 23 2.4 
 Max Mean cIMT (mm) 939 23 2.4 
 Mean Max cIMT (mm) 939 23 2.4 
 Mean Plaque Thickness (mm) 939 54 5.4 
 Max Plaque Thickness (mm) 939 54 5.4 
 Plaque Score 939 34 3.6 
 Plaque Morphology 939 2 0.2 
SIMD = Scottish Index of Multiple Deprivation, BP = blood pressure, HDL = high density lipoprotein, ABPI = ankle brachial 
pressure index, BMI = body mass index, eGFR = estimated glomerular filtration rate, ACR = albumin creatinine ratio, CRP = C 
reactive protein, IL-6 = interleukin 6, NTproBNP = N terminal pro-brain natriuretic peptide, cIMT = carotid intima media 
thickness  
 
 Characteristics of study populations at year 1  4.2.2
The characteristics of the study population at year 1 are presented in (table 4-5).  At 
year 1, subjects in the IMT analysis study population had a mean age of 68.9 ± 4.2 
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years, and 51.7% (474) were male.  There was a similar proportion of the sample in 
each of the quintiles of SIMD, with the exception of the most affluent quintile, which 
was over represented in the sample (quintile 5, 34.4% (315) vs quintile 1, 11.6% 
(106)).  The median duration of diabetes was 7.0 (8.0) years, with a mean HbA1c of 
7.18 ± 1.07%.  A high percentage of the sample (64.5% (591)) was using oral 
hypoglycaemic medications alone to manage their diabetes while fewer participants 
were treating their diabetes with diet modification alone (19.7% (180)) or with 
subcutaneous insulin (alone or in combination with oral hypoglycaemics) (15.8% 
(145)). The mean systolic blood pressure was 138.1 ± 18.4 mmHg, with a mean 
diastolic pressure of 74.1 ± 9.5 mmHg.  85.7% (785) of the sample reported using 
antihypertensive medication.  Mean total cholesterol was 4.15 ± 0.80 mmol/l and 
mean HDL cholesterol 1.23 ± 0.34 mmol/l.  84.3% (772) of participants reported use 
of lipid lowering medication.  13.0% (119) of the sample reported being current 
smokers, while 46.9% (430) reported that they were ex-smokers and 40.1% (367) 
reported that they had never smoked.  The mean ankle brachial index was 0.99 ± 
0.21 and the mean eGFR was 77.3 ± 18.6 ml/min/1.73m2. Median ACR value was 
1.80 (3.0) mg/mmol, median IL-6 was 2.82 (2.42) pg/ml, median CRP 1.76 (3.27) 
mg/l and NTProBNP had a median value of 74 (133) ng/ml.   
The corresponding values for the plaque analysis group were almost identical to 
those of the IMT group (table 4-5).   
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Table 4-5 Demographic variables, cardiometabolic factors and biomarkers of the study population 
at Year 1 ET2DS follow up 
  Subjects with valid IMT at year 1 
(n=916) 
Subjects with valid plaque 
assessment ay year 1 (n=905) 
Demographics Mean Follow up 
(years) 
3.53 (0.27) 3.53 (0.27) 
 Age (years) 68.9 (4.2) 69.0 (4.2) 
 Sex (male) 474 (51.7) 465 (51.4) 
 SIMD   
 Quintile 1 106 (11.6) 104 (11.5) 
 Quintile 2 169 (18.4) 170  (18.8) 
 Quintile 3 160 (17.5) 158 (17.5) 
 Quintile 4 166 (18.1) 167 (18.5) 
 Quintile 5 315 (34.4) 305 (33.7) 
Diabetes Duration of Diabetes 
(years) 
7.0 (8.0) 7.0 (8.0) 
 HbA1C (% Hb) 7.18 (1.07) 7.19 (1.08) 
 Diabetes Medication   
 Diet Alone 180 (19.7) 172 (19.0) 
 Oral Hypoglycaemics 591 (64.5) 590 (65.3) 
 Insulin ± oral 
hypoglycaemics 
145 (15.8) 142 (15.7) 
Blood Pressure Systolic Blood 
Pressure (mmHg)  
138.1 (18.4) 138.0 (18.5) 
 Diastolic Blood 
Pressure (mmHg)  
74.1 (9.5) 74.0 (9.5) 
 On antihypertensive  
(yes) 
785 (85.7) 775 (85.7) 
Lipids Total Cholesterol 
(mmol/l) 
4.15 (0.80) 4.15 (0.80) 
 HDL Cholesterol  
(mmol/l) 
1.23 (0.34) 1.23 (0.34) 
 Lipid lowering meds 
(yes) 
772 (84.3) 762 (84.3) 
Smoking Smoking status    
 Current smoker 119 (13.0) 115 (12.7) 
 Ex smoker 430 (46.9) 425 (47.0) 
 Never smoker 367 (40.1) 364 (40.3) 
Obesity Index BMI (kg/m
2
) 31.3 (5.7) 31.3 (5.7) 
CVD Risk Marker Ankle Brachial Index 0.99 (0.21) 0.99 (0.21) 
Renal Function eGFR (ml/min/1.73m
2
) 77.3 (18.6) 77.0 (18.2) 
 ACR (mg/mmol) 1.80 (3.0) 1.8 (3.0) 
Plasma Biomarkers IL6 (pg/ml) 2.82 (2.42) 2.82 (2.43) 
 CRP (mg/l) 1.76 (3.27) 1.76 (3.29) 
 NTProBNP (pg/ml) 
 
74 (133) 74 (133) 
Values are mean (SD), median (Interquartile range) or %(n) SIMD=Scottish Index of Multiple Deprivation, HDL=high density 
lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 
6, CRP=C reactive protein, NTProBNP=N terminal pro-brain natriuretic peptide,  
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4.3 Carotid intima media thickness  
This section describes the results of the cIMT measurement validation study and a 
description of cIMT distribution and change in the study sample.   
 cIMT validation study at year 4 follow up 4.3.1
Because of the well documented issues regarding the reliability and repeatability of 
ultrasound measurements of cIMT, an assessment was made of the measurements 
performed by the ET2DS sonographer.  This was carried out at the year 4 follow up 
clinics, at which time 52 subjects returned for repeat cIMT measurement.  As there 
was only 1 sonographer, only intra-observer variability could be assessed.  Data was 
assessed for normality using Kolmogorov-Smirnov tests at a 99% confidence level 
and found to be normal.   
Mean values for the mean cIMT recorded at each attendance are reported in table 4-
6.  Mean cIMT at the first attendance was 0.89mm and at the repeat attendance 
0.90mm.  The difference between the means was not statistically significant 
(p=0.537).  Pearson correlation coefficient between the means of the first and second 
sessions was 0.948 (p<0.001). Intra-class correlation was also determined using a 
two way random model with absolute agreement and was found to be 0.947 (0.910-
0.969) (p<0.001).  These analyses were repeated on two subgroups defined by time 
between the first and second reading (less than or more than 4 months apart).  There 
were no significant differences in the results for each group, suggesting that the time 
between readings did not affect cIMT measurement. 












Overall 52 0.89 0.90 0.537       0.948*** 0.947 (0.910-0.969)*** 
<4 months 
apart 
27 0.93 0.91 0.520       0.912*** 0.954 (0.898-0.979)*** 
>4 months 
apart 
25 0.88 0.88 0.958       0.983*** 0.991 (0.980-0.996)*** 
*** significant at  p<0.001.  Values for each attendance are mean cIMT.   
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Bland Altman plots were then created to visually evaluate agreement.  95% limits of 
agreement were calculated and plotted for the whole validation sample and the sub 
groups based on time between readings.    No clinically significant bias was seen in 
any of the measurements.   
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 Description of cIMT in the study population 4.3.2
Mean values for the various cIMT measurements derived from year 1 recordings are 
described in table 4-7.  Year 1 mean cIMT was 0.94 ± 0.14mm, and year 1 maximum 
cIMT 1.06 ± 0.19mm.  Year 1 maximum mean cIMT and mean maximum cIMT 
were 0.99 ± 0.17mm and 0.99 ± 0.16mm respectively.  All measures of cIMT were 
higher in men than in women, and also higher in older participants than younger 
participants (table 4-8).  Additionally, mean cIMT was higher in the left carotid 
artery than the right (for both men and women in all age categories) – (table 4-8).    
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Table 4-7 cIMT measured at year 1 and year 4 of the ET2DS 
 Year 1 (n=916) Year 4 (n=781) Change (n=765) P for change 
Mean cIMT (mm) 0.94 (0.14) 0.92 (0.15) -0.02 (0.11)     0.001** 
Max cIMT (mm) 1.06 (0.19) 1.04 (0.22) -0.02 (0.19)     0.001** 
Max Mean cIMT (mm) 0.99 (0.17) 0.97 (0.17) -0.02 (0.17) 0.052 
Mean Max cIMT (mm) 0.99 (0.16) 0.99 (0.20) -0.02 (0.14)    <0.001*** 
Mean Right cIMT (mm) 0.92 (0.15) 0.90 (0.16) -0.02 (0.14)     0.001** 
Mean Left cIMT (mm) 0.96 (0.17) 0.94 (0.20) -0.02 (0.13)    <0.001*** 
Values are mean (SD), cIMT=carotid Intima Media Thickness ** significant at o<0.01, *** significant at p<0.001 
 
Table 4-8 cIMT in five year age bands for men and women, including left and right measurements 
for mean cIMT 
  Mean cIMT 
Max cIMT Max Mean cIMT Mean Max cIMT 
 Age Mean R L 
Men 61-66 0.93 0.90 0.96 1.05 1.00 0.99 
 66-71 0.97 0.96 0.99 1.10 1.03 1.03 
 71-76 0.99 0.96 1.02 1.13 1.06 1.05 
Women 61-66 0.88 0.87 0.89 0.99 0.93 0.93 
 66-71 0.91 0.90 0.91 1.01 0.95 0.96 
 71-76 0.93 0.91 0.95 1.04 0.98 0.98 
Values are mean (mm). Age categories are in years. R=right, L=left  
 
After follow up, year 4 mean cIMT was 0.92 ± 0.15mm and maximum cIMT 1.04 ± 
0.22mm.  Maximum mean cIMT and mean maximum cIMT were 0.97 ± 0.17mm 
and 0.99 ± 0.20mm respectively. Seven hundred and sixty five individuals had cIMT 
measurements at both year 1 and year 4.  Overall, there was a small negative change 
in IMT between these time points, which was statistically significant for all measures 
except maximum mean cIMT (table 4-7).  Average change in mean cIMT was -0.02 
±0.11mm and for maximum cIMT was -0.02 ± 0.19mm.  Max mean cIMT and mean 
max cIMT also demonstrated a negative change (-0.02 ±0.17mm and -0.02 ± 
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0.13mm respectively). Because all the measures of cIMT demonstrated a similar 
change with time, only change in mean cIMT was further analysed. Because of the 
potential effect of some medications on cIMT progression, change in mean cIMT 
was evaluated in those who were and were not taking antihypertensive medication 
and lipid lowering medication.  No statistically significant difference was noted in 
either group, although it is important to note that the direction of the change was 
different for those taking and not taking lipid lowering medication (taking -0.016mm 
vs not taking 0.002mm, p=0.111).   
 
4.4 Carotid plaque  
This section describes the frequency and distribution of carotid plaque in the study 
population.  Table 4-9 describes the frequency and distribution of carotid plaque in 
the ET2DS. 
 Description of carotid plaque thickness in the study 4.4.1
population 
Plaque variables measured at year 1 and year 4 of the ET2DS are summarised in 
table 4-9.  The prevalence of carotid plaque at year 1 in the ET2DS was high – 
97.8% (884) of participants had at least 1 plaque (of any size and type) present on 
carotid ultrasound.  Plaque was most common in the carotid bifurcations (right 
90.7% and left 92.7%) and the internal carotids (right 59.8% and left 61.9%); and 
least common in the common carotids (right 32.0% and left 42.4%) and the external 
carotids (right 28.9% and left 26.2% ).  In most divisions of the carotid artery, plaque 
was more common on the left than right, with the exception of the internal carotids.  
Mean values for mean plaque thickness and maximum plaque thickness at year 1 
were 2.44 ± 0.90 mm and 2.81± 1.11 mm respectively. 
At year 4, the prevalence of plaque remained similar, with 99.6% (751) of 
participants demonstrating at least 1 plaque.  Plaque remained most common in the 
carotid bifurcations (96.7% right and 97.2% left) and internal carotids (70.7% right 
and 71.1% left) and least common in the common carotids (55.0% right and 65.0% 
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left) and external carotids (42.5% right and 36.8% left).  Plaque was most common 
on the right side than the left side, with the exception of the bifurcation, in contrast to 
the findings at year 1.   Mean values for mean plaque thickness and maximum plaque 
thickness at year 4 were 2.81 ± 1.07mm and 3.26 ± 1.32 mm respectively.    
The percentage of individuals with at least 1 plaque was similar at both year 1 and 
year 4 (97.8% and 99.6% respectively). However, the percentage of individuals with 
plaque present at each division of the carotid artery was significantly higher at year 4 
than at year 1.  Mean plaque thickness increased significantly from Year 1 to Year 4 
by 0.40 ± 0.67 mm, p<0.001, which is in contrast to cIMT measures.  Maximum 
plaque thickness also demonstrated a significant increase between the two time 
points (0.47 ± 0.67mm, p<0.001). 
 Plaque score 4.4.2
Because of the method by which plaque was assessed (thickness of only 1 plaque on 
each side measured) and limitations set by the ultrasound machine used in this study, 
it was not possible to calculate plaque burden by more traditional methods such as 
total plaque volume or plaque area.  As such, a proxy for plaque burden was created 
using the presence of plaque in each of the segments of the carotid tree. A plaque 
score was calculated by totaling the number of areas of the right and left carotid 
arteries in which plaque was present.  Values ranged from 0 (no plaque in any area) 
to 8 (presence of at least 1 plaque in all 8 areas).   
At year 1, the majority of individuals (79.7% (720)) had a plaque score of between 2 
and 6.  15.2% of individuals had a score of 7 or 8 and 5.1% had a score of 1 or 0. 
Mean plaque score was 4.39 (1.9). This can be summarized more clearly by 
exploring the percentage of participants who had a high plaque score (greater than 
four) - 45.2% of participants had a plaque score >4 at year 1.   
At year 4, 81.8% of individuals had a plaque score of between 4 and 8, while 19.2% 
had a score of 3 or less.  Again, by exploring the percentage of participants with a 
plaque score great than or less than 4, it can be seen that 65.0% had a plaque score 
>4 at year 4.  The difference in percentage of participants with a plaque score >4 at 
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year 1 and year 4 was significant (p<0.001), suggesting that plaque burden may have 
increased in this time period. 
 Plaque morphology  4.4.3
At year 1, heterogeneous plaque (plaque where >20% of the plaque echogenicity 
differs from the rest of the plaque) was present in 44.8% (404) of participants (at 
least 1 heterogeneous plaque) and echolucent plaque in 37.0% (334) (at least 1 
echolucent plaque).  At year 4, 70.4% (529) participants had at least 1 heterogeneous 
plaque and 77.1% (579) had at least 1 echolucent plaque.   
When these results are broken down further, at year 1 12.5% of participants had only 
echolucent plaque, 20.3% had only heterogeneous plaque, 24.5% had both 
echolucent and heterogeneous plaque and 42.7% had neither type of plaque (which 
means that they had predominantly echogenic plaque or no plaque).  By summarizing 
plaque morphology as high risk (either echolucent or heterogeneous plaque) or low 
risk (no plaque or echogenic plaque), it can be seen that 57.3% of participants had 
high risk plaque at year 1.   
At year 4, 20.4% had echolucent plaque only, 13.7% had heterogeneous plaque only, 
56.7% had both echolucent and heterogeneous plaque and 9.2% had echogenic 
plaques.  A clear comparison can be made with year 1 by examining high risk versus 
low risk.   At year 1, 56.1% of participants had “high risk” plaque, while at year 4, 
this had risen to 89.8%.  This was significantly higher.   
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Table 4-9 Carotid plaque measured at year 1 and year 4 of the ET2DS 
 Year 1 (N 
max=904) 




P value (N 
max=761) 
Mean Plaque Thickness (mm) 2.44 (0.90) 2.81 (1.07) 0.40 (0.67) <0.001*** 
Max Plaque Thickness (mm) 2.81 (1.11) 3.26 (1.32) 0.47 (0.91) <0.001*** 
At least 1 plaque in any area 
of carotids 
97.8 (884) 99.6 (748) - 0.138 
Plaque Present in:     
Right Common Carotid 32.0 (289) 55.0 (413) - <0.001*** 
Left Common Carotid 42.4 (383) 65.0 (488) - <0.001*** 
Right Internal Carotid 59.8 (541) 70.7 (531) - <0.001*** 
Left  Internal Carotid 61.9 (560) 71.1 (534) - <0.001*** 
Right External Carotid 28.9 (261) 42.5 (319) - <0.001*** 
Left External Carotid 26.2 (237) 36.8 (276) - <0.001*** 
Right Bifurcation 90.7 (820) 96.7 (726) - 0.064 
Left Bifurcation 92.7 (838) 97.2 (730) - 0.003*** 
Plaque Score:     
0 2.1 (19) 0.4 (3) -  
1 3.0 (27) 1.1 (8) -  
2 14.5 (131) 8.1 (61) -  
3 16.3 (147) 8.5 (64) -  
4 18.6 (168) 16.9 (127) - <0.001*** 
5 16.5 (149) 15.4 (116) -  
6 13.8 (125) 16.5 (124) -  
7 7.2 (65) 14.9 (112) -  
8 8.0 (72) 18.1 (136) -  
Plaque Score Category     
≤4 54.5 (492) 35.0 (263) - <0.001*** 
>4 45.2 (411) 65.0 (488) -  
Plaque Morphology     
Echolucent plaque only 12.5 (113) 20.4 (153) -  
Heterogeneous plaque only 20.3 (183) 13.7 (103) - <0.001*** 
Both Types of Plaque 24.5 (221) 56.7 (426) -  
Neither type of plaque 42.7 (386) 9.2 (69) -  
Plaque Risk Type     
Low risk  42.7 (386) 9.2 (69) - <0.001*** 
High risk 57.3 (517) 89.8 (682) -  
Values are mean (SD) or % yes (n) *** significant at p<0.0001 
 
4.5 Inter-correlation of cIMT and carotid plaque 
parameters at Year 1 
The associations of cIMT and plaque variables with each other are described in 
tables 4-10 – 4-12.  cIMT variables were highly correlated with one another (range: 
r=0.911-0.977).  Right and left cIMT correlated moderately with each other (r=0.533, 
p<0.001) as did right and left plaque thickness (r=0.488, p<0.001).  Summary 
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measures of cIMT correlated substantially with one another (r=0.911-0.977).  They 
also correlated (albeit more modestly), with the plaque thickness measurements 
(range of r=0.223 - 0.278).    Mean cIMT and mean plaque thickness were more 
moderately correlated (r=0.268, p<0.001), as were maximum cIMT and maximum 
plaque thickness (r=0.254, p<0.001).   
Individuals with a higher plaque score (>4) tended to have a higher cIMT than those 
without (mean cIMT in those with high score 0.99 (0.15)mm versus those with low 
score 0.89 (0.12)mm).  Individuals with a higher plaque score also had more high 
risk plaque than those with a low score (76.9% versus 40.7% respectively).  
Individuals with high risk plaque also tended to have a higher cIMT (mean cIMT 
0.97mm) than those without (mean cIMT 0.89mm), as well as a higher plaque score 
(61.2% had plaque score >4 compared with those with low risk plaque (24.6%).  
 





Table 4-10 Association of continuous cIMT with continuous carotid plaque thickness measurements at year 1 of the ET2DS 















































































































Mean Plaque Thickness - - - - - - - - 0.959
***
 





Table 4-11 Association of plaque score with cIMT, plaque thickness and plaque type 
 Plaque score<=4 (n=479) Plaque score >4 (n=402) P value 
Mean cIMT (mm) 0.89 (0.12) 0.99 (0.15)    <0.001*** 
Max cIMT (mm) 1.00 (0.16) 1.14 (0.20)    <0.001*** 
Max Mean cIMT (mm) 0.94 (0.14) 1.07 (0.18)    <0.001*** 
Mean Max cIMT (mm) 0.94 (0.13) 1.06 (0.16)    <0.001*** 
Mean Plaque Thickness (mm) 2.05 (0.72) 2.89 (0.88)    <0.001*** 
Max Plaque Thickness (mm) 2.36 (0.89) 3.33 (1.12)   <0.001*** 
Plaque morphology    
No or echogenic plaque 59.3 (291) 23.1 (95)  
Echolucent plaque only 14.1 (69) 10.7 (44)    <0.001*** 
Heterogeneous plaque only 15.5 (76) 26.0 (107)  
Both Types 11.2 (55) 40.1 (165)  
Plaque morphology category    
Low risk 59.3 (291) 23.1 (95)    <0.001*** 
High risk 40.7 (200) 76.9 (316)  
*** significant at p<0.001 
 
Table 4-12 Association of plaque type with cIMT, plaque thickness and plaque score 
 Low Risk (n=386) High Risk (n max=516) P value 
Mean cIMT (mm) 0.89 (0.13) 0.97 (0.14)    <0.001*** 
Max cIMT (mm) 1.00 (0.17) 1.10 (0.19)    <0.001*** 
Max Mean cIMT (mm) 0.94 (0.15) 1.03 (0.19)    <0.001*** 
Mean Max cIMT (mm) 0.95 (0.14) 1.02 (0.16)    <0.001*** 
Mean Plaque Thickness (mm) 2.05 (0.79) 2.72 (0.87)    <0.001*** 
Max Plaque Thickness (mm) 2.34 (0.97) 3.15 (1.08)    <0.001*** 
Plaque Score    
0 4.7 (18) 0.0 (0)  
1 6.7 (26) 0.2 (1)  
2 24.6 (95) 7.0 (36)  
3 22.5 (87) 11.6 (60)  
4 16.8 (65) 20.0 (103)    <0.001*** 
5 12.2 (47) 19.8 (102)  
6 7.3 (28) 18.8 (97)  
7 3.4 (13) 10.1 (52)  
8 1.8 (7) 12.6 (65)  
Plaque score category    
<=4 75.4 (291) 38.8 (200)    <0.001*** 
>4 24.6 (95) 61.2 (316)  
*** significant at p<0.001 
 
4.6 Serial cIMT measurements 
cIMT measurements at year 1 were repeated in 235 participants using a computer 
aided method for measuring cIMT.  These mean values for these measurements are 
reported in table 4-13, in addition to the corresponding sonographer value.  The 




maximum was 60, with an average number of measurements per participant of 192.  
For the sonographer measurements, the average number of measurements was 6 per 
participants (3 left and 3 right).  The mean serial cIMT was significantly lower than 
mean sonographer cIMT in the sample (0.91vs0.92mm, p<0.001 respectively).  The 
correlations between mean serial cIMT and mean cIMT were strong (r=0.811, 
p<0.001).   
Table 4-13 Comparison of cIMT measurements made by sonographer with computer aided method 
 Sub-sample (n=235) 
Serial cIMT   
Mean number of measurements per participant 192 (10.6) 
Mean serial cIMT (mm) 0.91 (0.14) 
Sonographer cIMT  
Mean number of measurements of participant 6 (0) 
Mean sonographer cIMT (mm) 0.92 (0.14) 
  
P value for difference in mean cIMT measurements 0.034* 
Values are mean (SD), * significant at p<0.05 
 
4.7 Chapter summary 
This chapter describes the socio-demographic characteristics and representativeness 
of the ET2DS study population and the sub-population used for analyses presented in 
this thesis as well as descriptive statistics of the ET2DS study sample.  It further 
describes the results of carotid ultrasound measurements in the study.  Participants in 
the ET2DS are generally representative of older adults with Type 2 diabetes living in 
Edinburgh and the Lothians and those who attended for year 1 cIMT measurements 
were representative of the cohort as a whole.  cIMT was normally distributed in the 
sample and was higher in men, as well as older participants.  cIMT was also higher 
in the left carotid artery than the right (for both men and women).  Change in cIMT 
between year 1 and year 4 follow up of the ET2DS showed a small, but significant 
regression.  cIMT measurement in the ET2DS was validated and found to be highly 
repeatable.  In comparison with computer aided measurements, the sonographer 
measurements were on average, slightly higher than the computer measurements but 




There was a high prevalence of carotid plaque in the ET2DS.  High risk plaques were 
particularly prevalent in the study sample, affecting 57% of participants and plaque 
was widely distributed in the carotid artery, as measured by plaque score.   
Continuous measurements of cIMT were highly correlated with one another, but less 
so with measures of plaque thickness.  Similarly, measures of plaque thickness 
correlated highly with one another.  Individuals with a high plaque score tended to 
have a high cIMT and more high risk plaque than those with a low plaque score.  
Similarly, those with a high risk plaque tended to have a higher cIMT and a higher 








Chapter 5: Results 2 - Cross Sectional 
Relationships between Carotid Ultrasound 
Parameters and Cardiovascular Disease in the 
ET2DS 
 
This chapter presents the results of cross sectional analyses of year 1 cIMT and 
plaque measurements, assessing the associations with traditional cardiovascular risk 
factors (including those in the UKPDS risk score) and with the more novel 
biomarkers of cardiovascular risk (ABI, eGFR, ACR, IL-6, CRP and NTproBNP), as 
well as prevalent cardiovascular disease.   
 
5.1 Association of cIMT with vascular risk factors and 
biomarkers 
Unadjusted Pearson correlation coefficients and p values for associations of cIMT 
with continuous vascular risk factors and biomarkers, and ANOVA parameter 
estimates coefficients for categorical variables are presented in table 5-1.  Age and 
sex adjusted values are presented in table 5-2.  The ANOVA statistic quoted 
quantifies the difference in the mean value of the variable between the test group and 
the reference category.   
 cIMT and vascular risk factors 5.1.1
There were significant unadjusted associations between cIMT and traditional 
vascular risk factors.  Increasing mean cIMT was associated with increasing age 
(r=0.164, p<0.001), higher systolic BP (r=0.075, p=0.024) and lower HDL 
cholesterol (r=-0.101, p<0.001).  Men were more likely to have a higher cIMT than 
women and those using lipid lowering medication tended to have a higher cIMT than 
those who did not. Similarly, current and ex-smokers had significantly higher mean 
cIMT than non-smokers (p<0.001).  Following adjustment for age and sex, the 




higher systolic BP (r=0.075, p<0.001) remained associated with a higher mean 
cIMT, as did use of lipid lowering medication.   
All other measures of cIMT were significantly associated with age, sex, systolic 
blood pressure, HDL cholesterol, lipid lowering medication and smoking.  The only 
differing associations were the association of maximum cIMT and mean maximum 
cIMT with lower total cholesterol (r=-0.081 and r=-0.076 respectively)) and 
maximum mean cIMT with lower diastolic blood pressure (r=-0.070).  After age and 
sex adjustment, all other measures of cIMT, except maximum cIMT remained 
associated with increased systolic blood pressure and the use of lipid lowering 
medication.  In addition, they all retained a positive association with lower HDL 
cholesterol and both maximum cIMT and maximum mean cIMT remained associated 
with a lower diastolic blood pressure.   
The key difference between the age and sex adjusted associations of mean cIMT and 
other measures with risk factors, was the association of the other measures with HDL 
cholesterol, where no association existed for mean cIMT.    
 cIMT and novel biomarkers of cardiovascular risk 5.1.2
Increasing mean cIMT was significantly associated with lower ABI (r=-0.099, 
p<0.001), increased IL-6 (r=0.069, p<0.001) and increased NTproBNP (r=0.126, 
p<0.001).    Following adjustment for age and sex, these significant associations 
remained - IL-6 (r=0.068, p<0.001) and NTproBNP (r=0.107, p<0.001) remained 
moderately positively correlated with mean cIMT while ABI retained its negative 
association (r=-0.136, p<0.001) 
All other measures of cIMT were associated with ABI and NTproBNP.  In addition, 
mean maximum cIMT was associated with increasing IL6 and ACR.  These 
associations remained after adjustment for age and sex, with the exception of the 








Table 5-1 Unadjusted correlation of cIMT with traditional cardiovascular risk factors and with novel biomarkers of cardiovascular risk 
  Mean cIMT Max cIMT MaxMean cIMT Mean Max cIMT 
  Correlation Anova*  Correlation Anova* Correlation Anova* Correlation Anova* 
Demographics Age 0.164*** - 0.141*** - 0.147*** - 0.149*** - 
 Sex (male) - 0.063*** - 0.087*** - 0.075*** - 0.072*** 
 SIMD         
 Quintile 1 (Most Deprived) - -0.001 - 0.005 - -0.005 - 0.006 
 Quintile 2 - 0.016 - 0.024 - 0.020 - 0.018 
 Quintile 3 - 0.009 - 0.018 - 0.019 - 0.014 
 Quintile 4 - 0.014 - 0.018 - 0.016 - 0.016 
 Quintile 5 (Least Deprived) - - - - - - - - 
Diabetes Duration of DM 0.031 - 0.017 - 0.013 - 0.028 - 
 HbA1C  0.009 - 0.007 - 0.013 - 0.008 - 
 T2DM Meds         
 Diet Alone - - - - - - - - 
 Oral  - -0.024 - -0.036 - -0.027 - -0.032 
 Insulin ± oral  - -0.015 - -0.025 - -0.016 - -0.022 
Blood Pressure Systolic BP   0.075* - 0.061 - 0.069* - 0.067* - 
 Diastolic BP -0.057 - -0.064 - -0.070* - -0.057 - 
 Antihypertensive (yes) - 0.009 - 0.008 - 0.013 - 0.009 
Blood Lipids Total Cholesterol  -0.065 - -0.081* - -0.064 - -0.076* - 
 HDL Cholesterol  -0.101** - -0.134*** - -0.114** - -0.121*** - 
 Cholesterol med (yes) - 0.029* - 0.043* - 0.037* - 0.032* 
Smoking Smoking status          
 Current smoker - 0.029* - 0.043* - 0.042* - 0.034* 
 Ex smoker - 0.040*** - 0.049*** - 0.043*** - 0.044*** 
 Never smoker -  -  - - - - 
Obesity Index BMI  -0.054 - -0.055 - -0.060 - -0.051 - 
CVD Risk Marker Ankle Brachial Index -0.099** - -0.092** - -0.100** - -0.098** - 
Renal Function eGFR -0.047 - -0.033 - -0.038 - -0.044 - 
 ACR 0.093 - 0.090 - 0.081 - 0.105* - 
Plasma Biomarkers IL6 0.069* - 0.048 - 0.051 - 0.067* - 
 CRP -0.007 - -0.019 - -0.018 - 0.003 - 
 NTProBNP 0.126*** - 0.105** - 0.114** - 0.119*** - 
For continuous variables, P earson correlation coefficients and corresponding p values are quoted.  *For categorical variables, the ANOVA statistic reported quantifies the difference in mean or maximum plaque thickness for the given 
categorical variable compared with the reference level (reference levels are female sex, least deprived SIMD quintile,  diet alone treatment for diabetes,  no lipid lowering medication, no anti-hypertensive medication, never 
smoker)SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL -6=interleukin 6, CRP=C reactive protein, 








 Table 5-2 Age and sex adjusted association of cIMT with traditional cardiovascular risk factors and with novel biomarkers of cardiovascular risk 
  Mean cIMT Max cIMT Max Mean cIMT Mean Max cIMT 
  Correlation Anova* Correlation Anova* Correlation Anova* Correlation Anova* 
Demographics SIMD         
 Quintile 1 (Most Deprived) - 0.012 - 0.022 - 0.011 - 0.021 
 Quintile 2 - 0.021 - 0.031 - 0.026 - 0.024 
 Quintile 3 - 0.009 - 0.018 - 0.018 - 0.013 
 Quintile 4 - 0.014 - 0.018 - 0.016 - 0.016 
 Quintile 5 (Least Deprived) - - - - - - - - 
Diabetes Duration of DM  0.023 - 0.009 - 0.014 - 0.027 - 
 HbA1C  0.033 - 0.028 - 0.034 - 0.030 - 
 Diabetes Medication         
 Diet Alone - - - - - - -  
 Oral Hypoglycaemics - -0.021 - -0.032 - -0.024 - -0.029 
 Insulin ± oral hypoglycaemics - -0.007 - -0.016 - -0.008 - -0.014 
Blood Pressure Systolic BP 0.075* - 0.064 - 0.070* - 0.069* - 
 Diastolic BP -0.058 - -0.068* - -0.074* - -0.061 - 
 On antihypertensives (yes) - 0.013 - 0.013 - 0.017 - 0.013* 
Blood Lipids Total Cholesterol  -0.010 - -0.026 - -0.011 - -0.021 - 
 HDL Cholesterol  -0.064 - -0.095** - -0.076* - -0.081* - 
 Cholesterol lowering meds (yes) - 0.024* - 0.036* - 0.032* - 0.027 
Smoking Smoking status         
 Current smoker - 0.022 - 0.032 - 0.034 - 0.025 
 Ex-smoker - 0.024* - 0.026 - 0.024 - 0.026* 
 Never smoker - - - - -  - - 
Obesity Index BMI  0.019 - 0.014 - 0.008 - 0.020 - 
CVD Risk Marker Ankle Brachial Index -0.136*** - -0.128*** - -0.135*** - -0.135*** - 
Renal Function eGFR -0.011 - -0.003 - -0.005 - -0.012 - 
 ACR 0.088 - 0.086 - 0.079 - 0.100 - 
Plasma Biomarkers IL6 0.068* - 0.048 - 0.050 - 0.068* - 
 CRP 0.047 - 0.035 - 0.034 - 0.059 - 
 NTProBNP 0.107** - 0.089** - 0.097** - 0.103** - 
For continuous variables, Pearson correlation coefficients and corresponding p values are quoted.  .  *For categorical variables, the ANOVA statistic reported quantifies the difference in mean or maximum plaque thickness for the given 
categorical variable compared with the reference level (reference levels are female sex, least deprived SIMD quintile,  diet alone treatment for diabetes,  no lipid lowering medication, no anti -hypertensive medication, never smoker) 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate , ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C reactive protein, NTProBNP=N 




5.2 Association of plaque thickness with vascular 
risk factors and biomarkers 
Unadjusted Pearson correlation coefficients and p values for associations of plaque 
thickness with continuous vascular risk factors and biomarkers, and ANOVA 
coefficients for associations with categorical variables are presented in table 5-3.  
Age and sex adjusted values are presented in table 5-4. 
 Plaque thickness and vascular risk factors 5.2.1
A variety of risk factors demonstrated a cross sectional association with mean plaque 
thickness.  A higher mean plaque thickness was significantly associated with 
increasing age (r=0.197) and male sex, as well as longer duration of diabetes 
(r=0.101), increased systolic blood pressure (r=0.124), lower BMI (r=-0.075), use of 
antihypertensive medication and cigarette smoking. Following adjustment for age 
and sex, mean plaque thickness remained significantly associated with a longer 
duration of diabetes (r=0.089), systolic BP (r=0.124), the use of antihypertensive 
medication and cigarette smoking. Maximum plaque thickness demonstrated the 
same age and sex adjusted associations.   
 Plaque thickness and novel biomarkers of 5.2.2
cardiovascular risk  
Mean plaque thickness was also associated with novel marker of cardiovascular risk. 
Increasing plaque thickness was significantly associated with a lower ABI (r=-
0.170), reduced eGFR (r=-0.114), increased ACR (r=0.102), increased IL6 (r=0.111), 
and higher NTproBNP (r=0.185).   Following age and sex adjustment, these 
associations persisted with limited attenuation of the magnitude of association, with 
the exception of the association with ACR which lost significance.  Maximum plaque 
thickness demonstrated the same pattern of association.  
Effect Size 
It is important to note that the effect sizes described in this section are not large.  




associations were ABI and NTproBNP (>0.1).   Therefore, despite their significant p 





Table 5-3 Unadjusted association of plaque thickness parameters with traditional cardiovascular 
risk factors and with novel biomarkers of cardiovascular risk  
  Mean Plaque thickness (mm) Max Plaque Thickness (mm) 
  Correlation ANOVA*  Correlation ANOVA*  
Demographics Age 0.197*** -  0.197*** -  
 Sex (male) - 0.376***  - 0.444***  
 SIMD       
 Quintile 1(Most Deprived) - 0.107  - 0.119  
 Quintile 2 - 0.130  - 0.094  
 Quintile 3 - 0.079  - 0.056  
 Quintile 4 - -0.011  - 0.005  
 Quintile 5 (Least Deprived) - -  - -  
Diabetes Duration of DM  0.101** -  0.092** -  
 HbA1C  0.011 -  -0.001 -  
 T2DM Meds       
 Diet Alone - -  - -  
 Oral  - -0.043  - -0.025  
 Insulin ± oral  - 0.041  - 0.015  
Blood Pressure Systolic BP  0.124*** -  0.101** -  
 Diastolic BP  -0.043 -  -0.049 -  
 Antihypertensives (yes) - 0.199*  - 0.251*  
Blood Lipids Total Cholesterol  -0.060 -  -0.056 -  
 HDL Cholesterol  -0.067 -  -0.058 -  
 Cholesterol med (yes) - 0.157  - 0.174  
Smoking Smoking status        
 Current smoker - 0.647***  - 0.751***  
 Ex smoker - 0.377***  - 0.437***  
 Never smoker - -  - -  
Obesity Index BMI  -0.075* -  -0.078* -  
CVD Risk Marker Ankle Brachial Index -0.170*** -  -0.153*** -  
Renal Function eGFR -0.114** -  -0.112** -  
 ACR 0.102* -  0.105* -  
Plasma Biomarkers IL6 0.111** -  0.091** -  
 CRP 0.058 -  0.056 -  
 NTProBNP 0.185*** -  0.182*** -  
For continuous variables, Pearson correlation coefficients and corresponding p values are quoted.  .  *For categorical variables, the 
ANOVA statistic reported quantifies the difference in mean or maximum plaque thickness for the given categorical variable compared with the 
reference level (reference levels are female sex, least deprived SIMD quintile,  diet alone treatment for diabetes,  no lipid  lowering medication, no 
anti-hypertensive medication, never smoker) SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, 
BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C 
reactive protein, NTProBNP=N terminal pro-brain natriuretic peptide, Pack years = geometric mean.* significant at p<0.05, ** 




Table 5-4 Age and sex adjusted associations of plaque thickness parameters with traditional 
cardiovascular risk factors and with novel biomarkers of cardiovascular risk 
 
 
Mean Plaque Thickness 
(mm) 
Max Plaque Thickness 
(mm) 
  Correlation ANOVA*  Correlation ANOVA*  
Demographics SIMD       
 Quintile 1(most deprived) - 0.192  - 0.221  
 Quintile 2 - 0.165*  - 0.136  
 Quintile 3 - 0.078  - 0.054  
 Quintile 4 - -0.018  - -0.004  
 Quintile 5 (least deprived) - -  - -  
Diabetes Duration of DM  0.089** -  0.080* -  
 HbA1C  0.036 -  0.024 -  
 T2DM Meds       
 Diet Alone - -  - -  
 Oral  - -0.023  - 0.000  
 Insulin ± oral  - 0.092  - 0.075  
Blood Pressure Systolic BP  0.124*** -  0.099** -  
 Diastolic BP   -0.033 -  -0.038 -  
 Antihypertensives (yes) - 0.176*  - 0.223*  
Blood Lipids Total Cholesterol  -0.011 -  -0.008 -  
 HDL Cholesterol  -0.032 -  -0.025 -  
 Cholesterol med (yes) - 0.134  - 0.149  
Smoking Smoking status       
 Current smoker - 0.630***  - 0.733***  
 Ex smoker - 0.299***  - 0.345***  
 Never smoker - -  - -  
Obesity Index BMI -0.002 -  -0.006 -  
CVD Risk Marker Ankle Brachial Index -0.209*** -  -0.189*** -  
Renal Function eGFR -0.069* -  -0.068* -  
 ACR 0.087 -  0.091 -  
Plasma Biomarkers IL6 0.117** -  0.086** -  
 CRP 0.119*** -  0.113** -  
 NTProBNP 0.162*** -  0.157*** -  
For continuous variables, Pearson correlation coefficients and corresponding p values are quoted.  .  *For categorical variables, the 
ANOVA statistic reported quantifies the difference in mean or maximum plaque thickness for the given categorical variable compared with the 
reference level (reference levels are female sex, least deprived SIMD quintile,  diet alone treatment for diabetes,  no lipid lowering medication, no 
anti-hypertensive medication, never smoker)SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, 
BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C 
reactive protein, NTProBNP=N terminal pro-brain natriuretic peptide, Pack years = geometric mean. 





 Association of plaque score with vascular risk factors 5.2.3
and biomarkers 
Associations of plaque score (≤4 or >4) with vascular risk factors are presented in 
table 5-5.  A further, more detailed analysis of the association between individual 
score values and risk factors is presented in table 5-6. 
Individuals with a higher plaque score (>4) were on average almost a year older 
(69.5 vs 68.5 years respectively) than those with a low score and were more likely to 
be male.  They tended to have a lower diastolic blood pressure, were more likely to 
have a history of cigarette smoking and had a lower BMI (all p<0.01).  Those with a 
higher plaque score also had a higher prevalence of previous CVD (45% vs 27%, 
p<0.001).  Several novel biomarkers were also associated with higher plaque score – 
lower ABI, reduced eGFR and increased NTproBNP (p<0.01).   
Upon inspection of the individual score values, men tended to have a higher plaque 
score than women. A higher percentage of those with a plaque score of 8 were male 
(64.8%) compared with those with a plaque score of 0 (47.4%), however the trend 
across the scores was not strictly linear. There was a linear increase in age from 
group 0 to group 8 (66.8 ± 4.6 years).  An overall negative trend in diastolic blood 
pressure across the groups was noted, however this was not linear. There were 
significantly more current and ex-smokers and fewer never smokers in group 8 
(22.5%, 59.2% and 18.3% respectively) compared with group 0 (5.3%, 31.6% and 
63.2% respectively).  Baseline BMI had an unexpected negative relationship with 
plaque score.  Those in group 0 had a higher BMI than those in group 8 (BMI 33.5 ± 
7.8 and 30.2 ± 4.9 respectively. The overall trend for ABI across the groups was 
downwards (group 0 ABI 1.01 ± 0.14 vs group 8 0.92 ± 0.24) although again this 
was not a liner relationship. There was a significant negative linear trend between 
eGFR and plaque score, with mean eGFR 85.4 ± 13.9 ml/min/1.73m2 in those with a 
plaque score of 0 and mean eGFR of 70.31 ± 22.3 ml/min/1.73m2). NT proBNP was 
also higher in those with a higher plaque score (group 0 67.0 ± 125.0 pg/ml vs group 




Table 5-5 Comparison of cardiovascular risk factors and novel risk markers in those with plaque 
score ≤4 or >4 
  Score ≤4 (n=386) Score>4 (n=517) P value 
Demographics Age (years) 68.5 (4.2) 69.5 (4.08)    0.001** 
 Sex (male) 46.3 (228) 57.4 (236)   0.001** 
 SIMD    
 Quintile 1(most deprived) 11.6 (57) 11.4 (47)  
 Quintile 2 17.7 (87) 20.0 (82)  
 Quintile 3 17.9 (88) 17.0 (70) 0.787 
 Quintile 4 19.7 (97) 17.0 (70)  
 Quintile 5 (least deprived) 33.1 (163) 34.5 (142)  
Diabetes Duration of Diabetes (years) 7.0 (8.0) 8.0 (7.00) 0.117 
 HbA1C (% haemoglobin) 7.17 (1.07) 7.23 (1.08) 0.405 
 Diabetes Medication    
 Diet Alone 20.7 (102) 17.0 (70)  
 Oral Hypoglycaemics 65.4 (322) 65.2 (268) 0.147 
 Insulin ± oral hypoglycaemics 13.8 (68) 17.8 (73)  
Blood Pressures Systolic Blood Pressure (mmHg)  137.0 (17.0) 139.3 (20.1) 0.069 
 Diastolic Blood Pressure (mmHg)  75.1 (9.2) 72.8 (9.6)   <0.001*** 
 On antihypertensives  (% yes) 84.6 (416) 87.1 (358) 0.160 
Blood Lipids Total Cholesterol (mmol/l) 4.17 (0.79) 4.11 (0.81) 0.262 
 HDL Cholesterol  (mmol/l) 1.25 (0.35) 1.21 (0.33) 0.068 
 Lipid lowering meds (% yes) 823.1 (409) 85.6 (352) 0.173 
Smoking Smoking status     
 Current smoker 9.3 (46) 16.8 (69)  
 Ex smoker 42.1 (207) 52.8 (217)    <0.001** 
 Never smoker 48.6 (239) 30.4 (125)  
Obesity Index BMI (kg/m2) 32.0 (6.0) 30.5 (5.1)    <0.001*** 
CVD Risk Marker Ankle Brachial Index 1.01 (0.18) 0.96 (0.24)    <0.001*** 
Renal Function eGFR (ml/min/1.73m2) 78.9 (18.0) 74.8 (19.5)      0.001** 
 ACR (mg/mmol) 1.6.5 (2.6) 1.9 (3.6) 0.088 
Plasma Biomarkers IL6 2.72 (2.40) 3.01 (2.62) 0.174 
 CRP (mg/l) 1.69 (3.12) 1.92 (3.34) 0.167 
 NTProBNP (pg/ml) 66.0 (114) 82.0 (172)    <0.001*** 
CVD History Previous CVD 27.8 (137) 44.8 (184) <0.001*** 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index,  eGFR=estimated 
glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C reactive protein, NTProBNP=N terminal 










Table 5-6 Comparison of individuals carotid plaque score with traditional cardiovascular risk factors and novel biomarkers of cardiovascular risk 
 Plaque Score 
 0 1 2 3 4 5 6 7 8 
Age (years) 66.8 (4.6) 67.6 (4.3) 67.7 (3.9) 68.7 (4.18) 69.3 (4.16) 69.1 (4.0) 69.2 (4.1) 69.4 (4.3) 70.8 (3.8) 
Sex (male) 47.4 (9) 42.3 (11) 33.1 (42) 49.3 (71) 53.7 (88) 53.7 (79) 57.7 (71) 55.7 (34) 64.8 (46) 
SIMD          
Quintile 1(most deprived) 10.5 (2) 7.7 (2) 12.6 (16) 10.4 (15) 11.6 (19) 7.5 (11) 12.2 (15) 19.7 (12) 12.7 (9) 
Quintile 2 10.5 (2) 15.4 (4) 14.2 (18) 22.9 (33) 16.5 (27) 22.4 (33) 15.4 (19) 21.3 (13) 19.7 (14) 
Quintile 3 21.1 (4) 19.2 (5) 19.7 (25) 17.4 (25) 17.7 (29) 19.0 (28) 17.9 (22) 9.8 (6.0) 18.3 (13) 
Quintile 4 15.8 (3) 23.1 (6) 18.1 (23) 24.3 (35) 16.5 (27) 15.6 (23) 15.4 (19) 21.3 (13) 19.7 (14) 
Quintile 5 (least deprived) 42.1 (8) 34.6 (9) 35.4 (45) 25.0 (36) 37.8 (62) 35.4 (5) 39.0 (48) 27.9 (17) 29.6 (21) 
Duration of Diabetes (years) 6.0 (6.0) 6.5 (6.25) 7.0 (7.0) 6.0 (7.0) 8.0 (7.0) 7.0 (7.0) 8.0 (9.0) 8.0 (9.0) 8.5 (9.0) 
HbA1C (% haemoglobin) 7.4 (1.0) 7.6 (1.1) 7.3 (1.2) 7.0 (0.9) 7.1 (1.1) 7.3 (1.2) 7.3 (1.0) 7.1 (0.9) 7.1 (1.2) 
Diabetes Medication          
Diet Alone 21.1 (4) 11.5 (3) 18.1 (23) 22.9 (33) 22.6 (37) 20.4 (30) 16.3 (20) 19.7 (12) 11.3 (8) 
Oral Hypoglycaemics 57.9 (11) 69.2 (18) 66.9 (85) 68.1 (98) 60.4 (99) 63.9 (94) 64.2 (79) 62.3 (38) 70.4 (50) 
Insulin ± oral hypoglycaemics 21.1 (4) 19.2 (5) 15.0 (19) 9.0 (13) 17.1 (28) 15.6 (23) 19.5 (24) 18.0 (11) 18.3 (13) 
Systolic Blood Pressure (mmHg)  135.4 (15.2) 134.2 (19.5) 132.9 (15.6) 137.0 (17.2) 138.8 (17.6) 138.7 (19.0) 140.6 (20.3) 139.2 (20.6) 137.1 (21.0) 
Diastolic Blood Pressure (mmHg)  74.5 (10.7) 74.5 (9.3) 76.15 (9.6) 73.8 (9.2) 75.3 (8.7) 73.0 (8.2) 72.6 (9.0) 72.6 (11.6) 72.7 (10.7) 
On antihypertensives  (% yes) 68.4 (13) 80.8 (21) 79.5 (101) 87.5 (126) 87.2 (143) 85.0 (125) 87.0 (107) 88.5 (54) 91.5 (65) 
Total Cholesterol (mmol/l) 4.08 (0.89) 4.29 (0.98) 4.14 (0.80) 4.21 (0.79) 4.15 (0.75) 4.08 (0.82) 4.19 (0.78) 4.17 (0.80) 4.02 (0.83) 
HDL Cholesterol  (mmol/l) 1.22 (0.39) 1.31 (0.29) 1.24 (0.38) 1.28 (0.33) 1.23 (0.35) 1.22 (0.34) 1.24 (0.32) 1.22 (0.33) 1.17 (0.32) 
Lipid lowering meds (% yes) 73.7 (14) 69.2 (18) 79.5 (101) 81.9 (118) 89.6 (147) 84.4 (124) 88.6 (109) 82.0 (50) 85.9 (61) 
Smoking status           
Current smoker 5.3 (1) 11.5 (3) 5.5 (7) 10.4 (15) 12.2 (20) 14.3 (21) 12.2 (15) 24.6 (15) 22.5 (16) 
Ex smoker 31.6 (6) 38.5 (10) 43.3 (55) 41.7 (60) 41.5 (68) 47.6 (70) 52.8 (65) 59.0 (36) 59.2 (42) 
Never smoker 63.2 (12) 50 (13) 51.2 (65) 47.9 (69) 46.3 (76) 38.1 (56) 35.0 (43) 16.4 (10) 18.3 (13) 
BMI (kg/m2) 33.5 (7.8) 33.2 (7.5) 33.0 (6.1) 32.1 (6.1) 30.8 (5.3) 31.2 (5.5) 30.1 (5.0) 30.4 (4.6) 30.2 (4.9) 
Ankle Brachial Index 1.01 (0.14) 1.02 (0.12) 1.02 (0.16) 0.99 (0.19) 1.03 (0.18) 0.99 (0.20) 0.95 (0.22) 0.94 (0.35) 0.92 (0.24) 
eGFR (ml/min/1.73m2) 85.4 (13.9) 83.15 (16.2) 78.25 (17.66) 77.56 (19.06) 79.15 (17.84) 77.24 (17.76) 74.44 (19.7) 75.08 (17.23) 70.31 (22.3) 
ACR (mg/mmol) 1.3 (0.0) 1.75 (3.8) 2.30 (3.7) 1.40 (1.9) 1.75 (2.8) 1.3 (2.5) 2.30 (5.3) 1.95 (2.8) 3.00 (6.2) 
IL6 1.8 (2.06) 2.96 (3.80) 2.73 (2.30) 2.70 (2.09) 2.90 (2.52) 2.60 (2.12) 2.78 (2.34) 3.23 (3.13) 3.67 (3.28) 
CRP (mg/l) 1.45 (2.18) 1.77 (4.11) 1.7 (3.56) 1.82 (3.08) 1.57 (3.39) 1.69 (2.51) 1.76 (2.90) 2.69 (6.03) 2.65 (5.36) 
NTProBNP (pg/ml) 67.00 (125) 74.00 (137) 60.00 (119) 64.50 (99) 74.00 (126) 70.00 (111) 85.00 (233) 100 (236) 118.5 (213) 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C 
reactive protein, NTProBNP=N terminal pro-brain natriuretic peptide, Pack years = geometric mean..  a=No SD as n is 1 





 Association of plaque morphology with vascular risk 5.2.4
factors and biomarkers 
Associations of plaque morphology (low risk or high risk) with vascular risk factors 
are presented in table 5-7 and table 5-8.   
Individuals with high risk plaque (echolucent or heterogeneous) were significantly 
older than those with low risk plaque (69.2 vs 68.6 years), however they were no 
more likely to be male than female.   They were more likely to be using lipid 
lowering medications and had a lower BMI.  They were also more likely to have 
history of CVD.  There were no differences in blood pressure or blood lipids between 
the groups.  Several novel biomarkers were associated with the presence of high risk 
plaques.  Those with high risk plaques tended to have reduced eGFR (75.8 vs 
78.5ml/min/1.73m2, p=0.041), and increased NTproBNP (106.0 vs 69.0 pg/ml, 
p<0.001).   
If one examines the individual categories of plaque morphology mean age was 
highest in those with both types of plaque (69.8 ± 4.3 years) and lowest in those with 
echogenic or no plaque (68.5 ± 4.3 years). ABI was lowest in those with both types 
of plaque (0.94 ± 0.23).  eGFR was significantly lower in the group with both types 
of plaque (72.7 ± 19.5 ml/min/1.72m2) and ranged from 77.7-79.0 in the other 3 
groups. NT pro BNP showed a linear increase across the groups of plaque, and was 






Table 5-7 Association of plaque type with cardiovascular risk factors and novel risk markers 
  Low Risk (n=386) High Risk (n=517) P value 
Demographics Age (years) 68.6 (4.23) 69.2 (4.08)     0.029** 
 Sex (male) 50.0 (193) 52.6 (272) 0.239 
 SIMD    
 Quintile 1(most deprived) 10.76 (41) 12.2 (63)  
 Quintile 2 17.6 (68) 19.7 (102)  
 Quintile 3 18.1 (70) 17.0 (88) 0.838 
 Quintile 4 18.9 (73) 18.2 (94)  
 Quintile 5 (least deprived) 34.7 (134) 32.9 (170)  
Diabetes Duration of Diabetes (years) 7.0 (6.0) 8.0 (8.0) 0.217 
 HbA1C (% haemoglobin) 7.2 (1.01) 7.2 (1.13) 0.858 
 Diabetes Medication    
 Diet Alone 19.9 (77) 18.4 (95)  
 Oral Hypoglycaemics 65.8 (254) 64.8 (335) 0.534 
 Insulin ± oral hypoglycaemics 14.2 (55) 16.8 (87)  
Blood Pressure Systolic Blood Pressure (mmHg)  136.9 (17.6) 138.9 (19.1) 0.105 
 Diastolic Blood Pressure (mmHg)  74.6 (9.5) 73.6 (9.4) 0.108 
 On antihypertensives  (% yes) 85.2 (329) 86.1 (445) 0.396 
Blood Lipids Total Cholesterol (mmol/l) 4.17 (0.81) 4.13 (0.79) 0.397 
 HDL Cholesterol  (mmol/l) 1.24 (0.33) 1.23 (0.34) 0.895 
 Lipid lowering meds (% yes) 81.6 (315) 86.3 (446)   0.035* 
Smoking Smoking status     
 Current smoker 10.6 (41) 14.3 (74)  
 Ex smoker 45.9 (177) 48.0 (248) 0.109 
 Never smoker 43.5 (168) 37.7 (195)  
Obesity Index BMI (kg/m2) 31.9 (6.1) 30.9 (5.3)     0.005** 
CVD Risk Marker Ankle Brachial Index 1.00 (0.18) 0.98 (0.23) 0092 
Renal Function eGFR (ml/min/1.73m2) 78.5 (18.7) 75.8 (18.8)     0.041* 
 ACR (mg/mmol) 1.7 (2.6) 1.9 (3.3) 0.176 
Plasma Biomarkers IL6 2.75 (2.37) 2.85 (2.59) 0.322 
 CRP (mg/l) 1.76 (2.98) 1.76 (3.41) 0.452 
 NTProBNP (pg/ml) 66.0 (113) 82 153) 0.008** 
CVD History Previous CVD 28.8 (111) 40.8 (211) <0.001*** 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated 
glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C reactive protein, NTProBNP=N terminal 
pro-brain natriuretic peptide, Pack years = geometric mean.  





Table 5-8 Association of individual carotid plaque morphology categories with traditional 
cardiovascular risk factors and novel biomarkers  
 







Age 68.5 (43) 68.8 (3.8) 68.8 (3.9) 69.8 (4.3) 
Sex (male) 50.9 (204) 33.0 (37) 61.1 (110) 55.7 (123) 
SIMD     
Quintile 1 10.7 (43) 15.2 (17) 8.9 (16) 13.6 (30) 
Quintile 2 17.2 (69) 19.6 (22) 20.0 (36) 19.0 (42) 
Quintile 3 17.7 (71) 15.2 (17) 20.0 (36) 15.8 (35) 
Quintile 4 18.0 (72) 18.8 (21) 16.1 (29) 19.9 (44) 
Quintile 5 36.4 (146) 31.3 (35) 35.0 (63) 31.7 (70) 
Duration of DM (years) 7.0 (7.0) 6.0 (7.0) 8.0 (8.0) 8.0 (9.0) 
HbA1C  7.20 (1.0) 7.13 (1.2) 7.20 (1.1) 7.23 (1.2) 
T2DM Meds     
Diet Alone 21.2 (85) 14.3 (16) 20.0 (36) 19.0 (42) 
Oral  64.3 (258) 70.5 (79) 63.9 (115) 62.4 (138) 
Insulin ± oral  14.5 (58) 15.2 (17) 16.1 (29) 18.6 (41) 
Systolic BP (mmHg)  137.1 (17.4) 137.7 (14.3) 136.6 (18.2) 141.0 (21.6) 
Diastolic BP (mmHg)  74.75 (9.7) 74.9 (8.3) 72.8 (9.7) 73.5 (9.5) 
Antihypertensives (n, % yes) 85.3 (342) 81.3 (91) 86.7 (156) 87.8 (194) 
Total Cholesterol  4.18 (0.8) 4.24 (0.8) 4.06 (0.8) 4.12 (0.8) 
HDL Cholesterol  1.23 (0.33) 1.27 (0.4) 1.22 (0.3) 1.22 (0.4) 
Cholesterol med (n, % yes) 81.5 (327) 83.9 (94) 90.0 (162) 84.6 (187) 
Smoking status (%)     
Current smoker 11.2 (45) 15.2 (17) 13.3 (24) 14.9 (33) 
Ex smoker 45.9 (184) 43.8 (49) 45.6 (82) 52.0 (115) 
Never smoker 42.9 (172) 41.1 (46) 41.1 (74) 33.0 (73) 
BMI  31.9 (6.1) 31.9 (5.3) 31.4 (5.6) 30.0 (5.0) 
Ankle Brachial Index 0.99 (0.18) 1.00 (0.19) 1.00 (0.25) 0.94 (0.2) 
eGFR 79.0 (18.2) 79.0 (17.6) 77.7 (18.4) 72.7 (19.5) 
ACR 1.7 (2.7) 1.45 (3.2) 1.5 (2.5) 2.25 (4.0) 
IL6 2.73 (2.32) 2.81 (2.7) 2.51 (2.4) 3.07 (2.9) 
CRP 1.76 (3.1) 2.16 (3.9) 1.42 (2.7) 2.25 (3.7) 
NTProBNP 66.5 (117) 59.0 (106) 78.0 (162) 95.0 (219) 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated 
glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C reactive protein, NTProBNP=N terminal 
pro-brain natriuretic peptide, Pack years = geometric mean. 
* significant at p<0.05, ** significant at p<0.01, *** significant at p<0.001 
 
5.3 Multifactorial associations of cIMT and carotid 
plaque  
Linear regression models were used to explore the multivariable association of risk 
factors with cIMT and plaque thickness.  Logistic regression was used to explore the 
same associations with plaque score and plaque morphology.  Two models were used 
to explore these relationships.  The first model examines only traditional 
cardiovascular risk factors (model 1).  The second models incorporate traditional 
cardiovascular risk factors and the more novel biomarkers (model 2).  Results for 
linear regression models, logistic regression models and the explained variance of 





Traditional cardiovascular risk factors were entered as covariates into a linear 
regression model (model 1) for mean cIMT, maximum cIMT, maximum mean cIMT, 
mean maximum cIMT (table 5-9).  Age, male sex and systolic blood pressure 
showed a positive independent association with each cIMT variable.  In addition to 
these factors, maximum cIMT was associated with HDL cholesterol.  Interestingly, 
diastolic pressure demonstrated a negative association with each variable, which is 
not the expected direction of association.  This may be a reflection of the high 
percentage of individuals in the ET2DS that are taking antihypertensive medication. 
In the second model (table 5-10), both traditional cardiovascular risk factors and 
novel biomarkers of cardiovascular risk were entered into a linear regression model 
for each cIMT variable. In this model, ABI and NTproBNP were associated with all 
measures of cIMT after accounting for traditional risk factors.    
For mean cIMT, maximum cIMT, maximum mean cIMT and mean maximum cIMT, 
these models containing traditional cardiovascular risk factors explained 10.8%, 
10.6%, 10.4% and 10.8% of variance respectively, suggesting that these factors do 
not completely explain the variance seen in cIMT (table 5-11).  When novel 
cardiovascular risk factors were added to the traditional risk factors, these new 
models explained 16.7%, 14.2%, 14.8% and 16.4% of variance for mean cIMT, 
maximum cIMT, maximum mean cIMT, and mean maximum cIMT respectively.   
 Carotid plaque thickness 5.3.2
On entry of covariates to model 1, age, male sex, systolic and diastolic BP, and 
smoking status had a significant independent association with both mean plaque 
thickness and maximum plaque thickness. All the associations were positive, with 
the exception of diastolic pressure which, as for cIMT, had a negative association 
with both mean and maximum plaque thickness.   
Addition of novel risk factors to the model containing traditional cardiovascular risk 




with mean plaque thickness.  For maximum plaque thickness, only NTproBNP was 
independently associated following multifactorial adjustment. 
Model 1, containing only traditional risk factors explained 15.7% of the variance of 
mean plaque thickness and 14.0% of maximum plaque thickness.  Adding novel risk 
factors to the model increased variance to 18.9% and 17.6% respectively.   
 Plaque score and plaque morphology 5.3.3
Logistic regression models for the association of plaque score (<=4 or  >4) are 
presented in table 5-12.  After multifactorial adjustment, risk factors that were 
independently associated with a higher plaque score were increasing age, increasing 
systolic BP and diastolic BP, cigarette smoking and a low BMI.   
Logistic regression models for the association of plaque morphology (high risk or 
low risk) are presented in table 5-13.  After multifactorial adjustment, risk factors 
that were independently associated with high risk plaque were increasing systolic BP 








Table 5-9 Multifactorial associations of cIMT and plaque thickness with traditional cardiovascular risk factors (Model 1) 
 Mean cIMT Max cIMT Max Mean cIMT Mean Max cIMT Mean Plaque Thickness Max Plaque Thickness 
 Β coeff P value Β coeff P value B coeff P value B Coeff P value Β coeff P value B Coeff P Value 
Age (years) 0.142 <0.001*** 0.116 0.001 0.121 <0.001*** 0.128 <0.001*** 0.176 <0.001*** 0.178 <0.001*** 
Sex (male) -0.218 <0.001*** -0.208 <0.001*** -0.206 <0.001*** -0.216 <0.001*** -0.155 <0.001*** -0.146 <0.001*** 
SIMD -0.022 0.513 -0.025 0.459 -0.016 0.609 -0.030 0.345 -0.046 0.154 -0.030 0.362 
Duration of diabetes 0.022 0.536 0.010 0.782 -0.003 0.943 0.025 0.480 0.082 0.021* 0.075 0.035* 
HbA1c 0.032 0.366 0.032 0.373 0.037 0.299 0.032 0.363 0.025 0.473 0.020 0.563 
Diabetes Medication -0.048 0.196 -0.057 0.125 -0.039 0.290 -0.062 0.096 -0.037 0.300 -0.040 0.270 
Systolic BP (mm Hg) 0.149 <0.001*** 0.143 <0.001*** 0.157 <0.001*** 0.145 <0.001*** 0.168 <0.001*** 0.139 0.001** 
Diastolic BP (mm Hg) -0.144 <0.001*** -0.146 <0.001*** -0.163 <0.001*** -0.141 <0.001*** -0.099 0.011* -0.092 0.019* 
Antihypertensive Use -0.058 0.086 -0.053 0.115 -0.061 0.068 -0.057 0.093 0.050 0.131 0.058 0.080 
Total Cholesterol 0.022 0.463 0.017 0.636 0.028 0.441 0.017 0.649 0.037 0.302 0.039 0.284 
HDL Cholesterol -0.051 0.144 -0.081 0.021* -0.066 0.055 -0.067 0.051 -0.017 0.619 -0.012 0.733 
Lipid lowering medication 0.060 0.073 0.062 0.068 0.065 0.056 0.056 0.096 0.035 0.286 0.033 0.326 
Smoking status -0.051 0.125 -0.054 0.107 -0.059 0.080 -0.054 0.108 -0.230 <0.001*** -0.222 <0.001*** 
BMI 0.015 0.660 0.001 0.971 0.005 0.890 0.011 0.751 -0.031 0.416 -0.032 0.367 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C 
reactive protein, NTProBNP=N terminal pro-brain natriuretic peptide, Pack years = geometric mean. 









Table 5-10 Multifactorial associations of cIMT and plaque thickness with novel risk factors after adjustment for traditional risk factors (Model 2) 
 Mean cIMT Max cIMT Max Mean cIMT Mean Max cIMT Mean Plaque Thickness Max Plaque Thickness 
 Β coeff P value Β coeff P value B coeff P value B Coeff P value Β coeff P value B Coeff P value 
ABI -0.161 0.004** -0.145 0.011** -0.146 0.010* -0.148 0.008** -0.139 0.011* -0.106 0.070 
eGFR 0.066 0.283 0.086 0.168 0.083 0.186 0.079 0.200 0.024 0.688 0.020 0.747 
ACR 0.025 0.656 0.027 0.483 0.019 0.740 0.037 0.515 0.008 0.885 0.028 0.615 
IL-6 -0.081 0.196 -0.045 0.705 -0.072 0.256 -0.041 0.511 0.085 0.167 0.091 0.141 
CRP -0.001 0.989 -0.046 0.468 -0.017 0.788 -0.010 0.866 -0.029 0.630 -0.048 0.433 
NTproBNP 0.241 <0.001*** 0.199 0.002*** 0.221 <0.001*** 0.223 <0.001*** 0.142 0.020* 0.155 0.012* 
Adjusted for Age (years), Sex (male), SIMD, Duration of diabetes, HbA1c, Diabetes Medication, Systolic BP (mm Hg), Diastolic BP (mm Hg), Antihypertensive Use, Total Cholesterol, HDL Cholesterol, 
Lipid lowering medication, Smoking status, BMISIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate, 
ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C reactive protein, NTProBNP=N terminal pro-brain natriuretic peptide, Pack years = geometric mean* significant at p<0.05, ** significant at p<0.01, 
*** significant at p<0.001 
 
Table 5-11 Explained variance for linear regression models of continuous ultrasound parameters (R
2
) 





Model 1 0.108 0.106 0.104 0.108 0.157 0.140 
Model 2 0.167 0.142 0.148 0.164 0.189 0.176 
Model 1 – traditional cardiovascular risk factors   




Table 5-12 Multifactorial associations of plaque score and plaque morphology with traditional 
cardiovascular risk factors (Model 1) 
 Plaque score >4 High risk plaque 
 Exp (B) P value Exp (B) P value 
Age (years) 1.04 0.020* 1.03 0.129 
Sex (male) 1.24 0.186 1.02 0.912 
SIMD 1.11 0.689 0.77 0.287 
Duration of diabetes 0.87 0.614 1.05 0.842 
HbA1c 1.07 0.400 0.993 0.921 
Diabetes Medication 1.42 0.219 1.25 0.416 
Systolic BP (mm Hg) 1.02 <0.001** 1.01 0.012* 
Diastolic BP (mm Hg) 0.96 <0.001*** 0.98 0.029* 
Antihypertensive Use 1.19 0.429 1..08 0.720 
Total Cholesterol 1.04 0.685 1.00 0.967 
HDL Cholesterol 0.74 0.202 0.98 0.945 
Lipid lowering medication 1.05 0.819 1.36 0.0.129 
Smoking status 1.95 <0.001*** 1.17 0.310 
BMI 0.95 0.001** 0.97 0.012* 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated 
glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C reactive protein, NTProBNP=N terminal 
pro-brain natriuretic peptide, Pack years = geometric mean.* significant at p<0.05, ** significant at p<0 .01, *** significant at 
p<0.001 
Table 5-13 Multifactorial associations of plaque score and plaque morphology with novel risk 
factors after adjustment for traditional risk factors (Model 3) 
 Plaque score >4 High risk plaque 
 Β coeff P value Β coeff P value 
ABI 0.19 0.014* 0.62 0.450 
eGFR 1.00 0.788 0.99 0.434 
ACR 0.77 0.351 1.07 0.814 
IL-6 0.57 0.270 0.99 0.977 
CRP 1.40 0.278 1.11 0.726 
NTproBNP 2.38 0.003** 2.10 0.007** 
Adjusted for Age (years), Sex (male), SIMD, Duration of diabetes, HbA1c, Diabetes Medication, Systolic BP (mm Hg), 
Diastolic BP (mm Hg), Antihypertensive Use, Total Cholesterol, HDL Cholesterol, Lipid lowering medication, Smoking status, 
BMI, SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated 
glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C reactive protein, NTProBNP=N terminal 






5.5 Change in cIMT and vascular risk factors 
A univariate correlation analysis (table 5-14) of change in cIMT between year 1 and 
year 4 follow up with risk factors revealed that only baseline cIMT was correlated 
with change in cIMT (r=-0.300, p<0.001).  Multifactorial regression modelling (table 
5-15) of change in mean cIMT revealed the independent predictors of change in 
cIMT were baseline mean cIMT (B -0.300, p<0.001) and BMI (-0.184, p=0.005). 
Table 5-14 Univariate association of risk factors and baseline cIMT with change in mean cIMT 
  Change mean cIMT 
  Correlation Anova 
Demographics Age -0.024 - 
 Sex (male) -  0.004 
 SIMD   
 Quintile 1 (Most Deprived) -  0.012 
 Quintile 2 -  0.013 
 Quintile 3 - -0.007 
 Quintile 4 - -0.004 
 Quintile 5 (Least Deprived) - - 
Diabetes Duration of DM (years) -0.046 - 
 HbA1C  -0.026 - 
 T2DM Meds   
 Diet Alone - -0.009 
 Oral  - -0.004 
 Insulin ± oral  - - 
Blood Pressure Systolic BP (mmHg)  0.068 - 
 Diastolic BP (mmHg)  0.080 - 
 Antihypertensives (n, % yes) -  0.004 
Blood Lipids Total Cholesterol  0.008 - 
 HDL Cholesterol  -0.064 - 
 Cholesterol med (n, % yes) - -0.018 
Smoking Smoking status (%)   
 Current smoker -  0.035 
 Ex smoker -  0.006 
 Never smoker - - 
Obesity Index BMI -0.050 - 
CVD Risk Marker ABI -0.020 - 
Renal Function eGFR -0.012 - 
 ACR -0.109 - 
Plasma Biomarkers IL6 0.008 - 
 CRP 0.036 - 
 NTProBNP -0.061 - 
Carotid Ultrasound Baseline cIMT       -0.300*** - 
For continuous variables, Pearson correlation coefficients and corresponding p values are quoted.  For categorical variables,  
ANOVAs quantify the difference in mean and maximum plaque thickness for the given categorical variable compared with  the 
reference level (reference levels are female sex, least deprived SIMD quintile,  diet alone treatment for diabetes,  no lipid 
lowering medication, no anti-hypertensive medication, never smoker) SIMD=Scottish Index of Multiple Deprivation, 
HDL=high density lipoprotein, BMI=body mass index, ABI =ankle brachial index, eGFR=estimated glomerular filtration rate, 
ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C reactive protein, NTProBNP=N terminal pro-brain natriuretic 




Table 5-15 Multifactorial associations of change in mean cIMT with cardiovascular risk factors and 
baseline cIMT 
 Change mean cIMT 
 Β coeff P value 
Age (years) -0.023 0.721 
Sex (male) -0.052 0.479 
SIMD 0.061 0.320 
Duration of diabetes 0.011 0.875 
HbA1c -0.018 0.771 
Diabetes Medication 0.114 0.082 
Systolic BP (mm Hg) 0.115 0.116 
Diastolic BP (mm Hg) 0.099 0.198 
Antihypertensive Use 0.027 0.668 
Total Cholesterol -0.043 0.507 
HDL Cholesterol -0.114 0.089 
Lipid lowering medication -0.038 0.531 
Smoking status -0.054 0.390 
BMI -0.183     0.005** 
ABI -0.090 0.157 
eGFR -0.110 0.109 
ACR -0.083 0.186 
IL-6 -0.013 0.965 
CRP -0.003 0.845 
NTproBNP -0.061 0.389 
Baseline cIMT  -0.327     <0.001*** 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated 
glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C reactive protein, NTProBNP=N terminal 
pro-brain natriuretic peptide, Pack years = geometric mean.** significant at p<0.01 *** significant at p<0.001 
 
5.6 Prevalent vascular disease 
Prevalence of cardiovascular disease is reported in table 5-16.  At year 1, previous 
myocardial infarction was recorded for 129 (14.1%) participants, a diagnosis of 
angina for 250 (27.3%), previous stroke for 50 (5.5%) and previous TIA for 29 
(3.2%).  When vascular diseases were categorized into broader categories, 280 
(30.6%) had a history of any coronary artery disease (MI and/or angina), 79 (8.6%) 
had a history of any cerebrovascular disease (stroke and/or TIA) and 317 (34.6%) 




Table 5-16 Prevalence of Vascular Disease in the ET2DS year 1 study population 
 % participants (n)  
Myocardial Infarction 14.1 (129) 
Angina 27.3 (250) 
Stroke 5.5 (50) 
Transient Ischaemic Attack 3.2 (29) 
Any Cardiovascular Disease 34.6 (317) 
Any Coronary Artery Disease 30.6 (280) 
Any Cerebrovascular Disease 8.6 (79) 
The groups reported are not mutually exclusive.  Prevalence is reported for individuals who have ever had any of the above 
diagnoses, regardless of whether they had also been diagnosed with one of the other diagnoses ie a participant who has had both 
an MI and a TIA is counted in both groups, and so the percentages do no total 100.  For the amalgamated groups, the group 
‘any cardiovascular disease’ has more participants because participants could be in both any CAD and any Cerebrovascular 
disease but only be counted once in the any CVD group.   
 
 Association of prevalent cardiovascular disease with 5.6.1
vascular risk factors and plasma biomarkers 
Distribution of cardiovascular risk factors and novel plasma biomarkers in those with 
grouped CVD outcomes are detailed in table 5-17.   
Any CVD 
Individuals with any CVD were older (69.35 vs 68.55 years, p=0.016), were more 
likely to be male (61.5% vs 46.6%, p<0.001) and more likely to be from less affluent 
social groups (p<0.001) than those with no history of CVD.  They had a longer 
duration of diabetes (8.0 vs 7.0 years, p=0.018) but there was no significant 
difference in HbA1c between the groups.  Slightly more individuals with a history of 
CVD used insulin in addition to oral medications compared to those without disease 
(19.9% vs 13.7%, p=0.045).   
Systolic blood pressure was broadly similar between the groups (139.26 vs 137.42 
mmHg, p=0.151) however diastolic blood pressure was significantly lower in those 
with CVD (72.763 vs 74.75 mmHg, p<0.001), a surprising finding which may be 
accounted for by the increased use of antihypertensive medication in this group 




vs 4.198 mmol/l, p=0.010), as was HDL cholesterol (1.145 vs 1.276 mmol/l, 
p<0.001), while use of lipid lowering medications was higher (88.0 vs 82.3%, 
p=0.024).  While one might expect to see lower HDL cholesterol in those with CVD, 
while total cholesterol tends to be higher.  The unexpected finding of lower total 
cholesterol might be accounted for by the increased use of lipid lowering medication 
in the disease group.  A higher percentage of those with CVD were current or ex-
smokers compared to those without disease (67.5 vs 55.9%, p=0.003).  BMI was 
similar in both groups (31.8 vs 31.1, p=0.095).   
A lower ABI was also noted in those with disease (0.961 vs 1.001, p=0.006).  
Individuals who experienced any cardiovascular disease had poorer renal function 
than those who did not, with lower mean eGFR (72.97 vs 79.53 ml/min/1,73m2, 
p<0.001, respectively) and higher ACR (2.5 vs 1.5 mg/mol, p<0.001 respectively). 
Inflammatory markers were also higher in those with CVD (IL6 3.29 vs 2.59 pg/ml, 
p<0.001; CRP 2.19 vs 1.56 mg/l, p<0.001).  NTproBNP was also higher (144.5 vs 
59.0 pg/ml, p<0.001).   
Coronary Artery Disease 
Differences in risk factors and biomarkers in those with and without coronary artery 
disease were broadly similar to those seen for individuals with any cardiovascular 
disease, except that in the CAD group, there was no significant difference in the type 
of treatment for diabetes.   
Cerebrovascular Disease 
Differences in risk factors and plasma biomarkers between those with and without 
cerebrovascular disease were not as pronounced as in those with any cardiovascular 
disease or any CAD.  Those with cerebrovascular disease tended to be older and 
male, with a longer duration of diabetes and increased frequency of insulin use, than 
those without cerebrovascular disease.  They also had lower HDL cholesterol and a 
greater prevalence of current smoking.   They also tended to have a lower ABI and 




higher in those with cerebrovascular disease than those without.  Again, NTproBNP 
was higher in the disease group than those without disease.   
 Association of prevalent cardiovascular disease with 5.6.2
carotid ultrasound parameters  
Distribution of cardiovascular risk factors and novel plasma biomarkers in those with 
grouped CVD outcomes are detailed in table 5-18.   
Any CVD 
In subjects with any cardiovascular disease, mean cIMT was higher (0.99 vs 0.92 
mm, p<0.001) as were maximum cIMT (1.15 vs 1.04mm, p=0.001), maximum mean 
cIMT (1.06 vs 0.98mm, p=0.001) and mean maximum cIMT (1.07 vs 0.98, 
p<0.001).  There was no significant difference in change in mean cIMT. 
Mean plaque thickness was also higher (2.75 vs 2.28mm, p<0.001).  Individuals with 
CVD were more likely to have a higher plaque score. When plaque score and plaque 
morphology were considered as dichotomous variables (plaque score: ≤4 or >4 and 
plaque type: high risk/low risk respectively), those with disease tended to have a 
higher plaque score (57.3 vs 39.0%, p<0.001) and more high risk plaque (65.5 vs 
52.7%, p<0.001).   
Coronary Artery Disease 
Continuous carotid ultrasound variables were also significantly higher in individuals 
with CAD (mean cIMT 0.96 vs 0.93 mm, p=0.001; max cIMT 1.09 vs 1.05 mm, 
p=0.001, max mean cIMT 1.02 vs 0.98 mm, p=0.001; mean plaque thickness 2.78 vs 
2.29 mm p<0.001).  There was no significant difference in change in mean cIMT.  
Plaque score tended to be higher in those with CAD (>4 58.2 vs <=4 39.8%, 
p<0.001) and individuals with CAD tended to have more high risk plaque when 






Mean cIMT was higher in those with cerebrovascular disease (0.96 vs 0.93 mm, 
p<0.001) as was max cIMT (1.09 vs 1.05 mm, p<0.001), max mean cIMT (1.02 vs 
0.99, p<0.001) and mean plaque thickness (2.85 vs 2.41, p<0.001).  There was no 
significant difference in change in mean cIMT.  Individuals with a history 
cerebrovascular disease were more likely to have a plaque score >4 when compared 
to those without disease (62.5 vs 43.9% respectively, p=0.002) but there was no 








Table 5-17 Prevalent Cardiovascular Disease, Cardiovascular Risk Factors and Novel plasma biomarkers 
 Any CVD No CVD P value Any CAD No CAD P value Any Cerebro No Cerebro P value 
Age (years) 69.35 (4.01) 68.66 (4.08) 0.016 69.5 (4.4) 68.64 (4.05) 0.003 68.9 (4.05) 68.89 (4.18) 0.893 
Sex (male) 61.5 (195) 46.6 (279) <0.001 61.8 (173) 47.3 (301) <0.001 67.1 (53) 50.3 (421) 0.004 
SIMD          
Quintile 1 14.8 (47) 9.8 (59)  15.0 (42) 10.1 (64)  19.0 (15) 10.9 (91)  
Quintile 2 23.7 (75) 15.7 (94)  23.6 (66) 16.2 (103)  24.1 (19) 17.9 (15)  
Quintile 3 19.6 (62) 16.4 (98) <0.001 18.6 (52) 17.0 (108) 0.002 24.1 (19) 16.8 (141) 0.006 
Quintile 4 15.4 (46) 20.0 (120)  15.4 (43) 19.3 (123)  8.9 (7) 19.3 (159)  
Quintile 5 27.4 (87) 38.1 (228)  27.5 (77) 37.4 (27.5)  24.1 (19) 35.4 (296)  
Duration of Diabetes (years) 8.0 (7.0) 7.0 (8.0) 0.018 8.00 (7.00) 7.0 (8.0) 0.037 9.00 (8.25) 7.0 (8.0) 0.013 
HbA1C (% haemoglobin) 7.239 (1.158) 7.154 (1.023) 0.257 7.199 (1.092) 7.176 (1.064) 0.764 7.372 (1.364) 7.165 (1.039) 0.101 
Diabetes Medication          
Diet Alone 19.6 (62) 19.7 (118)  18.9 (53) 20.0 (127)  21.5 (17) 19.5 (163)  
Oral Hypoglycaemics 60.6 (192) 66.6 (399) 0.045 62.1 (174) 65.6 (417) 0.234 53.2 (42) 65.6 (549) 0.033 
Insulin ± oral hypoglycaemics 19.9 (63) 13.7 (82)  18.9 (53) 14.5 (92)  25.3 (20) 14.9 (125)  
Systolic BP (mmHg)  139.26 (20.248) 137.42 (17.310) 0.151 139.19 (20.591) 137.55 (17.321) 0.216 140.29 (19.011) 137.85 (18.331) 0.261 
Diastolic BP (mmHg)  72.73 (10.30) 74.75 (8.99) 0.002 72.56 (10.384) 74.71 (9.023) 0.002 72.40 (10.037) 74.21 (9.449) 0.108 
On antihypertensives  (% yes) 96.5 (306) 80.0 (479) <0.001 98.2 (275) 80.2 (510) <0.001 92.4 (73) 85.1 (712) 0.075 
Total Cholesterol (mmol/l) 4.054 (0.817) 4.198 (0.794) 0.010 4.035 (0.822) 4.197 (0.792) 0.005 4.071 (0.765) 4.155 (0.808) 0.380 
HDL Cholesterol  (mmol/l) 1.145 (0.283) 1.276 (0.354) <0.001 1.138 (0.274) 1.271 (0.354) <0.001 1.128 (0.300) 1.240 (0.339) 0.005 
Lipid lowering meds (% yes) 88.0 (279) 82.3 (493) 0.024 89.6 (251) 81.9 (521) 0.003 81.0 (15) 84.6 (708) 0.404 
Smoking status           
Current smoker 14.5 (46) 12.2 (73)  14.3 (40) 12.4 (79)  16.5 (13) 12.7 (106)  
Ex smoker 53.0 (168) 43.7 (168) 0.003 52.9 (148) 44.3 (282) 0.013 57.0 (45) 46.0 (385) 0.037 
Never smoker 32.5 (103) 44.1 (264)  32.9 (92) 43.2 (275)  26.6 (21) 41.3 (346)  
Ankle Brachial Index 0.961 (0.242) 1.001 (0.188) 0.006 0.966 (0.249) 0.997 (0.189) 0.039 0.891 (0.246) 0.996 (0.204) <0.001 
BMI (kg/m2) 31.76 (5.61) 31.10 (5.72) 0.095 31.71 (5.61) 31.16 (5.71) 0.176 31.55 (5.54) 31.30 (5.70) 0.709 
eGFR (ml/min/1.73m2) 72.97 (20.26) 79.53 (17.307) <0.001 72.65 (20.43) 79.29 (17.42) <0.001 71.64 (22.15) 77.81 (18.19) 0.005 
ACR (mg/mmol) 2.5 (4.2) 1.5 (2.2) <0.001 2.5 (4.3) 1.5 (2.3) <0.001 2.85 (4.5) 1.7 (3.0) 0.012 
IL6 3.29 (2.81) 2.59 (2.24) <0.001 3.31 (2.87) 2.66 (2.25) <0.001 3.28 (2.30) 2.76 (2.43) 0.083 
CRP (mg/l) 2.19 (4.24) 1.56 (3.03) <0.001 2.18 (4.23) 1.6 (3.08) 0.002 2.26 (4.62) 1.67 (3.15) 0.011 
NTProBNP (pg/ml) 144.5 (269) 59.0 (83) <0.001 164.5 (285) 59.0 (82) <0.001 93.5 (232) 72.0 (129) 0.004 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C 








Table 5-18 Prevalent cardiovascular disease, carotid intima media thickness and carotid plaque 
 Any CVD No CVD P value Any CAD No CAD P value Any Cerebro No Cerebro P value 
Mean cIMT (mm) 0.99 (0.15) 0.92 (0.14) <0.001 0.96 (0.14) 0.93 (0.14) 0.001 0.96 (0.14) 0.93 (0.14) <0.001 
Max cIMT (mm) 1.15 (0.22) 1.04 (0.19) 0.001 1.09 (0.19) 1.05 (0.19) 0.001 1.09 (0.19) 1.05 (0.19) <0.001 
Max Mean cIMT (mm) 1.06 (0.20) 0.98 (0.17) 0.001 1.02 (0.17) 0.98 (1.02) 0.001 1.02 (0.17) 0.99 (0.17) <0.001 
Mean Max cIMT (mm) 1.07 (0.17) 0.98 (0.15) <0.001 1.02 (0.16) 0.98 (0.16) <0.001 1.02 (0.17) 0.99 (0.15) <0.001 
Mean Plaque Thickness (mm) 2.75 (0.94) 2.28 (0.84) <0.001 2.78 (0.93) 2.29 (0.84) <0.001 2.85 (1.15) 2.41 (0.86) <0.001 
Max Plaque Thickness (mm) 3.15 (1.15) 2.62 (1.04) <0.001 3.20 (1.16) 2.64 (1.04) <0.001 3.33 (1.46) 2.76 (1.06) 0.001 
Change in mean cIMT -0.01 (0.12) -0.01 (0.11) 0.774 -0.01 (0.11) -0.01 (0.11) 0.940 0.01 (0.15) -0.02 (0.11) 0.096 
Plaque Score          
0 1.2 (4) 2.6 (15)  0.7 (2) 2.7 (17)  2.5 (2) 2.1 (17)  
1 0.9 (3) 4.1 (24)  1.1 (3) 3.9 (24)  1.3 (1) 3.2 (26)  
2 9.3 (30) 17.4 (101)  8.5 (24) 17.2 (107)  10.0 (8) 14.9 (123)  
3 14.3 (46) 17.4 (101)  13.8 (39) 17.4 (108)  12.5 (10) 16.6 (137)  
4 16.8 (54) 19.6 (114) <0.001 17.7 (49) 19.0 (118) <0.001 11.3 (9) 19.3 (159) 0.043 
5 18.7 (60) 15.3 (89)  17.4 (49) 16.1 (100)  17.5 (14) 16.4 (135)  
6 16.5 (53) 12.4 (72)  18.8 (53) 11.6 (72)  17.5 (14) 13.5 (111)  
7 9.0 (29) 6.2 (36)  8.9 (25) 6.4 (40)  11.3 (9) 6.8 (56)  
8 13.1 (42) 5.2 (30)  13.1 (37) 5.6 (35)  16.3 (13) 7.2 (59)  
Plaque Score           
≤4 42.7 (137) 61.0 (355) <0.001 41.8 (118) 60.2 (374) <0.001 37.5 (30) 56.1 (462) 0.001 
>4 57.3 (184) 39.0 (227)  58.2 (164) 39.8 (247)  62.5 (50) 43.9 (361)  
Plaque Morphology          
Echogenic/no plaque 34.5 (111) 47.3 (275)  32.5 (92) 47.4 (294)  37.5 (30) 43.3 (356)  
Echolucent only 9.6 (31) 14.1 (82) <0.001 10.2 (29) 13.5 (84) <0.001 6.3 (5) 13.1 (107) 0.002 
Heterogenous only 22.7 (73) 18.9 (110)  23.7 (67) 18.7 (116)  15.0 (12) 20.8 (171)  
Both types 33.2 (107) 19.6 (114)  33.6 (95) 20.3 (126)  37.5 (33) 22.8 (188)  
Plaque Morphology          
Low Risk  34.5 (111) 47.3 (275) <0.001 32.5 (92) 47.4 (294) <0.001 37.5 (30) 43.3 (356) 0.191 
High Risk 65.5 (211) 52.7 (306)  67.5 (191) 52.6 (326)  62.5 (50) 55.7 (467)  




5.7 Logistic regression analyses for cardiovascular 
events 
Logistic regression analyses were performed to assess the association of cIMT and 
carotid plaque with prevalent cardiovascular events before and after adjustment for 
traditional cardiovascular risk factors and the more novel biomarkers.  Results are 
reported as odds ratios for 1 SD change in the factor being measured in tables 5-19, 
5-20 and 5-21.    
cIMT (table 5-19) 
In the unadjusted models (model 1), a 1-SD increase in mean cIMT had an odds ratio 
of 1.26 (1.10-1.45), p<0.001 for any prevalent CVD.  Age and sex adjustment 
(model 2) attenuated the odds ratio slightly (OR 1.16 (1.01-1.34), p=0.036), while 
after additional adjustment for traditional cardiovascular risk factors (model 3) and 
for novel biomarkers and SIMD (model 4) the odds ratios became non-significant 
(p>0.05). Odds ratios for any coronary artery disease and any cerebrovascular 
disease were similar to those for any CVD and were again attenuated and became 
non-significant once traditional risk factors were adjusted for (see table 5-12, column 
1).   
Max cIMT had an unadjusted odds ratio of 1.25 (1.10-1.43), p=0.001, and an age and 
sex adjusted OR 1.16 (1.01-1.33), p=0.039.  As was seen for mean cIMT, the odds 
ratios were attenuated in models 3 and 4, and subsequently fell out of statistical 
significance.  A similar pattern was seen for coronary artery disease and 
cerebrovascular disease (see table 5-13, column 2).  
For maximum mean cIMT, the unadjusted and age and sex adjusted odds ratios for 
any cardiovascular disease were OR 1.24 (1.08-1.42), p=0.002, and OR 1.15 (0.99-
1.32), p=0.052 respectively.  Further adjustment for CV risk factors caused the odds 
ratios to fall out of significance.  The same was seen for coronary artery disease and 
cerebrovascular disease. (see table 5-13, column 3). 
For mean max cIMT, unadjusted and age and sex adjusted odds ratios for any 




p=0.018 respectively.  Again, further adjustment for traditional and then novel risk 
factor attenuated the odds ratios and cause them to fall out of statistical significance 
(see table 5-12, column 4).  The same pattern was seen for CAD and cerebrovascular 
disease.   
Plaque Thickness (table 5-20) 
Both mean and maximum plaque thickness demonstrated a more robust association 
with prevalent cardiovascular disease than cIMT. 
The unadjusted odds ratio of mean plaque thickness for cardiovascular disease was 
1.70 (1.47-1.97), p<0.001.  Adjusting for age and sex attenuated the odds ratio 
slightly to OR 1.60 (1.38-1.86), p<0.001.  However, unlike for cIMT variables, mean 
plaque thickness retained significant odds ratios upon additional adjustment for 
cardiovascular and novel risk factors (OR 1.50 (1.27-1.77), p<0.001 and OR 1.50 
(1.11-2.01), p=0.009 respectively). Similar odds ratios were seen for coronary artery 
disease and cerebrovascular disease and they remained significant for both following 
adjustment for cardiovascular risk factors, although mean plaque thickness lost 
significance for cerebrovascular disease once novel factors were accounted for (OR 
1.28 (0.86-1.91), p=0.0.224) (see table 5-13, column 1).   
Max plaque thickness had unadjusted odds ratio of 1.62 (1.40-1.88) p<0.001 and an 
age and sex adjusted OR of 1.52 (1.31-1.77), p<0.001 for any cardiovascular disease.  
Similarly to mean plaque thickness, further adjustment for both traditional and novel 
risk factors did not attenuated the odds ratio significantly (OR 1.45 (1.22-1.71), 
p<0.001 and OR 1.38 (1.03-1.83), p=0.030) (see table 5-13, column 2).  Similar odds 
ratios were seen for CAD and cerebrovascular disease, although, again, once novel 
risk factors were accounted for, max plaque thickness lost its association with 
cerebrovascular disease. 
Plaque score and plaque morphology (table 5-21) 
Similarly to the measures of plaque thickness, plaque score and plaque morphology 




adjustment for risk factors (OR 1.74, p=0.049 and HR 1.74, p=0.043 respectively).  
Plaque score and plaque morphology were also associated with prevalent CAD, 
although plaque score lost its association once novel biomarkers were adjusted for.  
There was no relationship between cerebrovascular disease and either plaque score or 








Table 5-19 Multifactorial adjusted associations between prevalent cardiovascular disease and cIMT 
 
 
Mean cIMT Max cIMT Max Mean cIMT Mean Max cIMT  
Outcome Odds Ratio CI P value Odds Ratio CI P value Odds Ratio CI P value Odds Ratio CI P value 
             
Any CVD             
Model  1 1.26 1.10-1.45 0.001 1.25 1.10-1.43 0.001 1.24 1.08-1.42 0.002 1.29 1.13-1.49 <0.001 
Model  2 1.16 1.01-1.34 0.036 1.16 1.01-1.33 0.039 1.15 0.99-1.32 0.052 1.19 1.03-1.38   0.018 
Model  3 1.06 0.91-1.25 0.442 1.05 0.90-1.23 0.556 1.05 0.90-1.23 0.559 1.08 0.92-1.27   0.351 
Model  4 0.99 0.75-1.30 0.938 0.97 0.75-1.26 0.833 0.97 0.75-1.25 0.805 0.99 0.75-1.31   0.964 
             
Coronary Artery Disease             
Model  1 1.28 1.11-1.47 0.001 1.27 1.10-1.45 0.001 1.25 1.09-1.44 0.001 1.29 1.13-1.50 <0.001 
Model  2 1.17 1.01-1.35 0.036 1.16 1.01-1.34 0.038 1.15 1.00-1.33 0.049 1.19 1.03-1.38   0.022 
Model  3 1.08 0.92-1.27 0.353 1.08 0.92-1.27 0.376 1.07 0.91-1.26 0.411 1.10 0.93-1.30   0.279 
Model  4 0.98 0.73-1.32 0.898 0.99 0.75-1.31 0.972 0.99 0.75-1.30 0.930 0.99 0.73-1.33   0.940 
             
Cerebrovascular Disease             
Model  1 1.46 1.18-1.81 0.001 1.51 1.22-1.86 <0.001 1.43 1.16-1.76 0.001 1.56 1.25-1.95 <0.001 
Model  2 1.41 1.12-1.76 0.003 1.45 1.17-1.81   0.001 1.37 1.11-1.70 0.004 1.51 1.20-1.89 <0.001 
Model  3 1.22 0.95-1.56 0.122 1.25 0.98-1.59   0.074 1.19 0.94-1.51 0.185 1.28 0.99-1.65   0.055 
Model  4 1.35 0.91-2.00 0.134 1.27 0.89-1.83   0.191 1.21 0.85-1.72 0.292 1.40 0.94-2.08   0.099 
             
model 1 unadjusted  
model 2 age and sex 
model 3 Age, sex,SIMD, duration of DM, HbA1C, diabetes treatment, systolic blood pressure, diastolic blood pressure, Antihypertensive use, total cholesterol, HDL cholesterol, lipid lowering medication use, 
smoking, BMI  
model 4 Age, sex, SIMD,duration of DM, HbA1C, diabetes treatment, systolic blood pressure, diastolic blood pressure, Antihypertensive use, total cholesterol, HDL cholesterol, lipid lowering medication 
use, smoking, BMI, ankle brachial index, albumin creatinine ratio, interleukin 6, c reactive protein, NTProBNP 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C 
reactive protein, NTProBNP=N terminal pro-brain natriuretic peptide, Pack years = geometric mean. 








Table 5-20 Multifactorial adjusted associations between prevalent cardiovascular disease and carotid plaque thickness 
 
 
Mean Plaque Thickness Max Plaque Thickness 
Outcome Odds Ratio CI P value Odds Ratio CI P value 
       
Any CVD       
Model  1 1.70 1.47-1.97 <0.001 1.62 1.40-1.88 <0.001 
Model  2 1.60 1.38-1.86 <0.001 1.52 1.31-1.77 <0.001 
Model  3 1.50 1.27-1.77 <0.001 1.45 1.22-1.71 <0.001 
Model  4 1.50 1.11-2.01   0.007 1.38 1.03-1.83   0.030 
       
Coronary Artery Disease       
Model  1 1.72 1.48-1.99 <0.001 1.66 1.43-1.92 <0.001 
Model  2 1.61 1.38-1.87 <0.001 1.55 1.33-1.81 <0.001 
Model  3 1.56 1.31-1.85 <0.001 1.52 1.27-1.80 <0.001 
Model  4 1.57 1.15-2.14   0.004 1.48 1.09-2.01   0.011 
       
Cerebrovascular Disease       
Model  1 1.55 1.25-1.90 <0.001 1.56 1.27-1.92 <0.001 
Model  2 1.49 1.19-1.85 <0.001 1.50 1.21-1.87 <0.001 
Model  3 1.32 1.03-1.70   0.028 1.37 1.07-1.75   0.012 
Model  4 1.28 0.86-1.91   0.224 1.28 0.85-1.91   0.234 
       
model 1 unadjusted  
model 2 age and sex 
model 3 Age, sex,SIMD, duration of DM, HbA1C, diabetes treatment, systolic blood pressure, diastolic blood pressure, Antihypertensive use, total cholesterol, HDL cholesterol, lipid lowering medication use, 
smoking, BMI  
model 4 Age, sex, SIMD,duration of DM, HbA1C, diabetes treatment, systolic blood pressure, diastolic blood pressure, Antihypertensive use, total cholesterol, HDL cholesterol, lipid lowering medication 
use, smoking, BMI, ankle brachial index, eGFR,  albumin creatinine ratio, interleukin 6, c reactive protein, NTProBNP 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C 
reactive protein, NTProBNP=N terminal pro-brain natriuretic peptide. 









Table 5-21 Multifactorial adjusted associations between prevalent cardiovascular disease and carotid plaque score and morphology 
 
 
Plaque Score >4 High Risk Plaque Type 
Outcome Odds Ratio CI P value Odds Ratio CI P value 
       
Any CVD       
Model  1 2.10 1.59-2.77 <0.001 1.71 1.29-2.26 <0.001 
Model  2 1.93 1.46-2.57 <0.001 1.66 1.25-2.21 <0.001 
Model  3 1.64 1.20-2.26   0.001 1.61 1.17-2.20   0.003 
Model  4 1.74 1.00-3.04   0.049 1.74 1.02-2.98   0.043 
       
Coronary Artery Disease       
Model  1 2.10 1.58-2.80 <0.001 1.87 1.40-2.51 <0.001 
Model  2 1.92 1.44-2.57 <0.001 1.82 1.35-2.45 <0.001 
Model  3 1.65 1.19-2.30   0.003 1.81 1.30-2.52 <0.001 
Model  4 1.71 0.94-3.09   0.078 2.64 146-4.76   0.001 
       
Cerebrovascular Disease       
Model  1 2.13 1.33-3.42   0.002 1.27 0.79-2.04   0.354 
Model  2 2.01 1.24-3.24   0.004 1.25 0.77-2.01   0.370 
Model  3 1.53 0.91-2.58   0.112 1.17 0.70-1.97   0.555 
Model  4 1.37 0.60-3.14   0.454 0.65 0.29-1.48   0.305 
       
model 1 unadjusted  
model 2 age and sex 
model 3 Age, sex,SIMD, duration of DM, HbA1C, diabetes treatment, systolic blood pressure, diastolic blood pressure, Antihypertensive use, total cholesterol, HDL cholesterol, lipid lowering medication use, 
smoking, BMI  
model 4 Age, sex, SIMD,duration of DM, HbA1C, diabetes treatment, systolic blood pressure, diastolic blood pressure, Antihypertensive use, total cholesterol, HDL cholesterol, lipid lowering medication 
use, smoking, BMI, ankle brachial index,eGFR,  albumin creatinine ratio, interleukin 6, c reactive protein, NTProBNP 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, IL-6=interleukin 6, CRP=C 
reactive protein, NTProBNP=N terminal pro-brain natriuretic peptide. 
* significant at p<0.05, ** significant at p<0.01, *** significant at p<0.001 
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5.8 Chapter summary 
This chapter describes the cross sectional relationship between cIMT, carotid plaque 
and vascular risk factors (both traditional and novel), as well as the relationship 
between cIMT and carotid plaque and prevalent vascular disease.  cIMT was 
predominantly associated with increasing age, male sex and increased systolic blood 
pressure, although these were not strong associations with some factors having only 
small effect sizes.  These associations persisted following multivariable linear 
regression.  In addition, increased cIMT was associated with adverse levels the novel 
biomarkers ABI and NTproBNP following multivariable regression.   Further, 
change in cIMT between year 1 and year 4 demonstrated a regression.  The main risk 
factors associated with change in cIMT were BMI and baseline cIMT following 
multifactorial adjustment. 
Plaque thickness demonstrated more extensive associations with traditional risk 
factors, including with increasing age, male sex, longer duration of diabetes, 
increased systolic blood pressure and cigarette smoking, all of which survived 
multifactorial modelling but which again like cIMT, had only small effect sizes 
suggesting only modest associations. It was also associated with ABI and NTproBNP 
in multifactorial models.  The relationship between plaque score and cardiovascular 
risk factors was more complex, although several key risk factors that were associated 
with increased plaque score were increased age, increased systolic and diastolic 
blood pressure, cigarette smoking and a lower BMI. Reduced ABI and increased 
NTproBNP were also associated with plaque score.  Plaque morphology was 
associated with systolic and diastolic blood pressure and lower BMI.  It also 
associated with lower ABI and increased NTproBNP.   
Vascular disease had a prevalence of 34.6% (MI, angina, stroke or TIA) in the 
ET2DS at year 1 and was associated with increased values of both cIMT and carotid 
plaque.  Age and sex adjusted logistic regression models revealed that all measures 
of cIMT and plaque were associated with prevalent cardiovascular disease and CAD.  
However, for cIMT, these relationships lost statistical significance after full 
adjustment for traditional cardiovascular vascular risk factors, whereas for mean and 
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maximum plaque thickness and plaque score and plaque morphology, they persisted 
following full adjustment including both traditional risk factors and novel 
biomarkers.  Neither cIMT, plaque score or plaque morphology were as strongly 
associated with cerebrovascular disease once full adjustment was performed.   
These results suggest that carotid plaque may be more strongly associated with 
prevalent cardiovascular disease than cIMT and thus may have more potential to 
predict incident cardiovascular events.   
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Chapter 6: Results 3 – Longitudinal Analysis of 
Carotid Ultrasound Markers and Incident 
Cardiovascular Events 
 
This chapter reports the results of longitudinal analyses of the relationship between 
carotid ultrasound parameters and incident cardiovascular events in the Edinburgh 
Type 2 diabetes study.   Incidence rates are described, as well as the cardiovascular 
risk factor profile of those who had an event.  Finally, survival analyses of cIMT and 
carotid plaque parameters for cardiovascular events are described. 
 
6.1 Incident cardiovascular events in the ET2DS 
In the period between cIMT measurement at year 1, and the end of year 4 follow up 
of the ET2DS (31st August 2011), there were 74 individuals in the cIMT analysis 
group with fatal or non-fatal incident cardiovascular events in the study population of 
this thesis (only first events were recorded), which translates to an incidence rate for 
any cardiovascular disease of 8.1%.  Of the fatal events, three were confirmed 
myocardial infarction, two were confirmed stroke and eleven were cases of other 
ischaemic heart disease (not specified).  Of the non-fatal events, fifteen were 
confirmed myocardial infarction, eighteen were new diagnoses of angina, twenty 
were confirmed non-fatal stroke, and five were confirmed transient ischaemic attack.  
Because these were first events, the individuals groups are mutually exclusive.  For 
the plaque group, the number of overall CVD events was 75.   
As the number of events in each individual category was small, for the purposes of 
analysis, the events were categorized into four composite endpoints to maximize the 
possibility of detecting associations.  These categories were: Any CVD (Any 
cardiovascular event), CAD (Fatal MI, Non-Fatal MI and Angina), Cerebrovascular 
(Fatal Stroke, Non-fatal Stroke and TIA) and Fatal CVD (Fatal MI, Fatal Stoke and 
Other Fatal IHD).  The number of participants in each group is detailed in table 6-1.  
These groups are not mutually exclusive, for example, individuals who experienced a 
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fatal MI appear in both any CAD and fatal CVD.  This also applies to those who had 
a fatal stroke.  In addition, because the group of fatal events includes diagnoses 
recorded as “fatal ischaemic heart disease”, these individuals were not included in 
the any CAD group because they could not be confirmed as MI or angina (the 
definition of any CAD used in this thesis).   
Table 6-1 Incident Cardiovascular Events in IMT group in the period between year 1 follow up and 
August 2011 in the ET2DS 
Outcome Number of events % of sample 
Fatal MI 3 4.1 
Non-Fatal MI 15 20.3 
Angina 18 24.3 
Fatal Stoke 2 2.7 
Non-Fatal Stroke 20 27.0 
TIA 5 6.8 
Other Fatal IHD 11 14.9 
Total 74 100.0 
Composite Outcomes   
Any CVD  74 8.1 
CAD  36 3.9 
Cerebrovascular  27 2.9 
Fatal CVD  16 1.7 
MI=myocardial infarction, TIA=transient ischaemic attack, IHD=ischaemic heart disease  
The individual events listed in the first part of the table are mutually exclusive because each event listed is a first  event.  For the 
second part of the table, an event could belong to more than one composite group.  Therefore, no totals are listed for this 
section.   
Absolute risk of MI in the year 1 IMT group was 5.6 events per 1000 patient years.  
If we compare equivalent rates in other groups with Type 2 diabetes, Mulnier et al 
found (in data derived from a GP data base of 1739 people with Type 2 diabetes and 
almost 4000 without, a rate of 19.4 events per 1000 patient years for MI in adults 
with Type 2 diabetes aged 65-74 years (similar to the ET2DS), which is considerably 
higher than that seen in the ET2DS (Mulnier, Seaman et al. 2008).  This same study 
estimated a rate for a similarly aged non-diabetic population of 7.03 per 1000 patient 
years. 
 
  188 
 
6.2 Demographics, vascular risk factors and incident 
cardiovascular events 
Demographic variables and traditional cardiovascular risk factors were compared in 
those participants with IMT measurements who had an incident cardiovascular event 
and those who did not (table 6-2).  Individuals who had an incident event were older 
and more likely to be male, but there was no difference in sociodemographic status 
between the groups.  Those with incident vascular events had a poorer diabetic 
profile than those with no event, with a longer median duration of diabetes, higher 
HbA1c and a higher percentage of individuals using insulin ± hypoglycaemics.  
When cardiovascular risk factors were compared between the groups, there was no 
significant difference in either systolic or diastolic blood pressure, but there was 
more antihypertensive medication use among those who had an event, which could 
explain why blood pressure was similar in each group.  There was no difference in 
total cholesterol levels between the groups and while HDL cholesterol was slightly 
lower in the incident event group, the difference did not reach statistical significance.  
There was however a higher percentage of individuals using lipid lowering 
medication in the group who experienced an event.  Smoking profiles did not vary 
between the groups, with no significant difference in the percentage of current, ex or 
never smokers in the groups.  Obesity indices were examined and BMI was found to 
be similar between the groups.  eGFR was also significantly lower in those who 
experienced an event, as was IL-6 and NTproBNP.  There was no difference in ABI, 
ACR or CRP between the groups.  Results were similar in the plaque analysis group. 
The relationship between prevalent cardiovascular and incident vascular disease was 
also explored.  Those individuals who experienced an incident event were more 
likely to have experienced a previous CVD event (51.4% previous CVD vs 34.0% no 
previous CVD, p=0.002).   
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Table 6-2 Demographics and Vascular Risk factors in Individuals with Incident Events and No 
events (IMT group) 
 Incident Event (n=74) No Event (n=842) P Value 
Age (years) 70.1 (3.9) 68.8 (4.2)    0.009** 
Sex (male) 63.5 (47) 50.7 (427)    0.023* 
SIMD    
Quintile 1(most deprived) 12.2 (9) 11.5 (97)  
Quintile 2 20.3 (15) 18.3 (154)  
Quintile 3 21.6 (16) 17.1 (144)    0.567 
Quintile 4 20.3 (15) 17.9 (151)  
Quintile 5 (least deprived) 25.7 (19) 35.2 (296)  
Duration of Diabetes (years) 9.0 (11.0) 7.0 (8.0)    0.010* 
HbA1C (% haemoglobin) 7.44 (1.19) 7.16 (1.06)    0.030* 
Diabetes Medication    
Diet Alone 16.2 (12) 20.0 (168)  
Oral Hypoglycaemics 50.0 (37) 65.8 (554)  <0.001*** 
Insulin ± oral hypoglycaemics 33.8 (25) 14.3 (120)  
Systolic BP (mmHg)  140.6 (19.3) 137.8 (18.3)    0.208 
Diastolic BP (mmHg)  72.4 (10.1) 74.2 (9.4)    0.120 
On antihypertensives  (% yes) 93.2 (69) 85.0 (716)    0.032* 
Total Cholesterol (mmol/l) 4.14 (0.96) 4.15 (0.79)    0.883 
HDL Cholesterol  (mmol/l) 1.16 (0.34) 1.24 (0.34)    0.061 
Lipid lowering meds (% yes) 91.9 (68) 83.6 (704)    0.037* 
Smoking status     
Current smoker 14.9 (11) 12.8 (108)  
Ex smoker 50.0 (37) 46.7 (393)    0.648 
Never smoker 35.1 (26) 40.5 (341)  
Pack Years  0.00 (0.00) 0.00 (0.00)    0.816 
BMI (kg/m2) 31.2 (5.2) 31.3 (5.7)    0.807 
ABI 0.96 (0.32) 0.99 (0.20)    0.257 
eGFR (ml/min/1.73m2) 69.2 (20.4) 77.9 (18.3)  <0.001** 
ACR 2.0 (8.) 1.7 (3.1)    0.147 
IL6 3.64 (2.6) 2.75 (2.4)    0.047* 
CRP 2.29 (3.3) 1.70 (3.3)    0.256 
NTproBNP 137.5 (235) 70.0 (126)  <0.001*** 
Previous History of CVD at baseline 51.4 (38) 34.0 (286)    0.002** 
SIMD=Scottish Index of Multiple Deprivation, HDL=high density lipoprotein, BMI=body mass index, eGFR=estimated 
glomerular filtration rate, CVD=cardiovascular disease  *=p<0.05, **p<0.01, ***significant at p<0.001 Values are mean (SD) , 
median IQR or % (n) 
 
6.3 IMT, plaque and incident vascular events 
The distribution of cIMT and plaque in individuals with incident events was 
examined using the students T test and chi squared statistic.  Further exploration 
through a series of Cox Proportional Hazards models examined the predictive ability 
of cIMT for incident CVD in people with diabetes. 
 Distribution of IMT and plaque in participants with 6.3.1
incident cardiovascular events 
All measures of cIMT were significantly higher in those who experienced an incident 
event when compared with those who did not (table 6-3).  Mean and maximum 
 
  190 
plaque thickness were also significantly higher in those who had an event although 
the absolute difference was not as great as that seen for cIMT.  There was no 
significant difference in change in mean cIMT.  Plaque score was considered as a 
dichotomous score of less than or greater than 4, revealing a significantly higher 
proportion of participants with a plaque score >4 in the group with incident events 
than without.  Plaque morphology was significantly different between the groups.  
Participants with incident events were less likely to have echogenic/no plaque, 
echolucent plaque alone or heterogeneous plaque alone, and more likely to have both 
types of plaque (p=0.008) than individuals who did not have an event.  However, 
when plaque morphology was categorized as high or low risk, there was no 
significant difference in plaque morphology between those with and without incident 
events.  These results were repeated in the plaque analysis group.   
Table 6-3 cIMT and Plaque Measurements in those with and without incident events 
 Incident Event (n=74) No Event (n=842) P Value 
Mean IMT (mm) 0.985 (0.14) 0.931 (0.14)  0.001** 
Max IMT (mm) 1.112 (0.17) 1.054 (0.193)  0.013* 
Max Mean IMT (mm) 1.047 (0.16) 0.990 (0.17)  0.006** 
Mean Max IMT (mm) 1.048 (0.15) 0.990 (0.16)  0.002** 
Mean Plaque Thickness (mm) 2.694 (0.91) 2.421 (0.89)  0.015* 
Max Plaque Thickness (mm) 3.116 (1.16) 2.786 (1.10)  0.017* 
Change in mean cIMT (mm) -0.02 (0.15) -0.01 (0.11)  0.753 
Plaque Score     
0 1.4 (1) 2.2 (18)  
1 0.0 (0) 3.2 (26)  
2 8.5 (6) 14.9 (121)  
3 9.9 (7) 16.9 (137)  
4 22.5 (16) 18.2 (148)  0.116 
5 16.9 (12) 16.6 (135)  
6 15.5 (11) 13.8 (112)  
7 12.7 (9) 6.4 (52)  
8 12.7 (9) 7.6 (62)  
Plaque score ≤ 4 42.3 (30) 55.5 (450)  0.022* 
Plaque Score >4 57.7 (41) 44.5 (361)  
Plaque Morphology    
Echogenic/no plaque 35.1 (26) 44.6 (375)  
Echolucent only 9.5 (7) 12.5 (105)  0.008** 
Heterogenous only 14.9 (11) 20.1 (169)  
Both types 40.5 (30) 22.7 (191)  
High risk plaque (yes) 64.9 (48) 55.4 (465)  0.072 
Variables are reported as mean (SD) or %,n P values determined by students T test, ANOVA or chi square 
 
 Cox regression models 6.3.2
In order to explore further the relationship between cIMT and incident cardiovascular 
disease in people with Type 2 diabetes, Cox proportional hazards models were 
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employed.  Three models were created – Model A: unadjusted, Model B: age, sex 
and previous CVD adjusted and Model C: age, sex, previous CVD and UKPDS risk 
factor adjusted.  By adjusting for these risk factors, it is possible to comment on the 
potential to use cIMT or carotid plaque over and above these risk factors in 
cardiovascular risk prediction.  Hazard ratios for each of the models are presented in 
tables 6-4, 6-5 and 6-6. 
Incident cardiovascular disease 
Survival modelling for any cardiovascular disease revealed the most interesting 
results.  All four cIMT measures were predictive of incident cardiovascular disease.  
In unadjusted models, for a 1-SD increase in both mean cIMT and mean maximum 
cIMT there was a 1.4 fold increase in risk for any cardiovascular disease, while 
maximum cIMT and mean maximum cIMT had a slightly lower risk (1.30 and 1.33 
respectively).  Further adjustment for age, sex and previous CVD caused maximum 
cIMT and maximum mean cIMT to lose statistical significance in the model.  Mean 
cIMT and mean maximum cIMT, however, survived this additional adjustment, 
albeit with a modest reduction in risk (HR 1.29 (1.03-1.61) and 1.28 (1.01-1.60) 
respectively).  Full adjustment for UKPDS risk factors caused mean maximum cIMT 
to lose significance in the model but mean cIMT survived full adjustment with a HR 
of 1.26 (1.00-1.58), p=0.046.   
In unadjusted models, a 1-SD increase in both mean plaque thickness and maximum 
plaque thickness corresponded to a 1.26 fold increase in risk for incident vascular 
disease, however both measures lost significance once age, sex and previous CVD 
were adjusted for.  Plaque score showed the same pattern of association as plaque 
thickness in the models, while plaque morphology did not achieve any significance 
in even the unadjusted model.   
Incident coronary artery disease 
In unadjusted models, all measures of cIMT were predictive of incident coronary 
artery disease.  For a 1-SD increase in mean cIMT and mean maximum cIMT, there 
was a 1.5 fold increase in risk for coronary artery disease, while estimates for 
maximum cIMT and maximum mean cIMT were slightly lower with HR 1.36 and 
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1.37 respectively. Adjustment for age, sex and previous CAD attenuated the risk 
modestly for all measures of cIMT and at this point, max cIMT and max mean cIMT 
fell out of significance in the models.  Both mean cIMT and mean max cIMT 
however, survived further adjustment for the risk factors included in the UKPDS risk 
score (HR 1.49 for both measures).   
Mean plaque thickness and maximum plaque thickness were entered first into the 
unadjusted Cox model but failed to achieve statistical significance.  This was also the 
case for plaque score and plaque morphology.   
Incident cerebrovascular disease 
In unadjusted models for incident cerebrovascular disease, only plaque morphology 
demonstrated a significant association, which survived adjustment for age, sex and 
previous cerebrovascular disease.  However, full adjustment for the UKPDS risk 
factors caused the hazard ratios to lose statistical significance.   
Incident fatal cardiovascular disease 
On entry to the unadjusted model for fatal CVD, none of the carotid ultrasound 
markers achieved a statistical association with risk.  This is likely due to the low 
number of events in this group. 
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Table 6-4 Cox regression models for incident cardiovascular events and cIMT  
  Mean cIMT (mm) Max cIMT (mm) Max Mean cIMT (mm) Mean Max cIMT (mm) 
 Events (n) HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value 
Any CVD Event 74             
Model A  1.41 1.14-1.74  0.001** 1.30 1.06-1.60  0.013* 1.33 1.08-1.63     0.006** 1.41 1.13-1.75 0.002** 
Model B  1.29 1.03-1.61 0.029* 1.18 0.95-1.47 0.141 1.22 0.98-1.51 0.074 1.28 1.01-1.60  0.038* 
Model C  1.26 1.00-1.58 0.046* 1.16 0.93-1.45 0.181 1.20 0.96-1.49 0.108 1.25 0.99-1.57 0.062 
CAD Events 36             
Model A  1.52 1.12-2.04  0.006** 1.36 1.01-1.82 0.041* 1.37 1.02-1.83 0.034* 1.53 1.13-2.07 0.007** 
Model B  1.47 1.08-2.01 0.015* 1.31 0.96-1.79 0.087 1.33 0.98-1.80 0.070 1.48 1.09-2.04 0.016* 
Model C  1.49 1.08-2.06 0.016* - - - - - - 1.49 1.07-2.07 0.017* 
Cerebrovascular Events 27             
Model A  1.38 0.97-1.97 0.070 1.29 0.92-1.82 0.145 1.31 0.94-1.84 0.117 1.39 0.97-1.99 0.079 
Model B  - - -    - - -    
Model C  - - -    - - -    
Fatal Events 16             
Model A  1.09 0.68-1.76 0.724 1.06 0.66-1.71 0.802 1.12 0.70-1.78 0.647 1.06 0.64-1.73 0.833 
Model B  - - - - - - - - - - - - 
Model C  - - -          
Model A Unadjusted 
Model B Age, Sex and Previous corresponding vascular events adjusted (except fatal events – previous any CVD used) 
Model C Age, Sex, Previous CVD and additional UKPDS risk factor adjusted (duration diabetes, HbA1c, systolic BP, cholesterol, HDL cholesterol, smoking) 
HR for 1SD change in each variable
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Table 6-5 Cox regression models for incident cardiovascular events and carotid plaque thickness 
  Mean Plaque Thickness (mm) Maximum Plaque Thickness (mm) 
 Number of Events HR 95% CI P value HR 95% CI P value 
Any CVD Event 74       
Model A  1.26 1.03-1.55   0.025* 1.26 1.02-1.54  0.029* 
Model B  1.10 0.88-1.38 0.403 1.10 0.88-1.38 0385 
Model C  - - - - - - 
CAD Events 36       
Model A  1.12 0.82-1.54 0.462 1.13 0.83-1.54 0.434 
Model B  - - - - - - 
Model C  - - - - - - 
Cerebrovascular Events 26       
Model A  1.37 0.98-1.91 0.069 1.35 0.97-1.89 0.076 
Model B  - - -    
Model C  - - -    
Fatal Events 16       
Model A  1.33 0.86-2.04 0.201 1.32 0.86-2.03 0.202 
Model B  - - - - - - 
Model C        
Model A Unadjusted 
Model B Age, Sex and Previous corresponding vascular events adjusted (except fatal events – previous any CVD used) 
Model C Age, Sex, Previous CVD and additional UKPDS risk factor adjusted (duration diabetes, HbA1c, systolic BP, cholesterol,  HDL cholesterol, smoking) 









Table 6-6 Cox regression models for incident cardiovascular events and carotid plaque score and morphology 
  Plaque Score >4  Plaque Morphology Dichotomous  
 Number of Events HR 95% CI P value Number of Events HR 95% CI P value 
Any CVD Event 75    75    
Model A  1.77 1.12-2.81 0.015*  1.40 0.87-2.24 0.161 
Model B  1.44 0.90-2.31 0.129  - - - 
Model C  - - -  - - - 
CAD Events 36    36    
Model A  1.75 0.90-3.40 0.0.098  0.89 0.46-1.72 0.731 
Model B  - - -  - - - 
Model C  - - -  - - - 
Cerebrovascular Events 27    27    
Model A  1.82 0.85-3.93 0.126  2.76 1.11-6.85 0.029* 
Model B  - - -  2.53 1.02-6.30 0.046* 
Model C  - - -  2.28 0.91-5.71 0.079 
Fatal Events 16    16    
Model A  1.24 0.464-3.30 0.670  1.31 0.47-3.60 0.605 
Model B  - - -  - - - 
Model C  - - -  - - - 
Model A Unadjusted 
Model B Age, Sex and Previous corresponding vascular events adjusted (except fatal events – previous any CVD used) 
Model C Age, Sex, Previous CVD and additional UKPDS risk factor adjusted (duration diabetes, HbA1c, systolic BP, cholesterol, HDL cholesterol, smoking) 
HR are quoted for the plaque score>4 versus plaque score less than 4, and for high risk plaque versus low risk plaque 
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 Assessment of model  6.3.3
Mean cIMT survived adjustment for UKPDS risk factors in the prediction of global 
CVD and CAD, and as did mean maximum cIMT for CAD.   In order to assess the 
impact of cIMT on risk classification, only the models for mean cIMT were 
explored, for two reasons.  Firstly, only mean cIMT was chosen because the hazard 
ratios produced for both mean cIMT and mean maximum cIMT were almost 
identical in the models and so to avoid repetition, only mean cIMT was analysed.  
And secondly, the number of events in the CAD model was almost half that of the 
global CVD model and because reclassification is calculated in events and non-
events, the low number of events in the CAD group may not provide a meaningful 
measure of change.   
The model containing both cIMT and UKPDS risk factors was compared with the 
model containing UKPDS risk factors only, in order to explore any improvement in 
risk prediction brought by cIMT.  Area under the ROC curve was initially used to 
assess model improvement upon addition of cIMT, after which net reclassification 
index (NRI) was determined to assess the reclassification of predicted risk.   
ROC curve analysis 
ROC curves were created using the predicted risk (X beta) provided by the Cox 
regression model in section 6.3.2 (figure 6-1).  Area under the curve was compared 
for the model containing UKPDS risk factors alone and the model containing both 
risk factors and mean cIMT (table 6-7).  The area under the curve for the model 
containing only traditional risk factors was found to be 0.691  (85% CI 0.629-0.753). 
When cIMT was added to the model, there was a small improvement in AUC to 
0.704 (95% CI 0.645-0.763), suggesting that cIMT may contribute additional, albeit 
modest, information to current risk classification models.  
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Figure 6-1 ROC curves of predicted risk in global CVD model containing risk factors only and model 
containing mean cIMT and traditional risk factors 
 
Table 6-7 AUC for models containing risk factors only, and cIMT in addition to risk factors 






Global CVD Model 1 TRF 0.691 0.629 - 0.753 <0.001 
 Model 2 TRF + mean cIMT 0.704 0.645 – 0.763 <0.001 










  198 
Figure 6-2 ROC curves of predicted risk in global CVD model containing risk factors only and model 
containing mean plaque thickness and risk factors 
 
When the ROC curve for mean plaque thickness versus traditional risk factors was 
plotted, the AUC was 0.695 for both he TRF model only and the TRF and plaque 
model, confirming what was demonstrated in the Cox regression – that adding plaque 
to traditional risk factors does not improve prediction of cardiovascular events.   
Net Reclassification Index 
To explore the effect of adding cIMT to the reclassification of risk category for 
global CVD, net reclassification index was determined for the addition of mean 
cIMT to each model (table 6-8).  Risk was calculated from arbitrary tertiles of 
predicted risk produced by the models and categorized at low (1st tertile), 
intermediate and high risk (3rd tertile) (de Ruijter W, Westendorp RGJ et al. 2009).  
For global CVD, in the event group, 5 individuals had their risk category reclassified 
upwards, and 5 were reclassified down.  In the non-event group, 77 individuals had 
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their risk category reclassified upwards and 81 were reclassified down, producing a 
net reclassification index of 0.25%.   
Table 6-8 Reclassification of incident cardiovascular events when cIMT is added to the model 
containing cardiovascular risk factors 
   Model with TRF and cIMT 
   Low Intermediate High 
Event Group Model with TRF Low 5 2 0 
  Intermediate 2 21 3 




Model with TRF and cIMT 
  Low Intermediate High 
Non-Event Group Model with TRF Low 248 38 2 
  Intermediate 40 191 39 
  High 0 41 213 
TRF=traditional risk factors 
 
6.4 Chapter summary 
This chapter aimed to explore the relationship between cIMT, carotid plaque and 
incident cardiovascular disease in older adults with Type 2 diabetes.  Incident 
cardiovascular events in the study population were associated with increased age, 
male sex, longer duration of diabetes, increased HbA1c and reduced eGFR, as well 
as a previous history of cardiovascular disease.  Those individuals who experienced 
an incident event had significantly higher cIMT and plaque thickness, as well as a 
higher plaque score and a tendency to have high risk plaque present in the carotid 
arteries.   
In unadjusted Cox regression models for global cardiovascular disease, both cIMT 
and carotid plaque (thickness, score and morphology) were predictive of incident 
events; however only mean cIMT survived full adjustment for cardiovascular risk 
factors used in the UKPDS cardiovascular risk score. Mean cIMT and mean 
maximum cIMT were also predictive of incident CAD.  No measures of cIMT or 
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plaque were predictive of cerebrovascular disease once traditional risk factors were 
adjusted for.   
Further analysis of the global CVD model revealed that while there was an increase 
in the area under the curve when cIMT was added to the model containing traditional 
cardiovascular risk factors, there was only a small improvement in risk classification.    
Therefore, the usefulness of cIMT in predicting cardiovascular events over and 
above traditional risk factors may only be limited.    
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Chapter 7: Discussion 
 
Introduction 
Year on year, cardiovascular disease continues to be the number one cause of death 
globally. Identifying individuals at high risk of cardiovascular events is particularly 
important for the targeting of preventive therapies, even in high risk individuals such 
as people with Type 2 diabetes.   While cardiovascular risk scores based on 
conventional cardiovascular risk factors are the primary means by which 
cardiovascular risk is estimated in the general population, exploration of more novel 
factors, such as cIMT and carotid plaque, as markers of cardiovascular risk has 
received considerable attention, although there is still no global consensus as to their 
use in predicting risk in this group.  The evidence for the use of cIMT in individuals 
with Type 2 diabetes is particularly sparse and has been identified as an important 
area for exploration by the recent USPSTF statement (United States Preventative 
Services Task Force 2009).  In addition, the use of cIMT as a surrogate end point in 
clinical trials of drugs used in the treatment of diabetes are based primarily on 
evidence from the general population of the association between cIMT and 
cardiovascular risk.  There is little evidence from studies of people with diabetes to 
directly support this use.   
This thesis aimed to explore the relationship of carotid intima media thickness and 
carotid plaque with cardiovascular disease in older adults with Type 2 diabetes, using 
data from the Edinburgh Type 2 Diabetes Study cohort.  Both cross sectional and 
longitudinal relationships of carotid intima media thickness and carotid plaque with 
cardiovascular disease outcomes were investigated using a variety of statistical 
methods. In addition, an exploration of measurement methods for cIMT was also 
undertaken. The current chapter discusses the results of these analyses in the context 
of current research and describes potential areas for future research.  Methodological 
strengths and limitations of the thesis are also discussed. 
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7.1 Summary of main findings 
In order to meet the primary aim of this thesis (to explore the association of cIMT 
and carotid plaque with cardiovascular risk in older people with Type 2 diabetes), a 
series of objectives was addressed.  The first objective was to describe the frequency 
and distribution of cIMT and carotid plaque in older adults with Type 2 diabetes. 
Participants in the ET2DS were generally representative of older adults with Type 2 
diabetes living in Edinburgh and the Lothians and those who attended for year 1 
cIMT measurements were largely representative of the cohort as a whole.  A 
validation study revealed that cIMT measurement in the study was highly repeatable 
and was comparable with computer aided measurements.  cIMT was normally 
distributed in the sample and was higher in men, as well as older participants.  cIMT 
was also higher in the left carotid artery than the right.  There was a high prevalence 
of carotid plaque in the ET2DS, with at least 1 plaque present in approximately 97% 
of the study population.  Continuous measurements of cIMT were correlated with 
one another but less so with measures of plaque thickness.  Similarly, measures of 
plaque thickness correlated with one another.  Surprisingly, the change in mean 
cIMT was negative between year 1 and year 4, suggesting there was an improvement 
in cIMT over the follow up period.  
The second objective of this thesis was to describe the cross sectional relationship of 
cIMT and carotid plaque with vascular risk factors (both traditional and novel), as 
well as the relationship of cIMT and carotid plaque with prevalent vascular disease.  
Increased cIMT was predominantly associated with older age, male sex and higher 
systolic blood pressure and these associations persisted following multivariable 
linear regression, suggesting that these factors are independently associated with 
cIMT.  In addition, increased cIMT was associated with adverse levels of the novel 
biomarkers ABI and NTproBNP following multivariable regression.   However, it 
should be noted that the small effect sizes demonstrated were small, which may 
suggest that these were not strong relationships between cIMT and cardiovascular 
risk factors.   
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Increased plaque thickness demonstrated more extensive independent associations 
with traditional vascular risk factors than cIMT, namely older age, male sex, longer 
duration of diabetes, higher systolic blood pressure, and cigarette smoking. Plaque 
thickness was also positively associated with ABI and NTproBNP following 
multivariable adjustment.  Again, in some cases, the effect size was noted to be small 
and may suggest only a weak association between plaque and risk factors.  Plaque 
score was independently associated with increasing age, raised systolic and reduced 
diastolic blood pressure, smoking and lower BMI and was independently associated 
with reduced ABI and increased NTproBNP.  Plaque morphology was independently 
associated with raised systolic blood pressure, lower diastolic blood pressure and low 
BMI, as well as ABI and NTproBNP.  
There was a high prevalence of vascular disease (MI, angina, TIA, stroke) in the 
ET2DS at year 1 and the prevalence of vascular disease was associated with 
increased values of both cIMT and carotid plaque.  Age and sex adjusted logistic 
regression models revealed that all measures of cIMT and plaque were associated 
with prevalent cardiovascular disease.  However, for cIMT, these relationships lost 
statistical significance after adjustment for traditional cardiovascular risk factors, 
whereas for mean and maximum plaque thickness, they persisted following full 
adjustment including both traditional risk factors and novel biomarkers.   Plaque 
score and plaque morphology remained associated with CVD and CAD following 
full adjustment.  These results raise the possibility that carotid plaque may have more 
potential to predict incident cardiovascular events than cIMT.   
Building on the findings of the cross sectional analysis, the third objective, addressed 
in chapter 6, was to explore the relationship of cIMT and carotid plaque and incident 
cardiovascular disease.  Incident cardiovascular events in the study population were 
associated with older age, male sex, longer duration of diabetes, higher HbA1c and 
lower eGFR, as well as a previous history of cardiovascular disease.  Those 
individuals who experienced an incident event had significantly higher cIMT and 
plaque thickness, as well as a higher plaque score and a tendency to have high risk 
(echolucent or heterogeneous plaque) present in the carotid arteries.  In unadjusted 
cox regression models, both cIMT and carotid plaque measures were predictive of 
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incident cardiovascular events. However, only the association with mean cIMT 
survived full adjustment for cardiovascular risk factors used in the UKPDS 
cardiovascular risk score.  Only mean cIMT and mean maximum cIMT were 
predictive of CAD after multifactorial analysis but neither cIMT nor plaque global 
was predictive of cerebrovascular disease.  Further analysis of the model for any 
cardiovascular disease and mean cIMT revealed that while there was a small increase 
in the area under the curve for the model containing mean cIMT, there was a 
negligible improvement in risk classification, suggesting that while cIMT may be an 
independent predictor of cardiovascular risk and carotid plaque may not, the ultimate 
usefulness of cIMT in predicting cardiovascular events over and above traditional 
vascular risk factors may be limited.   
 
7.2 Strengths of the ET2DS 
The Edinburgh Type 2 Diabetes study is a longitudinal cohort study of individuals 
with Type 2 diabetes living in Edinburgh and the Lothians.  This study design, with a 
representative risk population, is ideally suited to the evaluation of potential risk 
prediction markers (Hlatky MA, Greenland P et al. 2009).  The study also possesses 
other factors highlighted by an American Heart Association Scientific Statement 
(Hlatky MA, Greenland P et al. 2009) as important in the evaluation of novel risk 
markers, including an accurate definition and ascertainment of outcome events, as 
well as robust reporting.  Hlatky et al highlight the “Strengthening the Reporting of 
Observational Studies in Epidemiology” (STROBE) guidelines (von Elm E, Altman 
DG et al. 2007; Hlatky MA, Greenland P et al. 2009) as the standard to which studies 
should be reported.  The reporting of the analyses presented in this thesis complies 
with the key areas in the STROBE guidelines.   
Bias, Chance and Confounding 
If one considers the key epidemiological concepts of bias, chance and confounding, 
the design of the ET2DS goes a long way to addressing each of these.   Bias was 
minimised by having robust data collection protocols, including SOPs for the clinics, 
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which were adhered to by a small team of dedicated study staff.  Generalizability was 
addressed by using a well-structured, random sampling frame which recruited a 
representative sample of individuals from the population of older people with Type 2 
diabetes living in Edinburgh and the Lothians.  Chance was addressed by the use of 
robust statistical testing.  Finally, the wide ranging data collection performed in the 
study produced a well phenotyped cohort, allowing researchers to adequately address 
many possible sources of confounding through multiple risk factor adjustment in 
statistical models.   
 Study recruitment, response and representativeness 7.2.1
Following recruitment and attendance of 1066 participants at baseline, 939 
participants returned to follow up at 1 year.  While there was a range of reasons for 
non-attendance at this time point, for many of which little could be done (e.g. death, 
inability to complete examination), the majority of reasons given by participants 
were related to inability or unwillingness to attend an appointment.  Vigorous 
attempts were made to encourage attendance by providing a choice of appointment 
time, as well as providing transport to and from the clinic if necessary.  In addition, a 
further appointment was offered in the case of non-attendance or illness.  Travel 
expenses were also offered on a case by case basis.  While this took considerable 
time and effort, it did result in 88.0% of the baseline participants returning for 
follow-up at year 1.   
Because of the time that had elapsed between year 1 and year 4 follow up, several 
attempts were made, prior to invitation to clinics, to determine current contact details 
for all ET2DS participants who were not already coded as withdrawn from the study, 
in order to maximize participation in the follow up study.  An initial strategy of 
posting a study newsletter to the last known address for each participant managed to 
capture up-to-date contact details for the majority of participants and where it was 
not possible after further exploration to identify a current address (or in the absence 
of a notification of the participants death), it was accepted that these individuals had 
been lost to follow up (n=15). In order to further encourage as high an attendance as 
possible, a similar vigorous strategy for appointment making to that used at year 1 
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was adopted.  This, combined with the robust approach to obtaining contact details, 
encouraged 77.9% of the original cohort to participate in year 4 follow up.  Despite 
the reduction in the size of the cohort attending year 4, the follow up of incident 
events remained nearly complete for the full cohort due to ISD data linkage which 
allows for follow up even without clinic attendance.  This is similar to follow up 
rates demonstrated by other studies of individuals with diabetes (Wang, Van Belle et 
al. 2004; Kramer CK, Muhlen D von et al. 2010).  
In comparison to some other larger collaborative studies of cIMT in people with 
diabetes eg USE IMT (Den Ruijter HM, Peters SA et al. 2012) or large single cohort 
studies such as the Framingham Study in which subpopulations of people with 
diabetes are identified from within the larger study population, the population of the 
ET2DS was recruited directly from a representative sampling frame of all individuals 
in Edinburgh with Type 2 diabetes, in order to examine specific outcomes in 
individuals with diabetes.  All participants were subject to the same entry criteria at 
recruitment, and measurement of cIMT and plaque was made using the same SOP 
and ultrasonographer, in comparison to larger studies that have drawn participants 
from multiple studies using different radiological SOPs and using different criteria to 
define diabetes (Den Ruijter, Peters et al. 2013).  This will have gone some way to 
addressing the effect that these sources of variability will have exerted on the results 
of larger studies.   
Representativeness 
The ET2DS is a cohort of older adults with Type 2 diabetes living in Edinburgh and 
the Lothians.  The representativeness analyses are presented in chapter 4 of this 
thesis and have been published previously (Marioni, Strachan et al. 2010).  The 
variables used to compare the two groups were limited to relevant demographic and 
cardiometabolic variables available on the Lothian Diabetes Register in order to 
allow comparison between attenders and non-attenders.  The analysis demonstrates 
that at baseline, those who agreed to participate in the ET2DS were broadly similar 
to those who did not participate, suggesting that the study sample is largely 
representative of the invited target population, although slightly more men 
participated in the study than did not, and individuals from the least deprived quintile 
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of SIMD were slightly overrepresented in the participant group, while those from 
more deprived quintiles slightly underrepresented.  This suggests that those from the 
least deprived quintile may have been more likely to agree to take part than those 
from more deprived quintiles.   
When this analysis was extended to compare baseline demographic and 
cardiometabolic characteristics of those that attended baseline, year 1 and year 4 
follow up, a more extensive panel of variables was selected from the baseline data 
collection, as these would be available for all participants and allow for a fuller 
comparison. This was important to assess given the loss to follow up over the course 
of the study and the risk of introducing bias as a result.  It was found that there were 
very few differences in baseline characteristics between those who attended each 
follow up, suggesting that at each wave of follow up, participants were broadly 
representative of the target population, and of each other.  A slightly higher 
proportion of the follow up cohorts were non-smokers at baseline compared with the 
original baseline cohort.  One explanation for this finding is the survivor effect 
(Arrighi HM and Hertz-Picciotto I 1994), whereby smokers might be more likely to 
have co-morbidities that could prevent attendance at follow up clinics, whereas non-
smokers are more likely to suffer less ill health and consequently be available to 
return for follow up.  The overall effect of the difference however is likely to be 
small given the small absolute difference in smoking prevalence between the groups. 
Because not all participants in the study underwent cIMT measurement, additional 
comparisons were made of baseline variables in those who had valid cIMT 
measurements at year 1 and those who did not.  There were no significant differences 
in major vascular risk factors, with the exception of smoking status, whereby those 
who did not have valid cIMT measurements were more likely to be smokers than 
those who did have cIMT measurements.  One explanation for this may have been 
that it was perhaps more technically challenging to identify the carotid arteries in 
smokers or again, that the smokers may have had co-morbidities preventing re-
attendance.  As several of those without valid cIMT did in fact have measurements 
that were made, but that were made incorrectly and were therefore unrelated to the 
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individuals concerned, it is possible that the differences in smoking may be related 
purely to chance.   
 Completeness and accuracy of data collection 7.2.2
A key aspect of a longitudinal or indeed, any epidemiological study, is complete, 
accurate data collection.  In particular for longitudinal studies, complete follow up 
data for identification of incident events is often the more difficult but most 
important data to obtain.  This section discusses the completeness and accuracy of 
data collection at year 1 and year 4 of the ET2DS.  Overall, missing data in the 
analysis population chosen for this thesis was low (<2%) for all variables with the 
exception of ACR, and some plaque measurements.   
Self-completed questionnaires 
In most cases at both year 1 and year 4, participants completed the questionnaire 
prior to attending the clinics.  In cases where the questionnaire was not completed, 
assistance was given to participants by study staff at the clinics.  For the small 
number of participants who were not withdrawn from the study but did not attend 
clinics, questionnaires were posted out either to individuals or to their GPs for 
completion.  This strategy allowed for a high rate of completion of the questionnaires 
and maximized data completeness which was especially important for the 
determination of incident cardiovascular events. 
Blood Sampling at Baseline and Year 1 
Individuals in whom it was not possible to obtain a blood sample on the day of clinic 
attendance were invited to return for repeat venipuncture.  Whilst some samples were 
processed by the NHS Lothian haematology and biochemistry labs, other samples 
were processed and stored by study staff for use at a later date (eg NTproBNP, 
inflammatory markers).  Extensive training for study staff in the processing and 
storage of remaining blood samples encouraged a high rate of sample viability.  
Circumstances out with the control of the study included loss or damage of samples 
in transit or storage, or during processing in external labs.   
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Clinical Examination at Year 1 
The data used from the clinical examination at year 1 was the systolic and diastolic 
blood pressure, which was obtained as part of the measurement of pulse wave 
analysis.  Measurements were performed by only one examiner, which eliminated the 
potential effect of inter-observer variability in the measurements although no official 
assessment of this was made.   
cIMT and Plaque Measurements 
Carotid ultrasound scans were performed on each participant that attended the clinics 
at both year 1 and year 4, unless there was a medical reason for not performing the 
scan.  A thorough scan was performed and every attempt made to visualize the 
carotid arteries, within the limits of the ultrasound SOP (appendix D) and 
recommended clinical guidelines.  Nearly 100% of participants were scanned at year 
1; however, on later visual inspection of individual scan results that were identified 
as outlying values, 23 individuals had their measurements excluded from the final 
dataset.  In the case of readings that were lower than expected, this was mostly due to 
incorrect caliper placement.  In the case of measurements that were higher than 
might be biologically plausible, incorrect readings were usually made in areas with 
plaque present.  As these problems contradicted the SOP for measurement of cIMT 
and plaque in the study, these measurements were excluded from the dataset.   
 Cardiovascular Event Follow Up 7.2.3
In order to provide conditions essential for a robust analysis of the association 
between cIMT and cardiovascular disease in the ET2DS, complete follow up for 
incident cardiovascular events was necessary. In order to maximize the capture of 
events and reduce misdiagnosis, several sources were used to identify and 
corroborate potential cases (self-completed questionnaires, ECGs and ISD data 
linkage). A formal event identification pathway was created in order to ensure 
impartiality and uniformity for each case and in cases were a diagnosis was 
ambiguous or unclear, decisions were agreed upon by a panel of clinically qualified 
member of the study team.  These methods resulted in a high degree of success in 
identifying potential events.  ISD linkage data was analyzed in the first instance, as 
this captures all hospital in patient stays in Edinburgh and the Lothians between 
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prescribed dates.  Patient self-reports and ECGs were then searched for potential 
events and the results combined with the data linkage.   
 IMT measurement methods  7.2.4
In order to minimize recording bias in cIMT and plaque measurements, all 
measurements were performed by only one sonographer, which eliminated inter-
observer variability in the study.  Nonetheless, it was important to assess the intra-
observer variability of the measurements made in the ET2DS to ensure confidence in 
the readings.  The validation study performed on year 4 measurements confirmed a 
high correlation between repeat measures of cIMT, suggesting that there was a good 
degree of repeatability in the measurements, which in turn increases confidence in 
accuracy of the cIMT measurements.  Although only the year 1 rather than the year 4 
cIMT measurements were used for the main analyses of this thesis, the sonographer 
at year 1 and year 4 was the same, suggesting that the accuracy of the readings at 
year 4 can be taken as a marker that the year 1 readings were performed to the same 
standard, although this must also be taken into consideration in the interpretation of 
results.   
Alternative method for measuring cIMT 
Limitations in the ultrasound technology and type of images saved at year 1 of the 
ET2DS prohibited the use of fully automated edge detection systems.  These have 
been recommended by consensus statements on the measurement of cIMT (Stein JH, 
Korcarz CE et al. 2008; Touboul PJ, Hennerici MG et al. 2012) in which the use of 
edge detection systems is suggested to improve measurement accuracy and to reduce 
variability in cIMT measurements both within and between studies by reducing the 
bias introduced by using different sonographers and SOPs (human error), as well as a 
reduction in cost and time required to perform measurement.  However, in an attempt 
to explore the effect of more extensive and perhaps accurate measurement of cIMT 
in the ET2DS, a partially-automated programme designed to take multiple 
measurements of cIMT along a user-defined section of cIMT was implemented.  The 
advantages of such a programme over that of the ultrasonographer’s measurements 
lies in the ability to take multiple measurements over a longer segment of the arterial 
wall, which may capture a more comprehensive measure of the cIMT of the vessel 
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wall and thus provide a measure which more truly reflects the relationship between 
cIMT and vascular risk. The major limitation of this approach lies in the continued 
dependence upon user identification (human error) of the artery wall interfaces. An 
additional limitation is the added time to process the images after the initial data 
collection.  However, as this was to be considered an exploratory analysis only, it 
was felt that these limitations could be accepted.   
Each individual who underwent cIMT measurement at year 1 by the study 
sonographer had a maximum of 6 (3 right and 3 left) carotid images stored.  Due to 
time limitations, a sample of 233 individuals was processed using the semi-
automated software.  These images were processed by myself and two other study 
team members, identifying the area to measure allowing for multiple measurements 
to be taken along the length of wall identified.  The distance between measurements 
was arbitrarily set as 10 pixels and the line of best fit was every 50 pixels.  The 
minimum number of measurements made in any image was 10 and the maximum 
was 60.  The mean number of measurements for any given individual was 192 
measurements, which is considerably more extensive than the 6 measurements made 
by the sonographer.   
A summary statistic of the serial cIMT measurements was calculated as the mean of 
all the measurements made for an individual (mean serial cIMT).  While mean serial 
cIMT was statistically significantly lower than mean sonographer cIMT in the 
sample (0.91vs0.92mm, p<0.001), the correlations between mean serial cIMT and 
mean cIMT were strong (r=0.811).  This, in combination with the small absolute 
difference between the measures (0.01mm) suggests that multiple measures along the 
vessel wall may not improve on sonographer cIMT measurement in the ET2DS.  The 
ultimate method of testing whether taking more measurements of cIMT provides a 
more representative measure of cIMT in the ET2DS would be to examine the 
association of both measures of cIMT with risk factors.  However, the small sample 
size of individuals with serial cIMT measurements in the ET2DS prohibits this at the 
time of writing, as the true direction and strength of any relationships may not be 
captured.   
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The serial, computer aided measurements made in this thesis are still considered as 
“manual” measurements, as the method by which the actual IMT boundaries are 
identified is by manual tracing by the reader.  Several studies have compared similar 
“manual” measures with edge detection methods.  A recent study by Peters et al 
compared manual and semi-automated measurements of cIMT of the far wall  of the 
common carotid artery in the METEOR study (Peters SA, den Ruijter HM et al. 
2011).  They identified that the measurements made by each method were 
comparable. The authors reported that the automated measurements were lower than 
the “manual” measurements, with an absolute difference of 0.02mm between the 
manual and automated readings (for both treatment and control groups).  In addition, 
they found the same associations with risk factors for each method. The MESA 
investigators also compared edge detected and manual measures of cIMT, although 
they report that edge detected measures were greater than manual readings, which 
contrasts with the findings of both the METEOR study and this thesis.  However, 
they did find similar (although slightly weaker) associations between edge detected 
cIMT and risk factors as they found between manual measurements and risk factors.  
Taking the results of this thesis in the context of the results of these studies, they 
could suggest that the serial measures made in the ET2DS might be comparable with 
those that could be obtained by edge detection.  Therefore, by extension, because of 
the good correlation between the serial measurements and the sonographer 
measurements, they may suggest that the sonographer measurements provide as good 
a measure of cIMT as might be obtained with edge detection methods.  However, 
this conclusion does constitute quite a leap and cannot be considered a definite 
statement, but more a hypothesis. 
Recommendations for future research would include the assessment of the full 
ET2DS cohort using the manual serial method to allow for a more meaningful 
comparison between the two methods.   
Summarising cIMT and carotid plaque 
In general, the method by which cIMT is summarised and reported in studies has not 
been formalised.  Studies often report a variety of summaries of IMT and do not 
always create the variables in the same way.  The way in which IMT is measured on 
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ultrasound plays a large part in how IMT can be summarised.  Measurement of cIMT 
in the common carotid artery leads to less flexibility in the summary statistics than if 
IMT is measured in the internal carotid, external carotid and bifurcation also.   
The Mannheim consensus provides brief guidance on the summarisation of cIMT 
measures.  The options they discuss include the mean, maximum and composite 
measures from both sides and different arterial sites (CCA, bifurcation and ICA). 
They highlight that the mean IMT values are less susceptible to outliers.  However 
the maximal IMT may reflect more advanced thickening, although care must be 
exercised with maximum cIMT as it may be more susceptible to measurement error.   
They also suggest that the values from both the right and left can be averaged, 
although it should be noted that the left cIMT is often higher than that of the right 
(Foerch, Buehler et al. 2003) and it may be that averaging the values could attenuate 
the associations between cIMT and vascular risk .  They also suggest avoiding 
composite scores including both plaque and cIMT.  In terms of plaque measurement 
they recommend the measurement of plaque location, thickness, area and number, 
scanned in longitudinal and cross-sections must be recorded.  The ET2DS was able 
to record plaque presence, location (summarised as plaque score), thickness and 
morphology. 
The cIMT parameters used in this thesis showed a high degree of inter-correlation 
(range of r=0.911-0.977).  This may suggest that the choice of cIMT summary in 
future analyses could be flexible.  The association of each cIMT measure with 
cardiovascular risk factors was examined to further explore this relationship.  The 
multifactorial adjusted associations between the individual summary statistics and 
cardiovascular risk factors were broadly similar (age, sex, systolic and diastolic 
blood pressure).  The same was seen for the novel markers ABI and NTproBNP. 
Whether or not this impacts upon the choice of summary statistic remains open for 
discussion.  The strong overall correlation between the measures, and broad 
similarities in association with risk factors, add weight to the suggestion that none 
should be used in preference to the others.  However, further brief consideration of 
the findings from the prospective analysis of cIMT and incident vascular disease 
found that the mean cIMT was most closely associated with future vascular risk.   
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When one considers carotid plaque thickness measures, there was a high degree of 
correlation between mean plaque thickness and maximum plaque thickness (r=0.959) 
and the relationship between mean and maximum plaque thickness and 
cardiovascular risk factors was identical, suggesting that again , neither need be used 
in preference to the other.   Plaque score and plaque morphology were also 
associated with similar risk factors to plaque thickness and were also associated with 
prevalent vascular disease. However, given the negative findings of the association 
of carotid plaque with incident vascular disease, it is difficult to come to a firm 
conclusion of which measure of plaque thickness is best to use.   Several consensus 
statements highlight that the evidence for which measure of plaque to use in risk 
prediction is not clear and indeed, further evidence is required before any firm 
recommendations can be made regarding these measures (Touboul PJ, Hennerici MG 
et al. 2012).   
 
7.3 Study Limitations 
One of the major limitations of the study is that cIMT was measured 1 year after the 
baseline risk factors, which may have attenuated the strength of the relationship 
between the cIMT parameters and measured vascular risk factors.  The reason 
underlying the collection of cIMT at year 1 rather than baseline was funding 
considerations. Assessment of cohort representativeness found that the cohort at 
baseline and year 1 were very similar when baseline risk factors were compared.  
The time discrepancy was addressed by selecting variables from year 1 where 
possible and where variables were not available, substituting baseline variables.  
Whilst this was not ideal, all steps possible were taken to minimise the number of 
variables that were substituted.  For some variables, the 1 year difference may only 
have had a small impact on the magnitude of any associations eg BMI, which may be 
expected to change only a small amount over the course of the year.  In the ET2DS, 
mean BMI at baseline was 31.3, while at year 4, was 31.4, suggesting that mean BMI 
remained fairly stable across the course of the study follow-up.  In addition, smoking 
variables were taken from baseline.  It is unlikely (although not impossible) that 
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individuals in the study would have taken up smoking during the study, and so any 
change in smoking habits between baseline and year 1 is likely to have been a 
decline in current smokers and an increase in ex-smokers. The effect of this would be 
an underestimation of the association between carotid ultrasound parameters and 
smoking.  Indeed, when smoking rates in year 1 and year 4 are assessed, there were 
fewer people reporting current smoking at year 4 than at year 1 (14.0% vs 9.4%).   
Carotid ultrasound in the study did not provide as extensive a set of measures as 
some other studies of cIMT (O'Leary DH, Polak JF et al. 1999; Iglesias del Sol A, 
Moons KG et al. 2001; Iglesias del Sol A, Bots ML et al. 2002).  cIMT was 
measured only in the CCA, with 6 measures taken in total.  Other studies of cIMT 
have measured in several areas including CCA, internal carotids and the bifurcation 
and included a greater number of measurements (Iglesias del Sol A, Bots ML et al. 
2002).  However, there is evidence that suggests that while measurements in other 
areas of the carotids do not necessarily predict measures at other sites, the CCA is 
sufficient for use due to its greater ease of access (Touboul PJ, Hennerici MG et al. 
2012).  Carotid plaque information was also limited in comparison to some other 
studies.  In terms of quantitative measures, only plaque thickness, and the presence 
or absence of plaque in different segments of the carotid arteries, were noted and it 
was not possible to quantify total plaque area or plaque volume.  In addition, plaque 
morphology measurements were limited by the subjective qualification of 
morphology by the sonographer.  More recent techniques such as gray scale median 
(GSM) (Irie, Katakami et al. 2013) were not used in this study due to limitations in 
the technology and quality of the images produced.  This may have an effect on the 
magnitude of the relationships between carotid plaque and vascular disease in this 
thesis, and may underestimate the risk.  In addition, the Mannheim consensus 
recommends measurement of the inter-adventitial diameter and the intraluminal 
diameter, as IMT is related to arterial diameter (Touboul PJ, Hennerici MG et al. 
2012), however, these measures are not available in the ET2DS data. 
The number of incident cardiovascular events recorded in the study was small 
relative to the number of participants in the study.  The use of a composite endpoint 
allowed for a maximization of the numbers included in each analyses, increasing the 
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likelihood of finding the true association between carotid ultrasound parameters and 
incident vascular disease.  Interestingly, the event rate for MI in the ET2DS was 5.6 
events per 1000 patient years.  If this is compared with figures published by Mulnier 
et al in 2008, for a similarly aged group they found an equivalent rate of 19.4 events 
per 1000 patient years (Mulnier, Seaman et al. 2008).  The rate they found for those 
without diabetes was 7.3 events per 1000 patient years, highlighting that the rate in 
the ET2DS was low, even for a general population.   
As this thesis was in the final stage of completion, the NICE guidelines were revised 
(NICE CG 181 2014).  There was a change in their recommendations for 
cardiovascular risk prediction in people with Type 2 diabetes.  As of 2014, they 
recommend the QRISK2 score for assessing cardiovascular risk rather than the 
UKPDS Score, which they recommended previously. The majority of risk factors 
included in QRISK2 are similar to those included in the UKPDS used in this thesis, 
with the exception of rheumatoid arthritis, atrial fibrillation, BP treatment, 
deprivation, family history.  The impact of this change on the results of this thesis is 
unknown.  Some of the risk factors mentioned above are not available in the ET2DS 
(AF and family history) but the others are potentially available.  Therefore, 
recommendations for future research would include a recalibration of the models to 
include the additional risk factors in the QRISK2 score in order to produce up to date 
estimates for the association between cIMT and carotid plaque with incident vascular 
disease in the ET2DS.   
The ET2DS specifically aimed to recruit individuals between the age of 60 and 75 
years of age as the major outcomes of the study included cognition, liver disease and 
heart disease.  Therefore, the study sample does not include younger adults with 
Type 2 diabetes.  In addition, the majority of the study participants were white and 
there were only a few individuals of other ethnicities participating in the study.  
These two factors together impose limits upon the generalizability (external validity) 
of the results to other populations.   
Summary 
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The ET2DS has much strength, including sample size, good external validity and 
high quality, complete data collection for both risk factors and cardiovascular events.  
Limitations include the time between cIMT measurement and risk factor 
measurement and the limitations discussed regarding cIMT measurement.  However 
these issues have been addressed as far as possible and are likely to impact only in a 
small way on the results described in this thesis. 
The following sections discuss the key results from the various phases of analysis 
(summarized in section 8.1) in more detail. 
 
7.4 Frequency and distribution of cIMT and Carotid 
Plaque in People with Type 2 Diabetes  
 cIMT 7.4.1
Because of the similarity in the relationship between the different summary measures 
of cIMT and vascular risk factors (discussed in section 8.2.4), only mean cIMT will 
be discussed in any great detail in this section.   
Mean cIMT was normally distributed in the ET2DS and the mean value was 
0.94mm.  A comparison of mean cIMT with both studies in general populations and 
studies of people diabetes is summarised in table 7-1.  In general the ET2DS mean 
cIMT was comparable with mean cIMT values described in other studies of people 
with diabetes (range 0.83-1.21mm).  In addition, it was higher than the range of 
cIMT reported in several studies from the general population (range 0.59-0.84mm).  
This is in keeping with the results of a 2006 systematic review that identified 21 
studies of cIMT in people with diabetes and glucose intolerance  (Brohall G, Odén A 
et al. 2006).  Among the 24 111 individuals in the studies included in the review, 
4019 had Type 2 diabetes.  The authors identified that in 20 out of the 21 studies, 
individuals with diabetes had a higher cIMT than the healthy controls (Brohall G, 
Odén A et al. 2006).  They performed a random effects meta-analysis of the results 
and found that on average, mean CCA cIMT in people with diabetes was 0.13mm 
higher than in the control groups.  Mean CCA cIMT in individuals with diabetes 
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included in the meta-analysis ranged from 0.73-1.44mm.  The mean CCA cIMT in 
ET2DS was comparable with this range. It was also comparable with the range for 
similar ethnic groups (Caucasian European range 0.798-1.44mm).  This suggests that 
the mean cIMT in the ET2DS may be higher than comparable healthy individuals, 
although the nature of the ET2DS does not allow for firm conclusions on this topic as 
no controls were available for direct comparison (longitudinal cohort study).   





Population Age Mean IMT 
ET2DS n/a 916 Diabetes 67.9 0.94 ± 0.14 
      
Insulin Resistance 
Atherosclerosis Study 
(Wagenknecht, D'Agostino Jr 
et al. 1998) 
1392 Diabetes  
57 (established 
DM) 
0.890 ± 0.02 
 
   58 (new DM) 
0.858 ± 
0.016 
Hoorn Study (Henry RMA, Kostense PJ et al. 
2004) 
301 Diabetes 67.8 0.88 ± 0.17 
n/a (Sigurdardottir V, Fagerberg B 







   61 (new DM) 
0.85 ± 
0.0315 
n/a (Rajala U, Laakso M et al. 2002) 208 Diabetes 62 0.99 ± 0.04 
n/a (Niskanen L, Rauramaa R et al. 
1996) 
203 Diabetes 67 1.21 ± 0.04 
n/a (Geroulakos G, Ramaswami G 
et al. 1994) 
194 Diabetes 49 0.83 ± 0.02 
      
ARIC (Chambless LE, Heiss G et al. 
1997) 
12841 General 53.7 (f) 0.60 ± 0.00 
    54.3 (m) 0.66 ± 0.01 
CHS (O'Leary DH, Polak JF et al. 
1999) 
4476 General 72.5 - 
Rotterdam (Iglesias del Sol A, Bots ML et 
al. 2002) 
2073 General 70.0 (No MI) - 
    72 (MI) - 
MDCS 
(Rosvall M, Janzon L et al. 
2005) 
5077 General 57.4 (No CAD) 0.760 (n/a) 
    60.5 (CAD) 0.840 (n/a) 
CAPS (Lorenz MW, von Kegler S et al. 
2006) 
5056 General 50.1 
Left 0.71 ± 
0.17 
 
    
Right 0.74 ± 
0.20 
MESA (Folsom, Kronmal et al. 2008) 6698 General 45-84 - 
Framingham Offspring (Polak, Pencina et al. 2011) 2965 General 57.3 (no CVD) 0.59 ± 0.13 
    62.9 (CVD) 0.69 ± 0.15 
Improve (Baldassarre D, Hamsten A et 
al. 2012) 
3703 General 64.2 
0.71 ± 0.65-
0.8 
All reported measures are for common carotid artery (CCA) 
 Plaque presence and thickness  7.4.2
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There was a high prevalence of carotid plaque in the ET2DS at year 1 (97.6% of 
participants had at least 1 plaque).  Plaque was most common at the carotid 
bifurcation.  This is an area of altered intravascular dynamics and it is well 
documented that carotid plaque is more prevalent at the bifurcation (Imparato, Riles 
et al. 1979).  The prevalence of carotid plaque reported in this thesis was 
considerably greater than both the general population and at risk populations 
prevalences of between 30% - 78% quoted by previous studies (Fabris F, Zanocchi 
M et al. 1994; Joakimsen O, Bønaa KH et al. 1999; Kwon TG, Kim KW et al. 2009; 
Sillesen H, Muntendam P et al. 2012). The mean age of participants with a plaque 
prevalence of 30% was 59.7 year, while the mean age for participants in the study 
with prevalence of 78% was 68.8 years, which is comparable with the ET2DS. 
However, the prevalence in the ET2DS was considerably higher, at 97.6%, 
suggesting that carotid plaque may be more prevalent in people with Type 2 diabetes 
than in the general population.   
Published data concerning carotid plaque prevalence in people with Type 2 diabetes 
is limited.  A Chinese study published in 2010 reported carotid plaque prevalence of 
91% in persons who had Type 2 diabetes and suspected cerebrovascular disease 
(mean age 66 years) (He C, Yang Z et al. 2010).  While the participants in this study 
were not directly comparable with the ET2DS in that they were all suspected of 
having cerebrovascular disease, the mean age of participants was similar.  Another 
study from Macedonia in 2007 identified carotid plaque prevalence of just over 80% 
in a sample of 145 individuals with Type 2 diabetes and coronary artery disease.  The 
mean age of the participants was 59 years (Bosevski, Borozanov et al. 2007), which 
was only slightly lower than that of the ET2DS.  In 2005, Bernard et al reported a 
plaque prevalence of 50% in 229 individuals with Type 2 diabetes (Bernard S, 
Sérusclat A et al. 2005).  Another Chinese study of 250 individuals with and without 
microalbuminuria had a plaque prevalence of approximately 53%, which is markedly 
lower than that of the ET2DS (Zhang YH, Gao Y et al. 2013).  Participants in both 
this study and the Bernard study had a mean age of around 50 years, which was 
considerably younger than the ET2DS participants; this may go some way to 
explaining the differences in plaque prevalence.   
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Carotid plaque was assessed using several different methods in the ET2DS.  Mean 
plaque thickness and maximum plaque thickness were continuous measurements that 
were made on carotid ultrasound.  A prospective study by Irie et al examined carotid 
plaque in 287 individuals with Type 2 diabetes (Irie, Katakami et al. 2013).  They 
authors reported a mean plaque thickness of 2.26 ± 0.86mm which was comparable 
with the mean plaque thickness of the ET2DS (2.44mm).   
The correlation between plaque thickness and measures of cIMT was only moderate, 
suggesting that cIMT and carotid plaque are not interchangeable measures of 
atherosclerosis in the study.  This finding supports the results of study of 98 Oji-Cree 
adults published in 2005 (Pollex RL, Spence JD et al. 2005).  The authors found that 
the correlation between cIMT and total plaque volume was modest at 0.7 (which was 
higher than the correlation seen in the ET2DS).  This may support the theory that 
cIMT and plaque represent different aspects and stages of carotid atherosclerosis.   
 Plaque score and plaque morphology 7.4.3
The plaque score in the ET2DS was based on a method used by Lee et al (Lee EJ, 
Kim HJ et al. 2007) in a study of carotid plaque and stroke in people with Type 2 
diabetes.  It reflects the presence of at least 1 plaque in each of the sections of the 
carotid artery assessed. This was created as a proxy measure of plaque burden as 
more extensive measures such as total plaque area or total plaque volume were not 
available in this study.  In the ET2DS, plaque score ranged from 0-8 while in the Lee 
study, the range was 0-6.  In the ET2DS, most participants (79.9%) had a plaque 
score between 2 and 6, while in the Lee study, 77.5% of participants had a score of 
only 0-3, suggesting that the plaque burden in the ET2DS was higher than that 
demonstrated by Lee et al. The association of high plaque score (>4) with increasing 
cIMT and the presence of high risk plaques suggests that it is a good proxy measure 
for plaque burden.  
This thesis presents relatively unique data concerning carotid plaque morphology in 
people with Type 2 diabetes.  As reported earlier, there was a high prevalence of 
carotid plaque in the ET2DS but different plaque morphologies are associated with 
different risks of CVD.  Echolucent and heterogeneous plaques are thought to 
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represent a higher risk of rupture and thrombosis than fibrotic, echogenic and 
homogenous plaques, although the exact nature and strength of this risk remains 
uncertain.  In the ET2DS, there was a high prevalence at year 1 of so called “high 
risk” plaques (56.1%) and at year 4 (91%).  Reinforcing their status of “high risk”, 
these plaques were associated with increased cIMT, increased plaque thickness and a 
higher plaque score.  A study of plaque morphology measured by dual source CT 
angiography in 125 patients with type 2 diabetes  describes the prevalence of carotid 
and cerebrovascular plaques (He C, Yang Z et al. 2010).  The prevalence of non-
calcified or mixed plaques (high risk plaques) in the extracranial arteries and the 
intracranial ICA in the study by He et al was 18.2% and 74.8% respectively.  It is 
difficult to compare these results with the ET2DS because while the ET2DS 
measured plaque prevalence using ultrasound in the common carotid, internal 
carotid, bifurcation and external carotid, the study by He et al used CT to determine 
plaque presence in both the carotids and the cerebral vasculature.  The also divided 
the entire arterial tree up in to 40 segments which are not easily compared with the 
ET2DS. An earlier study of 47 T2DM participants and 51 controls had found that 
individuals with T2DM had more echolucent plaque than non-diabetic individuals 
(Ostling G, Hedblad B et al. 2007).  Again, it is difficult to directly compare the 
results of this study with those presented in this thesis as the authors quantify plaque 
echogenicity using GSM as a continuous measure, rather than describing simply 
presence of echolucent plaque as in the ET2DS. In the general population, Joakimson 
et al report the prevalence of high risk (soft) plaque in those with morphologically 
classifiable plaque as 37.7% (Joakimsen O, Bønaa KH et al. 1999).   
 Change in cIMT and plaque 7.4.4
In this thesis, analysis of cIMT over the course of follow up revealed a small but 
significant regression in mean cIMT over a mean follow up period of 3.5 years.  
Multifactorial analysis revealed the only independent predictors of change were 
baseline cIMT and BMI.  The negative β coefficients suggest that change in cIMT is 
smaller in those who have a larger cIMT and in those with a larger BMI.   
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The lack of progression, and indeed regression of cIMT in the ET2DS is a somewhat 
unexpected result as the association of increasing cIMT with increasing age would 
suggest that cIMT would progress over the course of follow up. Indeed, 
Wagenknecht et al have reported that cIMT not only progresses in people with 
diabetes, but that progression is greater than that seen in people without diabetes 
(Wagenknecht, Zaccaro et al. 2003).  Progression has also been reported in the 2000 
study by Yamasaki et al, where the authors identified a progression in cIMT of 
0.04mm/year in their study of 287 individuals with Type 2 diabetes over a mean 
follow up period of 3.1 years (Yamasaki Y, Kodama M et al. 2000).  The authors 
identified that the independent predictors of cIMT change were baseline thickness 
and HbA1c, which is partly supported by the findings in this thesis.  However, they 
noted a positive correlation between cIMT change and baseline cIMT whereas in the 
ET2DS, the correlation was negative.  In the general population, the ARIC study has 
also examined the determinants of change of cIMT with time and found that baseline 
diabetes, smoking, HDL cholesterol, pulse pressure, white blood cell count and 
fibrinogen were associated with change in cIMT (Chambless, Folsom et al. 2002). 
Further risk factors identified by the Rotterdam study include age, BMI, male sex, 
current smoking, systolic BP and hypertension (van der Meer, Iglesias del Sol et al. 
2003).  It is not easy to explain these differences, although the high frequency of 
lipid lowering medication use in the ET2DS in comparison to these studies (84.3% 
vs 48.7% (Yamasaki) and 9.7% (Wagenknect)) may go some way to explaining this 
phenomenon, as lipid lowering medications have been show to slow or indeed 
reverse cIMT progression (Hedblad B, Zambanini A et al. 2007; Yu CM, Zhang Q et 
al. 2007; Kastelein JJ, Akdim F et al. 2008).   
The lack of progression in cIMT in the ET2DS is puzzling and there are several 
potential explanations for this.  Firstly, the lower mean cIMT identified at the year 4 
follow up may reflect the loss to follow up of those with a higher cIMT (who may be 
at increased risk of morbidity and mortality and therefore less likely to reattend for 
measurement of cIMT).  However, the absolute difference in year 1 mean cIMT in 
those who did and did not have a cIMT measurement at year 4 was small  (no follow 
up 0.93 v follow up 0.94mm, p=0.775) and is unlikely to be the reason underlying 
 
  223 
the lack of progression of cIMT in the ET2DS.  A second potential explanation may 
be measurement error and the resultant variability in cIMT measurements.  The 
validation study performed in the ET2DS at year 4 suggested that measurement of 
cIMT by the sonographer was reliable and was not influenced by time between 
readings.  While a validation study was not performed to confirm this at year 1, these 
findings were extrapolated to year 1 because the same sonographer was used at both 
times points. Therefore, it is unlikely that measurement error would explain the 
change in cIMT.   
Another potential explanation for the regression of cIMT at year 4 may be that it 
could reflect the ongoing influence of vascular risk factor modification by 
medications such as statins or antihypertensive medications.  Clinical trials of drugs 
such as statins have demonstrated a slowing and even regression of cIMT in the 
treatment group (Fleg, Mete et al.).  Further analysis of cIMT progression in those 
taking and not taking antihypertensives in the ET2DS revealed no statistically 
significant difference in progression between these groups and both groups showed a 
regression in cIMT.  When this analysis was extended to lipid lowering medication, 
those who were not taking these medications did have a positive change in cIMT 
(0.002mm) while the group taking medication showed regression, however the 
difference was not statistically significant so little comment can be made upon the 
effect of statins on cIMT change.    Therefore, it may be that the most likely 
explanation for the lack of progression in cIMT in the ET2DS is the short follow up 
time.  The development of atherosclerosis and vessel wall changes reflects years of 
influence from cardiovascular risk factors (Lorenz, Polak et al. 2012), whereas the 
change as measured between two follow up clinics represents only a very short 
period of time in comparison.  It may be that there is not sufficient change in the 
cIMT to be recorded between these two points, in addition to the modifying effect of 
drugs such as statins on the vessel wall and vascular risk factors such as hypertension 
that are known to impact on the cIMT.   
With regards to the association of cIMT change with cardiovascular risk and its use 
as a surrogate cardiovascular endpoint, as highlighted in the literature review, change 
in cIMT was analysed in those with and without both prevalent and incident vascular 
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events.  There was no significant difference in the change in mean cIMT between the 
groups, suggesting that change in cIMT is not related to future vascular risk in the 
ET2DS.    
Plaque thickness, in contrast to cIMT, showed a significant increase between year 1 
and year 4 of the ET2DS.  As discussed previously, carotid plaque may represent a 
more advanced and active disease process than cIMT and therefore, active rapid 
change in these measures may not be surprising as continued exposure to vascular 
risk factors has a more acute effect on the nature of atherosclerotic plaques, with 
rupture and fibrosis of plaques being influenced by these factors.  The constant active 
remodelling of plaques may explain why a change in plaque thickness was noted in 
contrast to cIMT.  Plaque score and morphology were also significantly altered at 
year 4 follow up in comparison with year 1.  Plaque was more extensive at year 4 
than at year 1, as demonstrated by the higher plaque score at year 4, and individuals 
tended to have more high risk plaque at follow up.  Only 9% of individuals had no 
plaque or echogenic plaque at year 4, compared with 44% at year 1.  This means that 
91% of the study population had at least 1 high risk plaque after 3 years of follow up, 
compared with 56.1% at year 1.  This is a considerable increase in such a short 
period. It is possible that this may be attributable to variability in the way the 
sonographer classified plaque morphology between year 1 and year 4.  However it is 
difficult to comment on this as no validation study was performed to assess this in 
the ET2DS. A study by Joakimsen in 1997 revealed that in general, reproducibility of 
plaque assessment was good.  Some aspects of plaque assessment had better inter 
and intra-reader variability (plaque presence and plaque morphology) in comparison 
with others that displayed only moderate agreement (plaque thickness) (Joakimsen 
O, Bønaa KH et al. 1997).  In view of this, in the ET2DS, it is perhaps most likely 
that the change in plaque morphology and distribution is simply related to the 
ongoing influence of vascular risk factors with time rather than any error in plaque 
assessment.   
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7.5 Association of cIMT with cardiovascular risk 
factors and prevalent CVD 
This section discusses the reported associations of cIMT with risk factors and 
prevalent CVD.   
 Cardiovascular risk factors 7.5.1
In this study, all cIMT parameters were significantly higher in males than females, 
and increased with age for both sexes which is in keeping with current research 
(Joakimsen O, Bønaa KH et al. 1999).  Mean cIMT was associated (after adjustment 
for age and sex) with increased duration of diabetes, raised systolic and reduced 
diastolic blood pressure, as well as cigarette smoking.  Full multifactorial analysis 
then revealed that the independent predictors of cIMT in the ET2DS were increased 
age, male sex and raised systolic blood pressure.  However, it should be noted that 
the effect sizes determined in this thesis are in some cases small.  For example, the 
age and sex adjusted correlation coefficient between systolic BP and mean cIMT is 
only 0.075 but is statistically significant.  While there is statistical significance, the 
clinical significance of such a small correlation must be questioned.  In the case of 
the parameters where the correlation coefficient is <0.1, it is possible the association 
may only be significant because of the sample size.  Similarly, the small ANOVA 
statistics also raise a similar question with regards to the categorical variables.   
Associations between risk factors and cIMT have been reported in several general 
population studies. The most common risk factors associated with cIMT are 
increasing age, male sex, raised systolic and diastolic blood pressure, reduced HDL 
and elevated total cholesterol.  An early study by Gariepy et al, of 788 men and 
women aged 17 to 65 years old, found associations between increasing cIMT and 
cardiovascular risk factors such as systolic and diastolic blood pressure, total and 
HDL cholesterol (women only) and blood glucose (men only) (Gariepy J, Salomon J 
et al. 1998).  A study from 2000 using data from 963 Italian adults attending a 
metabolic study centre in Milan found that cIMT correlated with systolic blood 
pressure, total, LDL and HDL cholesterol and triglycerides (Baldassarre, Amato et 
al. 2000).  In studies of cIMT and vascular risk factors in people with Type 2 
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diabetes (which are less widespread), several risk factors have been associated with 
cIMT, including serum triglycerides and HDL cholesterol (Temelkova-Kurktschiev, 
Koehler et al. 1999; Temelkova-Kurktschiev, Koehler et al. 2000), Butt 2009).  Other 
studies identified associations with age, BMI (Güvener, Tütüncü et al. 2000) and 
microalbuminuria (Agewall S, Wikstrand J et al. 1995; Mykkänen L, Zaccaro DJ et 
al. 1997). 
The most striking difference between these studies and the ET2DS is the lack of an 
association between cIMT and blood lipids in the ET2DS.  The most likely 
explanation for this discrepancy lies in the high use of lipid lowering medication in 
the ET2DS, which may have masked the true relationship between cIMT and blood 
lipids.  Another surprising finding is the lack of association of cIMT with smoking.  
The reasons for this are not clear but it may hint at the underlying pathology of cIMT 
as a precursor of atherosclerosis rather than atherosclerosis itself.  
 Prevalent vascular disease 7.5.2
Individuals in the ET2DS with a history of previous CVD displayed an altered 
cardiometabolic risk profile to those who with no history of CVD.  They were older 
and more likely to be male, and had a longer duration of diabetes - all of which are 
well-established risk factors for CVD.  There was no difference in HbA1c or systolic 
blood pressure, which probably reflects the increased use of insulin and 
antihypertensives in the disease group of high risk individuals.  Medication use may 
also explain the lower total cholesterol in the group with disease.  They also 
demonstrated a higher prevalence of smoking, which is in keeping with increased 
risk of vascular disease.  They had significantly poorer renal function, increased 
inflammatory markers and a higher NTproBNP than individuals without disease, all 
suggestive of an increased vascular risk (Blankenberg, McQueen et al. 2006; Chronic 
Kidney Disease Consortium 2010). (Ridker PM, Rifai N et al. 2000)  
All measures of cIMT were significantly higher in individuals who had ever been 
diagnosed with cardiovascular disease (MI, angina, TIA or stroke). This was also 
seen when individuals with and without CAD and with and without cerebrovascular 
disease were compared. However, logistic regression modelling revealed that 
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although cIMT was associated with prevalent CVD, this relationship lost significance 
once traditional risk factors were adjusted for and was the same for CAD and 
cerebrovascular disease.  This contrasted markedly with measures of carotid plaque, 
all of which remained associated with prevalent CVD, CAD and cerebrovascular 
disease, even after adjustment for traditional risk factors and novel risk factors.  
These results suggest that it may in fact be carotid plaque that may be more useful in 
the prediction of cardiovascular disease, given the strong association between plaque 
and CVD. 
Studies in both general populations and Type 2 diabetes have reported the 
association of cIMT with prevalent vascular disease.  In 1999, Ebrahim et al reported 
an association between cIMT and prevalent vascular disease (Ebrahim, Papacosta et 
al. 1999).  They identified that common carotid artery cIMT was associated with 
prevalent stroke whereas cIMT at the bifurcation of the carotids was more strongly 
associated with ischaemic heart disease.  A 2002 study by Baldassarre et al also 
reported higher cIMT in individuals from the general population with CHD 
(Baldassarre, Amato et al. 2000).   A more recent study by Polak et al, using data 
from the Framingham Offspring cohort found a stronger relationship between cIMT 
and prevalent vascular disease than was seen in the ET2DS  (Polak, Pencina et al. 
2010).  Using multifactorial logistic regression models, they identified both CCA 
cIMT and ICA cIMT as independent predictors of prevalent cardiovascular disease.  
Critically, several studies in people with diabetes revealed that individuals with both 
stroke and CAD, identified using CT and MR, had increased cIMT (Lee, 2007, 
Djaberi 2009, Kasami 2011). The results of this thesis, in particular in relation to 
CAD and general CVD, further support the findings of these studies. 
 
7.6 Association of Carotid Plaque with cardiovascular 
risk factors and prevalent CVD 
 Cardiovascular risk factors 7.6.1
Carotid plaque thickness in the ET2DS demonstrated a different cross sectional 
relationship with cardiovascular risk factors than cIMT.  This difference in risk factor 
 
  228 
associations has been reported by other studies including the British Regional Heart 
Study (Ebrahim, Papacosta et al. 1999).  In the ET2DS, following multifactorial 
adjustment mean and maximum plaque thickness were associated with several risk 
factors – increasing age, male sex, longer duration of diabetes, increased systolic BP, 
reduced diastolic pressure and smoking history.  However, like cIMT, the effect size 
of the correlations was in some cases small and may not represent a strong 
relationship between the risk factors and plaque thickness (the strongest age and sex 
adjusted correlation was with systolic blood pressure (r=0.119)) and care must be 
taken not to overstate their importance.  The major difference between these 
associations and those seen for cIMT is the association with smoking.  Cigarette 
smoking is known to be a direct cause of atherosclerosis so it is not surprising to find 
this relationship with carotid plaque thickness but not with cIMT.  Carotid plaque 
burden as represented by individual plaque score in the ET2DS, appeared to be 
associated with a poor cardiometabolic profile however many of the differences were 
difficult to interpret as the relationships were not always completely linear.  In order 
to address this, plaque score was considered as a bivariate factor (score ≤4 or >4) and 
a similar risk factor profile to that of plaque thickness was identified for those people 
with a high plaque score (>4), with the additional exception of BMI, suggesting that 
plaque score may not provide any additional information on cardiovascular risk than 
plaque thickness.  The presence of high risk plaque was also associated with raised 
systolic and diastolic blood pressures, as well as also low BMI.  Interestingly, there 
was no association with smoking history.   
There are not many previous studies specifically of carotid plaque (in particular 
plaque thickness) and vascular risk factors in people with Type 2 diabetes.  One 
recent study by Irie et al demonstrated that male sex, BMI and low-HDL-cholesterol 
were strongly associated with plaque morphology in people with Type 2 diabetes 
(Irie, Katakami et al. 2014) which is in support of the finding of this thesis.  Cardoso 
et al also reported an association with smoking, which has been replicated in this 
thesis (Cardoso et al, 2012). In the general population, a review by Wyman et al 
highlighted that associations have been demonstrated between carotid plaque and 
age, systolic blood pressure, smoking, total/HDL cholesterol ratio and BMI (Wyman, 
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Fraizer et al. 2005).  It is interesting to note that the relationship between carotid 
plaque and blood lipids demonstrated by other studies is absent in the ET2DS.   
In terms of plaque morphology in the general population, Joakimsen et al noted that 
high risk plaques were more common in men from the general population (at all 
ages) although they do not describe the association of high risk plaques with risk 
factors (Joakimsen O, Bønaa KH et al. 1999).  In the ET2DS, while men were more 
likely to have high risk plaque than women, this difference disappeared following 
multifactorial adjustment.  Data from the Tromsø Study established that HDL 
cholesterol was associated with echolucent carotid plaques (adjusted OR 0.69 
(95%CI 0.52-0.93) in 6727 participants in a population health survey (Mathiesen EB, 
Bønaa KH et al. 2001).  Again, this relationship with HDL cholesterol was not 
demonstrated in the ET2DS.   
 Prevalent vascular disease 7.6.2
All parameters of carotid plaque considered in this thesis were more prevalent in 
individuals who had a history of any CVD.  The absolute differences in mean and 
maximum plaque thickness were considerable (0.6mm for mean plaque thickness and 
0.5mm for max plaque thickness).   
In a study by Lee et al, which examined the relationship between cIMT, plaque and 
stroke in 133 people with Type 2 diabetes, the authors found that individuals who 
had experienced a stroke tended to have a higher plaque score than those who had 
not (Lee et al, 2007).  This finding has been replicated in the ET2DS, where 
individuals with prevalent cerebrovascular disease (stroke or TIA) had a higher 
plaque score than those without.  This finding was also replicated for CAD and any 
CVD.  Also in accordance with the Lee study were the results of logistic regression 
models in which the association between plaque score and prevalent cerebrovascular 
disease was attenuated by adjustment for risk factors in logistic regression models. 
However, this thesis did find that the association between plaque score and CAD, as 
well as any CVD, survived full cardiovascular risk factor adjustment (including 
novel risk factors in the case of any CVD), suggesting a stronger relationship 
between plaque score and prevalent CAD and CVD rather than stroke.  This is 
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supported by the findings of Akazawa et al who reported that plaque score was 
associated with the extent of CAD after risk factors adjustment (Akazawa et al, 
2012).  In addition, high risk plaques were more common in people with prevalent 
CVD than those without, suggesting that they may also be associated with an 
increased risk for CVD.  
 
7.7 Usefulness of cIMT and Carotid Plaque in 
prediction of incident CV events over and above 
conventional risk factors in the ET2DS 
In the ET2DS, cIMT was independently associated with established cardiovascular 
risk factors and demonstrated a modest association with prevalent cardiovascular 
disease while carotid plaque showed a more robust relationship with both 
cardiovascular risk factors and prevalent vascular disease.  This suggested that 
carotid plaque may be more useful in the prediction of cardiovascular events than 
cIMT.  However, the results of the analysis of these factors with incident 
cardiovascular disease demonstrate that cIMT had a stronger relationship with 
incident vascular disease than carotid plaque.   
 cIMT and incident vascular events 7.7.1
Cox proportional hazards’ modelling was chosen to analyse the relationship between 
cIMT measurements made at year 1 in the ET2DS and incident cardiovascular 
events.  Unadjusted models for all cIMT variables and incident events revealed that 
all measures of cIMT were associated with incident CVD and most with CAD.  
There was no such association for fatal events or cerebrovascular disease, which may 
reflect the small number of events seen in each of these categories. This finding 
supports much of the research from general population studies which demonstrates a 
stronger link between cIMT and both general CVD and CAD, rather than stroke.   
Adjustment for age, sex, previous CVD and UKPDS cardiovascular risk factors 
attenuated the predictive ability for any CVD as well as CAD, for all measures of 
cIMT with the exception of mean cIMT, and mean maximum cIMT for CAD only.  
 
  231 
Assessment of the usefulness of mean cIMT in prediction of cardiovascular disease 
over and above UKPDS risk factors was assessed using area under the curve and 
NRI.  AUC improved marginally on addition of mean cIMT to the model containing 
risk factors (0.691-0.704) and NRI was found to be 0.25% suggesting that there is an 
overall minimal improvement in risk prediction for cardiovascular events when mean 
cIMT is added to traditional risk factors, the clinical significance of which is 
uncertain.  These findings are similar to several studies that are discussed below, in 
addition to a large meta-analysis which will be discussed separately.   
Five epidemiological cohort studies (3 prospective and 2 retrospective) and one 
meta-analysis assessing the usefulness of cIMT on top of traditional cardiovascular 
risk factors in people with Type 2 diabetes were identified in chapter 1 of this thesis.  
It is important to compare the demographic and cardiometabolic characteristics of 
these studies with the ET2DS in order to make meaningful comparisons with their 
results.  The study population used in this thesis is a cohort of older adults with Type 
2 diabetes living in Edinburgh and the Lothians.  The average age of the participants 
at the time of carotid ultrasound assessment was 68.9 years, making the cohort 
slightly older than previous studies of cIMT and future cardiovascular risk in people 
with Type 2 diabetes (range 51.4-65.0 years) (Yamasaki Y, Kodama M et al. 2000; 
Bernard S, Sérusclat A et al. 2005; Ataoglu, Saler et al. 2009; Malik S, Budoff M et 
al. 2011).  The ET2DS also differed from previous study populations in a number of 
other respects.  For example, while the use of medication to manage diabetes was of 
a similar prevalence to that seen in the study by Bernard et al (Bernard S, Sérusclat A 
et al. 2005) the use of antihypertensive and lipid lowering medications was higher.  
Mean systolic and diastolic pressure was similar to that in the study by Yamasaki et 
al but lower than that in Ataolugo et al (Yamasaki Y, Kodama M et al. 2000; 
Ataoglu, Saler et al. 2009), which may be explained by the high prevalence of anti-
hypertensive use in the ET2DS.  Mean lipid levels in the ET2DS were poorer than 
that reported by Bernard et al but modestly better than that reported by Yamasaki et 
al (Yamasaki Y, Kodama M et al. 2000; Bernard S, Sérusclat A et al. 2005).   
The earliest of the prospective studies was that of Yamasaki et al who, in 2000, 
found that for a 1 unit increase in cIMT there was an almost 5 fold increase in risk of 
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non-fatal CAD after adjusting for cardiovascular risk factors in multifactorial logistic 
regression models (Yamasaki Y, Kodama M et al. 2000).  This thesis has identified 
that a 1 SD increase in mean cIMT led to a 1.5 fold increase in risk for incident non-
fatal CAD in the fully adjusted Cox regression models.  Whilst this is lower than the 
risk identified by Yamasaki et al, it should be noted that their logistic regression 
model takes no account of time to event, as is seen in Cox regression; therefore the 
risks may not be directly comparable.  However, the overall trend remains the same – 
that cIMT increased prediction of coronary artery disease over and above traditional 
risk factors. Unfortunately, they do not report any comparison of the models eg area 
under the curve or net reclassification, so it is impossible to comment on clinical 
impact of adding cIMT on risk classification in this study. 
In 2005, a further study by Bernard et al prospectively assessed the predictive ability 
of cIMT for cardiovascular events.  They found that for a 1 SD increase in mean 
cIMT there was an OR of 1.63 (95%CI 1.01-2.63) for cardiovascular events, after 
adjustment for age, sex, physical activity, microalbuminuria and HDL cholesterol.  
Their model for cardiovascular events containing only Framingham risk score had a 
similar AUC to the model containing only cIMT (0.720 vs 0.715 respectively) 
(Bernard S, Sérusclat A et al. 2005).  The AUC for the model containing only 
Framingham risk score was slightly higher than the same model in the ET2DS (AUC 
0.691).  When they combined both Framingham risk factors and cIMT into their 
model using a combined index, there was a significant improvement in prediction as 
demonstrated by increased survival in Kaplan-Meir curves (16.1, P=0.0003) - AUC 
is not reported for that model.  They also assessed Cox regression models of 
continuous cIMT in addition to FRS and found a global increase in chi square from 
14.1 to 18.1 (p=0.0035) when cIMT was added,  suggesting that cIMT may be 
predictive of cardiovascular events over and above FRS.  The results of this study are 
similar to the results found in the ET2DS.  They report an increase in global chi 
squared of 4.0 on addition of cIMT to the Framingham score, which is similar to the 
increase seen in the ET2DS on the addition of cIMT to UKPDS risk factors (3.87).  
Again, AUC and NRI are not reported for this study so no comparison is made with 
regards improvement in prediction. 
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Results from the Multi-Ethnic Study of Atherosclerosis (MESA), a large study of 
6814 participants aged 45-84, were published in 2011 (Malik S, Budoff M et al. 
2011).  Using 881 MESA participants who met the criteria for diabetes, they 
analysed maximum cIMT in quartiles and compared its predictive ability for CVD 
and CAD in models containing Framingham risk factors with that of coronary artery 
calcium (CAC).  In contrast to the results presented in this thesis, they found that 
while CAC adding to Cox models containing conventional risk factors significantly 
improved risk prediction for both CVD and CAD in people with diabetes, cIMT did 
not (4th vs 1st quartile cIMT HR 1.7 (0.7-4.3) and 1.0 (0.5-2.0) for CAD and CVD 
respectively).   ROC curve analysis however did show a small increase in AUC for 
CHD when the risk factor model was compared to a model with risk factors and 
cIMT (0.72 -0.74 respectively).  While the ET2DS cohort and the MESA participants 
included in this study were broadly similar in terms age and other risk factors, the 
MESA participants were drawn from a general population cohort, rather than being 
recruited into a diabetes specific study.  This may have introduced an element of 
heterogeneity into the study population which may have impacted upon the results of 
the analysis. 
The earliest retrospective cohort study that addressed the addition of cIMT to FRS 
for predicting vascular events in Type 2 diabetes was published in 2009 (Ataoglu, 
Saler et al. 2009).  The authors reported that in 102 subjects with diabetes, cIMT 
could be useful in addition to Framingham risk scoring in predicting vascular risk.   
The OR for cIMT following adjustment for FRS factors was 7.92.  However, caution 
must be applied to these results as they are the results of a retrospective cohort and 
the effect of bias and confounding may be greater in this cohort than in a prospective 
study.  Additionally, they do not report any reclassification statistics so the 
improvement in risk prediction cannot be compared with the results of this thesis.   
A further retrospective study from 2011 examined cIMT in relation to incident CVD 
events in a population of 783 type 2 diabetic adults (Yoshida, Mita et al. 2012).  
Using Cox regression models fitted for traditional cardiovascular risk factors, they 
identified that cIMT predicted risk for CVD events over and above the fitted risk 
factors (RR 2.39 (1.19-4.81, p=0.02).  ROC curves of models containing cIMT and 
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as well as Framingham risk factors revealed improved risk prediction with the AUC 
increasing from 0.645 for risk factors alone, to 0.656 on the addition of cIMT.  These 
results, in a study of comparable size, are very similar to the ET2DS.   
Because of the mixed and modest results demonstrated by these studies, a meta-
analysis was performed  by den Ruijter et al using data from 4,220 individuals with 
diabetes (and mean follow up of 8.7 years) in a large ongoing individual participant 
collaboration (USE IMT) involving 56,194 subjects from 17 population-based 
cohorts worldwide (Den Ruijter, Peters et al. 2013). Similarly to the methods used in 
this thesis, the authors used Cox regression models to assess the predictive ability of 
cIMT over and above Framingham risk factors.  They found a HR of 1.22 (1.14, 
1.32) for CVD events (MI or Stroke) for a 1SD increase in mean cIMT.  They then 
identified only a small improvement in NRI (1.7%).  This is highly comparable with 
the HR identified in this thesis for a 1DS increase in mean cIMT for CVD (HR 1.26 
(1.003-1.58).  The results of this thesis also demonstrated only a small increase in 
NRI (0.25% for tertiles of risk).   
Although the results of this thesis do not differ significantly from the findings of the 
somewhat larger meta-analysis performed by den Ruijter et al and some of the 
smaller individual studies, what this thesis adds to current research lies in addressing 
the methodological problems highlighted in the meta-analysis and the smaller 
studies.  If we first address the smaller studies, the obvious advantage of the ET2DS 
over these is sample size.  In contrast, while the numbers used in the meta-analysis 
are large, they were drawn from a large multi-centre collaboration.  Individuals with 
diabetes were identified from with large general population studies and the data 
pooled.  As den Ruijter et al highlight in their paper, there was considerable variation 
in the way that diabetes was defined and cIMT measured in each study.  The ET2DS 
was developed specifically to recruit a representative sample of individuals with 
Type 2 diabetes and each participant was subjected to the same entry criteria and the 
same study protocols.  In addition, important diabetes related factors such as duration 
of diabetes, which was controlled for in this thesis, were not available in the meta-
analysis. The authors also identify that they were unable to address carotid plaque in 
any way in their study, which this thesis was able to do.   In addition, to strengthen 
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the results of the models presented in this thesis, history of previous CVD was 
included in the models to account for the increased risk conferred by a previous 
cardiovascular event on future vascular risk.  The high prevalence of CVD in the 
ET2DS excluded the possibility of selecting a study sample that was free of CVD as 
the reduction in sample size would have had a considerable impact on the power of 
the study.  However, including previous CVD in the model goes some way to 
addressing this while maintaining a sufficient sample size.    
Therefore, while the results of this thesis do not differ dramatically from published 
research, aspects of the study perhaps allow more weight to be added to their 
findings.  In addition, the results from the ET2DS follow only 3.5 years of follow up, 
whereas the USE IMT meta-analysis was based on over 8 years of follow up.  Given 
the strength of the relationship between cIMT and incident events in the ET2DS after 
a comparably short period of follow up, there may value in performing further data 
linkage to extend the follow up to explore whether a stronger relationship might be 
found. 
 Plaque and incident cardiovascular disease 7.7.2
One of the aims of this thesis was to explore the relationship between carotid plaque 
and incident cardiovascular disease.  In this ET2DS, while individuals with incident 
vascular events had higher plaque thickness, higher plaque score and more higher 
risk plaques than those who did not have events, upon Cox regression modelling, no 
plaque parameters were associated with an increased risk for any type of incident 
event once cardiovascular risk factors were taken into account, and indeed most were 
not associated even in unadjusted models.  This is particularly surprising for the 
outcome of cerebrovascular disease, given the well documented relationship between 
carotid plaque (particularly plaque morphology) and stroke in the general population 
(Pedro LM, Pedro MM et al. 2000; Grønholdt MLM, Nordestgaard BG et al. 2001), 
although a similar result was reported in a general population study by the MESA 
group in 2013 .  There could be several potential explanations for this.  Firstly, the 
size of the study, although considerable, may not have been large enough to capture 
the relationship between carotid plaque and vascular risk.  The absolute differences 
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in carotid plaque between those with and without incident events were small and in 
addition, the small number of events in each outcome category may have weakened 
any associations between carotid plaque and incident events.  Thirdly, the way in 
which plaque was characterized may not have been as optimal for identifying any 
relationships as some more extensive measures of plaque eg total plaque volume.  
More complex measures of plaque may have captured more fully the cardiovascular 
risk associated with carotid plaque.  Although participants who experienced incident 
events had a higher plaque thickness than those who did not, the small absolute 
difference between the groups may not have clinical relevance in terms of risk 
prediction.   
A further possible explanation for the lack of association between carotid plaque and 
incident vascular disease may lie in the underlying pathology.  Carotid plaque is an 
active endothelial pathology.  It is possible that the very nature of carotid plaque 
means it is more closely associated to the current intravascular milieu, which is 
supported by the strong association of carotid plaque with prevalent vascular disease, 
rather than to any future vascular risk.   
There is evidence for a relationship between different measures of carotid plaque and 
incident cardiovascular disease in individuals from the general population (Wyman, 
Mays et al. 2006; Naqvi T and Lee M-S 2014), and a large meta-analysis has been 
conducted that concluded that in the general population, carotid plaque more 
accurately predicted CAD events than cIMT (Inaba, Chen et al. 2012).  However, 
data concerning the use of carotid plaque for cardiovascular risk prediction in Type 2 
diabetes are sparse (Den Ruijter HM, Peters SA et al. 2012) and indeed, literature 
searching revealed only a handful of papers that addressed mostly cross sectional 
relationships between carotid plaque and prevalent vascular disease in Type 2 
diabetes, rather than incident disease (Charvat, Michalova et al. 2006; Lee EJ, Kim 
HJ et al. 2007; Ostling G, Hedblad B et al. 2007; He C, Yang Z et al. 2010; 
Akazawa, Tojikubo et al. 2012).  Only two prospective studies in people with Type 2 
diabetes were identified (Katakami, Takahara et al. 2012; Irie, Katakami et al. 2013), 
both reporting results from the same study population.  A comparison of the ET2DS 
with these studies revealed that they were broadly similar in terms of demographics 
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and risk factors (Katakami, Takahara et al. 2012; Irie, Katakami et al. 2013).    
Katakami et al reported that low calibrated-IBS values (a measure of plaque 
echolucency) in a pilot study of 85 Type 2 diabetic persons could improve the risk 
prediction of cardiovascular events in asymptomatic type 2 diabetic patients with 
carotid plaque (Katakami, Takahara et al. 2012).  To expand this research, Irie et al 
demonstrated that in 287 individuals (from the same study population) with Type 2 
diabetes, echolucent plaques improved risk prediction after accounting for traditional 
risk factors (HR 4.55) and indeed, adding plaque echolucency to a model contained 
traditional risk factors and plaque thickness significantly increased the area under the 
curve for the models (Irie, Katakami et al. 2013).  In the ET2DS, while echolucent, 
high risk plaque was associated with cardiovascular risk factors and prevalent 
vascular disease, and indeed, was more prevalent in people with incident vascular 
disease, it did not demonstrate significant predictive value for incident events after 
traditional cardiovascular risk factors were accounted for. 
Although the results presented in this thesis do not support the current (limited) 
literature, the size of the ET2DS study in comparison with the two smaller studies 
discussed may point to the ET2DS being a closer reflection of the real relationship 
between carotid plaque and incident vascular disease in people with Type 2 diabetes.  
However, caution must be taken when interpreting this as the measures of carotid 
plaque in the two studies are not the same as those in the ET2DS so it is difficult to 
make a direct comparison.  Larger studies, with more extensive plaque assessment 
will be required to confirm the true relationship between carotid plaque and 
cardiovascular risk, including an analysis of which aspects of carotid plaque might be 
most useful in risk prediction in people with Type 2 diabetes.   
 
7.8 Novel biomarkers and cardiovascular disease in 
the ET2DS 
As this thesis progressed, it was noted that current literature was increasing regarding 
other potential markers of vascular risk (Ridker PM, Rifai N et al. 2000; 
Blankenberg, McQueen et al. 2006; Fowkes FG, Murray GD et al. 2008; 
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Donfrancesco C, Palleschi S et al. 2013).  While time limitations excluded the 
possibility of a full exploration of the potential for such markers to predict 
cardiovascular events in this thesis, exploratory analyses of the association between 
cIMT, carotid plaque, vascular disease and other novel markers of cardiovascular 
risk were performed.  Ankle brachial index (ABI), renal function (eGFR and 
microalbuminuria), markers of inflammation (CRP and IL-6) and NTproBNP (a 
marker of heart failure) were included.  cIMT and plaque were predominantly 
associated with ABI and NTproBNP following multifactorial regression.   
All measures of cIMT and plaque in the ET2DS were negatively associated with 
ABI.  A negative association between these two markers is expected as a decreasing 
ABI represents lower arterial distensability and subsequently, increased vascular risk 
whereas increasing cIMT and plaque represents increasing risk.  The relationship of 
cIMT and plaque with a proven marker of vascular risk could add weight to the 
evidence for the use of cIMT as a marker of risk, and conversely, may also support 
the use of ABI in people with diabetes.  Fowkes et al demonstrated that ABI is a 
reliable marker of cardiovascular risk in the general population and have validated its 
use as a risk model in a large collaboration of 18 cohorts (Fowkes FG, Murray GD et 
al. 2008; Fowkes, Murray et al. 2014).  In another Edinburgh based cohort, Price et 
al demonstrated that the addition of cIMT to ABI increased prediction of 
cardiovascular events (Price JF, Tzoulaki I et al. 2007) and the relationship between 
cIMT and ABI demonstrated in the ET2DS could suggest that combining cIMT and 
ABI may improve risk prediction in the cohort.  
Interestingly, no measures of cIMT or plaque were independently associated with 
renal function in the ET2DS.  Several recent studies, including a large meta-analysis, 
have identified eGFR and microalbuminuria (as measured by ACR) as potential 
markers of cardiovascular risk in the general population (Chronic Kidney Disease 
Consortium 2010; Donfrancesco C, Palleschi S et al. 2013), so the absence of any 
relationship between cIMT and eGFR in this study is perhaps surprising given the 
increased prevalence of chronic kidney disease and reduced renal function in people 
with Type 2 diabetes.   However, eGFR was significantly lower in participants who 
 
  239 
had an incident event, as well as in those who had prevalent vascular disease, which 
may hint at the potential for eGFR to predict risk in this population. 
When inflammatory markers were assessed, cIMT was positively associated with IL-
6 but not with CRP.  Following adjustment for age and sex, correlation coefficients 
for IL-6 were attenuated somewhat but significance was retained; however they did 
not survive multivariate adjustment.  Type 2 diabetes is known to be associated with 
low grade inflammation (Pickup 2004) and there is also considerable literature 
describing the relationship between inflammatory markers and cardiovascular 
disease (Epstein and Ross 1999), an indeed, the relationship between inflammation 
and CVD and cIMT in Type 2 diabetes (de Jager J, Dekker JM et al. 2006; Ray A, 
Huisman MV et al. 2009), Kang, 2004).  Therefore, it is surprising to find such a 
limited relationship between markers of inflammation and cIMT in the ET2DS.    
However, again, there was an association between higher inflammatory markers and 
the presence of prevalent and incident vascular disease, which may suggest the 
potential for markers of inflammation to be used in risk prediction in people with 
diabetes.    
cIMT and plaque were also associated with NTproBNP, even after multifactorial 
adjustment.  NTproBNP is a novel marker of heart failure that has received increased 
interest recently as a potential marker of cardiovascular risk (Blankenberg, McQueen 
et al. 2006).  As well as being associated with cIMT, a higher NTproBNP was seen 
in individuals with prevalent and incident vascular disease in the ET2DS, suggesting 
NTproBNP could have the potential for use in risk prediction in this cohort.   
 
7.9 Conclusions 
The main aim of this thesis was to describe the frequency and distribution of cIMT 
and carotid plaque in people with Type 2 diabetes, and to explore the association of 
cIMT and carotid with cardiovascular risk factors and prevalent cardiovascular 
disease.  This allowed for a subsequent well informed analysis of the predictive 
abilities of IMT and carotid plaque for incident cardiovascular disease, over and 
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above cardiovascular risk factors that are included in common risk prediction scores, 
which was achieved in two stages.  Firstly, cIMT and carotid plaque were described 
in the study population, followed by a cross sectional analysis of cIMT and carotid 
plaque with cardiovascular risk factors and prevalent cardiovascular disease.  Finally, 
a longitudinal survival analysis of cIMT and carotid plaque with incident events was 
performed, adjusting for traditional cardiovascular risk factors and previous vascular 
disease.  Additional aims of this thesis were also to analyse the measurement of 
cIMT in the ET2DS and to address the relationship of cIMT, carotid plaque and both 
prevalent and incident vascular disease with more novel markers of cardiovascular 
risk, including ABI, renal function, inflammatory markers and NTproBNP. 
Mean values of cIMT in the ET2DS were comparable with other studies of cIMT in 
people with Type 2 diabetes and may indeed be higher than cIMT in the general 
population.  Increasing cIMT was found to be associated with several cardiovascular 
risk factors including increased age, male sex and raised systolic blood pressure, as 
well as adverse levels of the more novel markers of vascular risk such ABI and 
NTproBNP.  Mean cIMT was associated with prevalent vascular disease and was 
predictive of incident cardiovascular events and coronary artery events (but not 
stroke) over and above UKPDS risk factors, although the clinical impact of this on 
reclassification of vascular risk (as demonstrated by NRI) may be limited.  
There was a high prevalence of carotid plaque in the ET2DS, and in particular, so 
called “high risk” plaques.  The different measures of carotid plaque were associated 
with several cardiovascular risk factors including increasing age, male sex, longer 
duration of diabetes, hypertension, smoking and low BMI.  In addition, all measures 
of carotid plaque were associated with the novel biomarkers ABI and NTproBNP.  
Carotid plaque was associated with a slightly more extensive range of cardiovascular 
risk factors than cIMT and was strongly associated with prevalent vascular disease.  
However, despite this strong association with risk factors and prevalent vascular 
disease, carotid plaque did not have any additional predictive value for incident 
cardiovascular events over and above UKPDS risk factors.   
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This thesis also aimed to address several cIMT measurement issues.  A validation 
study of cIMT measurement in the ET2DS found that cIMT measurement was highly 
repeatable, giving weight to the conclusions based on the results in this thesis.  As 
consensus statements recommend that cIMT is measured using automated edge 
detection methods, which were not possible in the ET2DS, measurement of cIMT 
using user defined, computer aided measurement algorithms were examined to 
compare multiple cIMT measurements with the more limited sonographer 
measurements.   Measurements made using the computer algorithm were found to be 
lower than those made by the sonographer although the absolute difference was 
small and the two measures were highly correlated.  Because this approach was 
tested on a small sub-sample of the ET2DS, further work is needed before firm 
conclusions can be drawn regarding the best method to use when measuring cIMT in 
the ET2DS.   
Finally, measures of cIMT and carotid plaque in the ET2DS were associated with the 
novel markers ABI and NTproBNP.  In addition these markers were significantly 
higher in those individuals with prevalent vascular disease, suggesting a more 
extensive exploration of the association of these markers in relation to cardiovascular 
disease in the ET2DS may be warranted.   
 
Final Summary 
In conclusion, this thesis reports that both cIMT and carotid plaque are modestly 
associated with traditional cardiovascular risk factors in people with Type 2 diabetes.  
Carotid plaque appeared to be associated with prevalent vascular disease but 
prospective analysis revealed that cIMT was predictive for incident vascular events 
in older adults with Type 2 diabetes, while carotid plaque was not.  However, the 
exact clinical benefit of measuring cIMT over and above traditional cardiovascular 
risk factors is not clear.  Additionally, cIMT and carotid plaque, as well as prevalent 
vascular disease, were associated with the more novel biomarkers ABI and 
NTproBNP.  There may be potential to use these novel markers to improve 
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cardiovascular risk prediction in people with Type 2 diabetes but exploration of these 
factors is out with the remit of this thesis.  Measurement of cIMT in this thesis 
appears to be accurate and broadly comparable with computer aided measurements in 
a subsample of participants, however further analysis of these measurements in the 
whole cohort are needed before a firm conclusion can be drawn as to the added value 
of multiple cIMT measurements.   
 
7.10 Recommendations for Further Research 
 What this study contributes to current research 7.10.1
This thesis has confirmed current research suggesting that while cIMT seems to be 
predictive of incident cardiovascular disease in people with Type 2 diabetes, the 
clinical utility of the improvement over traditional cardiovascular risk factors 
remains to be proved.  Although the findings are not dramatically different, they 
strengthen the findings of the meta-analysis by den Ruijter et al because the study 
sample was a specifically chosen, robustly phenotyped cohort that had cIMT 
measured in a clear and consistent way.   
The results of the analysis of carotid plaque with vascular risk in people with 
diabetes are relatively unique in the literature and demonstrate that carotid plaque 
does not appear to be of use over and above traditional cardiovascular risk factors in 
the prediction of disease in people with diabetes, despite the strong association with 
risk factors and prevalent disease, and the potential evidence in the general 
population that carotid plaque may be more predictive for cardiovascular events than 
cIMT. However, more, large prospective epidemiological evidence is required before 
a conclusion regarding the use of carotid plaque in the prediction of cardiovascular 
risk in people with Type 2 diabetes can be made.  Additionally, this thesis suggests 
that other more novel markers of vascular risk such as ABI and NTproBNP seem to 
be associated with vascular risk factors and prevalent disease, and may be of use in 
predicting cardiovascular risk in people with Type 2 diabetes. 
 
 
  243 
 Recommendations for future research 7.10.2
1. Longer follow up for the ET2DS may provide additional information on the 
relationship between cIMT and incident cardiovascular disease in the study.  
Follow up presented in this thesis was only for 3.5 years and follow up 
extended beyond this will increase the number of events available for analysis   
2. Despite the negative results presented in this thesis for the use of carotid 
plaque, larger studies may be needed to investigate this relationship further.  
Indeed, over the course of my PhD, I have worked with a large collaborative 
study (USE-IMT) which has published data regarding cIMT and future 
vascular risk, both in general populations and in people with diabetes (Den 
Ruijter HM, Peters SA et al. 2012; Den Ruijter, Peters et al. 2013).  Such a 
collaboration would be ideally suited to provide a robust analysis of carotid 
plaque.  In addition, longer follow up of the ET2DS may allow for a fuller 
assessment of the relationship of carotid plaque with incident vascular disease 
within the study. 
3. The association of cIMT, carotid plaque and prevalent vascular disease with 
ABI and NTproBNP in the ET2DS opens up the possibility of their use in 
CVD risk prediction in diabetes, particularly given the evidence for their use 
in the general population.  A  more in depth analysis of the relationship 
between incident CVD and these markers in the ET2DS, either compared 
with or in combination with cIMT or plaque, would be a sound primary step 
4. The findings presented in this thesis that describe the change in cIMT in the 
ET2DS highlight the need for further research into the progression or change 
in cIMT and carotid plaque over time, especially in relation to the use of 
cIMT as a surrogate end point in clinical trials in people with diabetes.  
Another large collaboration that I have been involved with in the course of 
my PhD is the PROG IMT collaboration which has specifically examined 
cIMT progression and future vascular risk (REF) and a meta-analysis of 
cIMT and progression and incident vascular disease is currently in final draft 
pre-submission. 
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5. Given the modest effect size of cIMT for predicting cardiovascular events 
and the negative findings for carotid plaque, a potential further avenue of 
exploration might be the combined predictive power of these markers.   
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